UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ | Preliminary Proxy Statement | ☐ | Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) | |||
☒ | Definitive Proxy Statement | |||||
☐ | Definitive Additional Materials | |||||
☐ | Soliciting Material Pursuant to§240.14a-12 |
INNOSPEC INC.
(Name of Registrant as Specified In Its Charter)
Payment of Filing Fee (Check the appropriate box):
☒ No fee required.
☒ | No fee required. |
☐ |
|
(1) | Title of each class of securities to which transaction applies: |
(2) | Aggregate number of securities to which transaction applies: |
(3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
(4) | Proposed maximum aggregate value of transaction: |
(5) | Total fee paid: |
☐ Fee paid previously with preliminary materials.
☐ | Fee paid previously with preliminary materials. |
☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
(1) | Amount Previously Paid: |
(2) | Form, Schedule or Registration Statement No.: |
(3) | Filing Party: |
(4) | Date Filed: |
2021
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
AND
PROXY STATEMENT
2018
Fuel Specialties
| Oilfield Services | Performance Chemicals | ||
INNOSPEC INC. 8310 South Valley Highway, Suite 350, Englewood, CO 80112
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
AND PROXY STATEMENT 2021
March 22, 201819, 2021
Dear Fellow Stockholder:
It is with great pleasure that we invite you to our 20182021 Annual Meeting of Stockholders. The meetingStockholders (“Annual Meeting”), which will be held on Wednesday, May 9, 20185, 2021 at 10.0010:00 a.m. Eastern Daylight Time at The Four Seasons, 1435 Brickell Ave, Miami, FL 33131.
Important notice regarding availability of Proxy Materials forTime. Due to the COVID-19 pandemic, the Annual Meeting will be held in a virtual format only again this year, to provide a safe experience for our stockholders, our employees and our community. You will be able to attend and participate in the Annual Meeting, vote your shares electronically and submit your questions prior to and during the Annual Meeting by visiting: https://www.meetingcenter.io/237172316, as further described in the Proxy Statement.
At the Annual Meeting, stockholders will be asked to elect and ratify nominees to the Board of StockholdersDirectors, to hold an advisory “say-on-pay” vote on the compensation of our named executive officers, to ratify the appointment of our independent registered public accounting firm for 2021, and to transact any other matters and business as may properly come before the Annual Meeting or any postponement or adjournment of the Annual Meeting. The Proxy Statement included with this letter provides you with information about the Annual Meeting and the business to be held on May 9, 2018:
We are continuing to take advantage of the Securities and Exchange Commission (the “SEC”) rules that allow companies to furnish proxy materials to stockholders via the internet. This electronic process gives you fast, convenient access to materials, reduces impact on the environment and reduces our printing and mailing costs. As you have received a Notice Regarding the Availability of Proxy Materials (“Notice”) by mail, you will not receive a printed copy of the proxy materials, unless you specifically request one. If you would still like to receive a printed copy of our proxy materials, you should follow the instructions for requesting these materials which are included in the Notice.conducted.
Whether or not you plan to attend the annual meeting,virtual Annual Meeting, your vote on matters to be acted upon at the meeting is important to us. We hope that you will vote by telephone or via the internet by following the instructions on your Notice Regarding the Availability of Proxy Materials (“Notice”) or proxy card. Alternatively, if you have requested written proxy materials, you may vote by signing, dating and returning your proxy card. If you are a holder of record and you sign and return your proxy card without specifying your voting choices, your proxy will be voted in accordance with the Board of Directors’ recommendations as set out in the Proxy Statement.
If you are a beneficial holder of our stock (i.e., with shares held in “street name”), we urge you to give voting instructions to your broker so that your vote can be counted. This is important because brokers are not able to cast votes with respect to the election of directors or executive compensation unless they have received instructions from the beneficial owner of stock.
If you have any questions concerning the meeting,Annual Meeting, please contact Mr. David B. Jones, Innospec’s Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at303-792-55541-303-792-5554 or david.jones@innospecinc.com.david.jones@innospecinc.com.
YOUR VOTE IS IMPORTANT TO US. We urge you to read the Proxy Statement carefully. Whether or not you plan to attend the Annual Meeting, we encourage you to vote promptly through the internet, by telephone, or by mail.
Thank you for your continued support. We look forward to seeing those of you who will be able to attend the 2018 Annual Meeting of Stockholders.
Sincerely,
Patrick S. Williams
President and Chief Executive Officer
INNOSPEC INC.NOTICE OF 2021 ANNUAL MEETING OF STOCKHOLDERS
8310 South Valley Highway, Suite 350
Englewood, CO 80112
|
Date and time | Wednesday, May | |||||
|
| |||||
| ||||||
| ||||||
Record Date | March | |||||
|
| |||||
Ratification of the election of one Class I Director | ||||||
Proposal 3 | Advisory approval of the Company’s executive compensation | |||||
Proposal 4 | Ratification of the appointment of the Company’s independent registered public accounting firm | |||||
To obtain Proxy Materials |
| |||||
| ||||||
|
Call 1-800-579-1639 (for beneficial owners with shares held in “street name”) | |||||
investorvote@computershare.com with “Proxy Materials Innospec Inc.” in the subject line (for stockholders of record) sendmaterial@proxyvote.com (for beneficial owners with shares held in “street name”) | ||||||
Voting Methods | www.envisionreports.com/iosp (for stockholders of record) www.proxyvote.com (for beneficial owners with shares held in “street name”) |
Call the toll-free number 1-800-652-8683 | ||||
Complete and return a proxy card (if you received a paper copy) | ||||
Attend virtually and vote at the |
Stockholders may also transact any other business properly brought before the meeting. At this time, the Board of Directors knows of no other proposals or matters to be presented.
On behalf of the Board of Directors:
David B. Jones
Vice President, General Counsel,
Chief Compliance Officer and Corporate Secretary
March 22, 2018
David B. Jones |
Vice President, General Counsel, |
Chief Compliance Officer and Corporate Secretary |
March 19, 2021 |
TABLE OF CONTENTS | Page No. | |||
INFORMATION ABOUT THE 2021 ANNUAL MEETING OF STOCKHOLDERS AND VOTING AT THE MEETING | 1 | |||
CORPORATE GOVERNANCE | 9 | |||
9 | ||||
9 | ||||
9 | ||||
11 | ||||
11 | ||||
14 | ||||
14 | ||||
14 | ||||
15 | ||||
Ø Executive Sessions of Independent Non-Management Directors | 15 | |||
15 | ||||
17 | ||||
17 | ||||
18 | ||||
18 | ||||
19 | ||||
19 | ||||
19 | ||||
20 | ||||
20 | ||||
Ø Copies of Code of Conduct, Corporate Governance Guidelines and Committee Charters | 20 | |||
20 |
PROXY STATEMENT
INFORMATION ABOUT THE 2021 ANNUAL MEETING OF STOCKHOLDERS AND VOTING AT THE MEETING
|
Why did you send me the Notice Regarding the Availability of Proxy Materials?
We sent you the Notice Regarding the Availability of Proxy Materials (the “Notice”) because the Board of Directors (the “Board”) of Innospec Inc. (“Innospec” or the “Corporation”“Company”) is soliciting your proxy to vote at the 20182021 Annual Meeting of Stockholders, which will be held on Wednesday, May 9, 20185, 2021 at 10.00 a.m. Eastern Daylight Time, in a virtual meeting format only at The Four Seasons, 1435 Brickell Ave, Miami, FL 33131.https://www.meetingcenter.io/237172316.
The Proxy Statement summarizes the information you need to vote at the 2018 Annual Meeting of Stockholders.Meeting. You do not need to attend the 2018 Annual Meeting of Stockholders in person to vote your stock. Alternatively, you may simply vote by telephone, over the internet, or, if you have requested written proxy materials, by completing, signing and returning the accompanying proxy card.
Innospec intends to commence distribution of the Notice to stockholders on or about March 27, 2018.23, 2021.
What proposals will be voted on at the Annual Meeting of Stockholders?
StockholdersYou are being asked to consider and vote on fivefour proposals at the 2018 Annual Meeting of Stockholders.Meeting. The following is a summary of the proposals and the voting recommendations of the Board with respect to each proposal:
SUMMARY OF PROPOSALS
NO. | PROPOSAL | HOW THE BOARD VOTE | MORE INFORMATION | |||
1 | Election of two Class II Directors | FOR ALL NOMINEES | Page 36 | |||
2 | Ratification of the election of one Class I Director | FOR THE NOMINEE | Page 38 | |||
3 | Advisory approval of the Company’s executive compensation | FOR | Page 54 |
| | 1 |
| ||||||
| ||||||
| ||||||
4 | ||||||
| Ratification of the appointment of the | FOR | Page 56 |
Important notice regarding availability of Proxy Materials for the Annual Meeting of Stockholders to be held on May 9, 2018.
Important notice regarding availability of Proxy Materials for the Annual Meeting of Stockholders to be held on May 5, 2021. |
Are proxy materials available on the internet?
Yes. OurThis Proxy Statement, including proxy card, for the 2018 Annual Meeting of Stockholders and our 20172020 Annual Report on Form10-K are available athttp://www.envisionreports.com/iospforstockholders for stockholders of record and http://www.proxyvote.comwww.edocumentview.com/iospfor beneficial holders.
1
Who is entitled to vote at the meeting?
March 15, 201811, 2021 is the record date for the 2018 Annual Meeting of Stockholders.Meeting. If you owned Innospec Common Stock at the close of business on March 15, 2018,11, 2021, you are entitled to vote. On this record date, we had 24,793,42524,842,239 shares of our Common Stock outstanding and entitled to vote at the 2018 Annual Meeting of Stockholders.Meeting. Our Common Stock is our only class of voting stock.
How many votes do I have?
You have one vote for each share of Common Stock that you owned at the close of business on the March 15, 201811, 2021 record date. Your Notice indicates the number of shares of Common Stock you are entitled to vote.
What is the difference between holding stock as a stockholder of record and as a beneficial owner?
Although many stockholders are the record holders of their stock, others hold their stock beneficially, which means it is held through a stockbroker, bank or other nominee rather than directly in the stockholder’s own name. As summarized below, there are some differences between stock held of record and thatstock owned beneficially.
Stockholder of Record
If your shares of Common Stock are registered directly in your name with our transfer agent, Computershare, you are considered, with respect to those shares, the stockholder of record and the Notice is being sent to you directly at your address of record. As the stockholder of record, you have the right to grant your voting proxy directly to Innospec or to vote in person at the Annual Meeting of Stockholders. Alternatively, you may voteby voting by telephone or via the internet, as describedor, if you have requested written materials, by signing, dating and returning your proxy card to Innospec. Alternatively, you may vote at the virtual only Annual Meeting. For more information on voting by telephone or via the internet see the description below under the heading “Information about the 20182021 Annual Meeting of Stockholders and Voting at the Meeting - May I vote by telephone or via the internet?”.
Beneficial Owner
If your Common Stock is held in a stock brokerage account or by a bank or other nominee, you are considered the beneficial owner of stock held in “street name” and our proxy materials are being forwarded to you by your
| | 2 |
broker or nominee who is considered the stockholder of record with respect to those shares. As the beneficial owner, you have the right to direct your broker or nominee on how to vote your stock and are also invited to attend the 2018 Annual Meeting of Stockholders.Meeting. However, since you are not the stockholder of record, you may only vote these shares in person at the 2018 Annual Meeting of Stockholders if you follow the instructions described below under the headingheadings “Information about the 20182021 Annual Meeting of Stockholders and Voting at the Meeting - How do I attend and vote in person at the 2018virtual Annual Meeting?” and “How do I register to attend the Annual Meeting of Stockholders?virtually on the internet?”.
Your broker or nominee has provided a voting instruction card for you to use in directing your broker or nominee as to how to vote your stock. You may also vote by telephone or via the internet by following your broker or other nominee’s directions as described below under the heading “Information about the 20182021 Annual Meeting of Stockholders and Voting at the Meeting - May I vote by telephone or via the internet?”.
How do I vote by proxy if I am a stockholder of record?
If you are a stockholder of record and you properly fill in your proxy card and it is received by us in time to vote, or you vote by internet or telephone, your “proxy” (i.e., one of the individuals named on your proxy card) will vote your stock as you have directed. If you sign the proxy card (including by electronic signature in the case of internet or telephonic voting), but do not make specific voting choices, the person holding your proxy will vote your stock as recommended by the Board as follows:
2
“FOR” the ratification of the appointment of the Company’s independent registered public accounting firm. |
|
|
If any other matter is presented at the meeting,Annual Meeting, your vote will be cast in accordance with the best judgment of the individuals named on your proxy card. As of the date of printing this Proxy Statement, we know of no such other matters that need to be acted on at the Annual Meeting of Stockholders.Meeting.
How do I give voting instructions if I am a beneficial holder?owner?
If you are a beneficial owner of stock, your broker will communicate with you directly and ask you how you want your stock to be voted. If you give the broker voting instructions, the broker will vote your stock as you direct. If you do not give the broker voting instructions, one of two things can happen, depending on the type of proposal in question. Brokers have discretionary power to vote your stock with respect to “routine” matters, but they do not have discretionary power to vote your stock on“non-routine” matters. Brokers holding stock beneficially owned by their clients do not have the ability to cast votes with respect to the election and ratification of directors or executive compensation unless they have received instructions from the beneficial owner of the stock because these are considerednon-routine“non-routine” matters.It is therefore important that you provide voting instructions to your broker if your shares of Common Stock are held beneficially through a broker so that your vote with respect to directors and executive compensation, the plans and any other matter treated as“non-routine”, is counted.
| | 3 |
May I vote by telephone or via the internet?
Yes, you may vote by telephone or via the internet. We encourage you to do so because your vote will be tabulated faster than if you mailed it. Please note the following depending on whether you are a stockholder of record or a beneficial owner whose shares are held by a bank or broker in “street name”:
If you are a stockholder of record, you may vote electronically through the internet atwww.envisionreports.com/iosp or by telephone Toll Free1-800-652-8683 within the U.S.A., U.S. Territories and Canada. Be sure to have your control number, which appears on your Notice or proxy card, with you when you vote.
If you are a beneficial owner and hold your stock in “street name,”name”, you may vote electronically through the internet atwww.proxyvote.com and you should contact your bank or broker to determine whether you will be able to vote by telephone. Be sure to have your control number, which appears on your Notice or proxy card, with you when you vote.
Whether or not you plan to attend the 2018 Annual Meeting of Stockholders in person,virtually, we urge you to vote. Doing so by returning the proxy card or voting by telephone or via the internet will not affect your ultimate right to attend and vote in person.at the meeting.
Proxies submitted by the internet or telephone must be received by 1:00 a.m. Eastern Daylight Time on May 9, 2018.
May I revoke my proxy?
Yes. If you change your mind after you vote, you may revoke your proxy by following any of the procedures described below. To revoke your proxy:
Send in another signed proxy with a later date or resubmit your vote by telephone or the internet; |
|
|
Send a letter revoking your proxy to Mr. David B. Jones, Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at Innospec Inc., 8310 South Valley Highway, Suite 350, Englewood, CO 80112; or
3Attend the virtual only Annual Meeting and vote in accordance with the instructions described below.
If you wish to revoke your proxy, you must do so sufficiently in advance to permit the necessary examination and tabulation of the subsequent proxy or revocation before the vote is taken.
How do I attend and vote in person at the 2018virtual Annual Meeting?
The Annual Meeting will be a completely virtual meeting of Stockholders?
Ifstockholders, which will be conducted exclusively by webcast. You are entitled to participate in the Annual Meeting only if you arewere a stockholder of record,the Company as of the close of business on the Record Date, or if you mayhold a valid proxy for the Annual Meeting. No physical meeting will be held.
You will be able to attend the Annual Meeting online and submit your questions during the meeting andby visiting www.meetingcenter.io/237172316. Questions pertinent to meeting matters will be answered during the meeting, subject to time constraints. You also will be able to vote your shares online by attending the Annual Meeting by webcast.
To participate in person. Ifthe Annual Meeting, you choosewill need to do so, please bringreview the information included on your Notice, oron your proxy card showingor on the instructions that accompanied your control number and proof of identification.proxy materials. The password for the meeting is OTL2021.
| | 4 |
If you are the beneficial owner of stock held in “street name”, you may votehold your shares in person only if you obtainthrough an intermediary, such as a signed proxy from the stockholder of record giving you the right to vote the stock. To do so,bank or broker, you must bringregister in advance using the instructions below, under the heading “How do I register to attend the Annual Meeting virtually on the Internet?”.
The online meeting will begin promptly at 10:00 a.m., Eastern Time. We encourage you to access the meeting prior to the 2018 Annual Meeting of Stockholders proof of identification, an account statement or letter fromstart time leaving ample time for the broker, bank or other nominee indicating that you arecheck in. Please follow the owner of the stock and a signed proxy from the stockholder of record giving you the right to vote the stock. The account statement or letter must show that you were the beneficial owner of the stock on March 15, 2018.registration instructions as outlined in this Proxy Statement.
Even if you plan to attend the 2018virtual Annual Meeting, of Stockholders in person, Innospec recommends that you vote your stock in advance by internet or telephone, or by returning the accompanying proxy card, as described above, so that your vote will be counted if you later decide not to attend the 2018Annual Meeting.
How do I register to attend the Annual Meeting virtually on the Internet?
If you are a registered stockholder (i.e., you hold your shares through our transfer agent, Computershare), you do not need to register to attend the Annual Meeting virtually on the Internet. Please follow the instructions on the notice or proxy card that you received.
If you hold your shares through an intermediary, such as a bank or broker, you must register in advance to attend the Annual Meeting virtually on the Internet.
To register to attend the Annual Meeting online by webcast you must submit proof of Stockholders.your proxy power (legal proxy) reflecting your Innospec Inc. holdings, along with your name and email address, to Computershare. Requests for registration must be labeled as “Legal Proxy” and be received no later than 5:00 p.m., Eastern Time, on April 29, 2021.
You will receive a confirmation of your registration by email after we receive your registration materials.
Requests for registration should be directed to us at the following:
By email
Forward the email from your broker, or attach an image of your legal proxy, to legalproxy@computershare.com.
By mail
Computershare
Innospec Inc. Legal Proxy
P.O. Box 505008
Louisville, KY 40202
What votes need to be present to hold the 2018 Annual Meeting of Stockholders?Meeting?
To have a quorum for our 2018 Annual Meeting, of Stockholders, the holders of a majority of the shares of Common Stock outstanding and entitled to vote need to be present in personvirtually or represented by proxy. Abstentions and broker“non-votes” are treated as present and entitled to vote and are counted in thedetermining whether we have a quorum.
| | 5 |
What vote is required to approve each proposal?
For Proposal 1, the affirmative vote of a plurality of the votes cast by holders of all stock entitled to vote on such proposal is required (meaning that the nominees for Innospec Director who receive the highest number of shares voted “for” their election are elected). While directors are elected by a plurality vote, we have a “majority vote” director resignation policy in place, as described below.
As Proposal 2 is an advisory vote, there is no specified vote requirement for approval. Innospec will consider that the affirmative vote of the majority of the stock present (in person or represented by proxy) and entitled to vote on such proposal reflects the advice of the stockholders.
4
For Proposals 3, 4 and 5, the affirmative vote of the majority of the stock present (in person or represented by proxy) and entitled to vote on such proposal is required.
Proposal | required? | |||||||
Proposal 1 | ||||||||
Election of two Class II Directors | Plurality of votes of shares present virtually or represented by proxy* | No | ||||||
Proposal 2 | Ratification of election of one Class I Director | Plurality of votes of shares present virtually or represented by proxy* | No | |||||
Proposal | Advisory approval of the | Majority of the stock present | No | |||||
Proposal 4 | ||||||||
Ratification of the appointment of the | Majority of the stock present | Yes |
What is our “Majority Vote” Director Resignation Policy?
According to the procedure set forth in the Corporation’s Corporate Governance Guidelines, in an uncontested election, any nominee for director (including incumbent directors) who receives a greater number of votes “withheld” from his or her election than votes “for” such election must offer his or her resignation promptly to the Board of Directors following certification of the stockholder vote. Upon receipt of the resignation, the Nominating and Corporate Governance Committee will consider the resignation offer and recommend to the Board of Directors whether to accept it. The Board of Directors will act on the Nominating and Corporate Governance Committee’s recommendation within 120 days following certification of the stockholder vote. The Nominating and Corporate Governance Committee and the Board of Directors may consider such factors they deem relevant in deciding whether to accept a Director’s resignation. Thereafter, the Corporation will promptly disclose the Board’s decision whether to accept the Director’s resignation offer (and the reasons for rejecting the resignation offer, if applicable) in a Current Report on Form8-K furnished to the SEC. This resignation policy does not apply to contested director elections.
* | While directors are elected by a plurality vote, we have a “majority vote” director resignation policy in place, as described on page 36. |
** | As Proposal 3 is an advisory vote, there is no specified vote requirement for approval. Innospec will consider that the affirmative vote of the majority of the stock present (virtually or represented by proxy) and entitled to vote on such proposal reflects the advice of the stockholders. |
How are votes counted?
In the election of Innospec Directors, your vote may be cast “FOR” each of the nominees or your vote may be “WITHHELD” with respect to one or more of the nominees.
Proposal | How your vote may be cast | Is broker discretionary | ||||
Proposal 1 | Election of two Class II Directors | “FOR” each of the nominees or “WITHHELD”* with respect to one or more of the nominees ** | No | |||
Proposal 2 | Ratification of election of one Class I Director | “FOR” the nominee or “WITHHELD”* with respect to the nominee ** | No | |||
Proposal 3 | Advisory approval of the Company’s executive compensation | “FOR”, “AGAINST” or “ABSTAIN” | No | |||
Proposal 4 | Ratification of appointment of the Company’s independent registered public accounting firm | “FOR”, “AGAINST” or “ABSTAIN” | Yes |
| | 6 |
* If you “withhold” authority to vote with respect to one or more nominees for Innospec Director, your vote will have no effect on the election of such nominees.
Your** While directors are elected by a plurality vote, may be cast “FOR”, “AGAINST” or “ABSTAIN” for the advisory approval of executive compensation, for the approval of the Innospec Inc. 2018 Omnibus Long-Term Incentive Plan, for the Innospec Inc. ShareSave Plan 2008 (as amended and restated)and for the ratification of the appointment of Innospec’s independent registered public accounting firm.we have a “majority vote” director resignation policy in place, as described on page 36.
If you sign (including electronic confirmations in the case of internet or telephone voting) your proxy card with no instructions on how to vote, your stock will be voted in accordance with the recommendations of the Board. If you sign (including electronic confirmation in the case of internet or telephone voting) your broker
5
voting instruction card with no instructions on how to vote, your stock will be voted in the broker’s discretion only with respect to “routine” matters, but will not be voted with respect to“non-routine” matters. As described in “How“Information about the 2021 Annual Meeting of Stockholders and Voting at the Meeting - How do I give voting instructions if I am a beneficial holder?owner?”, election of directors and executive compensation are considerednon-routine“non-routine” matters. We will appoint one or more inspectors of election to count votes cast in personvirtually or by proxy.
What is the effect of brokernon-votes and abstentions?
A broker“non-vote” occurs when a broker holding stock for a beneficial owner does not or cannot vote on a particular proposal because the broker does not have discretionary voting power for that particular proposal and has not received instructions from the beneficial owner.
Common Stock owned by stockholders electing to abstain from voting with respect to any proposal will be counted towards the presence of a quorum. Common stockStock beneficially owned and voted by the beneficiary through a broker will be counted towards the presence of a quorum, even if there are brokernon-votes with respect to some proposals, as long as the broker votes on at least onenon-routine“non-routine” proposal.
Abstentions and instructions to withhold votes with respect to any nominee for director election (which uses a plurality standard) will result in those nominees receiving fewer votes but will not count as votes “against” the nominee. Brokernon-votes will not be considered present and entitled to vote with respect to elections of directors and therefore will have no direct effect on the outcome of the election of directors. Abstentions will be treated as present and entitled to vote with respect to Proposals 2, 3 4 and 54 and, therefore, will have the effect of votes “against” these proposals. Brokernon-votes will have no direct effect on the outcome of these proposals.
What happens if the 2018 Annual Meeting of Stockholders is adjourned or postponed?
Your proxy will still be effective and will be voted at the rescheduled 2018 Annual Meeting of Stockholders.Meeting. You will still be able to change or revoke your proxy until it is voted.
Where can I find the voting results?
Final voting results will be disclosed in aForm 8-K to be filed with the SECU.S. Securities and Exchange Commission (“SEC”) within four business days after the 20182021 Annual Meeting of Stockholders. If official results are not available at that time, we will provide preliminary voting results in the Form8-K and will provide the final results in an amendment to the Form8-K as soon as they become available. You can find theForm 8-K on our website atwww.innospecinc.com.
Will Innospec’s independent accountants attend the 2018 Annual Meeting of Stockholders?Meeting?
A representative of KPMG Audit PlcPricewaterhouseCoopers LLP (“KPMG Audit”PwC”) and KPMG LLP,, our current independent accountants,registered public accounting firm, will be available by telephone at the 2018 Annual Meeting of Stockholders to answer questions and will have an opportunity to make a statement if they wish. (As noted in connection with the proposal relating to the ratification of the appointment of the Corporation’s independent registered public accounting firm, asuch representative of KPMG LLP will be available in view of KPMG LLP having recently been appointed to replace KPMG Audit as a result of some internal restructuring that has happened within the KPMG corporate group.)wishes.
| | 7 |
Do Directors attend the 2018 Annual Meeting of Stockholders?Meeting?
Our Corporate Governance Guidelines provide that Directors are expected to attend our annual meetings of stockholders and any special meeting of stockholders called by Innospec to consider extraordinary business transactions. Unless they are unable to do so as a result of special circumstances, Directors are encouraged to attend all other special meetings of stockholders called by Innospec. All of our Directors then in office telephonically attended the 20172020 Annual Meeting of Stockholders that was held on May 10, 2017.
6,
Can 2020, which was held as a stockholder or interested person communicate directly with our Board? If so, how?
Any stockholder and other interested person who may desire to contact the Chairman or any of the Directors of Innospec may do so via the followinge-mail address:contact.board@innospecinc.com, or by writing to them at Innospec Inc., 8310 South Valley Highway, Englewood, CO 80112, U.S. The Corporate Secretary or the Assistant General Counsel will review communications received electronically and forward themvirtual meeting due to the addressee of the communication. The Corporate Secretary will review the communications received by mail or courier and forward to the appropriate addressee.COVID -19 pandemic.
Whom should I call if I have any questions?
If you have any questions about the 2018 Annual Meeting, of Stockholders, voting or directions to attend the 2018 Annual Meeting, of Stockholders, please contact Mr. David B. Jones, Innospec’s Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary, at303-792-55541-303-792-5554 or atdavid.jones@innospecinc.com.
7
| | 8 |
Corporate Governance Highlights
We are committed to good corporate governance, which promotes the long-term interests of our stakeholders, strengthens Board and management accountability, and helps build public trust in the Company. The Corporate Governance section below describes our governance framework, which includes the following highlights:
Our Corporate Governance Framework
Corporate Governance Principles
Innospec places the strongest emphasis on high standards of Corporate Governance. We have policies to guide all of our employees, Directors and third party representatives and provide extensive training to assure that we operate to these standards throughout the Company. Through its Nominating and Corporate Governance Committee, the Board evaluates our corporate governance policies and practices, which form our corporate governance framework, against evolving best practices as benchmarks for assessing that we follow appropriate standards when conducting our business.
| | 9 |
One of the cornerstones of our Corporate Governance is transparency. Accordingly, you will find the following key policies and procedures on our website under the heading Corporate Governance at www.innospecinc.com/about-us/corporate-governance:
Anti-Corruption Policy
Corporate Governance Guidelines
Audit Committee Charter
Compensation Committee Charter
Nominating and Corporate Governance Committee Charter
Conflict Minerals Policy
Code of Conduct
Innospec Supplier Code of Conduct
Director Independence Policy
Gifts, Hospitality, Charitable Donations and Sponsorship Policy
Reporting Governance Concerns
Also available on our website are this Proxy Statement, our 2020 Annual Report on Form 10-K and our latest Responsible Business Report, being our 2019 report.
Corporate Governance Guidelines
Our Board of Directors believes that adherence to sound corporate governance policies and practices is important in ensuringso that the CorporationCompany is governed and managed with the highest standards of responsibility, ethics and integrity and intaking into account the best interests of the stockholders.all stakeholders. We have adopted a set of Corporate Governance PrinciplesGuidelines intended to reflect a set of core values that provide the foundation for our governance and management systems and our interactions with others.
Our Corporate Governance Guidelines address key governance matters, including, but not limited to:
Ø | Selection and composition of the Board; |
Ø | Director orientation and continuing education; |
Ø | Board membership criteria and selection process; |
Ø | Board operations, including the size of the Board and Board independence; |
Ø | Director responsibilities; |
Ø | Executive sessions of non-management Directors; |
Ø | Performance evaluations of the Board, Committees of the Board and individual Directors; |
Ø | Director compensation; |
Ø | Director access to management and outside advisors; |
Ø | Management succession; |
Ø | Resignation policy in uncontested Director elections; and |
Ø | Limits on Board members serving on other public company boards. |
The Board of Directors believes that corporate governance is an evolving process and periodically reviews and updates the Corporate Governance Guidelines. A current copy of those principlesthe Corporate Governance Guidelines can be found on our website under the
| | 10 |
heading Corporate Governance atwww.innospecinc.com/about-us/corporate-governance, or by writing to Mr. David B. Jones, Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at Innospec Inc., 8310 South Valley Highway, Suite 350, Englewood, CO 80112, U.S.80112.
Corporation’sInnospec’s Leadership Structure
The Board believes that the roles of Chairman of the Board (anon-executive position) and Chief Executive Officer (“CEO”) should remain separate so as to enable the Board to provide effective guidance to management and promote oversight and accountability of management. This separation preserves the distinction between the management and oversight functions, maintaining the responsibility of management to help develop corporate strategy and the responsibility of the Board to review and provide input on corporate strategy.
To fulfilfulfill the role, the Chairman of the Board, among other things: creates and maintains an effective working relationship between the Board and the Corporation’sCompany’s management; provides the CEO withon-going direction as to current Board needs, interests, views and expectations; and ensures thatdirects the Board agenda is appropriately directed to the matters of greatest importance to the Corporation.
The duties of thenon-executive Chairman of the Board include:Innospec.
The duties of the non-executive Chairman of the Board include: Øpresiding over |
| preparing the agenda for Board meetings in consultation with the CEO, CFO and other members of the Board; |
| calling and presiding over meetings of the independent Directors; |
Øco-ordinating periodic review of management’s strategic plan for the Ø |
after consulting with other Board members and the CEO, making recommendations to the Nominating and Corporate Governance Committee as to the membership of various Board |
| managing the Board’s process for Director self-assessment and evaluation of the Board; |
| presiding over |
| encouraging active participation by each member of the Board; and |
| performing such other duties and services as the Board may require. |
The Board’s Role in Risk Management
The Board’s role in risk oversight and management is consistent with the Corporation’sour leadership structure, with the CEO and other members of senior management having responsibility for assessing and managing the Corporation’sCompany’s risk exposure, and the Board and its committees providing oversight in connection with these efforts. Risk management is an integral part of Board and committee deliberations throughout the year. AsDuring 2020, the Senior Vice President, Corporate Development and Investor Relations, presented a partsummary of its general oversight function,the risks facing the Company at each Board meeting so the Board monitorscould discuss and evaluates how management operatesassess the Corporation. When making any decisions and approving strategies the Board considers, among other things, thekey risks and exposure the Corporation faces, including operationalmanagement of them on a timely and regulatory risks, their relative magnitude and management’s plan for mitigating these risks. The Audit Committee considers risk issues associated with the Corporation’s overall financial reporting, disclosure process and financial compliance. In
8
| | 11 |
addition to its regularly scheduled meetings, the Audit Committee meets with the Chief Financial Officer (“CFO”), the Head of Business Assurance and the independent registered public accounting firm in executive sessions at least quarterly. The Nominating and Corporate Governance Committee discusses legal and compliance risks and issues at its regularly scheduled meetings and meets with the Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary during such meetings, including with respect to promoting compliance with anti-corruption and other important applicable laws. The Audit Committee and the Board annually review an assessment of the primary operational and regulatory risks facing the Corporation, their relative magnitude and management’s plan for mitigating these risks, including cybersecurity risk. In addition, the Board discusses risks related to the Corporation’s business strategy at periodic strategic planning meetings and at other meetings as appropriate.Risk oversight - Who is responsible?
| | 12 |
| | 13 |
The Board, of Directors, after considering broadly all relevant facts and circumstances of which it is aware, including those matters set forthout below under Information about the Executive Officers – Family Relationships“Family Relationships” and under “Certain Other“Related Person Transactions and Relationships”, has determined that all of itsnon-executivenon-employee members are independent, within the meaning of the NASDAQNasdaq Marketplace Rule 5605(a)(2) applicable on the date of this Proxy Statement.
We have also adopted our own standards for director independence that can be found onin our web sitewww.innospecinc.com/about-us/corporate-governance.Director
The Board has determined that each member of the Board, who served during 2017
Independence Policy on our website at www.innospecinc.com/about-us/corporate-governance. The Board has determined that each member of the Board, who served during 2020 and/or who currently serves, except for Mr. | ALL OF OUR NON-EMPLOYEE DIRECTORS ARE INDEPENDENT |
President and CEO, he is an employee of Innospec. In addition, as part of the Corporation.independence determination, the Board monitors the independence of Audit and Compensation Committee members under rules of the SEC and Nasdaq listing standards that are applicable to members of the Audit Committee and the Compensation Committee.
No immediate family relationship exists between any of our Directors or Executive Officers and any other Directors or Executive Officers.
Related Person Transactions and Relationships
Mr. Williams, our President and CEO and Director of the Company, has been a non-executive director of AdvanSix Inc., a chemicals manufacturer, since February 2020. In 2020, the Company purchased product from AdvanSix Inc. for $335,987.
| | 14 |
The Company has retained and continues to retain Smith, Gambrell & Russell, LLP, a law firm with which Mr. Paller is Of Counsel. During the fiscal year ended December 31, 2020, the Company paid Smith, Gambrell & Russell, LLP, $767,526 in fees for services provided during the period.
Mr. Landless is a non-executive director of Ausurus Group Limited, which owns European Metal Recycling Limited (“EMR”). In 2020, the Company’s subsidiary, Innospec Limited, sold scrap metal to EMR for a value of $220,181. A tendering process is periodically operated by Innospec to select the best buyer for the scrap metal.
Related Person Transactions Approval Policy
Pursuant to our Code of Conduct, all senior officers must disclose to the Board any material transaction or relationship that could reasonably be expected to give rise to a conflict of interests. The Code of Conduct also states that no employee may seek to obtain special treatment from Innospec for family members, friends or for businesses in which family members or friends have an interest. During the year ended December 31, 2020, the Company did not make any charitable contributions to any charity on which any Director serves as an executive officer.
Executive Sessions of Independent andNon-Management Directors
Executive sessions of independent andnon-management Directors are led by the Chairman. An executive session is held in conjunction with each regularly scheduled Board meeting and other sessions may be called by the Chairman at his discretion or at the request of the Board. There were four executive sessions of independent non-management Directors during the fiscal year 2017.2020.
The Board will continue to monitor the standards for director independence established under applicable law or NASDAQNasdaq listing requirements and will ensure thatmaintain the Corporation’sCompany’s Corporate Governance PrinciplesGuidelines so they continue to be consistent with those standards.
Board CommitteesIdentifying and evaluating nominees for Director
The Board maintains the following committees to assist it in discharging its oversight responsibilities. The current membership of each committee is indicated under “Board Committee Membership” below:
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
|
The Audit Committee operates pursuant to a written Audit Committee Charter, and is responsible for monitoring and overseeing the Corporation’s internal controls and financial reporting process, the
9
independent audit of the Corporation’s consolidated financial statements by the Corporation’s independent registered public accounting firm, KPMG Audit (KPMG LLP from March 2018), and the other responsibilities detailed in its Charter, including assisting the Board with its oversight of legal and regulatory compliance requirements. A current copy of the Audit Committee Charter is available on our website under “Corporate Governance” at:www.innospecinc.com/about-us/corporate-governance.
The Audit Committee members are Mr. Landless Mr. Aldous and Mr. Roeser. Mr. Landless was appointed Chairman of the Audit Committee on May 4, 2016, when Mr. Hale, the previous Chairman, retired from the Board. Mr. Aldous was appointed to the Audit Committee on February 15, 2005. Mr. Roeser was appointed to the Audit Committee on May 9, 2012.
Each of the members of the Audit Committee meets the criteria for director independence required under the NASDAQ’s Marketplace Rules.
All Audit Committee members possess the required level of financial literacy and are independent for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and NASDAQ rules. The Board of Directors has determined that each of Messrs. Landless and Aldous qualify as “Audit Committee Financial Experts”, as such term is defined in Item 401(h) of RegulationS-K, and meet the standard for financial expertise as required by NASDAQ. In the case of Mr. Landless, the Board made this determination based on Mr. Landless’ qualification as a chartered management accountant and his experience as Group Finance Director of Bodycote plc and before that Finance Director of Courtaulds Coatings (Holdings) Limited. He also has direct experience as aNon-Executive Director and Audit Committee Chair of Luxfer Holdings plc as well as Audit Committee Chair of Reynold plc. In the case of Mr. Aldous, the Board of Directors made the determination based on Mr. Aldous’ qualification as a chartered accountant and his previous role as a partner and Chief Executive Officer of Robson Rhodes LLP, Chartered Accountants and partner of Grant Thornton LLP, Chartered Accountants.
The Corporation’s independent registered public accounting firm reports directly to the Audit Committee. The Corporation’s Business Assurance group also reports directly to the Audit Committee.
The Audit Committee meets with management and the Corporation’s independent registered public accounting firm prior to the filing of the CEO and CFO’s certifications with the SEC to receive information concerning, among other things, significant deficiencies or material weaknesses in the design or operation of internal controls.
Any stockholder or employee may submit at any time a good faith complaint regarding any questionable accounting, internal accounting controls, or auditing matters concerning the Corporation without fear of dismissal or retaliation of any kind. Employees are encouraged to report their concerns and complaints to the Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary or to the Audit Committee. Confidential, anonymous reports may be made by writing to: Mr. David B. Jones, Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary, 8310 South Valley Highway, Englewood, CO 80112, U.S. The Audit Committee has adopted a Complaint Monitoring Procedure Policy to enable confidential and anonymous reporting to the Audit Committee. All complaints received by the Corporation regarding accounting, internal accounting controls or auditing matters will be retained in accordance with the Corporation’s document retention policy.
The Corporation limits the number of Audit Committees of SEC reporting companies on which its Audit Committee members may serve to three or less.
The Audit Committee Report appears later in this Proxy Statement.
10
Compensation Committee
The Compensation Committee operates under a written Compensation Committee Charter that governs its duties and standards of performance. A copy of the Compensation Committee Charter is available on our website under “Corporate Governance” at:www.innospecinc.com/about-us/corporate-governance.
The Compensation Committee members are Mr. Roeser, Mr. Blackmore and Mr. Padfield. The Compensation Committee reviews management compensation programs, recommends compensation terms and agreements for senior Executive Officers to the Board for Board approval, reviews changes in compensation for senior Executive Officers andNon-Executive Directors (“NEDs”) and administers the Corporation’s stock option plans. Mr. Roeser was appointed to the Compensation Committee on July 28, 2008, and became its Chairman on October 1, 2009. Mr. Blackmore was appointed to the Committee on June 1, 2010. Mr. Padfield became a member of the Committee upon his appointment on December 1, 2012.
Each of the Compensation Committee members meets the criteria for director independence required under the NASDAQ Marketplace Rules.
The Compensation Committee Report appears later in this Proxy Statement.
Compensation Committee Interlocks and Insider Participation
During 2017 no Compensation Committee members were officers or employees of the Corporation, were former officers of the Corporation or were engaged in transactions with a related person that would be required to be disclosed by relevant SEC rules.
In addition, during 2017 none of the Corporation’s Executive Officers served as directors or board committee members of other entities where any executive officers served as a Director of the Corporation or as a member of any of the Corporation’s Board Committees.
Nominating and Corporate Governance Committee
The purpose of the Nominating and Corporate Governance Committee is to identify individuals qualified to become Board members consistent with criteria approved by the Board, recommend to the Board the persons to be nominated by the Board for election as Directors at the 2018 Annual Meeting of Stockholders, develop and recommend to the Board a set of corporate governance principles and oversee the evaluation of the Board and management. The Nominating and Corporate Governance Committee monitors the work of Legal and Compliance in ensuring observance of those principles.
The members of the Nominating and Corporate Governance Committee are Mr. Aldous, Mr. Blackmore and Mr. Paller. Mr. Aldous was appointed to the Nominating and Corporate Governance Committee on July 28, 2008, as its Chairman. Mr. Blackmore was appointed to the Nominating and Corporate Governance Committee effective May 9, 2012. Mr. Paller originally served on the Nominating and Corporate Governance Committee between November 16, 2009 and April 26, 2013 and was subsequentlyre-appointed on February 17, 2015.
The Nominating and Corporate Governance Committee also plays an advisory role to the Board in helping shape the corporate governance policy of the Corporation which extends to involvement in promoting legal compliance by the Corporation, including through meetings and reviews with the Corporation’s Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary with respect to anti-corruption and other important laws that are applicable to the Corporation and its business, and providing an assessment of that review to the Board.
11
Each of the members of the Nominating and Corporate Governance Committee meets the criteria for director independence required under the NASDAQ Marketplace Rules.
The Nominating and Corporate Governance Committee operates under a written Nominating and Corporate Governance Committee Charter that governs its duties and standards of performance. A current copy of the Nominating and Corporate Governance Committee Charter is available on our website under the heading Corporate Governance at:www.innospecinc.com/about-us/corporate-governance.
The Nominating and Corporate Governance Committee uses a variety of methods for identifying and evaluating nominees for Director. The Nominating and Corporate Governance Committee considers each person’s judgement,judgment, experience, independence, understanding of our business or other related industries and such factors as the committee determines relativerelevant in light of the needs of the Board of Directors and the Corporation.Company. The Nominating and Corporate Governance Committee reviews the skills and attributes of Board members within the context of the currentmake-up of the full boardBoard and regularly assesses the appropriate size of the Board and whether vacancies on the Board are expected due to retirement or otherwise.
In the event that vacancies are anticipated, or otherwise arise, the Nominating and Corporate Governance Committee considers potential candidates for Director. Candidates may come to the attention of the Nominating and Corporate Governance Committee through current Board members, professional search firms, stockholders or other persons. It isIn addition, during 2019 and 2020, the Board’s policyNominating and Corporate Governance Committee retained a professional search firm to takeassist in identifying and evaluating potential candidates for nomination at the Annual Meeting. In line with our Board Diversity Policy, the Board considers diversity into account in the nominating process, as a specific consideration, along with other criteria, for potential Director candidates.candidates and specifically requests that females and minority candidates are included in every Director search pool. The recruitment specification for new Directors concentrates on candidates who are seasoned executive officers, with significant relevant experience, both at board level and within industry.relevant industries.
These
| | 15 |
The Director candidates are evaluated at regular or special meetings of the Nominating and Corporate Governance Committee and may be considered at any time during the year. The nominees for election at this year’s Annual Meeting of Stockholders were recommendedapproved for nomination by NEDsthe Board upon the recommendation of the Corporation.Nominating and Corporate Governance Committee.
Our Director recruitment process is as follows:
The policy of the Nominating and Corporate Governance Committee is to consider properly submitted stockholder nominations for election to the Board as described in the Corporate Governance Guidelines which may be found on the Corporation’s website under the heading Corporate Governance at:www.innospecinc.com/about-us/corporate-governance.Board. In order for any candidate to be considered by the Nominating and Corporate Governance Committee, and if nominated, included in the Proxy Statement, such recommendation should be received no later than the deadline for submission of stockholder proposals. See “Stockholders’ Proposals for the 20192022 Annual Meeting of Stockholders”. Recommendations should be sent to the Corporate Secretary and should specify the nominee’s name, qualification for Board membership and any
| | 16 |
other information required by the Corporation’sCompany’s Bylaws. All properly submitted stockholder proposalsnominations for Director Nomineescandidates received by the Corporate Secretary will be submitted to the Nominating and Corporate Governance Committee for review and consideration. The Nominating and Corporate Governance Committee will consider stockholder recommendations for Director candidates, but the Nominating and Corporate Governance Committee has no obligation to recommend such candidates. Assuming that appropriate biographical and background information (including qualifications) is provided for Director candidates recommended by stockholders, the Nominating and Corporate Governance Committee will use the same process to evaluate Director nominees recommended by stockholders as it does to evaluate nominees identified by other sources.
Director On-boarding and Continuing Education
Overview:
The Board and management conduct orientation for new Directors to become familiar with, amongst other things, Innospec’s business operations, strategies, financial matters, ethics, fiduciary duties, corporate governance and all other Company policies. It is the responsibility of management and the Nominating and Corporate Governance Committee to advise Directors about continuing education opportunities, which they are encouraged to pursue. The Legal and Compliance Department provides training to the Board at least annually and the Chief Compliance Officer regularly updates the Nominating and Corporate Governance Committee and full Board on evolving law, best practices and stockholder expectations.
Orientation:
When new Directors join the Board, they participate in a comprehensive on-boarding program to learn about our industry, business, strategies and policies. Our on-boarding program includes provision of reading material regarding director duties and responsibilities, meetings with division heads and senior executives to discuss our businesses, strategy, operations and our corporate functions such as finance, information technology, research and development and legal and compliance. New Directors also meet with the executives and staff supporting the Committees on which they sit, and are provided with information and training specific to the Board Committee(s) they are appointed to. In addition, every Director has to complete induction training on compliance within two weeks of being appointed and a more in depth training once they have been in office for six months.
Continuing education:
For continued education regarding our business and industry, at least annually, we provide presentations by internal and external experts during our regular Board meetings on topics such as, industry trends, risks facing the industry and the Company, corporate governance trends and key topics, and stakeholder expectations with particular focus on the implications and impact on the Company. In 2020, the Board received training on the following topics: environmental, social and governance, unsolicited offer process and stockholder expectations regarding board composition.
In 2017,2020, all Board and Committee meetings, with the exception of the February Board and Committee meetings, were held virtually due to the COVID-19 pandemic. The full Board met seventwelve times (including three times by conference call)(eight of those twelve meetings being special meetings), the Audit Committee met eight times (including four times by conference call)(and held four pre-meeting
| | 17 |
preparation calls), the Compensation Committee met fivesix times (including once by conference call), and the Nominating and Corporate Governance Committee met four times.times (and held four pre-meeting preparation calls). There were four Non-Executive Director Committee meetings. Directors are expected to attend all Board Meetings and meetings of Committees on which they serve. Directors are expected to attend all meetings of stockholders. All of the Directors attended the 2017 Annual Meeting of Stockholders. During the year ended December 31, 20172020, each of the Directors attended, in person, by telephone or by teleconference,video call, all the meetings of the Board and meetings of Committees of the Board on which he or she served that were held while he or she was a member. Directors are also expected to attend all meetings of stockholders. All of the Directors attended the 2020 Annual Meeting of Stockholders, which was held as a virtual meeting due to the COVID-19 pandemic.
Limitation on Other Board and Audit Committee Positions
The Board has adopted restrictions on the number of outside boards on which Directors may serve that are consistent with market standards and regulatory requirements, including limits on executive officers of publicly-traded companies. To help ensure Directors are able to dedicate sufficient time to Innospec’s Board, the Board established the following limits on our Directors serving on publicly-traded company boards and audit committees:
Director Category | �� | Limit on publicly-traded company board and audit | ||
Non-employee directors who are not full-time employees of a publicly-traded company | 4 public company boards maximum | |||
Board members who are full-time employees of a publicly-traded company | 2 public company boards maximum | |||
Non-employee directors who serve on Innospec’s Audit Committee | 3 audit committees maximum |
12Any Board member wishing to join the board of another publicly-traded company is required to first notify the Chair of the Nominating and Corporate Governance Committee, the Chairman of the Board, and Innospec’s General Counsel and Chief Compliance Officer prior to joining such other board or agreeing to be nominated or serve on a director slate at such other board. The Chair of the Nominating and Corporate Governance Committee and General Counsel and Chief Compliance Officer will review the proposed board membership to confirm compliance with applicable laws and policies. Potential conflicts of interest, if any, will be referred to the Chairman of the Board for review.
The Board has adopted a Code of Ethics,Conduct, violations of which may be reported to the ChairmanChair of the Nominating and Corporate Governance Committee or the Corporate Secretary. This Code of EthicsConduct is intended to
| | 18 |
promote, among other things, honest and ethical conduct, full and accurate reporting and compliance with applicable laws and regulations. A copy of the Code of EthicsConduct is available on our website under the heading Corporate Governance“Corporate Governance” at:www.innospecinc.com/about-us/corporate-governance.
Copies ofSupplier Code of Ethics, Corporate Governance GuidelinesConduct
Innospec believes that honest and Committee Charterstransparent business conduct is vital and is committed to ethical business practices and actively enforcing compliance with all applicable laws, regulations and rules. We have therefore adopted a Supplier Code of Conduct, pursuant to which our suppliers are required to comply with all applicable laws, rules and regulations, including those related to business integrity, human rights and safety, health and the environment. In addition, Innospec engages EcoVadis to conduct sustainability and risk assessments of its key suppliers and those operating out of high risk locations. Among other things, EcoVadis provides ongoing assessments to evaluate supplier policies and actions to enforce compliance with internationally recognized human rights standards and fair labor practices. Since December 2018, all new raw materials suppliers, regardless of location, are also required to undergo an EcoVadis assessment if the Company forecasts that its annual expenditures to such supplier will be above minimum value thresholds designated by the Company.
Any stockholder who requires aWe also have an internal protocol to support our review of, and response to, concerns raised regarding our supply chain. Innospec may invoke sanctions against suppliers, up to and including termination of the business relationship, if they violate modern slavery laws.
A copy of the Supplier Code of Ethics, CorporateConduct is available on our website under “Corporate Governance” at: www.innospecinc.com/about-us/corporate-governance.
Raising Issues and Reporting Violations
Our employees play a critical role in promoting and upholding our culture of compliance. We are committed to creating an environment in which employees and stakeholders may raise good faith concerns regarding any suspected illegal, fraudulent or unethical actions without fear of retaliation. If any employee believes that individuals have conducted or are conducting Innospec business in violation of Innospec’s Code of Conduct, the law or our other policies, they may report the suspected misconduct by following the procedures set out in our Reporting Governance GuidelinesConcerns policy without fear of dismissal or retaliation of any ofkind. Employees are encouraged to report their concerns and complaints via various channels including to the Board Committee charters may obtain one by writing to Mr. David B. Jones, Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary, atthe Nominating and Corporate Governance Committee or Global Compliance Counsel. Confidential, anonymous reports may also be made by employees emailing our dedicated EthicsPoint reporting system or calling our EthicsPoint confidential reporting hotline. A copy of our Reporting Governance Concerns Policy can be found on our website under “Corporate Governance” at: www.innospecinc.com/about-us/corporate-governance.
No Retaliation on Reporting Issues or Violations
Our Reporting Governance Concerns Policy states that we will not retaliate against anyone who acts in good faith to report concerns or to help address an issue or concern, including individuals making reports as well as witnesses interviewed during an investigation. Our employees and representatives may not retaliate against, intimidate, coerce, threaten, or discriminate against any individual who reports a legitimate suspicion or concern of misconduct. Innospec Inc., 8310 South Valley Highway, Englewood, CO 80112, U.S. These documentstreats violations of the anti-retaliation policy as serious offenses, which may be grounds for dismissal.
| | 19 |
Our Stock Trading Policy contains an anti-hedging provision that prohibits directors, officers and employees from hedging any stock, share or other securities issued by Innospec, (including through the use of financial instruments, such as prepaid variable forward contracts, equity swaps, collars and exchange funds) or otherwise engage in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of any stock, share or other securities, issued by the Company.
Our Stock Trading Policy contains a provision that prohibits directors, officers and employees from holding any stock, share or other securities issued by the Company in a margin account, or from otherwise pledging such securities as collateral for a loan, unless the person obtains approval in advance from the Nominating and Corporate Governance Committee. No approval will be granted unless that person clearly demonstrates the financial capacity to repay the loan (which must not constitute margin debt) without resorting to the pledged securities (pledges arising from certain types of hedging transactions are governed by the anti-hedging policy described above).
Copies of Code of Conduct, Corporate Governance Guidelines and Committee Charters
Copies of our Code of Conduct, Corporate Governance Guidelines and each of the Board Committee charters can also be accessed via the Corporation’sCompany’s website under “Corporate Governance” at:www.innospecinc.com/about-us/corporate-governance. The CorporationCompany intends to disclose on this section of its website any amendments to, or waivers from, its Code of EthicsConduct that are required to be publicly disclosed pursuant to the rules of the SEC or NASDAQ.Nasdaq.
Any stockholder and other interested person who may desire to contact the Chairman or any of the Directors of Innospec may do so via the following e-mail address: contact.board@innospecinc.com, or by writing to them at Innospec Inc., 8310 South Valley Highway, Suite 350, Englewood, CO 80112. The Corporate Secretary or the Assistant General Counsel will review communications received electronically and forward them to the addressee of the communication. The Corporate Secretary will review the communications received by mail or courier and forward to the appropriate addressee.
| | 20 |
The Board maintains the following committees to assist it in discharging its oversight responsibilities. The current membership of each committee is:
Board Member | Audit Committee | Compensation Committee | Nominating and Corporate Governance Committee | |||
Ms. Elizabeth K. Arnold | Member | |||||
Mr. Milton C. Blackmore | Member | Member | ||||
Mr. David F. Landless | Chair | Member | ||||
Mr. Lawrence J. Padfield | Chair | Member | ||||
Ms. Claudia P. Poccia | Member | Chair | ||||
Number of meetings in 2020: | 4 (and 4 pre-meeting preparation calls) | 6 | 4 (and 4 pre-meeting preparation calls) |
Audit Committee Financial Expert
| | 21 |
*In the case of Mr. Landless, the Board made this determination based on Mr. Landless’ qualification as a chartered management accountant and his previous experience as Group Finance Director of Bodycote plc. and before that, Finance Director of Courtaulds Coatings (Holdings) Limited. He also had direct experience as Chairman and member of the Audit Committee of Luxfer Holdings plc. as well as Audit Committee Chair of Renold plc.
In the case of Ms. Arnold, the Board made this determination based on Ms. Arnold’s qualifications and previous experience as Chief Financial Officer of Houghton International, Chief Financial Officer of Physiotherapy Associates and Chief Financial Officer of Tyco Flow Control and before that Chief Financial Officer of GE Silicones General Electric. Ms. Arnold also has experience as Audit Committee Chair at FreightCar America Inc.
** The Audit Committee comprised at least three members at all times during 2020, as required by our Audit Committee Charter.
| | 22 |
| | 23 |
| | 24 |
Board and Committee Self-Evaluations
Each year, the Nominating and Corporate Governance Committee oversees the Board, Committee and Director self-evaluation process. The Company’s management also assess the Board. The process is as follows:
The restrictions on travel and meetings driven by the COVID-19 pandemic created a wholesale change to the way we engaged with stockholders in 2020, with both conference and non-deal roadshows being forced very quickly into remote or virtual meetings.
Despite the inevitable early technology challenges, companies and investors alike seem to have settled into the new norm. After one face-to-face conference in New York in January, Innospec participated in six virtual conferences and one virtual non-deal-roadshow. This has allowed us to reach over 60 investor groups during the year, including the majority of our actively-managed largest investors.
The Company was represented by a minimum of two, and often three, of the senior executives comprising the CEO, the CFO, the Senior Vice-President, Corporate Development and Investor Relations and the Vice-President, Corporate Development and Investor Relations. In each case, an updated presentation was produced covering the business performance, the strategy and the financial management of the Company. This presentation was concurrently updated on the Company’s website so that all investors had access to the same information.
The virtual format has allowed us to involve a wider range of our own employees from a personal development and succession planning perspective and we have been able to include five additional senior managers in the process.
The Company’s senior management team also engaged with a wide range of investors and analysts in telephone calls, often focused in the period soon after the publication of quarterly results.
| | 25 |
As well as business performance and strategy, other issues were discussed as raised by investors. These included leadership, succession planning and compensation mechanisms and environmental, social responsibility and governance matters, as outlined in the Innospec Responsible Business Report for 2019, which is also available on the Company’s website at: www.innospecinc.com/about-us/corporate-social-responsibility/sustainability/sustainability-reports.
| | 26 |
ENVIRONMENTAL, SOCIAL AND GOVERNANCE (“ESG”)
Our Strategic Approach to ESG
As a global specialty chemical company, Innospec understands that the way we conduct our business is essential to the long-term success of Innospec. Our ESG strategy is built across the four pillars of responsible business: economic, social, environmental and governance. Within each of these pillars, we define our core values and the areas of focus that target the issues that matter most to our stakeholders. We believe this approach reflects our stakeholders’ priorities and demonstrates our commitment to striving to grow our business in what we believe to be a sustainable and socially responsible manner.
| | 27 |
Sustainability and ESG
Our Corporate Social Responsibility (“CSR”) program is overseen by the Board and our Responsible Care Executive Committee (“RESPECT”). RESPECT comprises of members of the senior leadership team who set annual CSR objectives in line with Innospec’s focus areas and meet quarterly to monitor progress towards achieving them.
ESG Performance Highlights from our 2019 Responsible Business Report
Health, Safety & Wellbeing | Community Engagement | |
• 9% decrease in accidents since 2018 • Active Near Miss reporting program for near miss incidents (defined as a learning event that did not cause harm but had the potential to cause injury or loss), with 9,743 Near Misses raised in 2019 • Innospec 2019 Employee Reportable Lost Time Accident Frequency Rate 0.07 per 100,000 hours – better than industry average of 0.15 • Process safety systems, procedures and leadership targeting the prevention of major accident hazard events • Behavioural safety program Journey to Zero Harm rolled out to all employees • Wellbeing support, training and advice offered to employees | • Over $0.5 million raised for 130 charities and good causes in 2019 • Innospec Cares, our global charitable program that enables employees to support their chosen charitable organizations through financial giving and volunteering days • Over $1million raised for the Penfed Foundation Military Heros Fund since 2007 • Over $400k donated by our European Fuel Specialties Business in Europe to the German Association for the Protection of Forests and Woodlands since 2008 • Engagement with schools and educational centers to help raise the awareness of careers in science and chemical industry | |
Environment | Governance | |
• Reducing our impact on the environment § 5% reduction in absolute scope 1 & 2 GHG emissions since 2018 and 25% since 2006 § 4% reduction in energy use since 2018 and 21% since 2006 § 1% reduction in water usage since 2018 and 53% since 2006 § Use of renewable electricity at European manufacturing sites since 2020 | • Regular Board and Executive Team oversight of environmental, social and governance issues • 2,100 employees and 465 third parties enrolled in our online compliance training and certification program • Sustainable Supply Chain § EcoVadis assessment incorporated into our supplier evaluation and approval process. Innospec’s supply chain continues to score better than the EcoVadis Average |
| | 28 |
• Verified performance § CDP Supply Chain Disclosure Program 2019 ○ Climate – Performance band score of B: Management - above program global average of C: Awareness ○ Water Security – Performance band score of B-: Management - at the program global average of B-: Management EcoVadis Supply Chain CSR Assessment – Gold medal Ranking status for 2019 | § Sustainable sourcing of palm program ○ Membership of Roundtable on Sustainable Palm Oil (RSPO) since 2013 and MB supply chain certified at all applicable manufacturing sites ○ Increased transparency of our palm based supply chain through our annual transparency and risk mapping assessment ○ Member of the Action for Sustainable Derivatives (ASD), a new collaborative initiative that is working to maximize sustainability throughout the palm supply chain | |
Sustainable Innovation | • $35.4 Million investment in product development and application • Provision of safe, sustainable products designed to meet the needs of society, while minimizing their environmental impact in manufacture and use • Expansion of existing R&T capability with new facilities at our Castiglione, Italy, Ellesmere Port, U.K. and Houston TX and Salisbury, NC, U.S. sites |
| | 29 |
Working towards the UN Sustainable Development Goals
Innospec recognizes that the private sector plays an important role in achieving the United Nations Sustainable Development Goals (“SDGs”) which address the world’s most important economic, social and environmental challenges. We have identified 13 of these goals that we can directly contribute to:
SDGs we contribute the most to: | Other SDGs we contribute to: | |
| | 30 |
ESG and Corporate Social Responsibility Reporting
As part of our commitment to being open and transparent about our performance, our latest Responsible Business Report, being our 2019 Report, was independently assured to assess its adherence to the globally recognized AA1000 Assurance Standard.
The Responsible Business Report, along with further information on our sustainability program and performance is available online in the “Corporate Social Responsibility” section of the Company’s website at https://innospecsustainability.com.
We work hard to | Human capital management is critical to Innospec’s ongoing business success. Our aim is to create an engaged and motivated workforce where employees are inspired by leadership, engaged in purpose-driven, meaningful work and have opportunities for growth and development. | |
An effective approach to human capital management requires that we invest in talent, development, culture and employee engagement. We aim to create an environment where our employees are encouraged to make positive contributions and fulfill their potential. |
Core Values & Culture
Our core values are:
Responsible Growth through Innovation and Customer Service: Financial stability and growth are essential to maintain our goal of making a positive contribution towards a more sustainable future. Generating economic benefits for our employees, stockholders, and local communities — encouraging ongoing innovation in our product portfolio alongside excellent customer service will allow our business to be competitive and sustainable.
Caring for People: We strive to create a safe and caring culture where our employees are supported and encouraged to make positive contributions. Our continued success depends on keeping people safe, promoting a healthy lifestyle, protecting human rights, improving education, training and maintaining good relations with our neighbors.
Conserving & Protecting the Environment: We aim to use resources as efficiently as practicable and minimizing the impact of our operations on the environment. We look to supply safe, sustainable products, designed to meet the needs of society now and in the future while minimizing their environmental impact.
Leading by Example: We understand that honest, ethical and transparent conduct is vital to our success and reputation. Every employee plays an essential part in complying with local and national laws, rules and regulations. We uphold a high standard of corporate and business integrity across all of our activities.
| | 31 |
At Innospec, we encourage our people to aspire to a culture that is:
Confident
We know what is expected of us and take responsibility for our own workload. We assume responsibility for making decisions and are flexible in our dealings with people. We take additional responsibility to meet customer needs and enhance performance.
Informed
We take pride in being good at what we do and actively seek to enhance our knowledge and skills to help improve performance. We use our expertise co-operatively to meet customer needs and enhance our performance. We respect each other and listen carefully to understand others’ points of view.
Clear
As an organization, we are open and transparent. We encourage and welcome feedback and we support people to deal with any unwelcome messages.
Innovative
Our people are forward thinking and inspired. We enjoy challenges and encourage new ideas. We seek continual improvement, and care about treating people well through periods of change.
Dynamic
We are performance driven, enthusiastic and quick to respond. We set clear targets and objectives and take satisfaction in achieving them. We want to be part of a successful team and business, and we make decisions quickly and implement them.
Employee Engagement
Attracting Talent. We believe our hardworking team of employees is our greatest asset. We employ approximately 1,900 people across 24 countries and we believe that the skills, commitment and enthusiasm of our employees helps us to deliver long-term growth for investors.
| | 32 |
Across our sites, we provide local support and opportunities for the next generation of talent in our industry by offering a range of placements, internships, work experience and apprenticeships. We strive to attract and retain the best talent in a changing and competitive working environment. | We have a very high | |
Pay and benefits. We offer what we believe are competitive reward and recognition programs, based on both business-wide and individual performance. Our packages have been designed to attract and retain the best employees, reward achievement and encourage our teams to deliver superior performance for our customers and our company. |
In addition to our company-wide performance incentive plans, we encourage our employees to share in the long-term success of our company with incentive programs, such as our Global Sharesave Plan. This plan gives employees the opportunity to participate in a savings plan linked to an option to buy shares in Innospec at a discount and, therefore, benefit from any growth in the share price over the savings period. We also provide a range of other benefits in line with the market practice in each location we operate in, including insurance and pension arrangements.
Performance Management Framework. We conduct an annual performance management process across the organization. Together with their line managers, employees agree upon annual objectives, and, at the end of the year, review with their line manager their performance against those objectives and their overall performance. The results of each annual performance review affect performance bonus amounts, pay reviews and career advancement decisions.
Senior Leadership Communications and Transparency. We actively seek opportunities for regular engagement and communication by our CEO and other senior executives with our broader employee population. Communications are through a variety of means including written communications, webcasts and conference calls. For example, we hold a CEO Call at least once a year, during which the CEO and CFO discuss current issues and developments in the business, including a Q&A session answering questions raised by employees. The CEO Call is accessible to all employees across the Company. In addition to the CEO Calls, each financial quarter, following the quarterly financial results announcement, the CEO and CFO provide a written review of the financial results to all employees.
Diversity and Inclusion
Innospec aims to attract and retain the best people by making employment decisions based on merit, performance and contribution to the Company. As part of our Global HR Policies, our diversity and equal opportunities policy means that current and prospective employees receive equal opportunities irrespective of gender, sexual orientation, race, color, ethnic or national origin, marital status, age, disability, religion or belief.
| | 33 |
Health and Safety
Objectives. We prioritize the safety of employees, communities and everyone involved in the manufacture, use or disposal of our products. We set high standards for process and occupational safety, which is managed by our network of Safety, Health and Environment (“SHE”) professionals throughout the business. SHE is a top priority for Innospec with our three core objectives being that:
by having leadership that comes from executive management. Our Responsible Care Executive Committee (known as RESPECT) comprises members of the senior leadership team and is led by the CEO. RESPECT is responsible for setting the group’s SHE policy and objectives across the global business. It also monitors ongoing performance throughout the year. Through this structure, we have established a strong culture of safety within our organization. The RESPECT group reports to the Board and conducts a major review of objectives and performance annually alongside quarterly interim reviews.
Training. Training is an essential part of our health and safety strategy. To minimize the risk of accident or injury, we give our employees the information they need, delivered effectively and at the appropriate time. Our ongoing training programs demonstrate our commitment to targeting zero accidents, making sure that safety is always front of mind and that we continually raise standards.
Every year, employees across our sites take part in a variety of site-specific training courses to enable them to be competent and safe in their roles.
A copy of the Company’s Safety, Health and Environment Policy can be found on the “Corporate Social Responsibility” section of the Company’s website at https://innospecsustainability.com.
Development and Training
As an organization, we are committed to making Innospec a great company to work for and we invest, as appropriate, in the development of our employees to meet this ambition.
Our employees are offered both internal and external training, where appropriate, to support their continued development and to meet the needs of our business. Where relevant, we support our employees’ ongoing professional training and development to encourage their progression within our business.
The Board is also actively involved in reviewing and approving executive compensation, selections and succession plans so that we have leadership in place with the requisite skills and experience to deliver results the right way. The CEO periodically provides the Board with an assessment of senior executives that have potential as successor for the CEO position, as well as perspectives on potential candidates for other senior management positions.
| | 34 |
Further information on our human capital management initiatives is available in our annual Responsible Business Report, available online in the “Corporate Social Responsibility” section of the Company’s website at https://innospecsustainability.com.
| | 35 |
PROPOSAL 1 – ELECTION OF TWO CLASS II DIRECTORS
(Item 1 on the Proxy Card)
The first proposal to be voted on at the meeting is there-election election of two classClass II directors.Directors. The directorsre-elected elected at this meeting will serve until the 20212024 Annual Meeting of Stockholders. The Board has nominated Mr. Milton C. Blackmore and Mr. Robert I. Paller, current classClass II directors,Directors, whose terms expire at the upcoming Annual Meeting of Stockholders, forre-election election to the Board.
The Bylaws of the Corporation provide that the number of directors shall be not less than three nor more than twelve members, the exact number of which shall be determined from time to time by resolution adopted by the Board of Directors, and that the Board shall be divided into three classes, designated class I, class II and class III. Each class shall consist, as nearly as may be possible, ofone-third of the total number of Directors constituting the entire Board of Directors.
The Bylaws of the Company provide that the number of directors shall be not less than three nor more than twelve members, the exact number of which shall be determined from time to time by resolution adopted by the Board, and that the Board shall be divided into three classes, designated Class I, Class II and Class III. Each class shall consist, as nearly as may be possible, of one-third of the total number of Directors constituting the entire Boards. The Board recommends that you vote “FOR” each Director nominee. The below chart includes this year’s nominees included in Proposal 1, along with their age, tenure, principal occupation and committee membership: Director Since Board Committee(s) Audit If a nominee becomes unable or unwilling to accept nomination or election, the Board will either select a substitute nominee or reduce the size of the Board. If you have submitted a proxy and a substitute nominee is selected, your The Board has no reason to believe that any nominee would be unable or unwilling to serve if elected. According to the Bylaws and Corporate Governance Guidelines, the Nominating and Corporate Governance committee recommended to the Board that the Board submit the Class II Directors to the vote of stockholders. The above-named nominees will be elected to the Board on a plurality of the votes of the shares present Our “Majority Vote” Director Resignation Policy According to the procedure set out in The Board recommends a vote “FOR” all nominees Age Independent Principal
Occupation Other Public Board
Position(s)Mr. Milton C.
Blackmore 73 2010 Compensation
Committee
Committee Retired None Mr. Robert I.
Paller 86 2009 None Attorney - “Of
Counsel” to
the law firm
Smith,
Gambrell and
Russell, LLP None stockshares will be voted for the election of the substitute nominee.(in person or represented by proxy) at the meeting and entitled to vote. However, as described abovemore detail, the Corporation’sour Corporate Governance Guidelines, requires thatin an uncontested election, any nominee for director (including an incumbent director) who receives morea greater number of votes “withheld” from his or her election than votes than “for” votes,such election, the nominee must submit aoffer his or her resignation which is subjectpromptly to acceptance or rejection by the Board following certification of Directors.
13
Biographical information about the nominees is included under “INFORMATION ABOUT THE BOARD OF DIRECTORS” below.stockholder vote. Upon receipt of the resignation, the Nominating and
| | 36 |
Corporate Governance Committee will consider the resignation offer and recommend to the Board whether to accept it. The Board will act on the Nominating and Corporate Governance Committee’s recommendation within 120 days following certification of the stockholder vote. The Nominating and Corporate Governance Committee and the Board may consider any factors they deem relevant in deciding whether to accept a director’s resignation. Thereafter, the Company will promptly disclose the Board’s decision whether to accept the director’s resignation offer (and the reasons for rejecting the resignation offer, if applicable) in a Current Report on Form 8-K furnished to the SEC. This resignation policy does not apply to contested director elections.
| | 37 |
PROPOSAL 2 – RATIFICATION OF ELECTION OF ONE CLASS I DIRECTOR
(Item 2 on the Proxy Card)
The second proposal to be voted on at the meeting is the ratification of the appointment of one Class I Director to serve until the 2023 Annual Meeting of Stockholders. The Board has appointed Ms. Elizabeth K. Arnold, to the Board as a Class I Director on November 1, 2020, with such appointment being submitted for ratification by the stockholders.
Age | Independent | Director Since | Board Committee(s) | Principal Occupation | Other Public Board Position(s) | |||||||||
Ms. Elizabeth K. Arnold | 56 |
| 2020 | Audit Committee | Retired CFO | Non-Executive Director FreightCar America Inc. |
If Ms. Arnold becomes unable or unwilling to accept the ratification, the Board will either select a substitute nominee for director or reduce the size of the Board. If you have submitted a proxy and a substitute nominee is selected, your shares will be voted for the election of the substitute nominee.
The Board has no reason to believe that Ms. Arnold would be unable or unwilling to serve upon ratification.
According to the Bylaws and Corporate Governance Guidelines, the Nominating and Corporate Governance committee recommended to the Board that the Board submit the appointed Class I Director to ratification by a vote of stockholders. Ms. Arnold’s appointment to the Board will be ratified on a plurality of the votes of the shares present (virtually or represented by proxy) at the meeting and entitled to vote.
Please see above in Proposal 1 for details of our “Majority Vote” Director Resignation Policy.
| | 38 |
INFORMATION ABOUT THE INNOSPEC BOARD
Innospec believes that having an independent, active and engaged Board is key to our success. We also believe that new perspectives and ideas are critical to a forward-looking and strategic Board. Our goal is to seek a balance between new points of view and the valuable experience and knowledge that longer-serving directors bring to the boardroom. We believe that we have assembled a Board with varied backgrounds, experiences and viewpoints who understand our markets, customers and employees. The Board seeks a mix of directors with qualities that result in a well-rounded, diverse Board that thinks critically and also functions effectively by reaching informed decisions. Our Directors have a diversity of experience and a variety of skills, education, qualifications and viewpoints that strengthen the Board’s ability to carry out its oversight role of the Company and effectively represent the interests of stockholders.
Since 2015:
all 3 new Directors are independent
2 of the new Directors are women
Board and Committee fast facts:
0 | 65 Years | 7 Years | 100% | |||||||||
No Over-boarded Directors |
Average Director Age |
Average Director Tenure | Independent Board Committee Members |
The table below is a summary of the range of attributes and experiences that each Director brings to our Board. As it is a summary, it is not intended to be a complete description of all of the skills and attributes that each of our Board members possesses.
Additional information about each Director’s background, business experience and other matters, as well as a description of how each individual’s experience qualifies him or her to serve as a director of the Company is provided under the heading “Director Biographies” beginning on page 41.
| | 39 |
Director Skill/Competency |
|
|
|
|
|
|
| |||||||||
Senior Leadership Experience Business and strategic management experience from service in a significant leadership position, such as CEO, CFO or other senior executive role. | • | • | • | • | • | • | • | |||||||||
Financial Literacy Directors with an advanced understanding of finance and accounting provide oversight of the preparation of financial statements and risk management. | • | • | • | • | ||||||||||||
Public Company Board Experience Experience serving on the boards of other public companies, which provides an understanding of corporate governance practices and the dynamics and operation of a corporate board, management accountability and protecting stockholder interests. | • | • | • | • | • | • | ||||||||||
Chemical Industry Experience In-depth knowledge of our industry, operations, and competitive environment. | • | • | • | • | • | • | ||||||||||
Corporate Governance Experience An understanding of corporate governance practices and the dynamics and operation of a corporate board, management accountability and protecting stockholder interests. | • | • | • | • | • | • | • | |||||||||
Manufacturing/Operations Experience Experience in an executive role responsible for the oversight of operations and the development of a business strategy. | • | • | • | • | • | • | ||||||||||
Human Capital Management Experience Experience with compensation, attracting and retaining top talent, development and succession planning. | • | • | • | • | • | |||||||||||
M&A Experience Experience driving strategic direction and growth, including expertise in mergers and acquisitions, capital markets, dispositions, financing, private equity and other business development activities. | • | • | • | • | • | • | ||||||||||
Global Experience Global business experience, including an understanding of diverse business environments, economic conditions, and cultures and a broad perspective on global business opportunities. | • | • | • | • | • | • | ||||||||||
Regulatory/Legal/Compliance Experience Experience interacting with governmental or regulatory entities and/or experience of legal/compliance issues affecting publicly listed companies.
| • | • | • | • | • | • | • | |||||||||
Board Composition | ||||||||||||||||
Age | 56 | 73 | 61 | 86 | 65 | 61 | 56 | |||||||||
Tenure (years) | <1 | 11 | 5 | 12 | 9 | 1 | 12 | |||||||||
Diversity | • | • |
| | 40 |
The following is biographical and other information about our current Directors, including the nominees for election at the 2018 annual meeting.Annual Meeting.
Class I Directors
|
Mr. Hugh G. C. Aldous
Age: 73
DirectorMs. Poccia has been serving as CEO of DragonflySage, a strategic consultancy she founded to advise luxury lifestyle and beauty brands, since January 11,2018, and has over 30 years’ experience in the beauty industry. Most recently, Ms. Poccia was the Chief Marketing Officer and Head of International Business Development of bareMinerals for Shiseido Americas Company, a beauty company, having previously served as President/CEO of Gurwitch Products from 2011 to 2015. Prior to that, Ms. Poccia was Global President, Beauty for Avon Products Inc. from 2009 to 2011, having joined them in 2005
Committees: Nominating and Corporate Governance (Chair) as President for the U.S. beauty business. From 1994 to 2005, Ms. Poccia worked for Estee Lauder Companies Inc., Audit
Mr. Aldous currently serves as Chairman of Downing StrategicMicro-Cap Investment Trust plc, quoted on the London Stock Exchange (appointed 2017) and SPL Guernsey ICC Limited, the umbrella company forin a number of cellssenior executive and business roles including President of Stila Cosmetic and VP of Business Develpment for the Estee Lauder brand. Her early career included seven years at Avon Products Inc., where she held a number of roles in Guernsey, allsales. Ms. Poccia has been Chairman of which he also chairs (appointed December 2009). Mr. AldousLuxie Holdings Inc., a beauty products company since May 2019, a Board member of Fashion Group International, a non-profit organization focusing on the fashion industry, since 2018 and is also aNon-Executive Director of two London listed public companies; Elderstreet Draper Esprit Venture Capital Trust plc (appointed March 2007) and Polar Capital Holdings plc, a parent company that controls an asset management business that includes two SEC registered entities (appointed July 2007). Mr. Aldous was a board member of Blue Mistral, LLC. Ms. Poccia is recognized as a leader in the U.K. Competition Commission from 1998 to 2001beauty industry and was appointed a U.K. Government Inspector of Companies several times between 1987 and 2003. He has authored several reports on corporate governance issues, has served as the audit committee chairperson for several public companies and currently chairs the audit committees of two London public companies (neither of which are SEC listed companies). From 2007 - 2015 Mr. Aldous was Chairman of Capita Sinclair Henderson Limited, a company servicing the fund management industry and a subsidiarynamed one of the London listed Capita Group plc. From 2007 to 2010 Mr. Aldous was Executive ChairmanTop 50 Most Influential People in Beauty by Beauty Inc. She has been the recipient of Melorio plc, a London quoted companyseveral awards in the training industry which was sold to Pearson plc in July 2010. Mr. Aldous wasincluding the Cosmetic Executive Women Achiever Award and Women’s Wear Daily Beauty Biz Award for thirty two years a partner in RSM Robson Rhodes (Chartered Accountants) of which he was CEO from 1987 to 1997 and Grant Thornton U.K. LLP.Innovative Marketer.
Key Attributes, Experience and Skills:
Mr. Aldous
Senior | Public | Chemical | Corporate | Manufacturing | Human | M&A | Global | Regulatory/ Legal/ Compliance |
Ms. Poccia has an in-depth knowledge of the international personal care industry, particularly the beauty sector and has held several senior positions during her career. She brings industry knowledge and marketing expertise to the Company.
For additional detail see our Board Skills Matrix on page 40.
| | 41 |
Ms. Arnold has served as an independent Director of FreightCar America, Inc., a wealth of experience in financial reporting, in the financial services industryrailroad freight car manufacturer, parts supplier and inlessor since 2019, and has served on its audit committee and nominating and corporate governance generally which providescommittee. From October 2014 to 2019, Ms. Arnold served as the BoardSenior Vice President, Chief Financial Officer and Treasurer of Houghton International, a specialty chemical company with an executive and leadership perspective on the management, operations and financial reporting and accounting oversight of a public listed company. As an Inspector of Companies for the U.K. Government he spent many years investigating matters of corporate governance. He also has a great deal of experience of listed companies, particularly in the U.K.
Mr. Joachim Roeser
Age: 64
Director since January 1, 2008
Committees: Compensation (Chair), Audit
Mr. Roeser wasinternational operations. From October 2012 to April 2014, Ms. Arnold served as the Chief ExecutiveFinancial Officer of the Amber Chemical Group, a global specialty silicone producer, owned by Caledonia Investments plc. for eight years, until March 2014. In July 2014 he became a Senior Adviser of Beyond Capital Partners GmbH, a German private equity firm, focussing onmid-size and family companies. He has been a Senior Adviser of Trumont International, a mergers and acquisition advisory firm for the chemicals industry and allied sectors since July 2011. In May 2015 he was appointed aNon-Executive
14
Director of C² Pharma, a global active pharmaceutical ingredients manufacturer/distributor. He wasNon-Executive Chairman of Fluidata Ltd, a business internet service provider company, from January 2007 until March 2015.
Mr. Roeser is a German national and has lived and worked in Belgium, France and Germany, as well as in the U.K. Previously, he was President and Chief Executive Officer of Luzenac, a Rio Tinto subsidiary and the world’s leading talc mining producer, for five years from May 2001 to April 2006.Physiotherapy Associates. Prior to that, Mr. Roeser was European PresidentMs. Arnold served as the Chief Financial Officer of Ferro CorporationTyco Flow Control from April 19982010 to December 2000. He started hisSeptember 2012, having previously served as the Vice President, Corporate Financial Planning & Analysis at Tyco Flow Control from 2003. Earlier in her career, over thirty five years agoMs. Arnold served in the emulsifiernumerous roles, including executive leadership positions, for General Electric, a global high-tech industrial company with products and starch industry before joining ARCO Chemical in 1983, where he held a number of senior management positions, ultimately serving as Global Business Director, Styrene for two years. Mr. Roeser earned his Bachelor of Science degree in Chemical Engineeringservices ranging from the University of Wuppertal.aircraft engines, power generation and oil and gas production to medical imaging.
Key Attributes, Experience and Skills:
Mr. Roeser has held senior positions within the chemicals industry for over thirty five years and brings a wealth of knowledge and expertise in this area as well as a global perspective due to his experience working across Europe, Asia, Australia as well as the U.S.
|
Financial | Public | Chemical | Corporate | Manufacturing/ | Human | M&A | Global | Regulatory/ Legal/ Compliance |
Ms. Arnold has an Mr. Milton C. Blackmorein-depth knowledge of the chemical industry and has held several senior management positions during her career. She brings industry knowledge and financial expertise to the Company.
Age: 70For additional detail, see our Board Skills Matrix on page 40.
Director since June 1, 2010; Chairman since May 9, 2012Class II Directors
Committees: Compensation, Nominating and Corporate Governance
Mr. Blackmore serves asNon-Executive Chairman of the Corporation.Company. Mr. Blackmore was most recently the Senior Vice President, Marketing and Product Supply for Sinclair Oil Corporation, one of the largest independent oil companies in the U.S., and served on their Boardboard of Directorsdirectors until his retirement in 2009, having previously held a number of senior marketing roles within thethat company. He was also Chairman of Sinclair Marketing Inc., the company’swhich
| | 42 |
is Sinclair Oil Corporation’s convenience store business. Before joining Sinclair in 1995, Mr. Blackmore was with Kerr-McGee Refining Corporation for twenty sixtwenty-six years, progressing through a variety of accounting, marketing and general management positions, ultimately serving as General Manager, Branded Marketing for three years. Mr. Blackmore has a Bachelor of Science degree in Business Administration from Panhandle State University in Oklahoma.
Key Attributes, Experience and Skills:
Senior | Financial | Chemical | Corporate | Manufacturing/ | Human | Global | Regulatory/ Legal/ Compliance |
Mr. Blackmore has anin-depth knowledge of the chemical industry, particularly the oil sector and has held several senior positions during his career. He brings industry knowledge, financial and marketing expertise to the Corporation.Company.
Mr. Robert I. PallerFor additional detail, see our Board Skills Matrix on page 40.
Age: 83
Director since November 1, 2009
Committees: Nominating and Corporate Governance (from February 17, 2015)
Mr. Paller has served on the board of numerous private companies andnon-profit corporations for over forty years. He is currently a member of the Council of National Trustees for the National Jewish Medical and Research Center in Denver, Colorado. An attorney by profession, Mr. Paller has been a partner with the law firm of Smith,
15
Gambrell & Russell LLP since 1965for many years specializing in corporate law, particularly mergers and acquisitions, originally serving since 1965 as a partner and is currently serving as “Of Counsel” to the firm. Mr. Paller has a Bachelor of Science degree in Business Administration from the University of North Carolina and an LLB degree from Emory University.
Key Attributes, Experience and Skills:
Senior | Public | Corporate | M&A | Global | Regulatory/Legal/ Compliance |
Mr. Paller has a wealth of directorship experience, having served on various boards for over forty years. He also has many years of legal experience which will assistassists the boardBoard in their deliberations on many topics andtopics. He is a valuable resource to the CorporationCompany, which operates, in a highly regulated industry.
For additional detail, see our Board Skills Matrix on page 40.
| | 43 |
Mr. David F. Landless
Age: 58
Class III Directors
Director since January 1, 2016
Committees: Audit Committee (Chair with effect from May 4, 2016)
Mr. Landless was the Group Finance Director for Bodycote plc, a U.K. listed company, which provides thermal processing services globally for a wide range of industries including aerospace, automotive, oil and gas and construction, for 17 years until December 2016. Since March 2013, he has been aNon-Executive Director for Luxfer Holdings plc,plc; a NYSE listed global materials technology company, and chairswas their Audit Committee.Committee Chair until May 2019, when he was appointed Chairman of the Board. In January 2017, he was appointed aNon-Executive Director of Renold plc, a U.K. listed global manufacturer of specialist industrial chain and machinery transmissions and also chairs their Audit Committee. He is also aNon-Executive Director of Ausurus Group Ltd the holding company of European Metal Recycling (EMR), a large private scrap metal recycling company and was appointed to this role in June 2017. Mr. Landless’ early career includes fourteen years with Courtaulds plc, where he held a number of finance roles, ultimately serving as the Finance Director of Courtaulds Coatings (Holdings) Limited from 1997 to 1999. Mr. Landless is a Chartered Management Accountant and has a Bachelor of Science degree in Management Sciences from the University of Manchester Institute of Science and Technology in the U.K. Mr. Landless is the Chairman of the Audit Committee.
Key Attributes, Experience and Skills:
Senior | Financial | Public | Chemical | Corporate | Manufacturing/ | M&A | Global | Regulatory/ Legal/ Compliance |
Mr. Landless brings significant financial expertise and knowledge of financial reporting with his wealth of experience as a Finance Director and as anon-executiveNon-Executive directorDirector during his career to date. Mr. Landless also has substantial experience in the chemicals, paint and engineering sectors.
Mr. Lawrence J. PadfieldFor additional detail, see our Board Skills Matrix on page 40.
Age: 62
Director since December 1, 2012
Committees: Compensation and Nominating and Corporate Governance (until February 17, 2015)
Mr. Padfield is currentlyhas recently retired as a principal and Executive Vice President of Blackline Partners LLC, a closely held private equity and midstream logistics and terminal development company. He also servescontinues to hold the position as the Board Chairman of CAP Technologies, a private U.S. company that has developed and markets a ground breakingground-breaking technology for cleaning and coating wire, rebar and plate steel. Prior to forming Blackline Partners, Mr. Padfield was a founding partner and Vice President of U.S. Development Group LLC, an industry leading biofuel and crude oil terminal development company. Mr. Padfield’s early career includes eighteen
| | 44 |
years at Shell Oil Company where he held a number of roles in marketing, engineering and product supply, ultimately serving as the Business Development and Acquisitions Manager for their terminal and pipeline business. Mr. Padfield has a degree in Civil Engineering from the University of Missouri.
16
Key Attributes, Experience and Skills:
Senior | Financial | Public | Chemical | Corporate | Manufacturing/ | Human | M&A | Regulatory/ Legal/ Compliance |
Mr. Padfield has almost thirty years’ experience in the oil and gas logistics industry, commercial marketing and business development, and his wealth of knowledge in this sector is a valuable resource to the Corporation.Company.
Mr. Patrick S. WilliamsFor additional detail, see our Board Skills Matrix on page 40.
Age: 53
Director since April 2, 2009
No Board Committees
Mr. P. Williams has served as Director, President and CEOChief Executive Officer of the CorporationCompany since his appointment to this position on April 2, 2009 and as a Director of the Company since May 11, 2009. Prior to holding this position, Mr. P. Williams was Executive Vice President and President, Fuel Specialties of the CorporationCompany from 2005 to 2009 and in addition assumed responsibility for the global Performance Chemicals business in 2008. He held a number of senior management and sales leadership positions in Innospec Fuel Specialties LLC, latterly acting as the Chief Executive Officer of this business from 2004 to 2009. Before joining the predecessor company of Innospec Fuel Specialties LLC, Starreon Corporation, in 1993, Mr. P. Williams established a number of businesses and currently holds equity positions in a small exploration and oil production company and a real estate business. Since February 2020, Mr. Williams has served as a Non-Executive Director of AdvanSix Inc., and as a member of its Compensation and Leadership Development Committee and Health, Safety, Environmental and Sustainability Committee.
Key Attributes, Experience and Skills:
Senior | Public | Chemical | Corporate | Manufacturing/ | Human | M&A | Global | Regulatory/ Legal/ Compliance |
As the only management representative on the Board, Mr. P. Williams provides an insider’s perspective in boardBoard discussions about the business and strategic direction of the Corporation.Company. Mr. P. Williams has particular experience in the Fuel Specialties, and Performance Chemicals and Oilfield Specialties businesses, and brings a wealth of knowledge to the Corporation.Company.
For additional detail, see our Board Skills Matrix on page 40.
| | 45 |
Section 14ADIRECTOR COMPENSATION
Elements of Director Compensation:
The non-employee director’s compensation is generally a flat annual fee based on the following arrangement:
Annual Retainer:
An annual retainer of $160,000, paid quarterly, to the Chairman of the Exchange Act enables our stockholdersBoard.
An annual retainer of $90,000, paid quarterly, for all other NEDs.
Additional Annual Retainers for Board Committee duties as follows:
An additional annual retainer of $10,000, paid quarterly, for the Chair of the Compensation Committee.
An additional annual retainer of $16,000, paid quarterly, for the Chair of the Audit Committee.
An additional annual retainer of $8,000, paid quarterly, for the Chair of the Nominating and Corporate Governance Committee.
An additional annual retainer of $5,000, paid quarterly, to votethe members of the Audit Committee.
No additional daily fees for attendance at Board or Committee meetings or calls, except as provided below.
In addition to approve, on an advisory(non-binding) basis, the compensation arrangements described above:
NEDs may receive an additional daily fee of $2,000 for additional days provided at the specific request of the CEO.
Each NED is entitled to reimbursement for any reasonable out-of-pocket expenses incurred in connection with travel to and from, and attendance at, meetings of the Board or its Committees and related activities.
Annual Equity grant:
Each NED also receives an annual grant of equity under the Innospec Inc. Long-Term Incentive Omnibus Plan (the “Omnibus Plan”) in February of each year, equal to $90,000, based on the closing stock price for Company stock on the date prior to grant (two-thirds of such awards to be full value equity awards to be granted at zero cost, one-third to be options granted with an exercise price equal to market price). Full value awards vest after three years. Options become exercisable normally after three years, with all options vesting at the end of this period. All options have a ten-year term.
The value of the full value awards for the Directors included in the “Director Compensation” table, under the column headed “Stock Awards”; the table discloses the grant date fair value of full value awards made under the Omnibus Plan. The value of the full value awards is determined using the number of stock awarded and the grant date fair value for each stock awarded are calculated using the Black-Scholes model, with reference to the underlying stock price, volatility of the Company’s stock price, risk free rate and expected dividend yield. For full value awards with additional characteristics, such as vesting criteria linked to stock market indices or stock price performance, a Monte Carlo simulation is used to model the
| | 46 |
range of potential outcomes. For further information on the assumptions underlying these grant date fair values refer to Note 18 of the Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. |
The value of the option awards for the Directors included in the “Director Compensation for fiscal 2020” table, under the column headed “Option Awards”, discloses the grant date fair value of options awarded under the Omnibus Plan. The value of the option awards is determined using the number of options awarded and the grant date fair value for each option made in the year. The grant date fair values on Company stock options are calculated in the same way as the full value awards described above.
Director Stock Ownership Guidelines
The Compensation Committee has determined that there should be a minimum stockholding requirement for the NEDs. All NEDs are required to acquire and hold stock valued at the equivalent of two times their annual retainer. These stock ownership levels must be reached within five years of appointment. At the end of 2020, the stockholding for all the NEDs, except Ms. Poccia and Ms. Arnold, was greater than 200% of the annual retainer. Ms Poccia has three more years to reach the required level and Ms. Arnold has five more years.
DIRECTOR COMPENSATION FOR FISCAL 2020:
Name | Fees Earned or Paid $
| Stock Awards $ | Option Awards $ | Total $ | ||||
Ms. Elizabeth K. Arnold
| 23,750 | 0 | 0 | 23,750 | ||||
Mr. Milton C. Blackmore
| 173,750* | 53,916 | 5,850 | 233,516 | ||||
Mr. David F. Landless
|
116,000*
|
53,916
|
5,850
|
175,766
| ||||
Mr. Lawrence J. Padfield
| 99,500 | 53,916 | 5,850 | 159,266 | ||||
Mr. Robert I. Paller
|
90,000
|
53,916
|
5,850
|
149,766
| ||||
Ms. Claudia P. Poccia
|
104,000*
|
128,713**
|
9,548
|
242,261
| ||||
Mr. Joachim Roeser §
| 52,500 | 53,916 | 5,850 | 112,266 | ||||
Mr. Hugh G.C. Aldous §§
| 51,500 | 53,916 | 5,850 | 111,266 |
* This amount includes $10,000 in fees for assistance in finding a new Director, based on days spent.
** This amount includes 1,000 shares awarded to Ms. Poccia in her first year, for joining the Board.
§ Mr. Roeser was a non-employee director for only part of the year, having passed away in April 2020. Compensation shown in the table is for the part of the year ended December 31, 2020 that he was a director.
§§ Mr. Aldous was a non-employee director for only part of the year ended December 31, 2020. He retired immediately following the 2020 Annual Meeting of Stockholders on May 6, 2020. Compensation shown in the table is for the part of the year ended December 31, 2020 that he was a director.
| | 47 |
The number of unexercised options and unvested full value equity awards outstanding as of January 31, 2021 for each NED is detailed in the table below:
Name | Number of Options | Number of Stock Awards | Grant Price $ | Date of Grant | ||||
Mr. Hugh G.C. Aldous * | ||||||||
370 | 81.07 | 02.25.19 | ||||||
293 | 0.00 | 02.20.18 | ||||||
880 | 68.20 | 02.20.18 | ||||||
283 | 0.00 | 02.21.17 | ||||||
850 | 70.60 | 02.21.17 | ||||||
1,030 | 44.18 | 02.22.16 | ||||||
1,035 | 43.95 | 02.23.15 | ||||||
Ms. Elizabeth K. Arnold | - | - | - | - | ||||
Mr. Milton C. Blackmore | 627 | 0.00 | 02.24.20 | |||||
313 | 95.70 | 02.24.20 | ||||||
370 | 81.07 | 02.25.19 | ||||||
740 | 0.00 | 02.25.19 | ||||||
293 | 0.00 | 02.20.18 | ||||||
880 | 68.20 | 02.20.18 | ||||||
850 | 70.60 | 02.21.17 | ||||||
1,030 | 44.18 | 02.22.16 | ||||||
1,035 | 43.95 | 02.23.15 | ||||||
Mr. David F. Landless | 627 | 0.00 | 02.24.20 | |||||
313 | 95.70 | 02.24.20 | ||||||
370 | 81.07 | 02.25.19 | ||||||
740 | 0.00 | 02.25.19 | ||||||
293 | 0.00 | 02.20.18 | ||||||
880 | 68.20 | 02.20.18 | ||||||
| | 48 |
Mr. Lawrence J. Padfield | 627 | 0.00 | 02.24.20 | |||||
313 | 95.70 | 02.24.20 | ||||||
370 | 81.07 | 02.25.19 | ||||||
740 | 0.00 | 02.25.19 | ||||||
293 | 0.00 | 02.20.18 | ||||||
880 | 68.20 | 02.20.18 | ||||||
283 | 0.00 | 02.21.17 | ||||||
850 | 70.60 | 02.21.17 | ||||||
1,030 | 44.18 | 02.22.16 | ||||||
1,035 | 43.95 | 02.23.15 | ||||||
977 | 46.03 | 02.14.14 | ||||||
1,108 | 40.58 | 05.15.13 | ||||||
Mr. Robert I. Paller | 627 | 0.00 | 02.24.20 | |||||
313 | 95.07 | 02.24.20 | ||||||
370 | 81.07 | 02.25.19 | ||||||
740 | 0.00 | 02.25.19 | ||||||
293 | 0.00 | 02.20.18 | ||||||
880 | 68.20 | 02.20.18 | ||||||
283 | 0.00 | 02.21.17 | ||||||
850 | 70.60 | 02.21.17 | ||||||
1,030 | 44.18 | 02.22.16 | ||||||
1,035 | 43.95 | 02.23.15 | ||||||
977 | 46.03 | 02.14.14 | ||||||
1,089 | 41.31 | 02.20.13 | ||||||
1,522 | 29.56 | 02.23.12 | ||||||
1,660 | 27.11 | 02.22.11 | ||||||
Ms. Claudia P. Poccia | 424 | 70.74 | 05.20.20 | |||||
848 | 0.00 | 05.20.20 | ||||||
1,000 | 0.00 | 05.20.20 | ||||||
* In the case of Mr. Hugh G.C. Aldous, who retired from the Board on May 6, 2020, the table shows the options which are outstanding as at January 31, 2021 and must be exercised before May 6, 2021, being the date which is 12 months from his retirement date.
| | 49 |
WHO OWNS OUR STOCK? INFORMATION ABOUT OUR COMMON STOCK OWNERSHIP
The table “Stock Ownership of Directors and Executive Officers” sets out information with regard to the Directors of the Company, our Executive Officers who are named in the “Summary Compensation Table” which appears later in this Proxy Statement (“Named Executive Officers” or “NEOs”), and all current Directors and Executive Officers of the Company as a group.
The table “Beneficial Owners at Fiscal Year-End 2020” sets out certain information with respect to the beneficial ownership of the Company’s Common Stock as of December 31, 2020 by holders of more than 5% of the Company’s outstanding Common Stock.
As of December 31, 2020 excluding treasury stock, there were 24,595,901 shares of Common Stock outstanding. To the knowledge of the Company, each stockholder listed in the tables below has sole voting and investment power with respect to the stock indicated as beneficially owned, unless otherwise indicated in a footnote. Unless otherwise indicated, the business address of each person is the Company’s corporate address.
STOCK OWNERSHIP OF DIRECTORS AND EXECUTIVE OFFICERS AS OF JANUARY 31, 2021
The following table sets out the amount of our Common Stock beneficially owned by each of the Directors, the CEO, the CFO and the other NEOs of the Company:
Name | Shares Owned Directly or Indirectly | Shares Underlying Options Exercisable within 60 Days | Total | Percent of Class | ||||||
Ms. Elizabeth K. Arnold | 0 | 0 | 0 | * | ||||||
Mr. Milton C. Blackmore | (1) | 7,000 | 3,795 | 10,795 | * | |||||
Dr. Philip J. Boon | 11,956 | 10,263 | 29,960 | * | ||||||
Mr. Ian C. Cleminson | 20,997 | 1,161 | 22,158 | * | ||||||
Mr. David F. Landless | 2,405 | 880 | 3,285 | * | ||||||
Dr. Ian M. McRobbie | 35,889 | 0 | 35,889 | * | ||||||
Mr. Lawrence J. Padfield | 2,904 | 6,163 | 9,067 | * | ||||||
Mr. Robert I. Paller | 10,328 | 9,326 | 19,654 | * | ||||||
Ms. Claudia Poccia | 0 | 0 | 0 | * | ||||||
Mr. Brian R. Watt | 24,888 | 4,017 | 28,905 | * | ||||||
Mr. Patrick S. Williams | 171,379 | 25,402 | 196,781 | * | ||||||
Directors and Executive Officers as a group (13 persons) | (2) | 302,746 | 70,664 | 373,410 | 1.26 |
Footnotes to “Stock Ownership” table:
(*) | Less than 1% |
(1) | In the case of Mr. Blackmore this figure includes 1,000 held by ‘The Milton & Janet Blackmore Trust’ |
(2) | Includes the above named directors and officers as well as Dr. Catherine Hessner and Mr. David Jones |
| | 50 |
BENEFICIAL OWNERS AT FISCAL YEAR END 2020 (INFORMATION AS REPORTED IN SCHEDULE 13G AS OF DECEMBER 31, 2020)
Name and Address of Beneficial Owner | Amount and Nature of
| Percent of Class | ||||
BlackRock, Inc. 55 East 52nd Street New York NY 10022
| (1) | 3,844,107 | 15.60% | |||
FMR LLC 245 Summer Street Boston MA 02210
| (2) | 2,654,447 | 10.80% | |||
The Vanguard Group 100 Vanguard Boulevard Malvern Pennsylvania PA 19355
| (3) | 2,528,521 | 10.29% | |||
Wells Fargo & Company 420 Montgomery Street San Francisco CA 94163
| (4) | 2,106,289 | 8.57% | |||
Dimensional Fund Advisors LP Building One 6300 Bee Cave Road Austin TX 78746
| (5) | 1,237,726 | 5.00% |
Based on a review of filings with the SEC, the Company is unaware of other holders of more than 5% of the outstanding shares of Innospec Inc. Common Stock.
Notes:
(1) | According to a Schedule 13G dated January 25, 2021, BlackRock, Inc. has sole voting power over 3,796,193 shares and sole dispositive power over 3,844,107 shares. |
(2) | According to a Schedule 13G/A dated February 8, 2021 filed jointly by FMR LLC (“FMR”) and Abigail P. Johnson (“Ms. Johnson”), neither FMR nor Ms. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act (“Fidelity Funds”) advised by Fidelity Management & Research Company (“FMR Co”), a wholly owned subsidiary of FMR, which power resides with the Fidelity Funds’ Boards of Trustees. FMR Co carries out the voting of the shares under written guidelines established by the Fidelity Funds’ Board of Trustees. |
| | 51 |
(3) | According to a Schedule 13G/A dated February 10, 2021, The Vanguard Group, has sole voting power over 50,408 shares, sole dispositive power over 2,458,400 shares, shared dispositive power over 70,121 shares and beneficially holds 2,528,521 shares. |
(4) | According to a Schedule 13G/A dated February 11, 2021, Wells Fargo & Company has sole voting power over 54,311 shares, sole dispositive power over 54,311 shares, shared voting power over 385,426 shares, shared dispositive power over 2,051,978 shares and beneficially held shares of 2,106,289 shares. |
(5) | According to a Schedule 13G/A dated February 12, 2021, filed by Dimensional Fund Advisors LP, it has sole voting power over 1,184,016 shares and sole dispositive power over 1,237,726 shares. Dimensional Fund Advisors LP, an investment adviser registered under Section 203 of the Investment Advisors Act of 1940, furnishes investment advice to four investment companies registered under the Investment Company Act of 1940, and serves as investment manager or sub-adviser to certain other commingled funds, group trusts and separate accounts (such investment companies, trusts and accounts, collectively referred to as the “Funds”). In certain cases, subsidiaries of Dimensional Fund Advisors LP may act as an adviser or sub-adviser to certain Funds. In its role as investment adviser, sub-adviser and/or manager, Dimensional Fund Advisors LP or its subsidiaries (collectively, “Dimensional”) may possess voting and/or investment power over the securities of the issuer that are owned by the Funds, and may be deemed to be the beneficial owner of the shares of the issuer held by the Funds. However, all securities reported in the Schedule 13G are owned by the Funds. Dimensional disclaims beneficial ownership of such securities. |
Delinquent Section 16(a) Reports
Based solely upon a review of the copies of Section 16(a) forms furnished to the Company, we believe that each of the Company’s officers, Directors and beneficial owners of more than 10% of the Common Stock complied with all Section 16(a) filing requirements applicable to them during fiscal 2020, except that a Form 3 for Graeme Blair was filed late due to an administrative error.
The following table summarizes information, as of December 31, 2020, relating to our current equity compensation plans approved by security holders, pursuant to which grants of options, full value options, restricted stock, restricted stock units or other rights to acquire stock have been granted from time to time under the Company Stock Option Plan (“CSOP”), Performance Related Stock Option Plan (“PRSOP”), Non-Executive Directors Stock Option Plan (“NEDSOP”) and Omnibus Plan.
The CSOP, PRSOP and the NEDSOP expired in May 2018 and no further options were granted under these plans after that date, although outstanding options granted under such plans remain exercisable until their respective expiration dates. Options and full value awards were granted under the Omnibus Plan. This plan provides for options exercisable for Common Stock and performance shares as well as cash incentive awards, which are payable in cash based on stock price.
| | 52 |
We do not have any equity compensation plans that have not been approved by stockholders. Additional information about the CSOP, PRSOP and Omnibus Plan can be found in the Compensation Discussion and Analysis section of this Proxy Statement.
Plan Category | Number of securities to
(a) | Weighted average
(b) | Number of securities
(c) | |||
Equity compensation plans approved by stockholders | 283,457 | $15.979 | 750,526 | |||
Equity compensation plans not approved by stockholders | - | - | - | |||
Total | 283,457 | $15.979 | 750,526 |
| | 53 |
PROPOSAL 3 – ADVISORY APPROVAL OF INNOSPEC’S EXECUTIVE COMPENSATION
(Item 3 on the Proxy Card)
Section 14A of the Exchange Act enables our stockholders to vote to approve, on an advisory (non-binding) basis, the compensation of our NEOs, as disclosed in this Proxy Statement including the Compensation Discussion and Analysis, the Compensation Tables and related material, in accordance with the compensation disclosure rules of the SEC. In accordance with Section 14A of the Exchange Act, we are offering to our stockholders anon-binding, advisory vote on 2017 compensation for the Named Executive Officers, including the compensation of our CEO.
The Corporation’s goal for its executive compensation program is to attract, motivate and retain a talented, highly qualified team of executives who will provide leadership for the Corporation’s success in the competitive global markets the Corporation operates in. The Corporation seeks to accomplish this goal in a way that is aligned with the long-term interests of the Corporation’s stockholders. The Corporation believes that its executive compensation program is strongly aligned with the long-term interests of its stockholders as it is competitive with the market, includes both short and long-term awards and is performance based, providing a strong link between executive compensation and the performance of the Corporation.
compensation disclosure rules of the SEC. In accordance with Section 14A of the Exchange Act, we are offering to our stockholders a non-binding, advisory vote on 2020 compensation for the Named Executive Officers, including the compensation of our CEO. Innospec’s goal for its executive compensation program is to attract, motivate and retain a talented, highly qualified team of executives who will provide leadership for our success in the competitive global markets we operate in. We seek to accomplish this goal in a way that is aligned with the long-term interests of our stockholders. We believe that our executive compensation program is strongly aligned with the long-term interests of our stockholders as it is competitive with the market, includes both short and long-term awards and is performance based, providing a strong link between executive compensation and the performance of the Company. | The Board recommends you vote
“FOR” the advisory resolution approving Named Executive Officer Compensation. | |
The Compensation Committee continually reviews the compensation programs for our NEOs to confirm that they achieve the desired goals of aligning our executive compensation structure with our stockholders’ interests and current market practices. The Compensation Discussion and Analysis beginning on page 62 of this Proxy Statement describes the Company’s executive compensation program in more detail. |
We believe that our executive compensation programs are structured in the best manner possible to support the CorporationCompany and our business objectives. We are asking our stockholders to indicate their support for our NEO compensation as described in the Compensation Discussion and Analysis section and the compensation tables and related narrative disclosure. This proposal, commonly known as a“say-on-pay” proposal, gives our stockholders the opportunity to express their views on our NEOs’ compensation. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our NEOs and the philosophy, policies and practices described in this Proxy Statement. Accordingly, we will ask our stockholders to vote “FOR” the following resolution at the Annual General Meeting:
“RESOLVED, that the compensation paid to the Corporation’sCompany’s Named Executive Officers, as disclosed pursuant to the compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, compensation tables and related material disclosed in this Proxy Statement is hereby APPROVED.”
As an advisory vote, this proposal is not binding upon the Corporation.Company. However, the Board of Directors will consider that the stockholders have approved executive compensation on an advisory basis if this proposal receives the affirmative vote of a majority of the votes present in person or represented by proxy. The Compensation Committee values the opinions that stockholders express through their votes and will consider the outcome of the vote when making future compensation decisions.
| | 54 |
Historical Say-On-Pay votes:
The Board recommends a vote “FOR”chart below sets out the approval of our 2017 Named Executive Officer Compensation as describedvoting in this Proxy Statement.Note: Stockholders are not voting to approve or disapprove the recommendationrespect of the Board of Directors regarding Proposal No. 2.“say-on-pay” proposal for the last three years:
|
The Board of Directors is asking stockholders to approve the proposed Innospec Inc. 2018 Omnibus Long-Term Incentive Plan (“Omnibus Plan”). The following summary of the Omnibus Plan is qualified in its entirety by the complete text of the Omnibus Plan contained in Appendix A.
Explanation
On February 12, 2018 the Compensation Committee recommended to the Board of Directors and on February 13, 2018 the Board of Directors approved for submission to the stockholders, for approval at the 2018 Annual Meeting of Stockholders, the Innospec Inc. 2018 Omnibus Long-Term Incentive Plan, which is seeking to reserve for issuance 900,000 shares of Common Stock. Equity compensation is an important component of our executive, employee and director compensation programs. We believe it aligns employee and director compensation with stockholder interests and motivates participants to achieve long-range goals. Stockholder approval of the Omnibus Plan would increase the number of shares of Common Stock available to award as employee incentive compensation, allowing the Board to attract and retain key employees, provide them competitive compensation, adapt to evolving compensation practices and account for the growth of the Corporation and its employees.
Upon stockholder approval, the Omnibus Plan will replace the Innospec Inc. Company Stock Option Plan, the Innospec Inc.Non-Employee Directors’ Stock Option Plan, and the Innospec Inc. Performance Related Stock Option Plan (the “Prior Plans”). The Prior Plans were adopted and approved by stockholders in 2008 and approved by stockholders as each was amended again in 2011. The Prior Plans terminate on May 5, 2018 and no further grants under the Prior Plans will be made after this date.
18
As of February 28, 2018, the Corporation had 276,382 remaining shares of Common Stock available under the Prior Plans. Following the termination of the Prior Plans on May 5, 2018, these shares will expire and will not be available for future grants under the Omnibus Plan, following its approval by stockholders. As of February 28, 2018, there were 376,969 stock options outstanding under all equity plans. This number includes 274,387 full-value stock options (exercise price of $0.00), and 102,582 stock options with a weighted average exercise price of $49.34 and a weighted average remaining term of 7.31 years. In addition, there were 430,504 Stock Equivalent Units, which settle only in cash, outstanding as of this same date.
The Corporation is seeking stockholder approval to make shares of Common Stock available for future grants under the Omnibus Plan as described below. The Omnibus Plan has been designed to include in one plan document the same flexibility previously contained in the three separate Prior Plans. Additionally, for reasons described below, the Corporation is submitting the Omnibus Plan for approval by the stockholders to satisfy the requirement that the performance goals be periodically approved by stockholders for purposes of Section 162(m) of the Internal Revenue Code.
Purpose of the Omnibus Plan
As described more generally above, the purpose of the Omnibus Plan is to:
|
|
|
|
The Omnibus Plan promotes the long-term financial interest of the Corporation and its subsidiaries, including the growth in value of the Corporation’s equity and enhancement of long-term stockholder return.
We use equity-based compensation granted under our long-term incentive plans as a key element of our executives’ compensation packages, and each year we disclose the prior year grants to and other compensation of our named executive officers in our proxy statement. We believe the Omnibus Plan assists with linking executives’ overall compensation opportunities to the enhancement of long-term stockholder return.
The Omnibus Plan provides for the grant ofnon-qualified and incentive stock options, full value awards, and cash incentive awards. The flexibility inherent in the plan permits the Board to change the type, terms and conditions of awards as circumstances may change. We believe that this flexibility and the resulting ability to more affirmatively adjust the nature and amounts of executive compensation are particularly important for our industry and to a global company such as ours, given the volatility of the public markets and reactions to economic and world events. Equity compensation, which aligns the interests of executives and our stockholders, is an important tool for the Board.
General Terms of the Omnibus Plan
The Omnibus Plan is administered by a committee, which we refer to as the Committee, of two or more Board members selected by the Board. Unless otherwise provided by the Board, the Committee’s functions will be performed by the Compensation Committee of the Board. The Committee selects the Participants, the time or
19
times of receipt of awards, the types of awards to be granted and the applicable terms, conditions, performance targets, restrictions and other provisions of such awards, to cancel or suspend awards, and to accelerate the exercisability or vesting of any award under circumstances designated by it. The Committee may delegate all or any portion of its responsibilities or powers under the Omnibus Plan to persons selected by it. If the Committee does not exist or for any other reason determined by the Board, and to the extent not prohibited by applicable law or the applicable rules of any stock exchange, the Board may take any action under the Omnibus Plan that would otherwise be the responsibility of the Committee.PROPOSAL 4 – RATIFICATION OF THE APPOINTMENT OF THE COMPANY’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
If the Omnibus Plan is approved by stockholders, the maximum number of shares that may be delivered to Participants and their beneficiaries under the Omnibus Plan will be (i) 900,000 shares of Common Stock; plus (ii) any shares of Common Stock that are represented by awards granted under the Prior Plans that are forfeited, expire or are cancelled after the effective date of the Omnibus Plan without delivery of such shares or which result in the forfeiture of the shares back to the Corporation to the extent that such shares would have been added back to the reserve under the terms of the applicable Prior Plan.
If an award denominated in Common Stock is settled in cash, the total number of shares with respect to which such payment is made shall not be considered to have been delivered. However, (i) if shares covered by an award are used to satisfy the applicable tax withholding obligation, the number of shares held back by the Corporation to satisfy such withholding obligation shall be considered to have been delivered; (ii) if the exercise price of any option granted under the Omnibus Plan is satisfied by tendering shares to the Corporation (including shares that would otherwise be distributable upon the exercise of the option), the number of shares tendered to satisfy such exercise price shall be considered to have been delivered; and (iii) if the Corporation repurchases shares with proceeds received from the exercise of an option issued under the Omnibus Plan, the total number of shares repurchased shall be deemed delivered.
Notwithstanding the minimum vesting limitations described below with respect to options and full value awards, the Committee may grant a certain number of options and full value awards that are not subject to such minimum vesting provisions. The total aggregate number of shares of Common Stock subject to options and full value awards granted pursuant to the Omnibus Plan that are not subject to such minimum vesting limitations may not exceed five percent of the limit of the total number of shares of Common Stock that may be delivered under the Omnibus Plan.
If the Omnibus Plan is approved by stockholders, the following additional limits apply to awards under the Omnibus Plan:
20
|
The shares of Common Stock with respect to which awards may be made under the Omnibus Plan shall be:
|
|
|
At the discretion of the Committee, an award under the Omnibus Plan may be settled in cash, shares of Common Stock, the granting of replacement awards, or a combination thereof; provided, however, that if a cash incentive award is settled in shares of Common Stock, it must satisfy the minimum vesting requirements related to full value awards. The closing price for our shares of Common Stock(Item 4 on the NASDAQ on February 28, 2018 was $64.95 per share.
The Committee may use shares of Common Stock available under the Omnibus Plan as the form of payment for compensation, grants or rights earned or due under any other compensation plans or arrangements of the Corporation or a subsidiary, including the plans and arrangements of the Corporation or a subsidiary assumed in business combinations.
In the event of a corporate transaction involving the Corporation (including, without limitation, any share dividend, share split, extraordinary cash dividend, recapitalization, reorganization, merger, amalgamation, consolidation, share exchange,split-up,spin-off, sale of assets or subsidiaries, combination or exchange of shares), the Committee shall adjust awards to preserve the benefits or potential benefits of the awards. Action by the Committee may include:
|
|
|
|
|
|
Except as otherwise provided by the Committee, awards under the Omnibus Plan are not transferable except as designated by the Participant by will or by the laws of descent and distribution.
21
Eligibility
All employees and directors of, and consultants and other persons providing services to, the Corporation or any of its subsidiaries (or any parent or other related company, as determined by the Committee) are eligible to become Participants in the Omnibus Plan, except thatnon-employees may not be granted incentive stock options. As of February 28, 2018, the Corporation and its subsidiaries had approximately 1920 employees.
Options
The Committee may grant an incentive stock option, atax-qualified option ornon-qualified stock option to purchase shares of Common Stock at an exercise price determined under the option. Each option shall be designated as an incentive stock option, atax-qualified option ornon-qualified stock option when granted. An incentive stock option is a stock option intended to satisfy additional requirements required by federal tax rules in the United States as specified in the Omnibus Plan (and any incentive stock option granted that does not satisfy such requirements shall be treated as anon-qualified stock option). Atax-qualified option is a stock option intended to comply with Schedule 4 to the Income Tax (Earnings and Pensions) Act 2003 of the United Kingdom as specified inExhibit A to the Omnibus Plan.
Except as described below, the exercise price for an option shall not be less than the fair market value of a share of Common Stock at the time the option is granted; provided, that the exercise price of an incentive stock option granted to any employee who owns more than 10 percent of the voting power of all classes of stock in the Corporation or a subsidiary shall not be less than 110 percent of the fair market value of a share of Common Stock at the time of grant. The exercise price of an option may not be decreased after the date of grant nor may an option be surrendered to the Corporation as consideration for the grant of a replacement option with a lower exercise price, except as approved by our stockholders or as adjusted for corporate transactions described above.
No option shall be surrendered to the Corporation in consideration for a cash payment or grant of any other award if at the time of such surrender the exercise price of such option is greater than the then current fair market value of a share of Common Stock, except as approved by our stockholders. In addition, the Committee may grant options with an exercise price less than the fair market value of the shares of Common Stock at the time of grant in replacement for awards under other plans assumed in connection with business combinations if the Committee determines that doing so is appropriate to preserve the benefit of the awards being replaced. No dividend equivalents may be granted under the Omnibus Plan with respect to any option.
The option shall be exercisable in accordance with the terms established by the Committee, but in no event shall an option become exercisable or vested prior to the earlier of (i) the first anniversary of the date of grant or (ii) the date on which the Participant’s termination occurs by reason of death or disability. In the event of the Participant’s termination occurs for any reason other than death, disability, retirement, or involuntary termination without cause, any unvested options will be forfeited. In the event the Participant’s termination occurs due to death, disability, retirement or involuntary termination without cause, any unvested options shall be exercisable only as determined by the Committee in its sole discretion.
The full purchase price of each share of Common Stock purchased upon the exercise of any option shall be paid at the time of exercise of an option. Except as otherwise determined by the Committee, the purchase price of an option shall be payable in cash, by promissory note, or by shares of Common Stock (valued at fair market value as of the day of exercise), including shares of stock otherwise distributable on the exercise of the option, or a combination thereof. If the shares remain publicly traded, the Committee may permit a Participant to pay the exercise price by irrevocably authorizing a third party to sell shares of Common Stock (or a sufficient portion of the shares of Common Stock) acquired upon exercise of the option and remit to the Corporation a sufficient portion of the sale proceeds to pay the entire exercise price and any tax withholding resulting from such exercise. The Committee, in its discretion, may impose such conditions, restrictions, and contingencies on shares of Common Stock acquired pursuant to the exercise of an option as the Committee
22
determines to be desirable. In no event will an option expire more than ten years after the grant date; provided, that an incentive stock option granted to any employee who owns more than 10 percent of the voting power of all classes of stock in the Corporation or a subsidiary shall not be more than 5 years.
The option will expire on the earliest to occur of (i) the last day of the term of the option as described in the award agreement; (ii) if the Participant’s termination occurs by reason of death, disability, retirement or an involuntary termination without cause, theone-year anniversary of such termination date; or (iii) if the Participant’s termination occurs for any reason other than those listed in clause (ii), the Participant’s termination date.
Full Value Awards
The following types of “full value awards” may be granted, as determined by the Committee:
|
|
|
Any such awards shall be subject to such conditions, restrictions and contingencies as the Committee determines. If the right to become vested in a full value award is conditioned on the completion of a specified period of service with the Corporation or the related companies, without achievement of performance targets or other performance objectives being required as a condition of vesting, and without it being granted in lieu of other compensation, then the required period of service shall not end prior to the earlier to occur of (i) the first anniversary of the date of grant and (ii) the date on which the Participant’s termination occurs by reason of death or disability. If the right to become vested in a full value award is conditioned on the achievement of performance targets or performance objectives, and without it being granted in lieu of other compensation, then the required performance period shall not end prior to the earlier to occur of (i) the first anniversary of the date of grant and (ii) the date on which the Participant’s termination occurs by reason of death or disability. In the event of the Participant’s termination occurs for any reason other than death, disability, retirement, or involuntary termination without cause, any unvested full value awards will be forfeited. In the event the Participant’s termination occurs due to death, disability, retirement or involuntary termination without cause, any unvested full value awards shall become vested only as determined by the Committee in its sole discretion.
Dividends or dividend equivalents settled in cash or shares of Common Stock may be granted to a Participant in relation to a full value award with payments made either currently or credited to an account. No dividend or dividend equivalents granted in relation to a full value award that is subject to vesting shall be settled prior to the date such full value award (or applicable portion thereof) becomes vested and is settled.
Cash Incentive Awards
The Committee may grant cash incentive awards (including the right to receive payment of cash or shares of Common Stock having the equivalent cash value) that may be contingent on service conditions or achievement of performance objectives over a specified period established by the Committee. The grant of cash incentive awards may also be subject to such other conditions, restrictions and contingencies, as determined by the Committee.
23
Performance Criteria and Internal Revenue Code Section 162(m)
Section 162(m) of the Internal Revenue Code limits the deductibility of annual compensation in excess of $1 million paid to covered employees of the Corporation unless the compensation satisfies an exception, which until recently included an exception for performance-based compensation. On December 22, 2017, President Trump signed the Tax Cuts and Jobs Act (the “Act”) into law, which, among other things, repealed the performance-based compensation exception to Section 162(m). The changes made by the Act to Section 162(m) are effective for any taxable year beginning after December 31, 2017. The Act includes a transition rule (the “Transition Rule”), which provides that the amendments to Section 162(m) do not apply to remuneration paid pursuant to a “binding written contract” that was in effect on November 2, 2017 and that was not materially modified on or after such date.
The Act also expands the definition of covered employee such that the compensation of more officers of the Corporation will be subject to the deduction limitation of Section 162(m). Under the amended Section 162(m), the covered employees of the Corporation will generally include anyone who (i) was the CEO or the CFO at any time during the year, (ii) was one of the other NEOs who were executive officers as of the last day of the fiscal year, and (iii) was a covered employee for any previous year after 2016.
There are many uncertainties with respect to the Transition Rule and the impact the amended Section 162(m) will have on state law. In addition, the requirements of the performance-based compensation exception are still generally considered to be good corporate governance practice. For these reasons, the Omnibus Plan has been drafted to provide for performance-based compensation that would satisfy the requirements of the exception under Section 162(m) prior to the effectiveness of the Act and we are seeking stockholder approval of the applicable performance measures.
The exercisability or payment of awards that are intended to qualify asperformance-based compensation pursuant to the Omnibus Plan may be based upon one or more of the following business criteria as established by the Committee: (i) earnings, including, but not limited to, operating income, earnings before or after taxes, earnings before or after interest, depreciation, amortization, or extraordinary or special items or book value per share (which may exclude nonrecurring items);(ii) pre-tax income orafter-tax income; (iii) earnings per share of Common Stock (basic or diluted); (iv) operating profit; (v) revenue, revenue growth or rate of revenue growth; (vi) return on assets (gross or net), return on investment, return on capital, or return on equity; (vii) returns on sales or revenues; (viii) operating expenses; (ix) stock price appreciation; (x) cash flow(s); (xi) implementation or completion of critical projects or processes; (xii) economic value created; (xiii) cumulative earnings per share growth; (xiv) operating margin or profit margin; (xv) common stock price or total stockholder return; (xvi) cost targets, reductions and savings, productivity and efficiencies; and (xvii) any combination of the foregoing. Each goal may be expressed on an absolute and/or relative basis, may be based on or otherwise employ comparisons based on internal targets, the past performance of the Corporation and/or the past or current performance of other companies or may be applied to the performance of the Corporation relative to a market index, a group of other companies or a combination thereof, and in the case of earnings-based measures, may use or employ comparisons relating to capital, stockholders equity and/or shares outstanding, investments or to assets or net assets, and may (but need not) provide for adjustments for restructurings, extraordinary, and any other unusual,non-recurring, or similar changes.
Change in Control
Except as otherwise provided in an award agreement, upon a Change in Control, all options which have not otherwise expired or been forfeited or cancelled will become immediately exercisable and vested, and all other awards which have not otherwise expired or been forfeited or cancelled will become fully vested. On a Change in Control, the Committee may cancel any outstanding awards in return for cash payment of the current value of the award, determined with the award fully vested at the time of payment, provided that in the case of an option, the amount of such payment will be the excess of value of the shares of Common
24
Stock subject to the option at the time of the transaction over the exercise price (and the option will be cancelled with no payment if the value of the shares at the time of the transaction are equal to or less than the exercise price).
For the purposes of the Omnibus Plan, a “change in control” is generally deemed to occur when:
|
|
|
|
Amendment and Termination
The Board may amend or terminate the Omnibus Plan at any time, and the Board or the Committee may amend any award granted under the Omnibus Plan, but no amendment or termination may adversely affect the rights of any Participant without the Participant’s written consent. The Board may not amend the provision of the Omnibus Plan related tore-pricing without approval of stockholders or make any material amendments to the Omnibus Plan without stockholder approval. The Omnibus Plan will remain in effect as long as any awards under the Omnibus Plan remain outstanding, but no new awards may be granted after the tenth anniversary of the date on which the stockholders approve the Omnibus Plan.
United States Income Tax Considerations
The following is a brief description of the U.S. federal income tax treatment that will generally apply to awards under the Omnibus Plan based on current U.S. income taxation with respect to Participants who are subject to U.S. income tax. Participants subject to taxation in other countries should consult their tax advisor (including Participants in the United Kingdom who are grantedtax-qualified options).
Non-Qualified Options. The grant of anon-qualified option will not result in taxable income to the Participant. Except as described below, the Participant will realize ordinary income at the time of exercise in an amount equal to the excess of the fair market value of the shares of Common Stock acquired over the exercise price for those shares. Gains or losses realized by the Participant upon disposition of such shares will be treated as capital gains and losses, with the basis in such shares of Common Stock equal to the fair market value of the shares at the time of exercise.
Incentive Stock Options. The grant of an incentive stock option will not result in taxable income to the Participant. The exercise of an incentive stock option will not result in taxable income to the Participant provided that the Participant was, without a break in service, an employee of the Corporation or a subsidiary during the period beginning on the date of the grant of the option and ending on the date three months prior to the date of exercise (one year prior to the date of exercise if the Participant is “disabled,” as that term is defined in the Internal Revenue Code).
25
The excess of the fair market value of the shares of Common Stock at the time of the exercise of an incentive stock option over the exercise price is an adjustment that is included in the calculation of the Participant’s alternative minimum taxable income for the tax year in which the incentive stock option is exercised. For purposes of determining the Participant’s alternative minimum tax liability for the year of disposition of the shares acquired pursuant to the incentive stock option exercise, the Participant will have a basis in those shares equal to the fair market value of the shares of Common Stock at the time of exercise.
If the Participant does not sell or otherwise dispose of the shares of Common Stock within two years from the date of the grant of the incentive stock option or within one year after the transfer of such shares of Common Stock to the Participant, then, upon disposition of such shares of Common Stock, any amount realized in excess of the exercise price will be taxed to the Participant as capital gain. A capital loss will be recognized to the extent that the amount realized is less than the exercise price.
If the above holding period requirements are not met, the Participant will generally realize ordinary income at the time of the disposition of the shares, in an amount equal to the lesser of (i) the excess of the fair market value of the shares of Common Stock on the date of exercise over the exercise price, or (ii) the excess, if any, of the amount realized upon disposition of the shares over the exercise price. If the amount realized exceeds the value of the shares on the date of exercise, any additional amount will be capital gain. If the amount realized is less than the exercise price, the Participant will recognize no income, and a capital loss will be recognized equal to the excess of the exercise price over the amount realized upon the disposition of the shares.
Full Value Awards. A Participant who has been granted a full value award will not realize taxable income at the time of grant, provided that the shares of Common Stock subject to the award are not delivered at the time of grant, or if the shares of Common Stock are delivered, it is subject to restrictions that constitute a “substantial risk of forfeiture” for U.S. income tax purposes. Upon the later of delivery or vesting of shares of Common Stock subject to an award, the holder will realize ordinary income in an amount equal to the then fair market value of those shares. Gains or losses realized by the Participant upon disposition of such shares will be treated as capital gains and losses, with the basis in such shares equal to the fair market value of the shares at the time of delivery or vesting. Dividends paid to the holder during the restriction period, if so provided, will also be compensation income to the Participant.
Withholding of Taxes. The Corporation may withhold amounts from Participants to satisfy withholding tax requirements. Except as otherwise provided by the Committee, Participants may satisfy withholding requirements through cash payment, by having shares of Common Stock withheld from awards or by tendering previously owned shares of Common Stock to the Corporation to satisfy tax withholding requirements. The shares of Common Stock withheld from awards may be used to satisfy not more than the maximum individual tax rate for the Participant in the applicable jurisdiction for such Participant (based on the applicable rates of the relevant tax authorities, including the Participant’s share of payroll or similar taxes, as provided in tax law, regulations, or the authority’s administrative practices, not to exceed the highest statutory rate in that jurisdiction, even if that rate exceeds the highest rate that may be applicable to the specific Participant).
Change In Control. Any acceleration of the vesting or payment of awards under the Omnibus Plan in the event of a change in control in the Corporation may cause part or all of the consideration involved to be treated as an “excess parachute payment” under the Internal Revenue Code, which may subject the Participant to a 20 percent excise tax and preclude deduction by a subsidiary.
ERISA. The Omnibus Plan is not subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended and is not intended to be qualified under Section 401 of the Internal Revenue Code.
26
Tax Advice
The preceding discussion is based on U.S. tax laws and regulations presently in effect, which are subject to change, and the discussion does not purport to be a complete description of the U.S. income tax aspects of the Omnibus Plan. A Participant may also be subject to state and local taxes in connection with the grant of awards under the Omnibus Plan. In addition, a number of Participants reside outside the U.S. and are subject to taxation in other countries. The actual tax implications for any Participant will depend on the legislation in the relevant tax jurisdiction for that Participant and their personal circumstances.
What Happens If Stockholders Do Not Approve This Proposal?
In the event this proposal is not approved by stockholders, the Corporation will no longer have the ability to grant equity compensation as a component of our executive, employee and director compensation programs following the expiration of the Prior Plans in May 2018.Proxy Card)
The Board of Directors recommends a vote “FOR” the approvalis seeking ratification of the Innospec Inc. 2018 Omnibus Long-Term Incentive Plan.
|
The Boardappointment of Directors is asking stockholders to approvePwC at the proposed Innospec Inc. ShareSave Plan 2008 (as amended and restated) (the “ShareSave Plan”). The following summaryAnnual Meeting in respect of the ShareSave Plan is qualified in its entirety by the complete text of the ShareSave Plan contained in Appendix B.
Explanation2021 fiscal year.
The Board of Directors adopted and the stockholders approved the ShareSave Plan in 2008, replacing a plan originally adopted in 1998. On February 12, 2018 the CompensationAudit Committee recommended to the Board of Directors and on February 13, 2018, the Board of Directors approved for submission to the Stockholders for approval at the 2018 Annual Meeting of Stockholders, themost recent amendment and restatement of the ShareSave Plan. The ShareSave Plan is intended to be a broad-based plan that generally permits all employees and directors (who meet criteria specified in the ShareSave Plan) of the Corporation and its affiliates who choose to participate in the ShareSave Plan to purchase shares of Common Stock in the Corporation as described in more detail below. We believe it aligns employee compensation with stockholder interests and motivates participants to achieve long-range goals. Stockholder approval of the ShareSave Plan would increase the number of shares of Common Stock available to be purchased pursuant to the ShareSave Plan, allowing the Board to encourage share ownership by the Corporation’s employees and directors. Stockholder approval would also extend the term of the ShareSave Plan to ten years from the date of approval by stockholders and would make certain other technical and clarifying changes. If the ShareSave Plan is not approved, the increase in the reserved shares, the extension of the term and the other changes made in the amendment and restatement would not take effect and the ShareSave Plan will expire on May 5, 2018.
Purpose of the ShareSave Plan
The purpose of the ShareSave Plan is to provide a means through which the Corporation and its subsidiaries and associated companies (as defined further in the ShareSave Plan, the “Group”) may attract able persons to enter and remain in the employ or service of the Group and to provide a means whereby eligible employees and directors of the Group can acquire shares of Common Stock, thereby strengthening their commitment to the welfare of the Corporation and the Group and promoting an identity of interest between stockholders and these employees and directors.
27
Term
The ShareSave Plan shall terminate on the tenth anniversary of the date of its approval by stockholders, or at any earlier time as may be determined by the Board of Directors of the Corporation or the Committee (as defined below). No further grants will be made after termination.
Award Grants, Approvals, and Maximum Number of Shares of Common Stock
The ShareSave Plan is comprised of three parts: Part A which provides for the grant of options to eligible employees and directors who meet criteria specified in Part A under a U.K. tax advantaged savings-related share option plan; Part B which provides for the making of awards to eligible employees under an employee stock purchase plan established in accordance with U.S. Internal Revenue Code (“Code”) Section 423; and Part C which provides for the grant of options or stock equivalent units to eligible employees and directors who meet criteria specified in Part C under a savings-related option plan which does not qualify for favored tax status in either the U.S. or the U.K. or any other country, and references to a specific Part of the ShareSave Plan shall be construed accordingly.
The present maximum aggregate number of shares of Common Stock which may be issued under the ShareSave Plan (including, for the avoidance of doubt, Parts A, B and C) is 750,000 shares. As at February 28, 2018 there were no outstanding options under the ShareSave Plan. Any shares of Common Stock subject to an option or other rights granted under the ShareSave Plan which have lapsed, been renounced or have otherwise become incapable of being exercised or vesting shall not be treated as issued for this purpose. As of February 28, 2018, 133,347 shares remain available for issuance pursuant to the ShareSave Plan. If the amendment and restatement of the ShareSave Plan is approved by stockholders, the maximum number of shares that may be issued pursuant to the ShareSave Plan will be increased by 900,000 shares to a total of 1,650,000 reserved for issuance.
Administration of the ShareSave Plan
The ShareSave Plan is administered by the Compensation Committee of the Board or any other duly authorized committee of the Board (the “Committee”). The Committee consists of two or morenon-employee directors, each of whom has been selected by the Board and may be removed by the Board. The members serve for a term of one (1) year, or until their successors are selected by the Board or until they are removed by the Board. The Board may fill vacancies, however caused, in the Committee.
The Committee has the power and authority (subject to the provisions of the ShareSave Plan) to construe the ShareSave Plan and the certificates issued thereunder and to establish rules and regulations relating to the ShareSave Plan and options granted thereunder. All determinations made and actions taken in connection with the interpretation and construction of any provision of the ShareSave Plan by the Committee are final and conclusive. The Committee is also the recordkeeper for the ShareSave Plan and options granted under the ShareSave Plan.
Eligibility
The ShareSave Plan establishes who is eligible to participate in each of the various Parts of the ShareSave Plan as described in greater detail below.
General Terms of Part A of the ShareSave Plan
Part A is for the purpose of granting options to U.K. employees and directors who meet criteria specified in Part A which have tax benefits due to theirtax-advantaged status under U.K. law. The Committee may decide, in its discretion, when to issue invitations under Part A of the ShareSave Plan, but if an invitation is issued, Part A requires that an invitation is issued to all employees or directors who are Part A Eligible Employees as of the date of such invitation. In general terms, a “Part A Eligible Employee” includes employees
28
and directors (who meet criteria specified in Part A) of the Corporation or an entity in the Group selected to participate in Part A. As of February 28, 2018, the Corporation and the entities in the Group had approximately 435 employees and directors who were eligible for purposes of Part A.
Part A Eligible Employees who are the recipients of an invitation and who wish to apply for a grant of an option will be required to enter into a savings contract for either three or five years pursuant to which they will make voluntary payroll deductions to cover the cost of the shares of Common Stock purchased at the end of the savings contract period. The terms of the options will permit Part A Eligible Employees to purchase shares of Common Stock at a discounted price of not less than 80% of the fair market value at the time they are invited to participate (or, in the case of an option which will be satisfied by the issue of new shares of Common Stock, the nominal value of a Share if higher than the fair market value), in compliance with Schedule 3 to the Income Tax (Earnings and Pensions) Act 2003. Each Part A Eligible Employee will be entitled to purchase a certain number of shares of Common Stock at the end of the savings contract period as determined by dividing the total amount of payroll deductions (plus a bonus payable at the end of the savings contract on a date specified in the invitation (the “Bonus Date”)) by the discounted price of the shares of Common Stock. All shares of Common Stock purchased under an option will be paid for in full at the time the option is exercised by transfer of the purchase price from the employee’s payroll deduction account. The Corporation will be required to transfer or issue the relevant shares of Common Stock to the participant not later than 30 days after exercise of the option. The closing price for our shares of Common Stock on the NASDAQ on February 28, 2018 was $64.95 per share.
Monthly contributions to be made by each Part A Eligible Employee cannot exceed the lesser of 500 British sterling pounds per month (or such other amount permitted by the relevant legislation from time to time) and such other maximum contribution as may be determined from time to time by the Committee. If valid applications are received for an aggregate number of shares of Common Stock that exceed a maximum number as set by the Committee, then the Committee may scale down applications to the extent necessary using a method stated in the ShareSave Plan or otherwise agreed with Her Majesty’s Revenue and Customs (“HMRC”).
Generally, options may only be exercised by a holder while he or she remains employed by the Corporation or the entities in the Group. The previous sentence does not apply if the holder ceases to be employed by the Corporation as a result of injury, disability, redundancy, retirement, a relevant transfer within the meaning of the Transfer of Undertakings (Protection of Employment) Regulations 2006, the holder’s employer ceasing to be within the Group by reason of a change in control, the holder’s employment terminating because it relates to a business or part of a business which is transferred to a person, who is not an associated company of the Corporation, where the transfer is not a relevant transfer within the meaning of the Transfer of Undertakings (Protection of Employment) Regulations 2006. Also, such sentence does not apply if the holder ceases to be employed for any reason after holding options for at least three years. In such cases, the option holder may exercise his or her options within thesix-month period following the date on which he or she ceases to be a director or employee of the Corporation or the entities in the Group. In the event of a holder’s death, his or her options may be exercised by a personal representative within one year following the date of death.
Subject to the above paragraph, stock options granted under Part A shall become exercisable on the Bonus Date and shall lapse and no longer be exercisable upon the earliest to occur of: (a) thesix-month anniversary of the Bonus Date; (b) the date when the option holder ceases to be employed by the Corporation or the entities in the Group (subject to the exceptions set out in the previous paragraph); (c) the date of the passing of a resolution or a court order for the compulsorywinding-up of the Corporation; (d) the date when the option holder becomes bankrupt or enters into a compromise with his creditors generally; (e) the date when the option holder purports to transfer, charge or otherwise alienate the option; or (f) the date when the option holder chooses to stop or provides notice of an intent to stop making monthly contributions under the savings contract before the end of that contract.
29
General Terms of Part B of the ShareSave Plan
Part B is for the purpose of making awards to Part B Eligible Employees. “Part B Eligible Employees” include employees of the Corporation or its subsidiaries for U.S. tax purposes selected to participate in Part B who are eligible under an employee stock purchase plan established in accordance with Section 423 of the Code. Any person who is a Part B Eligible Employee as of the first business day of a given offering period, which is a set period of time determined by the Committee, shall be eligible to participate in such offering period subject to the applicable requirements of the ShareSave Plan and the limitations of Section 423. At the discretion of the Committee, employees who are citizens or residents of a foreign jurisdiction may be excluded if granting them an option under the ShareSave Plan would violate the laws of such jurisdiction or if compliance with the laws of that jurisdiction would cause the ShareSave Plan to violate Section 423 of the Code. As of February 28, 2018, the Corporation and entities in the Group had approximately 650 employees who were eligible for purposes of Part B.
During the term of Part B of the ShareSave Plan, the Corporation may designate one or more offering periods as determined by the Committee, provided that for purposes of this Part B of the ShareSave Plan, no offering period shall exceed 27 months in any circumstances. The beginning and ending dates of each offering period and each purchase date will be determined by the Committee. During such offering periods, each Part B Eligible Employee may elect to purchase shares of Common Stock through voluntary payroll deductions during the applicable offering period. The maximum number of shares of Common Stock subject to the option to be purchased shall be determined as of the commencement of the offering period by dividing the participating Part B Eligible Employee’s total contributions for that offering period indicated in his or her enrollment documents by the purchase price subject to adjustment as provided under the ShareSave Plan. The purchase price for each offering will be at least 85% of the fair market value on the first day of the relevant offering period. The fair market value of the shares of Common Stock shall generally mean the closing price per share of Common Stock as reported in the Wall Street Journal (or other reporting service approved by the Board or Committee) on such date.
Each participating Part B Eligible Employee will be contacted and asked to confirm his or her intention to exercise his or her options. Upon confirmation, the participating Part B Eligible Employee’s option will be exercised as soon as administratively feasible on or before the last trading day of the offering period, but after the participating Part B Eligible Employee has made his or her final contribution to the ShareSave Plan in accordance with the enrollment documents. The shares of Common Stock purchased upon exercise of an option hereunder shall be deemed to be transferred to the participant as soon as practicable upon request or after the purchase date. Part B may allow participants to cancel or reduce (or both) their payroll deduction authorizations.
In accordance with the overall cap described above, and subject to stockholder approval at the 2018 Annual Meeting, no more than 1,650,000 shares of Common Stock (which is equal to the total reserve for the overall ShareSave Plan) may be sold pursuant to the Part B. In the event that the Committee determines that an adjustment is appropriate by reason of any stock split, reverse stock split, stock dividend, combination or reclassification of the shares of Common Stock, or any other increase or decrease in the number of shares of Common Stock effected without receipt of consideration by the Corporation, the Committee may proportionately adjust (a) the number of shares of Common Stock that have been authorized for issuance under the ShareSave Plan but have not yet been placed under option, (b) the maximum number of shares of Common Stock that may be purchased by a participant in an offering period, (c) the number of shares of Common Stock available under the ShareSave Plan, and (d) the price per Share of each option under the ShareSave Plan that has not yet been exercised. In the event of a dissolution or liquidation of the Corporation, any offering period then in progress will terminate immediately prior to the consummation of such action, unless otherwise provided by the Committee. In the event of a Corporate Transaction (generally includes a sale of all or substantially all of the Corporation’s assets or a merger or consolidation of the Corporation into another corporation), each option outstanding under the ShareSave Plan shall be assumed or an equivalent option shall be substituted by the successor corporation or a parent or subsidiary of such successor
30
corporation. In the event that the successor corporation refuses to assume or substitute for outstanding options, each offering period then in progress will be shortened and a new purchase date will be set, as of which date any offering period then in progress will terminate.
A Part B Eligible Employee will not be granted an option under Part B if the Part B Eligible Employee, immediately after the option is granted, owns stock having 5% or more of the total combined voting power or value of all classes of stock of the Corporation and/or holds outstanding options to purchase stock having 5% or more of the total combined voting power or value of all classes of stock of the Corporation. No Part B Eligible Employee will be granted an option that permits the Part B Eligible Employee to accrue rights to purchase shares of Common Stock under all employee stock purchase plans of the Corporation at a rate that exceeds $25,000 (or such other maximum as may be prescribed from time to time under the Code) of fair market value of such shares of Common Stock (determined at the date of grant) for each calendar year in which the option is outstanding at any time in accordance with the provisions of Section 423(b)(8) of the Code.
Upon termination of a participant’s status as an Part B Eligible Employee prior to the purchase date of an offering period for any reason, other than as a result of injury, disability, redundancy, retirement or death, the contributions and any interest credited to his or her account will be refunded to the Part B Eligible Employee or his or her beneficiary or estate as the case may be, through normal payroll processing as soon as administratively practicable following such termination.
If a participant ceases to be employed by the Corporation as a result of injury, disability, redundancy, death or retirement after reaching any age he or she is bound to retire under his or her employment contract, the option holder (or a personal representative in the case of death) may exercise his or her options within the three-month period following the date on which he or she ceases to be an Part B Eligible Employee, provided that the participant may only exercise his or her options using the accumulated contributions in his or her account (excluding any interest) at the date of cessation and in no circumstances can an option be exercised after the purchase date. If the participant fails to exercise his or her options within such three-month period, his or her account balance will be refunded to him or her or his or her beneficiary or estate, as the case may be, through normal payroll processing as soon as administratively practicable following such date of cessation.
All shares of Common Stock purchased under an option will be paid for in full at the time the option is exercised by transfer of the purchase price from the employee’s payroll deduction account. Any payroll deductions accumulated in a participant’s account that are not applied toward the purchase of shares of Common Stock due to limitations imposed by the ShareSave Plan will be returned to the participant with interest (unless otherwise specified in the enrollment documents) as soon as administratively feasible.
General Terms of Part C of the ShareSave Plan
Part C is for the purpose of granting options or stock equivalent units to employees and directors (other thannon-executive directors) of the Corporation and entities in the Group and to which the limitations of Part A or Part B are not intended to apply. As of February 28, 2018, the Corporation and entities in the Group had approximately 830 employees and directors who were eligible for purposes of Part C.
The terms of Part C are in general terms the same as those of Part A above except that:
31
Nontransferability of Options
Generally, options are not assignable or transferable by the holder in any way, except for transfer by the laws of inheritance upon the holder’s death. Any other attempt to assign, pledge (for example, as security for a loan), sell, make a gift of an option, or otherwise transfer an option will not be recognized by the Corporation. Except pursuant to permitted transfers described above, only the option holder (or his or her guardian or legal representative, if permitted by applicable Code provisions) may exercise his or her options during the option holder’s lifetime.
Recent Stock Price
The closing price for our shares of Common Stock on the NASDAQ on February 28, 2018 was $64.95 per share.
Amendments to and Termination of the ShareSave Plan
The ShareSave Plan generally may be amended, modified or terminated, in whole or in part, by the Committee in its sole discretion; provided however, that certain types of amendments will require the consent of the Corporation’s stockholders. No amendment, modification or termination may adversely affect existing rights under the ShareSave Plan except where the amendment has been approved by those who would be adversely affected by the amendment in such manner as required by the ShareSave Plan.
Amendments to Part A of the ShareSave Plan prior to HMRC approval may be made by the Committee as may be necessary or desirable in order to obtain HMRC approval. After receipt of HMRC approval, the Committee may amend the ShareSave Plan in its discretion acting reasonably.
No amendments to Part B of the ShareSave Plan may be made that would result in any provision of Part B failing to comply with Rule16b-3 of the Exchange Act or qualify under Section 423 of the Code. In addition, to the extent necessary to comply with Rule16b-3 of the Exchange Act or Section 423 of the Code (or any successor rule or provision or applicable law or regulation), the Corporation shall obtain stockholder approval with respect to any amendment in such a manner and to such a degree as required.
Unless sooner terminated by the Committee, the ShareSave Plan will terminate on the tenth anniversary of its approval by the Corporation’s stockholders; however, options granted prior to the ShareSave Plan’s termination will remain in force and continue to be governed by the provisions of the ShareSave Plan. The Committee may terminate the ShareSave Plan at any time and for any reason.
32
Adjustments
In the event that the Corporation undergoes a capitalization issue, subdivision, consolidation, or reduction of share capital, the Committee shall in accordance with the terms of the ShareSave Plan, proportionately adjust the number of shares of Common Stock over which an option is granted and the share price. Where the ShareSave Plan is subject to the approval of the Corporation’s stockholders, such adjustment will require the prior approval of the Corporation’s stockholders if required by law or the rules of any relevant exchange.
Governing Law
The ShareSave Plan and all options granted under the ShareSave Plan shall be governed by and construed in accordance with the laws of England and Wales, except for Part B of the ShareSave Plan which is governed by and determined in accordance with the laws of the State of Delaware of the United States.
Certain U.S. Federal Income Taxes and Tax Withholding
This discussion represents only a general, brief summary and is not intended to cover all tax consequences of options. Since tax laws and regulations may change, and interpretations of these laws and regulations may change their application for each individual participant, each participant is urged to consult his or her own tax advisor as to specific tax consequences.
The following discussion of the tax consequences of Part B of the ShareSave Plan is limited to the United States federal income tax consequences to individuals who are citizens or residents of the United States, other than those individuals who are taxed on a residence basis in a foreign country. Furthermore, the tax consequences outlined below apply only with respect to an employee whose income is subject to United States federal income tax during the period beginning with the grant of an option and ending with the disposition of the shares of Common Stock acquired through the exercise of the option. If during this period, the participant is subject to income tax in a foreign jurisdiction and/or the participant is subject to state/local income tax in the United States, the participant should consult an attorney or tax advisor to determine the applicable tax consequences.
In addition, the laws of any other jurisdiction that could be relevant either to the Corporation, a subsidiary of the Corporation or an option holder are not discussed here. In particular, the tax consequences under the laws of the United Kingdom, where a substantial number of option holders reside and a substantial portion of the Corporation’s operations occur, are not discussed. Information regarding tax consequences applicable to securities received under Parts A and C of the ShareSave Plan, if required, should be obtained from participants’ own personal tax advisors.
Part B of the ShareSave Plan is intended to qualify under Section 423 of the Code. Under this section, a participant will not be required to recognize taxable income at the time of the grant of the option or at the time shares are purchased under the Part B of the ShareSave Plan. The participant may, however, become liable for tax upon the disposition of the shares of Common Stock acquired, as described below.
In the event that shares acquired pursuant to Part B of the ShareSave Plan are not sold or disposed of (including by way of gift) prior to two years after the date of the grant of the option (as determined for tax purposes) or one year after the relevant exercise date, the lesser of (a) the excess of the fair market value of the shares at the time of such disposition over the purchase price, or (b) the excess of the fair market value of the shares at the date of grant (as determined for tax purposes) over an amount equal to what the purchase price would have been if it had been computed as of the date of the grant (as determined for tax purposes), will be treated as ordinary income to the participant. Any further gain on disposition will be treated as long-term capital gain and any loss will be treated as a capital loss.
In the event the participant sells or disposes of the shares before the expiration of the holding periods described above, the excess of the fair market value of the shares on the exercise date over the purchase price will be treated as ordinary income to the participant. This excess will constitute ordinary income even if
33
no gain is realized on the sale or a gratuitous transfer of the shares is made. The balance of any gain will be treated as a capital gain and will be treated as a long-term capital gain if the shares have been held for more than one year. If the shares are sold for less than their fair market value on the exercise date, the participant may recognize a capital loss equal to the difference between the sales price and the value of the shares on the exercise date.
Tax Advice
The preceding discussion is based on U.S. tax laws and regulations presently in effect, which are subject to change, and the discussion does not purport to be a complete description of the U.S. income tax aspects of the ShareSave Plan. A Participant may also be subject to state and local taxes in connection with the grant of awards under the ShareSave Plan. In addition, a number of Participants reside outside the U.S. and are subject to taxation in other countries. The actual tax implications for any Participant will depend on the legislation in the relevant tax jurisdiction for that Participant and their personal circumstances.
Other Tax Matters.The Corporation may withhold, or require the participant to pay, any applicable withholding or other taxes arising in connection with the grant, vesting or exercise of an option.
General.The ShareSave Plan is not qualified under Section 401(a) of the Code, nor is it subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended.
No Rights to Continued Employment or Future Benefits
Nothing in the ShareSave Plan, nor the grant of any option, shall be construed to give any person the right to be retained in the employ of the Corporation or any subsidiary or to affect the right of the Corporation or any such subsidiary to terminate the employment or engagement of any person at any time with or without cause, to the extent otherwise permitted by law. The ShareSave Plan creates no ongoing obligation of the Corporation or any subsidiary to provide any future benefit of similar value.
The Board of Directors recommends a vote “FOR” the approval of the ShareSave Plan.
|
On March 13, 2018, the Audit Committee appointed the accounting firm KPMG LLP (“KPMG LLP”)PwC to serve as the Corporation’sCompany’s independent registered public accounting firm with respect to the 20182021 fiscal year, to audit the consolidated financial statements of the CorporationCompany for the fiscal year ending December 31, 20182021 and to perform other appropriate audit related services.
A representative of KPMG Audit Plc (“KPMG Audit”), the Corporation’s independent registered public accounting firm and auditor for the fiscal year ending December 31, 2017, is expected to be available by telephone at the Annual Meeting. KPMG AuditPwC also served (with effect from May 24, 2019) as the Corporation’sCompany’s independent registered public accounting firm for the 2016, 2015, 2014, 2013, 20122019 fiscal year, having replaced KPMG LLP, which served from the 2018 Annual Meeting of Stockholders, and 2011 fiscal years. The available representative will have the opportunity to respond to questions and to make a statement if such representative desires to do so.
Although current law, rules, and regulations, as wellits predecessor KPMG Audit Plc, who served as the charter of the Audit Committee, require the Audit Committee to engage, retain, and supervise the Corporation’sCompany’s independent registered public accounting firm for fiscal year 2011 through the Board considersend of the selection of such firm to be an important matter of stockholder concern and is
The Board recommends you vote “FOR” the ratification of PwC as our independent accounting firm for 2021. | Although current law, rules and regulations, as well as the charter of the Audit Committee, require the Audit Committee to engage, retain and supervise the Company’s independent registered public accounting firm, the Board considers the selection of such firm to be an important matter of stockholder concern and is submitting the selection of PwC for ratification by stockholders as a matter of good corporate practice. In the event that our stockholders fail to ratify the selection, it will be considered a recommendation to the Board and the Audit Committee to consider the selection of a different firm. Even if the selection is ratified, the Audit Committee may, in its discretion, select a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of the Company and our stockholders. A representative of PwC is expected to be available by telephone at the Annual Meeting. The available representative will have the opportunity to respond to questions and to make a statement if such representative desires to do so. |
34
submitting the selection of KPMG LLP for ratification by stockholders as a matter of good corporate practice. In the event that our stockholders fail to ratify the selection, it will be considered a recommendation to the Board of Directors and the Audit Committee to consider the selection of a different firm. Even if the selection is ratified, the Audit Committee may in its discretion select a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of the Corporation and our stockholders.
See also “Audit Committee Report,” “Principal Accountant Fees and Services,” and “Audit CommitteePre-Approval Policies and Procedures” below for additional information.
Change of Independent Public AccountantsAccountant
As reported on the Corporation’s current reportCompany’s Current Report on Form8-K dated March 15, 2018, KPMG Audit, the Corporation’s independent registered public accounting firm and auditor for the fiscal year ending December 31, 2017, informed the Audit committee that due to a reorganization of KPMG’s U.K operations, KPMG in the U.K. instigated an orderly wind down of the business of KPMG Audit and, in view of that, requested a transfer over toApril 11, 2019, on April 5, 2019, KPMG LLP, of the audit services provided to the Corporation. Accordingly, in view of KPMG LLP’s agreement to accept the audit role, KPMG Audit has confirmed that it will not be able to accept appointment (and thereby ratification by the Corporation’s stockholders) as the Corporation’sCompany’s independent registered public accounting firm for the Corporation’s 2018 fiscal year andended December 31, 2018, notified the Company of its intention to auditresign as the financial statementsCompany’s independent registered public accounting firm in advance of the Corporationaudit for the fiscal year ending December 31, 2018. In view of this,2019. Following consultation with the Board, the Audit Committee has approved the appointment of KPMG LLP to replace KPMG Auditappointed PwC on May 24, 2019 as the Corporation’sCompany’s independent registered public accounting firm for the Corporation’s 2018 fiscal year and to audit the Corporation’s financial statements for the fiscal year ending December 31, 2018,2019 and KPMG’s appointment, is now being put to a stockholder ratification vote atprovide reviews of the Corporation’s 2018 annual meeting of stockholders.Company’s quarterly reporting for such fiscal year, other than for the quarter ended March 31, 2019, which was reviewed by KPMG LLP.
In connection with this change, the CorporationCompany confirms that the reports of KPMG LLP and its predecessor firm, KPMG Audit PLC (collectively “KPMG”), on the Corporation’sCompany’s consolidated financial statements for the most recent fiscal years ended December 31, 20172018 and 20162017 did not contain any adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principle.
| | 56 |
The audit reports of KPMG Audit on the effectiveness of the Corporation’sCompany’s internal control over financial reporting as of December 31, 20172018 and 20162017 also did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty or audit scope.opinion.
Furthermore, inDuring the Corporation’sfiscal years ended December 31, 2018 and December 31, 2017 and 2016 fiscal years andduring the subsequent interim reporting periodsperiod from January 1, 2019 through March 13, 2018to the date of KPMG LLP’s notification of its intention to resign, there were (i) no disagreements (as that term is defined in Item 304(a)(1)(iv) of RegulationS-K and the related instructions) between the CorporationCompany and KPMG Audit on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, that, if not resolved to the satisfaction of KPMG, Audit, would have caused KPMG Audit to make reference to the subject matter of the disagreement in connection with its reports on the Corporation’sCompany’s consolidated financial statements for such years or periods, and (ii) no “reportable events” (as that term is defined in Item 304(a)(1)(v) of RegulationS-K).
In connection with the transition from KPMG Audit over to KPMG LLP, the Corporation, asAs it iswas required to do, the Company provided KPMG Audit with a copy of the Form8-K dated March 15, 2018 (“the Form8-K”)reporting KPMG’s resignation and requested that KPMG Audit provide the CorporationCompany with a letter addressed to the Securities and Exchange CommissionSEC stating whether or not KPMG Audit agreedagrees with the disclosures contained in the Form8-K.above disclosures. A copy of KPMG Audit’sKPMG’s letter, dated March 15, 2018,April 10, 2019, in which KPMG Audit confirmed that it agreed with the Corporation’sCompany’s disclosures, was attached as Exhibit 16.1 to thesuch Form8-K.
DuringPrincipal Accountant Fees and Services
Aggregate fees for professional services rendered to the Corporation’s two mostly recently-auditedCompany by PwC and other global PwC member firms and KPMG LLP and other global KPMG member firms for the fiscal years that ended December 31, 20172020 and 2016, and during the subsequent interim reporting periods through March 13, 2018, neither the Corporation nor anyone acting on its behalf consulted KPMG LLP regarding any matters identified within Items 304(a)(2)(i) or (ii) ofRegulation S-K.
Fee Type | Fiscal 2020 $’000 | Fiscal 2019 $’000 | ||||
Audit | PwC | 2,562 | 2,400 | |||
KPMG | - | - | ||||
Audit Related | PwC | - | - | |||
KPMG | 40 | 100 | ||||
Tax | PwC | - | - | |||
KPMG | - | - | ||||
Other | PwC | 117 | 223 | |||
KPMG | - | - | ||||
Total | PwC | 2,679 | 2,623 | |||
KPMG | 40 | 100 | ||||
|
35
Note 1: | The aggregate fees included in Audit fees are fees billed for the fiscal years for the audits of the consolidated financial statements of the Company, statutory and subsidiary audits, and review of documents filed with the SEC. The aggregate fees included in each of the other categories are fees billed in the respective fiscal years. |
| | 57 |
Audit Committee Pre-Approval Policies and Procedures
The BoardAudit Committee pre-approves all audit and permitted non-audit services provided by the Company’s independent registered public accounting firm. The Audit Committee may delegate pre-approval authority to the Audit Committee Chair, provided all such delegated pre-approval decisions are reported to the Audit Committee at its next regularly scheduled meeting. General pre-approval of Directors recommends a vote “FOR” ratificationcertain audit, audit-related and tax services, which are detailed as to type of service, is granted by the appointmentAudit Committee at each quarterly meeting. The Audit Committee subsequently reviews fees that are paid for such pre-approved services. Specific pre-approval is required for all other services that are requested of KPMG LLP asour independent registered public accounting firm. These requests are reviewed quarterly, and the Corporation’sstatus of all such requests and services is reviewed with the Audit Committee.
In fiscal years 2020 and 2019, the Company did not make any payments to its independent registered public accounting firm for which the de minimis exception was used.
| | 58 |
The Board has adopted a written Audit Committee Charter.
As part of fulfilling its responsibilities, the Audit Committee:
1. | held meetings with the Company’s Business Assurance function and the independent registered public accounting firm, both in the presence of management and privately to discuss the overall scope and plans for the respective audits, the results of the audits, the evaluations of the Company’s internal controls and the overall quality of the Company’s final reports; |
2. | reviewed and discussed the audited consolidated financial statements for fiscal year 2020 with management and the independent registered public accounting firm; |
3. | discussed with the independent registered public accounting firm the matters required to be discussed by the applicable requirement of the Public Company Accounting Oversight Board and the SEC; and |
4. | received the written disclosure and the letter from PwC required by applicable requirements of the Public Company Accounting Oversight Board Rule regarding the independent accountant’s communications with the Audit Committee concerning independence, and discussed that firm’s independence with representatives of that firm. The Audit Committee has also considered whether PwC’s provision of non-audit services to the Company is compatible with its independence. |
Based upon these reviews and discussions, the Audit Committee has recommended to the Board, and the Board has approved, that the Company’s audited consolidated financial statements be included in the Company’s Annual Report on Form 10-K for the fiscal year endingended December 31, 20182020 filed with the SEC.
No portion of this Audit Committee Report shall be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or Securities Exchange Act of 1934, as amended (the “Exchange Act”), through any general statement incorporating by reference in its entirety the Proxy Statement in which this report appears, except to the extent that the Company specifically incorporates this report or a portion of it by reference. In addition, this report shall not be deemed to be filed under either the Securities Act or the Exchange Act.
The foregoing report has been approved by all members of the Audit Committee.
DAVID F. LANDLESS, Chair
MILTON C. BLACKMORE
ELIZABETH K. ARNOLD
| | 59 |
INFORMATION ABOUT OUR EXECUTIVE OFFICERS
|
Dr. Philip J. Boon
Age: 58Age: 61
Executive Officer since June 1, 2009
Dr. Boon was appointed as Chief Operating Officer effective November 2015. In this role, Dr. Boon has direct responsibility for the global Fuel Specialties business as well as an overseeing role with our global Personal CarePerformance Chemicals and Oilfield Specialties businesses and has a key role in the strategic development of Innospec. Prior to this, Dr. Boon was the Executive Vice President, Business Operations from June 2009 and was responsible for all our businesses in Europe, Middle East and Africa (EMEA). Dr. Boon joined the companyCompany in 1997 and has held various senior management positions covering most operational aspects of the business. He has over 2530 years international experience in the specialty chemicals industry and previously held positions with Ciba Geigy and FMC in the USAU.S. and Europe. He has a PhD in Chemistry from Leicester University.
Mr. Ian P. Cleminson
Age: 52
Mr. Ian P. Cleminson Age: 55 Executive Officer since July 3, 2006 |
Mr. Cleminson serves as Executive Vice President and Chief Financial Officer (“CFO”)CFO to the Corporation,Company, having joined it in February 2002. Prior to this appointment, Mr. Cleminson was Financial Controller for the Fuel Specialties and Performance Chemicals business units within the Corporation.Company. He joined the CorporationCompany from BASF plcplc. where, between 1999 and 2002, he served as Financial Controller of their SuperabsorbantsSuperabsorbents division. Previously, he worked as an accountant in private practice since 1989.
Dr. Catherine Hessner
Age: 59
Dr. Catherine Hessner Age: 62 Executive Officer since August 12, 2003 |
Dr. Hessner serves as Senior Vice President, Human Resources (“SVP, HR”) of the Corporation,Company, having joined it in March 2003. Prior to joining the Corporation,Company, she served as European Human Resources Director for Nova Chemicals, a U.S. commodity chemicals company. From 1995 to 1999, Dr. Hessner served as European HR Director, based in the U.K., for Anheuser-Busch, the U.S. brewing Corporationcorporation and, prior to that, spent nine years with various divisions of Mars Incorporated in a variety of human resources and general business roles. Dr. Hessner has informed the Company that she will retire, effective April 30, 2021.
Dr. Ian M. McRobbie
Age: 69
Dr. Ian McRobbie Age: 72 Executive Officer since May 7, 2002 |
Dr. McRobbie serves as Senior Vice President Research and Chief Technology Officer of the Company, having joined the Corporationit in January 2002. Between 1989 and 2002, he was Technical Director of A H Marks and Company Limited, a privately owned U.K. chemical company operating in agrochemical and specialty chemical markets. Prior to this, he worked in senior research and manufacturing roles for Seal Sands Chemical Co. Limited (a wholly owned subsidiary of the Hexcel Corporation based in California) and BTP plcplc. (now part of Clariant).
36
| | 60 |
Mr. Brian R. Watt
Age: 59
Mr Brian Watt Age: 62 Executive Officer since January 1, 2010 |
Mr. Watt was appointed Senior Vice President, Corporate Development and Investor Relations in August 2017. Mr. Watt has significant experience in the chemicals industry and prior to joining the CorporationCompany, he held commercial positions in Shell, ICI, Avecia and Astra Zeneca. Mr. Watt joined the CorporationCompany as Mergers and Acquisitions Manager in 2001 and latterly he then held positions in both the Performance Chemicals and Fuel Specialties business units and was appointed as Vice President, Strategic Planning and Regulatory Affairs in 2010, before taking up his current role. Mr. Watt has informed the Company that he has decided to retire, effective April 30, 2021.
Mr. David B. Jones
Age: 49
Mr. David B. Jones Age: 52 Executive Officer since March 1, 2018 |
Mr. Jones was appointed Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary on March 1, 2018. Before joining the Corporation,Company, Mr. Jones served as Vice President, Deputy General Counsel of West Corporation, and Chief Counsel of Lennox International, and prior to that he was a Partner with DLA Piper LLP. Mr. Jones is a Certified Public Accountant and was in private practice with Ernst & Young and PwCPricewaterhouseCoopers prior to commencement of his legal career.
Mr. David E. Williams
Age: 65
Executive Officer from September 17, 2009 to February 28, 2018
Mr. D. Williams retired with effect from 28 February 2018. Mr. D. Williams was appointed as Vice President, General Counsel and Chief Compliance Officer in September 2009. In December 2011, Mr. D. Williams was also appointed as Corporate Secretary. Before joining the Corporation, Mr. D. Williams worked as an attorney with MarkWest Energy Partners, LP, in Denver where he was responsible for commercial and regulatory legal matters. He has over thirty years’ experience as an attorney, covering a broad range of legal matters. Mr. D. Williams has a law degree from the University of Louisville, Brandeis School of Law, and an undergraduate degree in Management from Park University.
Family Relationships
There are no family relationships between any of the persons referred to in the sections “INFORMATION ABOUT THE BOARD OF DIRECTORS” OR “INFORMATION ABOUT THE EXECUTIVE OFFICERS” above.
37
| | 61 |
The following Compensation Discussion and Analysis (“CD&A”) is designed to explain the Company’s executive compensation philosophy and programs and describes the material elements of compensation for 20172020 for the individualsNEOs listed in the “Summary Compensation Table” as our NEOs.. The tables following the Compensation Discussion and AnalysisCD&A contain specific information on the compensation awarded to or earned by the NEOs in 2017.2020.
AtThis CD&A is organized into the 2017 Annual Meeting of Stockholders,following sections:
Section | Description | |
Executive Summary | Highlights of our executive pay programs, key results in the year and summary of Company’s compensation philosophy | |
Say-on-Pay Results | Our Say-on-Pay results for 2020 | |
How We Set Pay | Goals of our executive pay programs and summary of how our Compensation Committee establishes and governs the programs | |
Elements of Pay | Elements of pay and description of how our incentive compensation programs are designed to reward increases in stockholder value, company performance against financial targets and executive performance against personal objectives | |
Other Pay Programs and Policies | Information on other aspects of our compensation programs |
2020 Results
The Company’s financial results in 2020 were adversely impacted by the Corporation conducted anon-bindingCOVID-19 advisory vote on its executive compensation. At that meeting, approximately 99% ofpandemic and the stock present and entitled to vote onglobal economic environment. Unprecedented market conditions caused by circumstances outside management’s control meant we missed our financial targets for the proposal voted to “Approve” executive compensation. The Compensation Committee takes the outcome of the vote into consideration when reviewing its executive compensation programs and as the advisory vote approved the compensation, no changes or modificationsyear, which had been set prior to the executive compensation programs orpandemic. The impact of COVID-19 on our global business continues to evolve. However, we have maintained a strong balance sheet, delivered a higher total stockholder return (“TSR”) than our Comparator Group and continued to operate the compensation of any ofbusiness throughout the NEOs have been made aspandemic. Improving business conditions during the 3rd and 4th quarters combined with efforts by management to focus on cash generation enabled the Company to maintain its dividend for 2020 and enter 2021 with a $104.7 million net cash position.
| | 62 |
Corporate Free Cash Flow Ended year with net cash position of $104.7M and paid off all our external bank debt | Stockholder Dividend Continued dividend policy from 2019, paying $1.04 in 2020, an increase from $1.02 in 2019 and $0.89 in 2018 | Total Stockholder Return Delivered 33% over the last 3 years vs our 2020 Chemicals Industry Comparator Group average of 7% during the same period | ||||||
Continuity of Operations Operated manufacturing facilities throughout the pandemic | Enhanced Health and Safety Procedures Strengthened health and safety protocols in accordance with local guidelines at each of our operating facilities | Performance Chemicals Operating Income for 2020 up 8% over 2019 with growth in high margin segments and increased focus on driving sustainability strategy | ||||||
Oilfield Services Rebounded from all-time low oil prices and plummeting demand to finish the year EBITDA neutral and with a strengthened position in Middle East region | Fuel Specialties New products introduced and experienced good growth in 2020 in new markets in developing regions | Drag Reducing Agents Experienced strong growth in sales in Oilfield Services | ||||||
New Product Introduction and Commercialization Products launched in the last 5 years have accounted for 23% of total sales in 2020 |
| | 63 |
As a result of the advisory vote, althoughCOVID-19 pandemic, the demand for oil and fuel collapsed and the financial performance of our Fuel Specialties and Oilfield Services divisions fell below the threshold level for bonus payments. Overall, the financial performance of the Company was below the threshold level required to receive a pay-out under the rules of all Company bonus plans for all employees, including NEOs. As part of our pay-for-performance culture, the Compensation Committee has made certain modificationsthe discretion to consider the economic and refinements asbusiness challenges the Company faces. In recognition of the efforts, leadership and accomplishments of the NEOs and all other employees under extraordinary circumstances, the Compensation Committee exercised its discretion to make available a $12 million discretionary pool allowing for a potential one-time discretionary payment to employees. The size of the discretionary pool equates to approximately 50% of the value of the total potential bonus payments at target across all employees, including the NEOs. As part of its regular review process, as discussed herein.this, the Compensation Committee and the other independent members of the full Board approved one-time discretionary payments to the NEOs totaling $835,088, which equates to around 7% of the total discretionary pool.
Compensation Philosophy and Overall Objectivesphilosophy
The compensation philosophy of the CorporationCompany is to link executive compensation to continuous improvement in corporate performance and increases in stockholder value, while at the same time to allowallowing the CorporationCompany to attract and retain the executive talent required to successfully manage our business. The overall compensation program is designed to motivate our employees to achieve business objectives and maximize their long-term commitment to our success.
For the CEO, we target his base salary in the upper quartile of the relevant market for the role, given his track record of success and tenure with the Company. For the other NEOs, we target the market median (50th percentile) but consider other factors including individual experience and expertise, overall performance, internal pay equity and contribution to the Company.
Ø | Our CEO’s base salary was increased by 4% to $1,170,000 for 2020, which was within 25% of the average base salary for CEOs in the Comparator Group companies, as defined below, and 10% below the upper quartile of the U.S. survey group in the year. |
Ø | Following the 2020 increases, base salaries for the other NEOs increased by an average of 3.5% and were all within a 5% range of the market median data. |
NEOs for 2020 |
Mr. Patrick S. Williams President and Chief Executive Officer |
Mr. Ian P. Cleminson Executive Vice President and Chief Financial Officer |
Dr. Philip J. Boon Executive Vice President and Chief Operating Officer |
Mr. Brian R. Watt Senior Vice President, Corporate Development and Investor Relations |
Dr. Ian M. McRobbie Senior Vice President and Chief Technology Officer |
| | 64 |
Basic Compensation Practices
Our executive compensation program engages certain pay practices to accomplish our overall objectives while avoiding other, more problematic or controversial practices.
What We Do | ||||||
Pay for performance | Target executive pay around market median for NEOs and upper quartile for the CEO, while also considering tenure, experience and other factors | |||||
Emphasize long-term performance | Maintain minimum stock ownership guidelines | |||||
Design compensation package with mix of operational and market-based metrics | Engage independent advisors for Compensation Committee | |||||
Have a clawback policy | ||||||
What We Don’t Do | ||||||
| Allow directors and executive officers to |
| Pay dividends on unvested performance | |||
| Pay tax gross ups to our NEOs |
| Pay above market interest on deferred | |||
| Allow option repricing or share recycling |
| | 65 |
Compensation Elements and Performance Metrics
The Corporation aimsCompensation Committee seeks to achieve this by providingan appropriate balance between fixed and variable compensation elements to link a significant proportion of compensation to performance. The elements are designed to provide incentive for our NEOs to achieve goals that alignare important to the Company’s success.
Compensation Element | Performance Metrics for 2020 | Rationale | ||
Base Salary | Fixed pay targeted at upper quartile of relevant market for the CEO and market median for other NEOs | |||
Management Incentive Compensation Plan (MICP -annual cash incentive) | • Corporate/Business performance (Operating Income, Cash Flow) • Represents 80% of target bonus | Rewards operational performance and profitability | ||
• Performance against personal objectives • Represents 20% of target bonus | Rewards achievement of personal objectives relative to current economic and business challenges | |||
Market Value Stock Option Awards (Long-term equity) | Directly aligns with value delivered to stockholders as such options only have value if stock price increases over long period of time | |||
Full Value Stock Awards (Long-term, performance-based equity) | • Relative TSR performance vs • Revenue growth • Earnings per share growth | Full vesting requires delivery of long-term financial and relative TSR performance | ||
Market Value Cash Incentive Awards (Long-term and payable in cash) | Cash-based award that directly aligns with value delivered to stockholders as such awards only have value if stock price increases over long period of time | |||
Full Value Cash Incentive Awards (Long-term, performance-based and payable in cash) | • Relative TSR performance vs • Revenue growth • Earnings per share growth | Full vesting requires delivery of long-term financial and relative TSR performance |
| | 66 |
Balance of Fixed and Variable Compensation
For Executive Officers’ interestsOfficers, the target is at least 50% of total compensation is delivered through variable pay with stockholder valuea mix of long-term and achievementshort-term incentives and cash and equity compensation. In 2020 over 50% of overall compensation for the CEO and other NEOs was delivered through variable compensation.
Details of our long-term strategies withinpay programs in 2020, to include say-on-pay results, how we set pay, elements of pay and other pay programs are detailed in the frameworkfollowing sections of the CD&A.
At the 2020 Annual Meeting of Stockholders, the Company conducted a non-binding advisory vote on its executive compensation. At that meeting, approximately 99% of the stock present and entitled to vote on the proposal voted to “Approve” executive compensation. The Compensation Committee noted the high level of stockholder support when reviewing its executive compensation programs and made no changes or modifications to the programs as a direct consequence of this vote. The Compensation Committee takes the outcome of the vote into account when reviewing its executive compensation programs together with consideration of the interaction of our overall principlescompensation programs with our business objectives, input from the independent compensation consultant and executive market data. Each of good corporate governance.these factors is evaluated by the Compensation Committee in the exercise of its fiduciary duty to act in the best interests of the Company. As
| | 67 |
part of its regular review process regarding executive compensation, the Compensation Committee considered each of these factors and any modifications to its NEO compensation process are discussed herein.
The goals of the Corporation’sCompany’s executive compensation programs are to:
Ø | Establish pay levels that are necessary to attract and retain highly qualified executive officers, |
Ø | Recognize superior individual performance and taking on new responsibilities |
Ø | Balance short-term and long-term compensation to complement the |
Ø | Provide variable compensation opportunities linked to the |
Ø | Encourage |
Ø | Align Executive Officer compensation with the interests of stockholders; and |
Ø | Reward |
38
The CorporationCompany regularly reviews its executive compensation programs to ensureconfirm that each component is competitive and provides a balance between fixed elements of pay and performance related elements. No element of compensation is driven exclusively by tax, accounting or regulatory considerations. Further information on each of the key components of compensation is given in the Elements of Pay section below.
Role of the Compensation Committee and the Compensation Consultant
The Compensation Committee of the Board of Directors oversees the Corporation’sCompany’s compensation programs and practices for NEOs and other key Executive Officers and Directors. The Compensation Committee reviews and approves compensation for our Executive Officers, including salary, incentive programs, stock-based awards and compensation, retirement plans, perquisites and supplemental benefits, employment agreements, severance arrangements, change in control arrangements and other executive compensation matters. AdviceIn 2020, advice to the Compensation Committee iswas provided by Mr. Dion Read, an independent compensation consultant, who has significant experience in executive compensation, having worked for Hay Group and Watson Wyatt (now Willis Towers Watson) in this area.compensation. Mr. Read was retained by the Compensation Committee and meetshas met with the Compensation Committee at least annually and providesprovided advice at other times as the Compensation Committee deemsdeemed appropriate. Any other work undertaken by Mr. Readthe compensation consultant for the CorporationCompany must be approved by the Compensation Committee. In 2017,2020, Mr. Read did not perform any additional work for the Corporation.Company. The Compensation Committee has conducted an assessment ofassessed the independence of Mr. Read and has determined that he does not have any conflict of interest.
As a result of Mr. Read’s planned retirement in early 2021, the Compensation Committee appointed Exequity as independent compensation consultant to the Compensation Committee effective January 1, 2021.
| | 68 |
The Compensation Committee reviews and approves the compensation structure for ourNon-Employee Directors (NEDs) NEDs at least bi-annually, including retainers, fees, stock-based awards and other compensation and expense items. This review is discussed under the “Director Compensation” section of this Proxy Statement.
The processes and procedures for the Compensation Committee oversight of compensation programs are discussed in the “Corporate Governance” section of this Proxy Statement.
Role of the Chief Executive Officer and Other Executive Officers
The CEO attends Compensation Committee meetings by invitation only and does not attend Compensation Committee meetings when his compensation is being determined. Each year, the CEO, at the request of the Compensation Committee, provides his assessment of the performance of the other Executive Officers, including their achievement of individual objectives and contribution to the overall business performance. He then recommends adjustments to base salary, if appropriate.
The Compensation Committee then reviews all elements of compensation for the Executive Officers, taking into accountconsidering the recommendations of the CEO, as well as market data and information from the Senior Vice President, Human Resources (“SVP, HR”). The Compensation Committee also reviews all elements of compensation for the CEO and evaluates the CEO’s performance in light of those goals, taking into account the ChairmanChair of the Compensation Committee’s review and assessment of the performance of the CEO, overall business performance and results, competitive market data and other relevant information provided by the SVP, HR. The Compensation Committee reviews, discusses and determines the CEO’s compensation package without him being present.
The Compensation Committee makes decisions relating to the compensation of the Executive Officers,NEOs, including the CEO, which it recommends to the full Board of Directors for approval.
The SVP, HR assists the Compensation Committee, serving as the Compensation Committee’s Secretarysecretary, and provides information on compensation as requested by the Compensation Committee.
39
Competitive Market
The Compensation Committee reviews nationally recognized compensation survey data provided by Willis Towers Watson to compare the Corporation’sCompany’s compensation practice with the external market. In 2017, forFor the Executive Officers based in the U.S., Willis Towers Watson U.S. data for similar sized roles in organizations with over $1 billion revenue was used. These are standard Willis Towers Watson data sets and were not customized prior to use. In addition, the Compensation Committee also uses a Chemical Industry PeerComparator Group (“Comparator Group”) as an additional reference point for the CEOour CEO’s compensation. The companies included in the peer groupComparator Group were selected by the Compensation Committee based on a number ofseveral factors, including company size products and level of global operations.market capitalization. The Compensation data for these companies is collected from their proxy statementsCommittee reviewed the Comparator Group in November 2020 and analyzed by the Compensation Committee. The peer group of twelve companies for 2017 was:removed Cambrex, Innophos, Omnova Solutions and Polyone, who were no longer relevant due to M&A activity; and added Avient Corporation, Balchem Corporation, Koppers Holdings Inc., Rayonier Advanced Materials, Ingevity Corporation and Minerals Technologies Inc.
| | 69 |
The Comparator Group for 2021 consists of the following 18 companies:
• Albermarle Corporation | • American Vanguard | • Ashland Global Specialty | ||
• Avient Corporation | • Balchem Corporation | • Cabot Corporation | ||
• Ferro Corporation | • H.B. Fuller Company | • Ingevity Corporation | ||
• Koppers Holding Inc. | • Kraton Corporation | • Minerals Technologies Inc. | ||
• NewMarket Corporation | • Quaker Chemical Corporation | • Rayonier Advanced Materials | ||
• Sensient Technologies | • Stepan Company | • Tredegar Corporation |
Due to completed acquisition activity during 2017, Chemtura Corporation was removed from the peer group during 2017 and will not be included for 2018.
In 2017, forFor U.K. based Executive Officers, Willis Towers Watson U.K. data for similar sized roles in organizations with over $1 billion revenue was used. These are also standard Willis Towers Watson data sets and were not customized prior to use. All executive jobs arewere assessed and graded by Mr. Read, in his capacity as the compensation consultant using the Willis Towers Watson Global Grading methodology. Job sizes are then matched into the data to ensureso that comparisons are made at the appropriate level. Following the acquisition of the European Differentiated Surfactants (“EDS”) business from Huntsman Corporation (“Huntsman”) in the last quarter of 2016, the Compensation Committee asked Mr. Read to conduct a full assessment of the executive job sizes to ensure they reflected the significant increase in the size and complexity of the business. As a result, a number of roles werere-graded and the new grades were applied for 2017 onwards.
References to market data in this Compensation Discussion and Analysis,CD&A, unless otherwise noted, are to these foregoing sources.
Our Compensation Committee has designed our compensation program to align pay with performance. Our executives are rewarded for delivery of long-term stockholder value, performance against long and short-term financial targets and personal objectives aligned to our strategy.
Elements of Pay
The material elements of compensation for the Corporation’sCompany’s NEOs are:
Ø |
|
Ø |
|
Ø |
|
Ø |
|
These elements are explained and discussed in separate sections below. The Compensation Committee seeks to achieve an appropriate balance between fixed and variable compensation elements in line with our policy to link a significant proportion of compensation to performance. For Executive Officers the target is that at least 50% of total compensation should be delivered through variable compensation comprising a mix of long and short-term incentives and cash andnon-cash compensation. The Compensation Committee has formally reviewed the allocation of compensation between the different elements using market knowledge and input from its advisors and is satisfied that the balance is appropriate and generally in line with market practice. In 2017 over 50% of overall compensation for the CEO and other NEOs was delivered through variable compensation.
40
Annual Cash Compensation
Base Salary
A base salary is provided to our Executive Officers. The level of base salary is reviewed on an annual basis and is adjusted, if appropriate, to recognize the scope and complexity of a role, market data and individual performance. The Compensation Committee targets base salary at the median (50th percentile) of the survey group but considers other factors including individual experience and expertise, overall performance, internal pay equity and contribution to the Corporation.Company. We believe that this methodology enables us to remain competitive as an employer in our markets without incurring unnecessary costs. In the case of Mr. P. Williams, the Compensation Committee views Mr. P. Williams as key to the Corporation’sCompany’s continued success, given his unique skills and experience and his long and successful tenure as CEO, and therefore determined that it was appropriate to benchmark his position betweenbase salary in the median and upper quartile of the relevant market.
2017 Salary Increases
| | 70 |
Following there-grading of roles as a result of the acquisition of the Huntsman EDS business at the end of 2016, the survey data for 2017 indicated base salaries were generally around 10% to 15% below the market apart from in a small number of cases. As a result the 2017 base salary level increases for the NEOs, excluding the CEO, were on average 8.0%. Mr. P. Williams’ base salary was increased by 5.0% to $1,008,000 which was within 10% of the average base salary for CEOs in the peer group of companies and broadly in line with the upper quartile of the U.S. survey group.
Following the 2017 increases, base salaries for the NEOs were all within a 15% range of the market median data, which, based on the advice of their compensation advisor, the Compensation Committee believes is an appropriate salary range, given the experience of the NEOs.
Annual Incentives
The Corporation’sCompany’s Management Incentive Compensation Plan (“MICP”) is a short-term incentive plan, which provides for cash payments which are driven by annual performance. Payments are based on achievement againstpre-determined financial goals set by the Board each year. Targets are set for corporate performance and business unit performance (where appropriate) and for personal performance against objectives. All payments under the MICP are subject to an overall corporateCorporate Operating Income performance threshold of 90% of the agreed target for the year:year; if this target is not achieved, no payments under the MICP are made to any individual, regardless of personal and business unit performance.
Further, where an individual’s payment under the MICP includes a financial measure for a business unit, the business unit must also achieve a minimum of 90% of the operating income target or the individual will not receive any MICP bonus for that year for that element, irrespective of overall corporate and personal performance.
Actual MICP Bonus pay-outs are based on the following formula:
Following a review of the relevant market, the Compensation Committee determined that Mr. Williams’s bonus at target and maximum potential was below the median market level and therefore agreed to increase his Target MICP Bonus Percentage from 75% of base salary to 85% of base salary, with the maximum potential bonus increasing from 172.5% to 195.5%, effective January 1, 2020. The target percentage for the other Senior Executive Officers remained at 50%, with a maximum potential MICP incentive payment opportunityBonus pay-out as a percentage of salary of 115%. The levels of MICP target bonus are reviewed periodically and split between corporateare targeted at the median level against the market. The target and personal objectivesmaximum bonus percentages for the CEO are shownwithin 15% of the average levels for CEOs in the Comparator Group of companies and the median levels in the U.S. survey group, which the Compensation Committee believes to be appropriate.
The Financial Performance Multiplier is determined by the following table:
Proportion of MICP bonus at target split: | ||||||||
Corporate/ Business Performance | Personal objectives | Target MICP Bonus as % of | Maximum MICP Bonus as % of salary | |||||
CEO | 80% of target bonus | 20% of target bonus | 75% | 172.5% | ||||
Senior Executive Officers | 80% of target bonus | 20% of target bonus | 50% | 115% |
| % Business Achievement against
| Financial Performance
|
| |||
| Less than 90% | 0 | ||||
90% | 50% | |||||
100% | 100% | |||||
Equal to or more than 130% | 250% |
| | 71 |
The Financial Performance Multiplier increases on a linear basis. For example, a 95% Business Achievement results in a 75% Financial Performance Multiplier, and a 110% Business Achievement results in a 150% Financial Performance Multiplier.
The Compensation Committee reviews the allocation between business and personal performance each year to ensureverify that it is appropriate.
41
The financial performance measures are established by the Compensation Committee and are reviewed by them each year to ensureso that they remain appropriate and focusfocused on the delivery of high performance while recognizing the economic and business challenges the CorporationCompany faces. In 2017,2020, the Compensation Committee determined that, consistent with the approach taken in the previous year, the appropriate measures were corporate operating income before restructuring, which is a measure of earnings, and corporate free cash flow, which is seen as a measure of working capital management. follows:
Ø | Corporate Operating Income (before restructuring). This is a measure of earnings and represents operating income adjusted to exclude certain one-time/nonrecurring restructuring costs, such as severance, that are not reflective of our underlying operations for the period in which they are recorded and therefore mask our underlying trends. These one-time/nonrecurring items are approved by the Compensation Committee. |
Ø | Corporate Free Cash Flow. This is seen as a measure of working capital management and represents corporate operating cash flow after capital expenditure and before the cash effect of restructuring. |
Ø | Personal Performance against Objectives. Annual personal objectives for each NEO are established by the Compensation Committee at the start of the financial year and reflect the specific role and responsibilities of the NEO. |
The metrics are set at the start of the year and approved by the Compensation Committee. Corporate operating income before restructuring is operating income adjusted to exclude certainone-time/nonrecurring restructuring costs such as severance payments from the calculations, because they are not reflective of our underlying operations for the particular period in which they are recorded and, therefore, mask our underlying operating trends. Corporate free cash flow represents corporate operating cash flow after capital expenditure and before the cash effect of restructuring. Theseone-time/nonrecurring items are approved by the Compensation Committee. Corporate operating income before restructuring and corporate free cash flow arenon-GAAP measures. In addition, the Compensation Committee determines whether the performance measures for any NEO should also include operating income and operating cash flow for the relevant individual businesses, based on the NEO’s specific role and responsibilities. This determination is made at the start of the year. These measures were chosen as they are designed to align the NEOs with the balanced objectives of increasing earnings and improving cash flow through working capital management, which the Compensation Committee believes are key to the success of the Corporation.Company. Personal objectives are specific to the particular business unit(s) or function within which the Executive OfficerNEO operates. In addition to the personal element shown in the formula above, if an individual’s overall performance assessment for the year is below satisfactory, then no MICP bonus is paid to that individual at all.
The levels of MICP target bonus are reviewed periodically and are targeted at the median level against the market. The target and maximum bonus percentages for the CEO are within 20% of the average levels for CEOs in the peer group of companies and the median levels in the U.S. survey group, which the Compensation Committee believes to be appropriate.
Maximum incentive payments under the MICP are awarded when the CorporationCompany or, where relevant, an individual business unit exceeds its target performance measures by 30%.
No awards are made under the MICP scheme until the annual business results have been audited by the independent registered public accounting firm and approved by both the Audit Committee of the Board and the full Board.
A provision exists which allows for potential claw-back of bonuses already paid to all Executive Officers if, at some point in the future, it is identified that the audited annual financial results need to be materially restated.
In 2017,2020, for all NEOs, MICP incentive payments were based on achievement of targets set for corporate operating income (before restructuring) and consolidated operatingcorporate free cash flow. In the case of Dr. Boon, in addition to corporate targets, a proportion of his MICP incentive payment was based on achievement of targets set for operating cash flow for the global Fuel Specialties business unit and the achievement of targets set for the operating income for the regional Fuel Specialties businesses, with a proportion based on the operating income for both the global Performance Chemicals business unit and the global Oilfield Services business unit.
| | 72 |
The consolidated financial performance targets set for annual MICP incentive payments purposes andPersonal Performance Multiplier is determined by the actual level achieved for the Corporation as a whole in 2017 were as follows:following table:
|
Multiplier |
| ||||
| 46 – 50 | |||||
41 – 45 | 125% | |||||
36 – 40 | 100% | |||||
31 – 35 | 50% | |||||
26 – 30 | 25% | |||||
25 or less | 0 |
As a result MICP bonus levels for that part of the overall MICP incentive payment based on consolidated operating income were paid at 250% of the target MICP bonus levels and at 250% of the target level for that part of the overall MICP bonus based on consolidated operating cash flow.
42
In 2017 the Fuel Specialties global business unit achieved 106% of the target set for operating income and the regional businesses achieved 109%, 93% and 102% of the targets set for operating income. As a result, in the case of Dr. Boon, MICP bonus levels for those parts of his overall MICP bonus based on operating income for the global business was paid at 130% of the target level and the relevant regional Fuel Specialties businesses unit were paid at 145%, 65% and 110% of the target levels, respectively. The Performance Chemicals business unit achieved 121% of the target set for operating income, and the Oilfield Services business achieved 385% of the target set for operating income. As a result, MICP bonus levels for those parts of Dr. Boon’s overall MICP bonus based on operating income for the Performance Chemicals business unit and the Oilfield Services business unit were paid at 205% and 250% of the target levels, respectively.
In assessing the individual performance on personal objectives for each NEO, the Compensation Committee uses the following process.process:
Annual personal objectives for each NEO are established by the Compensation Committee at the start of the financial year. These objectives are also designed to focus on delivery of high performance and take into accountconsider the economic and business challenges the CorporationCompany faces. The Compensation Committee annually reviews the scoring mechanism for the personal objectives to ensuremake sure it rewards performance appropriately. Each objective is weighted to give a maximum potential total score in total of 50. A good performance on the personal objectives is defined as achieving an overall score at the end of the year of 36 to 40 and earns the target level for the 20% based on personal objectives. Achievement of the maximum score would representof 46 to 50 represents exceptional performance against the personal objectives and increases the 20% of the overall target MICP bonus based on personal objectives by a factor of 50%. The relationship between score on personal objectives and as shown in the amount of MICP bonus earned for personal performance is shown below:table above.
| ||
| ||
| ||
| ||
| ||
| ||
|
At the end of the year, as part of the annual performance review process, the performance against each objective is reviewed and marked against the weighting set at the start of the year givingto give a total score out of 50. In the case of the CEO, this assessment is done by the ChairmanChair of the Compensation Committee and the resultant score and assessment for each objective is reviewed and approved by the Compensation Committee as a whole prior to review and approval by the independent members of the full Board. In the case of the other NEOs, the assessment is done by the CEO, who reviews the objectives and proposes a mark for each objective against the weighting set at the start of the year giving a total score out of 50.year. This, together with the underlying rationale, is reviewed and approved by the Compensation Committee prior to review and approval by the independent members of the full Board.
The consolidated financial performance targets set for annual MICP payments purposes and the actual level achieved for the Company in 2020 were as follows:
43
The following table summarizes the incentive payments made under the MICP for 2017 performance for each of the NEOs, including selected relevant information about their performances:
Annual Incentive MICP | ||||||||||||||||
Executive | Target MICP Incentive Payment as % of Base Salary | Assessment of Personal Objectives | Achieved MICP Incentive Payment as % of Base Salary | MICP Incentive Award | ||||||||||||
Mr. Patrick S. Williams President and Chief Executive Officer | 75 | % | 47 | 172.5 | % | $ | 1,738,800 | |||||||||
Mr. Ian P. Cleminson Executive Vice President and Chief Financial Officer | 50 | % | 48 | 115.0 | % | $ | 373,004 | |||||||||
Dr. Philip J. Boon Chief Operating Officer | 50 | % | 46 | 83.16 | % | $ | 295,240 | |||||||||
Mr. Brian R. Watt Senior Vice President, Corporate Development and Investor Relations | 50 | % | 47 | 115.0 | % | $ | 298,810 | |||||||||
Dr. Ian M. McRobbie Senior Vice President, Research and Technology | 50 | % | 47 | 115.0 | % | $ | 274,287 |
The scoring for the personal objectives includes consideration of the following factors:
Mr. P. Williams led the development and implementation of a growth strategy for the Corporation, including regional expansion and development of new products and market segments. In particular, Mr. P. Williams led the successful integration of the EDS business from Huntsman, following the completion of this acquisition at the end of 2016. He has also driven the development of a new strategy and focus for the Performance Chemicals business to maximize the return of the investment in this business following the acquisition of the EDS business. In addition, Mr. P. Williams has provided strong leadership to the Oilfield Specialties business and spearheaded the drive to improve operating performance in this business. He has also driven the development of robust succession plans for the key leadership roles in the Corporation. The Corporation has also exceeded the target set for safety across the Corporation, with the lost time accident rate across the whole Corporation less than that of the industry average in the year. Based on his personal performance and the overall strong results of the Corporation in a difficult economic and competitive environment, the Board approved the Compensation Committee’s recommendations for Mr. P. Williams to be awarded a bonus of $1,738,800.
Mr. Cleminson has led the financial integration of the EDS acquisition, including the establishment of a new Finance organization and the development and implementation of a new computer system to support the business. In addition, he has led theon-going evolution and enhancement of our banking relationships and played a key role in the continued development of our Investor Relations strategy. He has also played an important role in the continued development of our organization wide computer system and had a key role in the continued development and management of our Compliance program.
Dr. Boon delivered good business results in operating income for the Fuel Specialties business in a very competitive global market. In addition, he has led the work on development of a new legal entity in China to support the growth strategy of the Corporation. He has also managed a detailed review of the Fuel Specialities business in the Americas and implemented a number of organization changes to improve efficiency and focus in order to position the business for future growth. He has also led the identification and delivery of a number of significant new commercial opportunities in very competitive markets.
Mr. Watt has taken a lead role on the integration of the EDS business, working across all functions to ensure a smooth transition. He has also worked closely with the Performance Chemicals business to develop the strategy
44
for key market segments for the combined business following the acquisition. In addition, Mr. Watt, together with Dr. Boon, has led the work on the development of a new strategy for the Fuel Specialties business to take account of the potential impact of new legislation on the market for diesel fuel. He also assumed responsibility for Corporate Development in addition to his responsibilities for strategic planning and Investor Relations.
Dr. McRobbie has continued to lead the development and commercialization of new products in both Performance Chemicals and Fuel Specialties. In particular, he has spearheaded the development of a new product strategy for the EDS business, including identification of new technologies and applications for key market segments. He has continued to drive the development of the new product strategy for the Oilfield Specialities businesses and the work to increase the Corporation’s manufacturing capability for key products. He also led a number of major joint research projects with a number of key strategic commercial partners.
A provision exists which allows for potential claw-back of bonuses already paid to all Executive Officers if, at some point in the future, it is identified that the audited annual financial results need to be materially restated.
Co-Investment Plan
To support the alignment of stockholder and Executive Officer interests, theCo-Investment Plan was introduced by the Corporation in 2004 and reviewed by the Compensation Committee in 2011. The Co-Investment Plan expired in May 2014 and, after careful consideration, the Compensation Committee determined that, given the level of stock holding of each of the Executive Officers, it was not necessary to implement a newCo-Investment Plan at this time. Accordingly, there were noCo-Investment Plan participants in 2015, 2016 or 2017.
Under the terms of theCo-Investment Plan an Executive Officer, who was required to participate in the plan for any year, was allowed to invest a portion of the MICP annual incentive payment (paid in accordance with the targets above) to acquire stock in the Corporation and receive an award of matching stock as described below. If the participating Executive Officer received an MICP incentive payment for exceeding his targets, then he had to use at leastone-third of the MICP incentive payment which is in excess of the MICP target payment to purchase stock, which was matched as follows:
Financial Performance Measure | Target Set for Annual Bonus Purposes | Actual Achieved for MICP Bonus | Achievement as % of Target | % of Target MICP Bonus Achieved | ||||
Corporate Operating Income (before restructuring) | $133.303 million | $63.193 million | 47% | 0% | ||||
Corporate Free Cash Flow | $62.335 million | $108.325 million | 174% | N/A since Corporate Operating Income threshold not met |
| | 73 |
As shown above, although the corporate free cash flow target for the Company was exceeded by over 70%, the minimum threshold of 90% was not achieved for the Corporate Operating Income financial performance measure. As a result, no MICP bonuses were payable under the plan in 2020, regardless of personal and business unit performance.
The following table summarizes the assessment of the personal performance scores for 2020 performance under the MICP for each of the NEOs. No incentive awards were made to any of the NEOs under the MICP for 2020.
NEO | Target MICP Bonus as a Percentage of | Personal Performance | MICP Incentive | ||||||||||||
Mr. Patrick S. Williams President and Chief Executive | 85% | 46 | $0 | ||||||||||||
Mr. Ian P. Cleminson Executive Vice President and | 50% | 46 | $0 | ||||||||||||
Dr. Philip J. Boon Executive Vice President and | 50% | 43 | $0 | ||||||||||||
Mr. Brian R. Watt Senior Vice President, | 50% | 46 | $0 | ||||||||||||
Dr. Ian M. McRobbie Senior Vice President and Chief | 50% | 46 | $0 |
| | 74 |
The score for the personal performance includes consideration of the achievement of the following selected relevant goals and objectives for each NEO. In 2020, the Compensation Committee set personal objectives for Mr. Williams, which focused on the key challenges and priorities for the Company, which included safety, strategic initiatives, financial and compliance goals. These were in addition to the financial targets for Corporate Operating Income and Free Cash Flow, on which 80% of Mr. William’s incentive compensation under the MICP is based. The key personal performance goals for Mr. Williams are summarized below, together with the actual performance achieved:
Personal Performance Goals and Objectives | Actual Performance vs Personal Goals and Objectives | |||||
• Completed roll-out of | • No serious accidents in year, but Company’s LTAFR for • Implemented robust procedures at all operating facilities to protect employees and mitigate the spread of COVID-19 in the work environment • Operated manufacturing facilities throughout the pandemic with no evidence of virus transmission at the Company facilities in 2020 | |||||
• Developed and implemented number of measures to allow sites to continue to operate during pandemic. • Vast majority of customer needs met despite restrictions of pandemic • Completed rail project for one of key Performance Chemicals facilities, which will improve efficiency and lower costs • Detailed plans developed to mitigate impact of Brexit in Europe and achieved no negative impact on supply to customers once Brexit implemented • Careful management of cash flow in difficult market conditions and achieved significant out-performance on cash flow target, while maintaining dividend payment | ||||||
Continue development of growth strategy, including commercialization of new products | • Updated 5-year strategy plan approved by Board • Sales of new products launched in last 5 years accounted for 23% of total sales in 2020. • Expanded capacity for Drag Reducing Agent product (“DRA”) which continued to grow ahead of expectations • Key strategic segments of Mining, Construction and Agriculture in Performance Chemicals had strongest year to date | |||||
Drive our Sustainability strategy forward | • Successfully maintained our Gold Medal on the EcoVadis Sustainability Rating despite implementation of more challenging criteria • Sulfate-free product range expanded including sustainable, higher performing surfactants in Performance Chemicals |
| | 75 |
Given Mr. William’s performance measured against the goals set, the Compensation Committee recommended Mr. Williams be awarded a score of 46 out of 50 for his personal objectives. However, no bonus was payable to Mr. Williams under the MICP plan in 2020 since the minimum threshold of 90% was not achieved for the Corporate Operating Income financial performance measure.
The relevant selected key personal performance goals and objectives for each of our other NEO’s are summarized below, together with the actual performance achieved. However, no incentive payment was made to any of our NEO’s under the MICP plan in 2020, regardless of their score for their personal goals and objectives, since the minimum threshold of 90% was not achieved for the Corporate Operating Income financial performance measure.
Mr. Ian P. Cleminson Personal Performance Goals and Objectives | Actual Performance vs Personal Goals and Objectives Awarded Score of 46 out of 50 | |
Develop and deliver a program to strengthen cyber security across the Company in response to the 2019 cyber incident | • Successfully delivered external auditor assessment recommendations, with follow up external audit showing significant progress in all areas • Successful implementation of program to strengthen IT infrastructure and new cyber security training program implemented for all employees to improve cyber security awareness | |
Provide lead financial support for the diligence and structuring of potential acquisitions | • Significant work completed on potential acquisitions including evaluation of alternative deal structures, potential synergies and outline integration plans. • Liaised with banking group and successfully gained full support for acquisition strategy | |
Drive a focus on working capital, with associated cash requirement, across the Company | • Led the focus on strong cash management across the Company during the pandemic. Achieved significant out-performance on cash flow target, while maintaining dividend payment • Paid off all external bank debt and ended the year with a net cash position of $104 million | |
Support development of new 5-year strategy for Performance Chemicals business | • Robust and improved financial model built to enable development of 5-year strategy for Performance Chemicals, focusing on identification and financial evaluation of organic growth opportunities |
| | 76 |
Dr. Philip J. Boon Personal Performance Goals and Objectives | Actual Performance vs Personal Goals and Objectives Awarded score of 43 out of 50 | |
Develop plans to mitigate impact of any | • All Fuel Specialties manufacturing facilities continued to • Plans developed and implemented to allow continued movement of | |
Lead the | • Led review of all Fuel Specialties operations in light of impact of COVID-19 pandemic on market demand and implemented number of cost saving programs • All manufacturing sites for | |
Drive regional growth strategy for Fuel Specialties | • Strong sales growth for key products in Asia-Pacific and Latin America regions, despite sharp fall in market demand as result of pandemic • Won first two accounts in China for diesel detergent product range | |
Drive sales of new products in Fuel Specialties globally | • Sales of new products launched in last 5 years accounted for 26% of total Fuel Specialties sales globally in 2020 • New Lubricity Improver launched, and new pour point depressant successfully introduced in Russian market |
Participants
Mr. Brian R. Watt Personal Performance Goals and Objectives | Actual Performance vs Personal Goals and Objectives Awarded score of 46 out of 50 | |
Lead development of new 5-year strategy | • Worked with all 3 businesses to develop new strategy, including identification of key market trends and new technologies • Worked closely with Performance Chemicals business to identify opportunities to leverage technology expertise to expand and create alternative markets • Full Company wide strategy approved by Board | |
Lead full risk management review across all businesses with emphasis on understanding and evaluation key risks | • Full review completed and approved by the Board • Detailed recovery plans developed for all key manufacturing sites to mitigate potential disruption to operations in event of any unplanned shutdown/closures | |
Lead acquisition strategy and identification of potential targets, including project management of due diligence and acquisition process for any potential acquisitions | • Worked closely with CFO and CEO on potential acquisition, including management of due diligence process, development of business plans for potential acquisition, including integration and synergies |
| | 77 |
Dr. Ian M. McRobbie Personal Performance Goals and Objectives | Actual Performance vs Personal Goals and Objectives Awarded score of 46 out of 50 | |
Continue to support DRA business, through developing product range and further improving our manufacturing process. | • Significant work done to successfully develop new product variants to enhance product range • Led the DRA plant capacity expansion project, with two phases of expansion successfully completed and further expansion coming on-line in 2021 to provide more capacity | |
Lead development of a long-term technology strategy for the Company, focussing on new technologies and product discovery | • Identified new approach to underpin product discovery, with focus on improving sustainability • Implemented new scientific program to underpin technology developed and established number of collaborative research activities with select academic groups | |
Continue to support development of strategic relationships with key customers, based on technology | • Joint research projects on new technologies and applications established with number of key strategic customers in Performance Chemicals business | |
Identify technology program to support business strategy for key product groups | • Strategy developed for key product groups and research projects identified and implemented to deliver strategy, with resources allocated to each key project |
Due to the economic challenges caused by the COVID 19 pandemic, including the collapse in oil and fuel demand, the overall Company financial performance fell below the threshold level required to receive a Co-Investmentpay-out Plan must generally remain employed for three yearsunder the 2020 MICP or other bonus plans. As a result, under the rules of the MICP and continueall other bonus plans, no bonuses were payable to holdany employees including the stock purchased under thisCo-Investment PlanCEO and other NEOs. During the first quarter of 2020, the Company’s priorities shifted from driving growth to adapting to maintaining commitments to our key stakeholders, including our employees, customers and stockholders. The Company’s primary focus was keeping employees safe and safely operating our manufacturing facilities in order to receivemeet customer demand. These efforts along with efforts by management to focus on cash generation enabled the matching stock. In 2014, Mr. B Watt wasCompany to maintain its dividend for 2020 and enter 2021 with a strong balance sheet and $104.7 million of cash.
As part of the only NEO who chosepay-for-performance philosophy, the Compensation Committee has the discretion to participateconsider the economic and business challenges the Company faces. Coupled with improving business conditions during the 3rd and 4th quarters, key accomplishments were delivered in the year, specifically:
Implemented procedures at our operating facilities to promote health and safety of our employees and to mitigate the spread of Co-InvestmentCOVID-19 Plan and as a result, and having satisfiedin the requirements above, he receivedwork environment
Operated manufacturing facilities throughout the matching stock relating to his 2014 participation in 2017. Aspandemic with no evidence of virus transmission at the endCompany facilities in 2020
Continuation of 2017, therethe dividend policy from 2019, paying $1.04 in dividends per share in 2020 (semi-annual dividend of $0.52), an increase from $1.02 in 2019 and $0.89 in 2018
Paid the Company’s external bank debt down to zero
Strong stock price recovery in fourth quarter
| | 78 |
Performance Chemicals operating income up 10% over 2019 and 8% over budget for the year despite the challenging environment
Employees continued to work throughout the pandemic, including remote working where possible in line with local guidance and regulations of relevant jurisdictions despite challenging environment
Major capital projects continuing to progress as planned, without the need to raise additional capital
After a full discussion and in recognition of the efforts, leadership and accomplishments of the NEOs and all other employees under extraordinary circumstances and adverse market conditions, the Committee exercised its discretion and recommended to the full Board that a pool of up to a maximum of $12 million be made available for employees. The recommendation and amount of the pool were approved at the February 2021 Board meeting. This provided for a one-off discretionary payment to all employees broadly equivalent to bonus payments that would have been based on achievement of financial performance at the minimum threshold level on average while recognizing individual personal performance.
The Compensation Committee approved one-time payments to the NEOs broadly equivalent to bonus payments that would have been based on achievement of corporate financial performance at the minimum threshold level, which equated to approximately 50% of the value of their total potential bonus payments at target. The payments were also subject to personal performance, in line with the approach for all employees. The final approved one-off discretionary payments to the NEOs are no more matching shares outstandingdetailed below and are included in the “Summary Compensation Table” under this Plan.the “Bonus” column:
NEO | One-Off Discretionary Payment | |
Mr. Patrick S. Williams President and Chief Executive Officer | $500,000 | |
Mr. Ian P. Cleminson Executive Vice President and Chief Financial Officer | $96,660 | |
Dr. Philip J. Boon Executive Vice President and Chief Operating Officer | $100,526 | |
Mr. Brian R. Watt Senior Vice President, Corporate Development and Investor Relations | $73,462 | |
Dr. Ian M. McRobbie Senior Vice President and Chief Technology Officer | $64,440 |
Long-Term IncentivesIncentive Plans
The Compensation Committee believes that equity basedequity-based long-term incentive awards are an important element of the overall compensation for the Corporation’sCompany’s Executive Officers. They are designed to giveprovide a focus on achievement of long-term performance goals that help create long-term value for stockholders, act as long-term retention incentives for executives and, through the ownership of common stockCommon Stock of the Corporation,Company, encourage long-term strategic decision makingdecision-making that is aligned with the interests of stockholders.
45
Long-Term Incentive PlansCompany Stock Option Plan and Performance Related Stock Option Plan
The Corporation operatesCompany offered two equity-based incentive plans in which the NEOs participate,prior to 2019, the CSOP and the PRSOP both of which provide for(together, the “Prior Plans”). The Prior Plans offered options exercisable for common stock as well asboth Common Stock and stock equivalent units
| | 79 |
(“SEUs”), which are payable in cash based on stock price. Both plans expired in May 2018 and no further options or SEUs were granted under these plans after that date. There are options and SEUs granted under the Prior Plans that remain outstanding.
The terms andkey features of the Prior Plans are summarized below:
CSOP and PRSOP Key Features | ||||||
CSOP | PRSOP | |||||
Options | SEUs | Options | SEUs | |||
Granted at market price | Granted at market price | Granted at zero cost | Granted at zero cost | |||
Exercisable for Common Stock | Redeemable for cash based on stock appreciation | Exercisable for Common Stock | Redeemable for cash based on stock appreciation | |||
No performance criteria | No performance criteria | Specified Performance criteria | Specified Performance criteria | |||
3-year vesting | 3-year vesting | Normally 3-year vesting | Normally 3-year vesting | |||
10-year term | 10-year term | 10-year term | 10-year term | |||
Immediate vesting upon change in control | Immediate vesting upon change in control | Immediate vesting upon change in control | Immediate vesting upon change in control |
As previously disclosed in November 2020, the Compensation Committee approved a modification to the performance period of the Company’s 2018 grants of options and PRSOPSEUs in response to the effects of the COVID-19 pandemic and other factors negatively impacting the Company’s industry, and in order to help retain and motivate the Executive Officers to achieve the performance targets in coming years as described below. Due to the impact of the pandemic, the performance goals set in 2018 for the performance period from 2018 through 2020 were not expected to be able to be achieved due to circumstances outside management’s control. Under the rules of the Prior Plans, when events have happened which cause the existing performance goals to have become unfair or impractical, the Compensation Committee can use discretion to modify goals in a way that would be no more or less difficult to achieve than when the goals were originally created. The Compensation Committee determined that targets extended through 2022 would be no more or less difficult to achieve than the original goals set to end in 2020. Additionally, the Compensation Committee considered its use of discretion in this case to be consistent with the intent of the Prior Plans to align the interests of the Executive Officers with stockholders given that the options and SEUs will ultimately only vest if such performance goals are described below.satisfied, which the Compensation Committee feels maintains strong focus on performance. If performance targets are not met, then the options and SEUs will lapse.
| | 80 |
As amended, the goals for the options and SEUs granted in 2018 remain based on (i) relative performance of total stockholder return versus the Russell 2000 index, measured comparing the average stock price during the last quarter of 2022 to the average stock price over the last six months of 2017, (ii) the growth in sales revenue for the Company comparing 2022 sales revenue to 2018, excluding the Company’s Octane Additives business unit, and (iii) the growth in earnings per share comparing 2022 earnings per share to 2018 earnings per share, excluding the Octane Additives business unit. Total vesting is based on the following formula:
The CSOP andperformance components are determined by the PRSOP both expirefollowing levels of growth, which must be achieved before awards vest:
Relative performance of TSR vs. Russell 2000 index from 2018-2022 | Proportion of the 35% allocated to TSR vesting | |
110%
| 100%
| |
100%
| 90%
| |
90%
| 80%
| |
80%
| 70%
| |
70%
| 60%
| |
Less than 70%
| 0%
|
Growth in Revenue excluding Octane Additives in 2022 vs. 2018 budget | Proportion of the 30% allocated to growth in Revenue vesting | |
Total growth vs. 2018 budget 8% | 100% | |
Total growth vs. 2018 budget 6% | 60% | |
Total growth vs. 2018 budget 4% | 20% | |
Less than 4% | 0 (nil) |
| | 81 |
Growth in Earnings per Share (EPS) excluding Octane Additives in 2022 vs. 2018 budget | Proportion of 35% allocated to growth in EPS vesting | |
Total growth vs. 2018 budget 3% | 100% | |
Total growth vs. 2018 budget 2% | 60% | |
Total growth vs. 2018 budget 1% | 20% | |
Less than 1% | 0 (nil) |
Awards vest on a straight-line basis between each threshold. For example, a total growth in May 2018. As set forthEPS of 2.5% versus the 2018 budget would result in “Proposal 3 - Approval80% of Innospec Inc.the options vesting. Other than the changes in the performance period described above, the 2018 options remain subject to all applicable terms of the Prior Plans.
Omnibus Long-Term Incentive Plan”, the Board of Directors has approved for submission to the Stockholders the Innospec Inc. 2018 Omnibus Long-Term Incentive Plan for approval at
At the 2018 Annual Meeting of Stockholders.Stockholders, the stockholders approved a new equity-based incentive plan, the Omnibus Plan. The Omnibus Plan provides for the grant of non-qualified and incentive stock options, full value awards and cash incentive awards. Full value awards, stock options and cash incentive awards were granted under the Omnibus Plan to the NEOs in 2020.
Company Stock OptionFollowing are the key features of this plan:
Omnibus Plan Key Features | ||||||
Stock Awards | Cash Incentive Awards | |||||
Options | Full Value | Market Priced | Full Value | |||
Granted at market price | Granted at zero cost | Granted at market price | Granted at zero cost | |||
Exercisable for Common Stock | Grant of Common Stock | Redeemable for cash based on stock appreciation | Redeemable for cash based on stock appreciation | |||
No performance criteria | Specified performance criteria | No performance criteria | Specified performance criteria | |||
Minimum 1-year vesting | Minimum 1-year vesting | Minimum 1-year vesting | Minimum 1-year vesting | |||
Immediate vesting upon change in control | Immediate vesting upon change in control | Immediate vesting upon change in control | Immediate vesting upon change in control |
Options granted under the Omnibus Plan (“CSOP”)
Under the CSOP, options are granted at market value andto any participant normally do not become exercisable after three years, with all options vesting ator vested prior to the endearlier to occur of (i) the first anniversary of the three-year period. Alldate on which it is granted and (ii) the participant’s
| | 82 |
termination date by reason of death or disability. In the event the participant’s termination date occurs for any reason other than death, disability, retirement or an involuntary termination without cause, any unvested options have aten-year term. Options areshall be forfeited, and in the event the participant’s termination date occurs by reason of death, disability, retirement or an involuntary termination without cause, unvested options will lapse unless the Compensation Committee determines otherwise in its sole discretion.
Full value awards granted within twenty days afterunder the public announcementOmnibus Plan normally require the achievement of the Corporation’s annual financial results or similar information. Except in certain circumstances participants must remain in employment with the Corporationspecified performance criteria in order to be able to exercise their options. The exceptions to this include death, injury,ill-health or disability, redundancy and the transfervest. When vesting is conditional on achievement of the part of the business within which the option holder works. In these cases, under the rules of the CSOP, options vest and the holder has a twelve month period within which to exercise the options.
In the event of a change of control of the Corporation, under the rules of the CSOP, all options become immediately exercisable.
Performance Related Stock Option Plan (“PRSOP”)
Under the PRSOP, options are granted at no cost and become exercisable normally after three years, provided that specifiedset performance criteria, are achieved. All options have aten-year term. However, if an option is granted to a participant who is, or would otherwise be, subject to Section 409A of the Code, with an exercise price less than the fair market value of the shares on the date of grant, it must be exercised (if at all) no later than March 15 of the calendar year immediately following the calendar year in which it is first capable of exercise under the Plan. The performancesuch criteria that are set are designed to be “stretch” targets, which focus on delivery of high performance and enhancing stockholder value, while recognizing the economic and business challenges the CorporationCompany faces. The performance criteria are regularly reviewed to ensure thatso they remain relevant and stretching. Vesting of a full value award may also be conditional on the participant’s completion of a specified period of service with the Company. All full value awards granted under the Omnibus Plan to any participant are subject to the same minimum vesting requirements described above for options, regardless of whether they are conditional on specified performance criteria and/or completion of a specified period of service. Upon vesting, shares subject to full value awards are transferred to the participant’s nominated brokerage account. Under the Omnibus Plan rules, except in certain circumstances, if a participant ceases to be employed with the Company, all unvested full value awards are forfeited. If the participant ceases employment by reason of death, disability, retirement or involuntary termination without cause, all unvested full value awards are forfeited unless the Compensation Committee determines otherwise, in their absolute discretion, in which case all awards made within 12 months of the termination date are forfeited and up to 100% of full value awards made more than 12 months prior to the termination date will become vested and participants have a 12-month period to exercise any vested options.
Cash incentive awards granted in 2020 were made in the form of units. The value of each award once vested will be equal to the number of units multiplied by the closing stock price of the Company on the date it is exchanged for cash. The Compensation Committee determines the grant date to be used in advance and the stock price used is typically the closing stock price at the end of the day prior to the agreed grant date. Cash incentive awards are subject to the same minimum vesting requirements described above for options and full value awards and are treated in the same way as options and full value awards if a participant ceases to be employed with the Company.
The criteria for full value and cash incentive awards made in 20172020 under the Omnibus Plan, where vesting is conditional on achievement of specific performance measures, are based on relative performance of total stockholder return versus the Russell 2000 index, measured over a three-year period starting with the financial year of the date of grant, the growth in sales revenue, for the Corporation, excluding the Octane Additives business, for the Company and the growth in earnings per share, excluding the Octane Additives business. The Octane Additives business is a declining legacy business and at the time of grant had one remaining customer that was transitioning away from this product. As a result, the Compensation Committee determined that, given the expected continued decline inend of this business, it is appropriate to exclude it from the Octane Additives business, theseperformance targets for long term incentive plans, and that the performance measures wouldset provide the appropriate focus on the continued growth of the CorporationCompany together with delivering stockholder value. The Company announced in August 2020 that there would be no further orders for the Octane Additives business and that this business had reached its conclusion. Total vesting for the 2020 awards is based on the following formula:
| | 83 |
The performance components are determined by the following levels of growth, which must be achieved before awards vest:
Relative performance of Total Shareholder Return (TSR) vs Russell 2000 index | Proportion of the 35% allocated to TSR vesting | |
110% | 100% | |
100% | 90% | |
90% | 80% | |
80% | 70% | |
70% | 60% | |
Less than 70% | 0 (nil) |
Relative performance of TSR vs. Russell
| Proportion of the 35% allocated to TSR
| |
110%
| 100%
| |
100%
| 90%
| |
90%
| 80%
| |
80%
| 70%
| |
70%
| 60%
| |
Less than 70%
| 0%
|
46
Growth in Revenue excluding Octane | Proportion of the 30% allocated to | |
Total growth | 100% | |
Total growth | 60% | |
Total growth | 20% | |
Less than | 0 (nil) |
Growth in Earnings per Share (EPS) | Proportion of the 35% allocated to | |
Total growth | 100% | |
Total growth | 60% | |
Total growth | 20% | |
Less than | 0 (nil) |
Awards vest on a straight-line basis between each threshold. For example, a total growth in EPS of 4% versus the 2020 budget would result in 80% of the options vesting.
| | 84 |
The grants are issued on a date set by the Compensation Committee each year. This is usually after the public announcement of the annual financial results. The Compensation Committee determines the grant date to be used in advance and the stock price used is typically the closing stock price at the end of the day prior to the agreed grant date.
If participants cease to be employed with the Corporation prior to the end of the vesting period awards will lapse unless the Compensation Committee determines otherwise.
In the event of a change of control of the Corporation, under the rules of the PRSOP, all options become immediately exercisable.
Stock Equivalent Units (“SEUs”)
Equity based awards, payable in cash, are made in the form of SEUs. SEUs are granted separately under either or both of the CSOP and PRSOP. The SEUs may be exercised separately from options that have been granted under the corresponding plan and such SEU exercise has no impact on those options. Two types of SEU awards have been made under these plans.
47
The performance criteria set in any one year are normally used for both SEU awards and any stock option awards under the PRSOP.
The value of the SEU once vested will be equal to the closing stock price of the Corporation on the date it is cashed. The grants of SEUs are issued on a date set by the Compensation Committee each year. This is usually after the public announcement of the annual financial results. The Committee determines the grant date to be used in advance and the stock price used is typically the closing stock price at the end of the day prior to the agreed grant date.
If participants cease to be employed with the Corporation prior to the end of the vesting period, the SEUs will lapse unless the Compensation Committee determines otherwise.
The SEUsoptions, together with the optionscash incentive awards, granted under the CSOP and PRSOPOmnibus Plan are intended to deliver an overall long-term incentive award in line with the grant policy as detailed below.
Grant Policy
In setting the policy for these plans,awards granted under the Omnibus Plan, the Compensation Committee considersconsidered market median practice in both the U.S. and the U.K., given the number of executives who are based in the U.K. The review and analysis of market practice in 2017 indicated that the grant policy was below market levels for both the CEO and Executive Officers, including the NEOs. The Compensation Committee determined, after taking input from their compensation consultant, that based on the market data it was appropriate to increase the grant policy for both the CEO and Executive Officers, including the NEOs. As a result the target amount for grants of PRSOPs and zero priced SEUs as a percentage of base salary increased from 90% to 220% for the CEO and from 55% to 90% for the Executive Officers. The revised grant policy therefore provides for target amounts as follows:
Grants of CSOPs and SEUs at market price as % of base salary | Grants of PRSOPs and zero priced SEUs as % of base salary | Grants of stock options and cash
| Grants of full value awards and
| |||||||||||||
Chief Executive Officer | 30 | % | 220 | % | 30%
| 220%
| ||||||||||
Executive Officers | 20 | % | 90 | % | 20%
| 90%
|
The Compensation Committee determinesdetermined the actual levels of grant utilizing the following matrices taking account of personal performance where:
Rating 1 | = | Outstanding performance | - | 150% of policy is granted | ||||||||
Rating 2 | = | Exceeding expectations | - | 125% of policy is granted | ||||||||
Rating 3 | = | Good performance | - | 100% of policy is granted | ||||||||
Rating 4 or 5 | = | Below Expectations | - | No grant is made |
The personal rating impacts the amount of actual grant awarded as follows:
Chief Executive Officer | Executive Officers | |||||||||||
Performance rating | Grants of CSOPs and market price SEUs as % of base salary | Grants of PRSOPs and zero priced SEUs as % of base salary | Performance rating | Grants of CSOPs and market price SEUs as % of base salary | Grants of PRSOPs and zero priced SEUs as % of base salary | |||||||
1 | 45 | 330 | 1 | 30 | 135 | |||||||
2 | 37.5 | 275 | 2 | 25 | 112.5 | |||||||
3 | 30 | 220 | 3 | 20 | 90 | |||||||
4 | 0 | 0 | 4 | 0 | 0 | |||||||
5 | 0 | 0 | 5 | 0 | 0 |
Chief Executive Officer | Executive Officers | |||||||||||
Performance rating | Grants of stock options and cash incentive awards at market price as % of base salary | Grants of full value awards and full value cash incentive awards as % of base salary | Performance rating | Grants of stock options and cash incentive awards at market price as % of base salary | Grants of full value awards and full value cash incentive awards as % of base salary | |||||||
1 | 45 | 330 | 1 | 30 | 135 | |||||||
2 | 37.5 | 275 | 2 | 25 | 112.5 | |||||||
3 | 30 | 220 | 3 | 20 | 90 | |||||||
4 | 0 | 0 | 4 | 0 | 0 | |||||||
5 | 0 | 0 | 5 | 0 | 0 |
48
| | 85 |
The performance of the Executive Officers, other than the CEO, is assessed by the CEO and the Compensation Committee. The CEO recommends a rating to the Compensation Committee. The Compensation Committee reviews these and separately assesses the performance of the CEO and makes a final recommendation on performance ratings for all Executive Officers to the full Board for approval. This provides for a rigorous performance-related grant policy, in addition to the performance elements of the grants themselves.
In 2017,2020, Mr. P. Williams was rated as 1“1” for his 20162019 performance and as such was eligible for long-term incentive awards at 150% of the policy levels for this role. In the case of the other NEOs, based on the assessment of their individual performance as approved by the Compensation Committee, Dr. McRobbie and Mr. Cleminson were also eligible for awards at 150% of the policy level, and Dr. Boon Dr. McRobbie and Mr. Watt were eligible for awards at 150%125% of the policy level.
As previously disclosed, from 2012,In line with the Compensation Committee’s policy, 75% of the awards due under the policy will be made in the form of full value awards to be granted at zero cost and option grants under the CSOP and PRSOP plans,Omnibus Plan, with the remaining 25% made in the form of SEUs. cash incentive awards.
The Compensation Committee have alsohas determined that in order to help manage option utilization rates and burn rates, the level of full value awards and option grants in any one year should be restricted to a burn rate of no more than 1% of the Corporation’sCompany’s stock outstanding with the balance of long-term incentives provided for undergranted as cash incentive awards that do not impact the policy bridged using SEU’s.burn rate. In 2017,2020, the level of full value awards and option grants under the policy was less than 1% of the Corporation’sCompany’s stock outstanding.
Exceptional Stock Option Awards
The Compensation Committee also hashad the discretion to grant options or SEUs under the CSOP or PRSOPOmnibus Plan outside of the stated policy to reflect extraordinary corporate performance. In addition, the Compensation Committee hashad the discretion to grant full value awards, options or SEUscash incentive awards under the CSOP or PRSOPOmnibus Plan outside of the standard policy levels and annual grant process for retention or recruitment purposes. In 2017, following the review2020, no such awards were made to any of the grant policy, which identified that this had been below market levels, the Compensation Committee recommended that an additional award under the PRSOP plan should be made to the CEO and each of the NEOs in order to recognize that the long-term incentive awards in previous years had been below market and to act as a retention tool. This was approved by the Board and Mr. P. Williams was awarded 25,000 SEUs at zero exercise price under the PRSOP plan, and Mr. Cleminson, Dr. Boon, Mr. Watt and Dr. McRobbie were each awarded 3,000 SEUs at zero price under the PRSOP plan. In each case, the SEUs will vest after two years, subject to the participant still being employed by the Corporation and not under notice of termination of employment on the vesting date and assessed as achieving a good performance in each year from grant date to vesting date.NEOs.
Additional Long-Term Incentive Plan
The acquisition of the Huntsman EDSEuropean Differentiated Surfactants (“EDS”) business at the end of 2016 representsrepresented a major step in the development of the Corporation.Company. At the same time, the Board have recognized the importance of both robust succession planning for the executive officersExecutive Officers over the next3-5 years and retaining the current team during this period. As a result, the Compensation Committee recommended an additional long-term incentive plan (“Additional LTIP”) designed to focus key executives on delivering a return on the investment on the acquisition by its successful integration and on the sustained growth of the larger business and, for the senior executives, delivering on the agreed succession plans for the key roles. The new planAdditional LTIP was approved by the Board in February 2018. The plan covers a three-year period that commencescommenced in January 2018 and will endended on December 31, 2020. Under this plan, a cash incentive award will beis payable to eligible participants based on achievement of specified performance measures. There are two levels to the plan, Level A and Level B. The performance measures and weightings for Level A participants are:
Ø | 40% weighting on the achievement of a stretch Earnings per Share (“EPS”) target for 2020, excluding the Octane Additives business, which would deliver an increase in EPS of over 40%, excluding the Octane Additives business, versus the 2017 achieved |
Ø | 40% weighting on delivery of the earnings before tax in the acquisition business plan for the EDS acquisition. |
49
Ø | 20% weighting on the delivery of the agreed succession plans and associated actions for key roles, as approved by the Board, by end 2020. |
| | 86 |
The performance measures for Level B participants are the same as for Level A participants excluding the measure relating to delivery of succession plans for key roles. In the case of Level B participants, there are three alternative weighting options for the performance measure as follows:
Performance Measure | Weightings – Option 1 | Weightings – Option 2 | Weightings – Option 3 | Weightings- Option 1 | Weightings- Option 2 | Weightings- Option 3 | |||||||||||||||
Achievement of stretch EPS target | 70% | 50% | 30% | 70% | 50% | 30% | |||||||||||||||
Achievement of earnings before tax target in EDS acquisition business plan | 30% | 50% | 70% | 30% | 50% | 70% |
The weighting option for a Level B participant is determined based on their role and responsibilities.
The following levels of each performance measures have tomeasure must be achieved before awards couldmay vest:
% of Stretch EPS Target, excluding TEL for 2020 | % of potential pay-out for EPS measure | |||
% of Stretch EPS Target excluding TEL for 2020 | % of potential pay-out for EPS measure | |||
100% | 100% | 100% | ||
95% | 80% | 80% | ||
90% | 60% | 60% | ||
Below 90% | 0 | 0 |
% of target EBIT for the EDS acquisitions achieved in 2020 | % of potential pay-out for acquisition measure | % of potential pay-out for acquisition measure | ||
110% | 100% | 100% | ||
100% | 80% | 80% | ||
90% | 60% | 60% | ||
Below 90% | 0 | 0 |
Achievement of agreed succession plan measures – | % of Potential Pay-out for Succession Plan Measure | |
20 | 100% | |
19 | 95% | |
18 | 90% | |
17 | 85% | |
16 | 80% | |
15 | 75% | |
Less than 15 | 0 |
50
| | 87 |
Achievement of agreed succession plan measures as assessed by Compensation Committee and scored out of 20 | % of Potential Pay-out for Succession Plan Measure | |
20 | 100% | |
19 | 95% | |
18 | 90% | |
17 | 85% | |
16 | 80% | |
15 | 75% | |
Less than 15 | 0 |
Anypay-out for the earnings before tax measure for the EDS acquisition is subject to an overall “floor” set at 75% of the cumulative target earnings before tax over the three years of the planAdditional LTIP i.e. 2018, 2019 and 2020. If the cumulative target earnings before tax is less than this floor, then nopay-out will be made for this element, regardless of the actual earnings before tax achieved for 2020.
The maximum aggregate amount payable under the planAdditional LTIP during the three-year life of the plan is $15 million. The amount was set at a level which would be an incentive for participants and, by incorporating EPS as a measure, would deliver value to stockholders. Participants have to be still in employment with the CorporationCompany at the end of the period in the same or similar role and must have achieved a minimum of a 3 (Good Performer) performance rating in each year of the plan in order to be eligible to receive any payment under this plan. In exceptional circumstances, the Compensation Committee can, at its absolute discretion, award some or all of any potential payment to a participant who leaves the CorporationCompany prior to the end of the performance period if they leave due to injury, disability,ill-health or death. Eligibility for participation in the plan was at the discretion of the Compensation Committee subject to approval by the Board. Mr. P. Williams, Mr. Cleminson, Dr. Boon, Dr. McRobbie and Mr. Watt are all eligible to participateparticipating in the PlanAdditional LTIP as Level A participants.
| | 88 |
There are six categories of participation for Level A participants and five categories for Level B participants. The maximum incentive award for each participant at each category is as follows:
Level A | Maximum Incentive Award Payable | Total number of participants at each level | Maximum Incentive Award Payable | Total number of participants at each level | ||||||
Category 1 | $4,175,000 | 1 | $4,175,000 | 1 | ||||||
Category 2 | $1,350,000 | 1 | $1,350,000 | 1 | ||||||
Category 3 | $1,250,000 | 1 | $1,250,000 | 1 | ||||||
Category 4 | $800,000 | 2 | $800,000 | 2 | ||||||
Category 5 | $750,000 | 1 | $750,000 | 1 | ||||||
Category 6 | $550,000 | 2 | $555,000 | 2 |
Level B | Maximum Incentive Award Payable | Total number of participants at each level | Maximum Incentive Award Payable | Total number of participants at each level | ||||||
Category 1 | $500,000 | 3 | $500,000 | 3 | ||||||
Category 2 | $300,000 | 2 | $300,000 | 2 | ||||||
Category 3 | $275,000 | 3 | $275,000 | 3 | ||||||
Category 4 | $250,000 | 1 | $250,000 | 1 | ||||||
Category 5 | $200,000 | 8 | $200,000 | 8 |
In the case of the NEOs, the Compensation Committee determined that Mr. P. Williams was eligible to participate in the PlanAdditional LTIP at LevelA-Category 1, Dr. Boon was eligible to participate in the planAdditional LTIP at LevelA-Category 2, Mr. Cleminson at LevelA-Category 3, Mr. Watt at LevelA-Category 4 and Dr. McRobbie at LevelA-Category 66.
In the event of a change of control of the Corporation,Company, the targets for the measures in additional long-term incentive planthe Additional LTIP will be deemed to have been fully achieved and participants will receive the maximum incentive award payable as detailed above.
A provision exists which allows for potential claw-back of any payment made under the additional long-term incentive planAdditional LTIP to any participant if, within 2 years of any payment made, it is identified that the audited annual financial results need to be materially restated. The additional long-term incentive planAdditional LTIP also provides for the potential claw-back of any payment made under such plan to an individual participant if, within 2
51
years of any payment, the actions of such participant bring the Company into disrepute, as determined by the Compensation Committee, regardless of whether the participant is still employed by the Company or not in that period.
| | 89 |
The Additional LTIP matured on December 31, 2020. The outcome for Level A participants, which includes the NEOs, for each Performance Measure is summarized below:
Performance Measure | Weightings | Achievement as at end 2020 | |||||
Earnings Per Share (“EPS”) target for 2020, excluding the Octane Additives business, which delivers an increase in EPS of over 40% for the Company, excluding the Octane Additives business, versus the 2017 achieved level | 40% | 66% of target set | |||||
Earnings before tax target for 2020 as set out in the acquisition business plan approved by the Board for the EDS acquisition | 40% | 137% of target set | |||||
Delivery of the agreed succession plans and associated actions for key roles, as approved by the Board | 20% | Score of 20 out of 20 as assessed by Compensation Committee |
Based on the outcome of the Performance Measures shown above, no participant in the Additional LTIP qualified for a pay-out against the EPS measure and all participants in the Additional LTIP qualified for a pay-out at 100% of target for the EDS EBIT measure and for the succession plan measure according to the weightings assigned to each participant. For the NEOs, performance measure weightings for achievement of the EPS, EDS EBIT and succession plan score measures were 40%, 40% and 20% respectively. Based on the results, the Board approved a total Plan pay-out of $7.937 million at the February 2021 meeting. In the case of the CEO and NEOs, this gave a total pay-out of 60% of the maximum potential payment. The approved payment amounts for each of the NEOs is detailed below and in the Summary Compensation table under the “Non-Equity Incentive Compensation” column:
NEO | Award payable as at end 2020 | |
Mr. Patrick S. Williams President and Chief Executive Officer | $2,505,000 | |
Mr. Ian P. Cleminson Executive Vice President and Chief Financial Officer | $750,000 | |
Dr. Philip J. Boon Executive Vice President and Chief Operating Officer | $810,000 | |
Mr. Brian R. Watt Senior Vice President, Corporate Development and Investor Relations | $480,000 | |
Dr. Ian M. McRobbie Senior Vice President and Chief Technology Officer | $333,000 |
| | 90 |
Other Pay Programs and Policies
Stock Ownership Guidelines
To further align stockholder and Executive Officer interests, the CorporationCompany has adopted a minimum stockholding requirement for the Executive Officers. The Compensation Committee reviewed this policy in 2014 and benchmarked it against their stated comparator group. As a result, the policy was revised to increase the stock holding requirements for the Executive Officers. With effect from January 1, 2015 the CEO is required to acquire and hold stock valued at the equivalent of four times his base salary and all other Executive Officers are required to acquire and hold stock valued at the equivalent of two times their base salary. Only stock which is registered in the Executive Officer’s name or held beneficially in “street name” on behalf of such Executive Officer are taken into accountis considered for these purposes. Unvested equity awards are not taken into account.considered. At the end of 2017,2020, the stockholding of the CEO equated to 11.111.5 times his year endyear-end salary using the average stock price during 20172020 of $64.41.$78.25. The stockholding of each of the other NEOs was also greater than 200% of theiryear-end salary using the same average stock price for 2017. With effect from January 1, 2015 the2020. The Compensation Committee determined that there should also be a similar minimum stockholding requirement for the NEDs. From January 1, 2015, allAll NEDs are required to acquire and hold stock valued at the equivalent of two times their annual retainer. At the end of 2017,2020, the stockholding for all the NEDs, except Mr. L. PadfieldMs. Poccia and Mr. D. Landless,Ms. Arnold, was also greater than 200% of the annual retainer. The new levels of stockholding for NEDs and Executive Officers must be reached within five years of appointment or the introduction of this policy, whichever is later, and Mr. L. Padfield and Mr. D. LandlessMs. Poccia therefore have two andhas three more years respectivelyand Ms. Arnold five more years to reach the required level.
Nonqualified Deferred Compensation Plan
The Company offers a Nonqualified Deferred Compensation Plan (the “Deferred Plan”). The select group of highly compensated employees eligible for the Deferred Plan are designated by the Company in its sole discretion, subject to top hat requirements. Eligible participants are permitted to elect to defer up to 25% of their base salary and up to 100% of any performance-based compensation which is paid in cash. In 2020, Mr. Williams was the only NEO eligible to participate in the Deferred Plan, as the other NEOs are not based in the U.S.
The Company makes discretionary contributions in any given Deferred Plan year equal to the amount of Company contributions that would have otherwise been allocated to the participant under a qualified plan. In this case, such Company contributions are equal to the amount of the participant’s eligible profit-sharing contributions that exceeds IRS employee plus employer contribution limits under the qualified plan. Additionally, the Company has complete discretion to determine each year whether to make an additional annual contribution on behalf of some or all participants in the Deferred Plan. Other discretionary employer contribution factors may include, but are not limited to, achievement of company financial performance objectives. In 2021, Mr. Williams was credited with a discretionary Company contribution of $12,109, which accrued during fiscal year 2020.
The amounts deferred are credited to accounts hypothetically invested in investments selected by the participant that mirror the investment alternatives available in the Company’s qualified retirement savings plans subject to IRC Section 401(a). Each participant in the Deferred Plan is 100% vested in that portion of his or her account that is attributable to employee elective deferrals. For participants receiving an employer discretionary contribution, the “3 Year Cliff” vesting schedule from the date of contribution applies.
Distribution of a participant’s vested accounts for participants who have reached Retirement (i.e. age 50 with a minimum of five years of service) will begin within 60 days of the participant’s separation from service, pursuant to the form of payment selected (lump-sum or instalments over a period not to exceed 10 years) on properly executed election forms. Vested account benefits will be paid in one lump sum to the participant’s beneficiary in the event of the participant’s death in service. A participant’s vested account benefits will be paid to the participant in one lump sum in the event of separation from service that is not Retirement. The Deferred Plan is subject to the rules of IRC Section 409A, which restricts the timing of distributions made to specified employees. As a result, commencement of payments to any eligible NEO participating in the Deferred Plan must be delayed for at least six months after separation from service.
| | 91 |
Other Benefits and Perquisites
TheseOther benefits are provided as appropriate and are set by reference toin line with median market practice. They generally consist ofWe provide our NEOs with pension arrangements, life, disability and medical insurance coverage consistent with that provided to all full-time employees in the relevant geographic area. In addition, we provide a company car or car allowance life, disability and medical cover. There are nonon-qualified deferred compensation plans.to our NEOs in some regions, consistent with that provided to all senior employees in that region. Full details are set out in the table “All Other Compensation”, following the “Summary Compensation Table”.Table.
Post-termination Compensation
Post-termination arrangements vary depending on the nature of the termination event and are designed to be in accordance with U.S. and U.K. market norms, depending on where the executive is based. Full details are set out in the footnotes to the “Post Employment Payments” table.
Employment Agreements
Each of the NEOs has a rolling twelve month12-month employment agreement with the Corporation.Company. Under these agreements, the CorporationCompany can terminate the agreement by giving one year’s notice to the NEO. In the case of Mr. P. Williams, he can terminate the agreement by giving the CorporationCompany one year’s notice, while the other NEOs are required to give the CorporationCompany six months’ notice if they wish to terminate the agreement. The employment agreement for each of the NEOs also includes a “Change ofin Control” clause. This specifies that, in the event of a change in control of the Corporation,Company, if the CorporationCompany terminates the NEO within twelve12 months of the change ofin control, or if the NEO terminates his employment within twelve12 months for good cause,reason, the NEO will be entitled to a compensation payment. If the CorporationCompany terminates the employment of the NEO during this period, the payment is calculated as twenty four months24 months’ compensation defined as base salary, bonus at target and any car allowance from the date of notice of termination. If the NEO terminates his employment for good reason during this period, the payment is calculated as twenty four months24 months’ compensation, defined as above, from the date of the change ofin control. In addition, under the rules of the stock option plans, all
52
options would vest on the change ofin control. The NEOs are treated in the same way as other employees who hold options under the plans. Change ofA change in control is deemed to have occurred if a person or group becomes the beneficial owner of 30% or more of the combined voting power of the Corporation;Company; there is a consolidation or merger and the CorporationCompany is not the surviving Corporation;company; the stockholders of the CorporationCompany approve plans or proposals for a liquidation or dissolution of the CorporationCompany or, if following a cash offer or merger, the members of the Board cease to constitute a majority of the Board. In addition, under their employment agreement, each of the NEOs, including the CEO and the CFO, is subject to a twelve month12-month non-solicitation period, with respect to customers and employees, and a twelve month12-month non-compete period, from the date their employment with the CorporationCompany ends.
Indemnification Agreements
The CorporationCompany has entered into indemnification agreements with each of the directorsDirectors and NEOs in furtherance of the indemnification provisions contained in the Corporation’sCompany’s Certificate of Incorporation and Bylaws, which indemnify the directors and officers of the CorporationCompany to the fullest extent authorized or permitted by law. The indemnification agreements provide for indemnification arising out of specified indemnifiable events, such as events relating to the fact that the indemnitee is or was a director or officer or agent of the CorporationCompany or any subsidiary of the CorporationCompany or is or was a director, officer member, manager, trustee or agent of another entity at the request of the Corporation,Company, including any action or inaction by the indemnitee in such a capacity. The indemnification agreements provide for advancement of expenses prior to final adjudication of the claim. To the extent that indemnification is unavailable, the agreements provide for contribution. The indemnification agreements set forth procedures relating to indemnification claims. The agreements also provide for maintenance of directors’ and officers’ liability insurance.
| | 92 |
All Employee Sharesave Plan
The Company provides a broad based employee stock purchase plan, which gives eligible employees the right to acquire Common Stock through payroll deductions over a pre-determined period at a purchase price which reflects a 15% discount (20% for participants outside of the U.S.) to the market price of our Common Stock. No participant may purchase more than $25,000 in value of Common Stock under this plan in any calendar year. All of our NEOs participated in the Sharesave Plan in 2020.
U.S. Tax Matters
Internal Revenue Code (IRC)(“IRC”) Section 162(m) limits the deductibility of annual compensation in excess of $1 million paid to “covered employees” (as defined by the IRC) of the Corporation, unless the compensation satisfied an exception, such as the exception for performance-based compensation. Performance-based compensation generally includes only payments that are contingent on achievement of performance objectives, and excludes fixed or guaranteed payments.
Company. On December 22, 2017, the Tax Cuts and Jobs Act (the Act)“Act”) was enacted, which, among other things, repealedeliminated the ability of companies to rely on the performance-based compensation exception to such deduction limitation under Section 162(m) and expanded the definition of covered employee. The changes to IRC Section 162(m) are effective for taxable years beginning after December 31, 2017. The Act includes a transition rule so that these changes do not apply to compensation paid pursuant to a “binding written contract” that was in effect on November 2, 2017 and that was not materially modified on or after such date.
Because of the performance-based compensation exception repeal, amounts paid pursuant to a contract effective after November 2, 2017 will not be deductible as performance-based compensation, and the Compensation Committee will not need to consider the requirements of the performance-based compensation exception when considering the design of any such future contracts as part of our compensation program. For amounts paid under contracts in effect on November 2, 2017 that were intended to constitute performance-based compensation, the Compensation Committee will continue to consider the performance-based compensation exception when making determinations of performance under those contracts.
The Act also expands the definition of covered employee. For 2017, our covered employees included the CEO and other NEOs (but not the CFO) who were executive officers as of the last day of our fiscal year. For 2018 and after, our covered employees will generally include anyone who (i) was the CEO or CFO at any time during the year, (ii) was one of the other NEOs who was an executive officerExecutive Officer as of the last day of the fiscal year, and (iii) was a covered employee for any previous year after 2016.
The changes to IRC Section 162(m) became effective for taxable years beginning after December 31, 2017. As a result, beginning in 2018, the Company is no longer able to take a deduction for any compensation paid to our covered employees in excess of $1 million unless the compensation originally qualified for the “performance-based” compensation exception and qualifies for transition relief applicable to certain arrangements in place on November 2, 2017.
53
As with prior years, although the Compensation Committee will consider deductibility under IRC Section 162(m) with respect to the compensation arrangements for executive officers,Executive Officers, deductibility will not be the sole factor used in determining appropriate levels or methods of compensation. Since our compensation objectives may not always be consistent with the requirements for full deductibility, we and our subsidiaries may enter into or modify compensation arrangements under which payments would not be deductible under Section 162(m) if the Compensation Committee believes that it is in the best interest of the CorporationCompany and its stockholders.
In addition, IRC Section 409A imposes restrictions on nonqualified deferred compensation plans. The deferred compensation plans maintained by the CorporationCompany are structured to either be exempt from the requirements of IRC Section 409A or, if not exempt, to satisfy the requirements of IRC Section 409A, and the CorporationCompany has reviewed and, where appropriate, has amended each of its deferred compensation plans to meet the requirements of IRC Section 409A.
Impact of Accounting Treatment
The Company accounts for employee stock options and its employee Sharesave plan in accordance with generally accepted accounting principles. For further information on stock-based compensation, see Note 18 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. |
The Compensation Committee assists the Board of Directors in its oversight of the Corporation’sCompany’s compensation process. The Compensation Committee’s responsibilities are more fully described in its charter, which is accessible on Innospec’s website atwww.innospecinc.com/corporate-governance.corporate-governance.
| | 93 |
The Compensation Committee has reviewed and discussed the foregoing Compensation Discussion and Analysis with management. Based on that review and those discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in the Corporation’s 2018Company’s 2021 Proxy Statement and incorporated by reference into the Corporation’sCompany’s Annual Report on Form10-K for the fiscal year ended December 31, 2017.2020. This report is provided by the following independent directors, who comprise the Compensation Committee.
No portion of this Compensation Committee Report shall be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (“Securities Act”) or the Securities Exchange Act of 1934, as amended (“Exchange Act”), through any general statement incorporating by reference in its entirety the Proxy Statement in which this report appears, except to the extent that the CorporationCompany specifically incorporates this report, or a portion of it, by reference. In addition, this report shall not be deemed to be filed under the Securities Act or the Exchange Act.
THE COMPENSATION COMMITTEE
JOACHIM ROESER,LAWRENCE J. PADFIELD, Chair
MILTON C. BLACKMORE
LAWRENCE J. PADFIELD
54
SUMMARY COMPENSATION TABLE
Name & Principal Position | Salary | Bonus | Stock Awards | Option Awards | Non Equity Incentive Compensation | Change in Pension fund value and other deferred benefits | All Other Compensation | Total | ||||||||||||||||||||||||||
(1) | (2) | (3) | (4) | (5) | (6) | |||||||||||||||||||||||||||||
Year | ($) | ($) | ($) | ($) | ($) | ($) | ($) | ($) | ||||||||||||||||||||||||||
Patrick S. Williams | 2017 | 1,026,462 | - | 4,491,214 | 1,738,800 | - | 98,655 | 7,355,131 | ||||||||||||||||||||||||||
President and Chief Executive Officer | 2016 | 977,692 | 243,881 | 1,091,109 | 4,428,000 | - | 95,862 | 6,836,544 | ||||||||||||||||||||||||||
2015 | 938,678 | - | 1,069,072 | 1,444,561 | - | 94,667 | 3,546,978 | |||||||||||||||||||||||||||
Ian P Cleminson | 2017 | 319,437 | - | 545,255 | 373,004 | - | 88,457 | 1,326,153 | ||||||||||||||||||||||||||
Executive Vice President and Chief Financial Officer | 2016 | 293,204 | 113,134 | 193,011 | 1,096,981 | - | 80,898 | 1,777,228 | ||||||||||||||||||||||||||
2015 | 283,466 | - | 243,273 | 238,170 | - | 78,906 | 843,815 | |||||||||||||||||||||||||||
Philip J. Boon | 2017 | 349,647 | - | 584,094 | 295,240 | -131,907 | 99,601 | 1,196,675 | ||||||||||||||||||||||||||
Executive Vice President, and Chief Operating Officer | 2016 | 322,752 | 131,791 | 218,685 | 1,298,985 | 354,472 | 89,791 | 2,416,476 | ||||||||||||||||||||||||||
2015 | 270,438 | - | 1,205,972 | 206,180 | -6,899 | 78,869 | 1,754,560 | |||||||||||||||||||||||||||
Brian R. Watt | 2017 | 252,717 | - | 479,072 | 298,810 | - | 77,122 | 1,107,721 | ||||||||||||||||||||||||||
Senior Vice President, Corporate Development and Investor Relations | 2016 | 234,351 | 63,731 | 185,123 | 703,356 | - | 68,424 | 1,254,985 | ||||||||||||||||||||||||||
2015 | 226,074 | - | 191,867 | 190,364 | - | 68,472 | 676,777 | |||||||||||||||||||||||||||
Ian M. McRobbie | 2017 | 237,352 | - | 474,100 | 274,287 | -6,954 | 75,656 | 1,054,441 | ||||||||||||||||||||||||||
Senior Vice President, Research and Technology | 2016 | 230,621 | 53,731 | 153,045 | 698,930 | 146,875 | 66,174 | 1,349,376 | ||||||||||||||||||||||||||
2015 | 224,815 | - | 193,091 | 188,862 | 5,389 | 64,981 | 677,138 |
Name & Principal Position | Year | Salary | Bonus | Stock Awards | Option Awards | Non Equity Incentive Compensation | Change in Pension fund value and other deferred benefits | All Other Compensation | Total | |||||||||||||||||||||||||||
(1) | (2) | (3) | (4) | (5) | (6) | (7) | ||||||||||||||||||||||||||||||
($) | ($) | ($) | ($) | ($) | ($) | ($) | ($) | |||||||||||||||||||||||||||||
Mr. Patrick S. Williams President and Chief Executive Officer | 2020 | 1,192,500 | 500,000 | 2,249,044 | 848,526 | 2,505,000 | - | 159,375 | 7,454,444 | |||||||||||||||||||||||||||
2019 | 1,125,000 | - | 2,322,870 | 908,841 | 1,611,563 | - | 111,013 | 6,079,287 | ||||||||||||||||||||||||||||
2018 | 1,089,028 | - | - | 2,836,652 | 1,394,366 | - | 93,222 | 5,413,268 | ||||||||||||||||||||||||||||
Mr. Ian P. Cleminson Executive Vice President and Chief Financial Officer | 2020 | 377,027 | 96,660 | 297,837 | 120,674 | 750,000 | - | 105,119 | 1,747,317 | |||||||||||||||||||||||||||
2019 | 359,905 | - | 262,480 | 112,295 | 345,657 | - | 101,043 | 1,181,380 | ||||||||||||||||||||||||||||
2018 | 345,386 | - | - | 425,136 | 304,243 | - | 93,837 | 1,168,602 | ||||||||||||||||||||||||||||
Dr. Philip J. Boon Executive Vice President, and Chief Operating Officer | 2020 | 402,319 | 100,526 | 269,159 | 109,033 | 810,000 | - | 116,682 | 1,807,719 | |||||||||||||||||||||||||||
2019 | 390,293 | - | 284,626 | 121,788 | 302,641 | - | 109,238 | 1,208,586 | ||||||||||||||||||||||||||||
2018 | 375,096 | - | - | 465,359 | 306,287 | - | 104,882 | 1,251,624 | ||||||||||||||||||||||||||||
Mr. Brian R. Watt Senior Vice President, Corporate Development and Investor Relations | 2020 | 287,568 | 73,461 | 192,400 | 77,952 | 480,000 | - | 86,656 | 1,198,037 | |||||||||||||||||||||||||||
2019 | 278,972 | - | 203,447 | 87,010 | 267,928 | - | 83,615 | 920,972 | ||||||||||||||||||||||||||||
2018 | 269,120 | - | - | 340,583 | 235,827 | - | 78,553 | 924,083 | ||||||||||||||||||||||||||||
Dr. Ian M. McRobbie Senior Vice President and Chief Technology Officer | 2020 | 256,409 | 64,440 | - | 289,239 | 330,000 | 68,615 | 100,556 | 1,109,259 | |||||||||||||||||||||||||||
2019 | 249,338 | - | - | 315,377 | 238,899 | 112,548 | 80,846 | 997,008 | ||||||||||||||||||||||||||||
2018 | 244,058 | - | - | 312,620 | 213,367 | 844 | 78,223 | 849,112 |
Footnotes to “Summary Compensation Table”:
1. | Mr. |
2. | As |
3. | The value of the |
| | 95 |
Black-Scholes model, with reference to the underlying stock price, |
55
these grant date fair values refer to Note |
4. | The value of the option awards for all NEO’s listed above for 2020 and 2019 discloses the grant date fair value of options awarded under the Omnibus Plan and the grant date fair value of any cash incentive awards granted in lieu of stock option awards and full value awards as required by the terms of the grant. In the case of Dr. McRobbie, 100% of the award was in the form of cash incentive awards. The value of the option awards and cash incentive awards are determined using the number of options awarded and, for the cash incentive awards, the number of units awarded, and the grant date fair value for each option or unit made in the year. The grant date fair values on Company stock options and cash incentive awards are calculated in the same way as the full value awards above. The value of the option awards listed above for 2018 discloses the value of options awarded under the CSOP and PRSOP and the grant date fair value of any SEUs awarded in lieu of stock option awards as required by the terms of the grant. The value of the option awards and SEUs are determined in the same way as for the option awards and cash incentive awards granted under the Omnibus Plan, as detailed above. For each Executive Officer, the value of the |
Name | Value of SEUs included under option awards | Proportion of value of SEUs relating to market price SEUs | Proportion of value of SEUs relating to zero price SEUs | Value of cash incentive awards | Proportion of value of cash incentive awards relating to those granted at market price | Proportion of value of cash incentive awards relating to those granted at zero cost | ||||||||||||
Mr. Patrick S. Williams | $ | 2,339,167 | 1.1 | % | 98.9 | % | $774,382
| 3.2%
| 96.8%
| |||||||||
Mr. Ian P. Cleminson | $ | 278,387 | 2.7 | % | 97.3 | % | $104,676
| 5.1%
| 94.9%
| |||||||||
Dr. Philip J. Boon | $ | 291,981 | 1.9 | % | 98.1 | % | $94,567
| 5.1%
| 94.9%
| |||||||||
Mr. Brian R. Watt | $ | 265,760 | 1.5 | % | 98.5 | % | $67,617
| 5.1%
| 94.9%
| |||||||||
Dr. Ian M. McRobbie | $ | 474,100 | 3.4 | % | 96.6 | % | $289,239
| 5.1%
| 94.9%
|
TheNon-Equity Incentive Compensation for all Executive Officers listed above relates to incentive compensation earned for the stated year under the MICP and |
Name | Incentive Compensation earned under the MICP in 2016 | Incentive Compensation earned in 2016 under the 2014 LTIP | ||||||
Mr. Patrick S. Williams | $ | 1,548,000 | $ | 2,880,000 | ||||
Mr. Ian P. Cleminson | $ | 335,126 | $ | 780,000 | ||||
Dr. Philip J. Boon | $ | 294,954 | $ | 1,020,000 | ||||
Mr. Brian R. Watt | $ | 267,858 | $ | 450,000 | ||||
Dr. Ian M. McRobbie | $ | 263,180 | $ | 450,000 |
Dr. McRobbie |
| | 96 |
7. | The amounts reflected under “All Other Compensation” for |
ALL OTHER COMPENSATION
56
|
Car Allowance | Leased Car Costs | Pension Allowance | Pension Contribution | Healthcare | Insurances | Other | Total | |||||||||||||||||||||||||||||
(1) | (1) | (2) | (3) | (4) | (4) | (5) | ||||||||||||||||||||||||||||||
($) | ($) | ($) | ($) | ($) | ($) | ($) | ($) | |||||||||||||||||||||||||||||
Mr. Patrick S. Williams | ||||||||||||||||||||||||||||||||||||
President and Chief Executive Officer | 2017 | 0 | 0 | 9,518 | 56,726 | 24,877 | 0 | 7,535 | 98,655 | |||||||||||||||||||||||||||
Mr. Ian P. Cleminson | ||||||||||||||||||||||||||||||||||||
Executive Vice President and Chief Financial Officer | 2017 | 17,622 | 0 | 63,889 | 0 | 2,022 | 4,924 | 0 | 88,457 | |||||||||||||||||||||||||||
Dr. Philip J. Boon | ||||||||||||||||||||||||||||||||||||
Executive Vice President, and Chief Operating Officer | 2017 | 17,622 | 0 | 69,931 | 0 | 2,022 | 7,127 | 2,899 | 99,601 | |||||||||||||||||||||||||||
Mr. Brian R. Watt | ||||||||||||||||||||||||||||||||||||
Senior Vice President, Corporate Development and Investor Relations | 2017 | 0 | 16,594 | 50,544 | 2,868 | 2,022 | 5,094 | 0 | 77,122 | |||||||||||||||||||||||||||
Dr. Ian M. McRobbie | ||||||||||||||||||||||||||||||||||||
Senior Vice President, Research and Technology | 2017 | 17,622 | 0 | 47,470 | 0 | 1,617 | 8,947 | 0 | 75,656 |
Car |
Leased |
Pension |
Retirement |
Healthcare |
Insurances |
Other |
Total | |||||||||||
(1) | (1) | (2) | (3) | (4) | (4) | (5) | ||||||||||||
($) | ($) | ($) | ($) | ($) | ($) | ($) | ($) | |||||||||||
Mr. Patrick S. Williams President and Chief Executive Officer | 2020 | 0 | 0 | 0 | 49,609 | 18,479 | 1,063 | 90,224 | 159,375 | |||||||||
Mr. Ian P. Cleminson Executive Vice President and Chief Financial Officer | 2020 | 17,592 | 0 | 75,405 | 0 | 2,060 | 10,062 | 0 | 105,119 | |||||||||
Dr. Philip J. Boon Executive Vice President, and Chief Operating Officer | 2020 | 17,592 | 0 | 80,463 | 0 | 2,060 | 13,345 | 3,222 | 116,682 | |||||||||
Mr. Brian R. Watt Senior Vice President, Corporate Development and Investor Relations | 2020 | 0 | 16,128 | 57,513 | 0 | 2,060 | 10,955 | 0 | 86,656 | |||||||||
Dr. Ian M. McRobbie Senior Vice President and Chief Technology Officer | 2020 | 17,592 | 0 | 51,281 | 0 | 1,647 | 30,036 | 0 | 100,556 |
Footnotes to “All Other Compensation” table:
(1) | Executive Officers based in the U.K. are entitled to a leased company car or an allowance in lieu of a car. The allowance is set at £13,650 ($ |
(2) | For U.K. based Executive Officers, where pensionable salary is subject to a cap, Executive Officers receive a salary supplement of 20% in lieu of pension for any salary above the |
(3) | The Company provides a number of |
| | 97 |
was $37,500. The |
(4) | The NEOs are eligible for healthcare insurance and life and disability insurance through programs which are available to substantively the majority of salaried employees in the relevant business unit. The cost |
57
of these insurances is detailed under “Healthcare” and “Insurances”, respectively, in the “All Other Compensation” table. In the case of Mr. |
(5) | Mr. |
Employment Agreements
Each of the NEOs has a rolling twelve-month employment agreement with the Corporation.Company. Under these agreements, the CorporationCompany can terminate the agreement without cause by giving one year’s notice to the NEO. In the case of Mr. P. Williams, he can terminate the agreement by giving the CorporationCompany one year’s notice, while the other NEOs are required to give the CorporationCompany six months’ notice if they wish to terminate the agreement. The employment agreement for each of the NEOs also includes a “Change of Control” clause, which is described in more detail in the narrative following the “Post Employment Payments” table.
In addition, under the employment agreement, Mr. P. Williams is entitled to a target bonus under the MICP of 75%85% of his base salary, with a potential maximum MICP bonus of 172.5%195.5%. All other NEOs have a MICP target bonus of 50% with a potential maximum of 115% of base salary. Each NEO is also entitled to participate in long-term incentive plans, which have been described in more detail, including grant policy for different NEOs, in the Compensation Discussion and Analysis section, above.
Each NEO is also able to participate in the pension arrangements relevant for the business unit and country where they are based. In the case of Mr. P. Williams, he participates in a Defined Contribution plan in line with other U.S. based employees and details of the amount paid into the plan are provided in the “Summary Compensation Table”. He is also eligible to participate in a non- qualified deferred compensation retirement plan, in line with other eligible employees in the U.S.. Details of the amount paid into this plan are included in the “All Other Compensation” table and further information is provided in the Non-Qualified Deferred Compensation table on page 109. As noted in the “Summary Compensation Table”, Dr. Boon and Dr. McRobbie werewas able to participate in the Innospec Limited Defined Benefit Pension Plan until its closure to future service accrual on March 31, 2010 and this is described more fully in the narrative following the Pension Benefit table on page 66. Mr. Watt participated in a defined contribution plan in line with other U.K. based employees.107. Mr. Cleminson, Dr. Boon, Mr. Watt and Dr. McRobbie also participateddo not participate in this scheme from April 2010the defined contribution plan for U.K. based employees due to limits on pension provision set by the U.K. government and detailsin line with the approach for other impacted U.K. employees, they receive a 20% salary supplement in lieu of pension provision. Details of the amounts of salary supplements paid into this plan are provided in the “All Other Compensation” table.
| | 98 |
The employment agreements for each NEO also provide medical insurance and life and disability insurance, through programs, which are available to the majority of salaried employees in the relevant part of the business unit. The costs of these insurances are provided in the footnotes to the “All Other Compensation” table.
In addition, under their employment agreement, each of the NEOs, including the CEO and the CFO, is subject to a twelve monthtwelve-month non-solicitation period, with respect to customers and employees, and a twelve monthtwelve-month non-compete period, from the date their employment with the CorporationCompany ends.
Pay Ratio Disclosure
In line with the SEC disclosure requirements, the CorporationCompany has determined the ratio of the total annual compensation of Mr. P. Williams, CEO, to the total annual compensation of the median employee for 2017,2020, the last completed fiscal year.
In 2017,2020, the total annual compensation of the CEO was $7,355,131.$7,454,544. The total annual compensation of the median employee was $97,275.$75,014. As a result, for 2017,2020, the ratio of the CEO’s total annual compensation to the total annual compensation of the median employee was approximately 7699 to 1.
58
The median employee was identified by examining compensation information derived from payroll records for all employees, excluding the CEO, who were employed by the CorporationCompany on November 1 2017.2020. As of such date, the CorporationCompany employed approximately 19151,900 people, with 680around 600 of these employees located in the United States and 1235around 1,300 located outside the United States. All employees were included, whether employed on a full-time, part-time, temporary or seasonal basis. In identifying the median employee, the CorporationCompany selected actual cash compensation for the 12 month period ending December 31 20162019 as the most appropriate measure of compensation, as there has been no change in the employee population or compensation arrangements that would have resulted in a significant change in the pay distribution to the workforce. Cash compensation was defined as base salary (for salaried employees), wages (for hourly employees), bonus and incentive payments earned in 2016,2019, and any cash allowances including shift allowance, car allowance and responsibility allowance, but excluding any payments relating to stock based incentives. In the cases where an individual was employed on November 1 2017,2020, but had not been employed in 2016,2019, the 20162019 compensation of an employee in a similar role and location was used as an estimate. In the cases where a full time or part time permanent employee was not employed by the CorporationCompany for all of 2016,2019, the compensation was annualized. Compensation was not annualizedanalysed for any temporary or seasonal workers. This measure was consistently applied to all employees included in the calculation.
To determine the annual total compensation of the CEO, we used the amount reported in the “Total” column of the Summary Compensation Table in this Proxy Statement, which includes salary, stock and option awards, bonus, change in pension value, and all other compensation. The median employee’s total annual compensation for 20172020 was calculated in accordance with the same requirements applicable to the CEO’s compensation as reported in the Summary Compensation Table and that number was used to calculate the ratio of the CEO’s pay to that of the median employee.
The SEC rules requiring pay ratio disclosure allow companies to exercise a significant amount of flexibility in making the determination as to who is the median employee and do not mandate that each company use the same method. We believe that the pay ratio information above is a reasonable estimate calculated in a manner consistent with the SEC rules. However, the total annual compensation of our median employee is unique to that person and is not necessarily a good indicator of the total annual compensation of any of the other employees of the Corporation,Company, and it is not comparable to the annual total compensation of employees at other companies. Similarly, we would not expect that the ratio of the CEO’s total annual compensation to that of the median employee to be a number that can be compared to the ratio determined by other companies in any meaningful fashion.
59
| | 99 |
GRANTS OF PLAN-BASED AWARDS IN FISCAL 2020
Name and Principal Position | Grant Date | Estimated Future Payouts Under Plan Awards | Estimated Future Payouts Under Equity Plan Awards | All other Stock Awards: No. of Securities, Shares of stock or units | All other Options Awards: No. of Securities underlying options | Exercise or Base Price of Option Awards | Grant Date Fair Value of Stock and Option Awards | |||||||||||||||||
Threshold | Target | Maximum | Threshold | Target | Maximum | |||||||||||||||||||
($) | ($) | ($) | ($) | ($) | ($) | ($) | ($) | |||||||||||||||||
Mr. Patrick S. Williams President and Chief Executive Officer | (1) | 02/21/17 | - | - | - | 705,421 | 1,390,095 | 2,074,769 | - | - | - | - | ||||||||||||
(2) | 02/21/17 | - | - | - | - | - | - | - | 1,530 | 70.60 | 25,765 | |||||||||||||
(3) | 02/21/17 | - | - | - | 235,161 | 463,406 | 691,651 | - | - | - | - | |||||||||||||
(4) | - | 340,200 | 750,000 | 1,738,800 | - | - | - | - | - | - | - | |||||||||||||
(5) | 02/21/17 | - | - | - | - | - | - | - | 4,589 | 70.60 | 77,279 | |||||||||||||
(3) | 02/22/17 | - | - | - | 1,621,750 | 1,621,750 | 1,621,750 | - | - | - | - | |||||||||||||
Mr. Ian P. Cleminson Executive Vice President and Chief Financial Officer | (1) | 02/21/17 | - | - | - | 85,542 | 168,568 | 251,594 | - | - | - | - | ||||||||||||
(2) | 02/21/17 | - | - | - | - | - | - | - | 302 | 70.60 | 5,086 | |||||||||||||
(3) | 02/21/17 | - | - | - | 28,528 | 56,217 | 83,906 | - | - | - | - | |||||||||||||
(4) | - | 72,979 | 162,176 | 373,004 | - | - | - | - | - | - | - | |||||||||||||
(5) | 02/21/17 | - | - | - | - | - | - | - | 907 | 70.60 | 15,274 | |||||||||||||
(3) | 02/22/17 | - | - | - | 194,610 | 194,610 | 194,610 | - | - | - | - | |||||||||||||
Dr. Philip J. Boon Executive Vice President and Chief Operating Officer | (1) | 02/21/17 | - | - | - | 93,633 | 184,512 | 275,391 | - | - | - | - | ||||||||||||
(2) | 02/21/17 | - | - | - | - | - | - | - | 331 | 70.60 | 5,574 | |||||||||||||
(3) | 02/21/17 | - | - | - | 31,211 | 61,504 | 91,797 | - | - | - | - | |||||||||||||
(4) | - | 79,880 | 177,512 | 408,278 | - | - | - | - | - | - | - | |||||||||||||
(5) | 02/21/17 | - | - | - | - | - | - | - | 993 | 70.60 | 16,722 | |||||||||||||
(3) | 02/22/17 | - | - | - | 194,610 | 194,610 | 194,610 | - | - | - | - | |||||||||||||
Mr. Brian R. Watt Senior Vice President, Corporate Development and Investor Relations | (1) | 02/21/17 | - | - | - | 68,375 | 134,739 | 201,102 | - | - | - | - | ||||||||||||
(2) | 02/21/17 | - | - | - | - | - | - | - | 242 | 70.60 | 4,075 | |||||||||||||
(3) | 02/21/17 | - | - | - | 60,342 | 44,940 | 67,075 | - | - | - | - | |||||||||||||
(4) | - | 58,463 | 129,917 | 298,811 | - | - | - | - | - | - | - | |||||||||||||
(5) | 02/21/17 | - | - | - | - | - | - | - | 725 | 70.60 | 12,209 | |||||||||||||
(3) | 02/22/17 | - | - | - | 194,610 | 194,610 | 194,610 | - | - | - | - | |||||||||||||
Dr. Ian M. McRobbie Senior Vice President, Research and Technology | (1) | 02/21/17 | - | - | - | - | - | - | - | - | - | - | ||||||||||||
(2) | 02/21/17 | - | - | - | - | - | - | - | 950 | 70.60 | 15,998 | |||||||||||||
(3) | 02/21/17 | - | - | - | 89,587 | 176,540 | 263,492 | - | - | - | - | |||||||||||||
(4) | 53,664 | 119,255 | 274,287 | - | - | - | - | |||||||||||||||||
(3) | 02/22/17 | - | - | - | 194,610 | 194,610 | 194,610 | - | - | - | - |
Name and Principal Position | Grant Date | Estimated Future Payouts Under Non-Equity Incentive Plan Awards | Estimated Future Payouts Under Equity Plan Awards | All other Stock Awards: No. of Securities, Shares of stock or units | All other Options Awards: No. of Securities underlying options | Exercise or Base Price of Option Awards | Grant Date Fair Value of Stock and Option Awards | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Threshold | Target | Maximum | Threshold | Target | Maximum | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
($) | ($) | ($) | ($) | ($) | ($) | ($) | ($) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Mr. Patrick S. Williams President and Chief Executive Officer | (1) | 02/24/20 | - | - | - | 764,675 | 1,506,859 | 2,249,044 | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
(2) | 02/24/20 | - | - | - | - | - | - | - | 1,323 | 95.70 | 24,727 | |||||||||||||||||||||||||||||||||||||||||||||||||
(3) | 02/24/20 | - | - | - | 254,883 | 502,269 | 749,655 | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
(4) | - | 447,525 | 994,500 | 2,287,350 | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
(5) | 02/24/20 | - | - | - | - | - | - | - | 3,967 | 95.70 | 74,143 | |||||||||||||||||||||||||||||||||||||||||||||||||
Mr. Ian P. Cleminson Executive Vice President and Chief Financial Officer | (1) | 02/24/20 | - | - | - | 101,265 | 199,551 | 297,837 | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
(2) | 02/24/20 | - | - | - | - | - | - | - | 286 | 95.70 | 5,345 | |||||||||||||||||||||||||||||||||||||||||||||||||
(3) | 02/24/20 | - | - | - | 33,772 | 66,551 | 99,331 | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
(4) | - | 85,509 | 190,021 | 437,050 | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
(5) | 02/24/20 | - | - | - | - | - | - | - | 856 | 95.70 | 15,999 | |||||||||||||||||||||||||||||||||||||||||||||||||
Dr. Philip J. Boon Executive Vice President and Chief Operating Officer | (1) | 02/24/20 | - | - | - | 91,514 | 180,336 | 269,159 | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
(2) | 02/24/20 | - | - | - | - | - | - | - | 258 | 95.70 | 4,822 | |||||||||||||||||||||||||||||||||||||||||||||||||
(3) | 02/24/20 | - | - | - | 30,513 | 60,129 | 89,745 | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
(4) | - | 90,963 | 202,141 | 464,924 | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
(5) | 02/24/20 | - | - | - | - | - | - | - | 774 | 95.70 | 14,466 | |||||||||||||||||||||||||||||||||||||||||||||||||
Mr. Brian R. Watt Senior Vice President, Corporate Development and Investor Relations | (1) | 02/24/20 | - | - | - | 65,416 | 128,908 | 192,400 | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
(2) | 02/24/20 | - | - | - | - | - | - | - | 185 | 95.70 | 3,458 | |||||||||||||||||||||||||||||||||||||||||||||||||
(3) | 02/24/20 | - | - | - | 57,727 | 42,987 | 64,159 | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
(4) | - | 65,018 | 144,485 | 332,316 | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
(5) | 02/24/20 | - | - | - | - | - | - | - | 553 | 95.70 | 10,336 | |||||||||||||||||||||||||||||||||||||||||||||||||
Dr. Ian M. McRobbie Senior Vice President and Chief Technology Officer | (1) | 02/24/20 | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
(2) | 02/24/20 | - | - | - | - | - | - | - | 789 | 95.70 | 14,746 | |||||||||||||||||||||||||||||||||||||||||||||||||
(3) | 02/24/20 | - | - | - | 93,327 | 183,910 | 274,492 | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
(4) | - | 57,973 | 128,830 | 296,309 | - | - | - | - | - | - | - |
Footnotes to “Grants of Plan-Based Awards” table:
(1) | Full Value awards issued under the |
(2) | Cash incentive awards issued at market price under the |
(3) | Cash incentive awards, with vesting dependent on achievement of performance measures, issued at zero cost under the |
(4) | Estimatedpay-outs under the MICP |
(5) | Options issued under the |
|
|
| | 100 |
• Details of the grant policy and performance criteria for the awards made in 2020 are covered earlier in the Compensation Discussion and Analysis.
• The CSOP.All Other Options areAwards column in the “Grants of Plan-Based Awards” table details the following types of awards made under the Omnibus Plan:
Options. Options were granted at market value and become exercisable normally after three years, with all options vesting at the end of this period. Cash based awards are also made in the form of SEUs which can be cashed after three years, assuming the NEO remains employed by the Corporation. The SEU awards are detailed under “All Other Option Awards” in the rows labelled (2) in the table. On cashing the SEU award, the NEO receives a payment for each SEU equal to the market stock price of the Corporation at that time less the market stock price at time of grant. The CSOP awardsoptions awarded are detailed under “All Other Option Awards” in the rows labelled (5). The grant date fair value for the option awards and SEUs under the CSOP has been determined using the fair value of the Corporation’sCompany’s stock on date of grant.
Cash incentive awards granted at market price. Cash incentive awards were also made in the form of units, which can be cashed after three years, assuming the NEO remains employed by the Company. The value of each award once vested will be equal to the number of units multiplied by the closing stock price of the Company on the date it is exchanged for cash, less the market stock price at time of grant. These awards are detailed under “All Other Option Awards” in the rows labelled (2) in the table. The grant date fair value for the cash incentive awards granted at market price has been determined using the fair value of the Company’s stock on the date of grant.
The PRSOP.Estimated Future Pay-Outs Under Equity Awards column in the “Grants of Plan-Based Awards” table details the following types of awards made under the Omnibus Plan:
Full Value AwardsOptions are. Full value awards were granted at zero cost, i.e. with an exercise price of zero and become exercisablevest after a minimum of two years but normally after three years, provided, that specified performance criteria
60
are achieved as set by the Compensation Committee. All options have aten-year term and once options vest, the recipient has the right to exercise them at any time prior to their expiration date. Under the Plan, cash basedThe full value awards are detailed under “Estimated Future pay-outs under Equity Plan Awards” in the row labelled (1)
Cash Incentive Awards granted at zero cost. Cash incentive awards were also made in the form of SEUs. SEUs are alsounits. These awards were granted at zero cost and become exercisable after a minimum of two years but normally after three years, subject to achievement of performance criteria set by the Compensation Committee. All SEUscash incentive awards granted at zero cost have aten-year term and once the SEUsawards vest, the recipient has the right to exercise them at any time prior to their expiration date. However, if optionthese cash incentive awards or SEUs under the PRSOP arewere granted to a participant who iswas or would otherwise be subject to Section 409A of the Code, with an exercise price less than the fair market value of the shares on the date of grant, it must be exercised (if at all) no later than March 15 of the calendar year immediately following the calendar year in which it is first capable of exercise under the PRSOP.Omnibus Plan. The SEU awardsCash Incentive Awards granted at zero cost are detailed under “Estimated FuturePay-outs under Equity Incentive Plan Awards” in the row under the grant date labelled (3) in the table above and the PRSOP option awards are also detailed under “Estimated Futurepay-outs under Equity Plan Awards” in the row labelled (1). above.
In 2017,2020, the relative weighting and performance criteria for both optionsthe full value awards and SEUs werethe cash incentive awards granted at zero costs:
35% weighting on the relative performance of the Company’s Total Shareholder Return (“TSR”) versus the Russell 2000 Total Return Index (“Index”). The threshold level is set as:at 70% of the Index performance over three years, in which case 60% of the full value awards and cash incentive awards granted at zero cost will vest. The target level is set at 90% of the Index performance, in which case 80% of the full value awards and cash incentive awards granted at zero cost will vest and the maximum level is set at 110% of the Index performance, in which case all the granted full value awards and cash incentive awards granted at zero cost will vest
|
30% weighting on the compound increase per annum in sales revenue, excluding the Octane Additives business. The threshold level is set at a total growth of 2% versus the 2020 budget figure, in which case 20% of the full value awards and cash incentive awards granted at zero cost will vest. The target level is set at a total growth of 3% versus the 2020 budget figure, in which case 60% of the full value awards and cash incentive awards granted at zero cost will vest and the maximum level is set at a total growth of 5% versus the 2020 budget figure, in which case 20% of the options and SEUs will vest. The target level is set at a total growth of 6% versus the 2017 budget figure, in which case 60% of the options and SEUs will vest and the maximum level is set at a total growth of 8% versus the 2017 budget figure, in which case all the granted options and SEUs will vest.
In addition, in 2017, Mr. P. Williams was awarded 25,000 SEUs under the PRSOP and Mr. Cleminson, Dr. Boon, Mr. Watt and Dr. McRobbie were each awarded 3,000 SEUs under the PRSOP plan. In each case, the SEUs will vest after two years, subject to the participant still being employed by the Corporation and not under notice of termination of employment on the vesting date and assessed as achieving a good performance in each year from grant date to vesting date. In the case of these options, the threshold, target and maximum levels have all been set such that all the granted SEUsfull value awards and cash incentive awards granted at zero cost will vest as that
35% weighting on the compound increase per annum in earnings per share (“EPS”), excluding the Octane Additives business. The threshold level is set at a total growth of 2% versus the outcome that2020 budget figure, in which case 20% of the Compensation Committee expects.full value awards and cash incentive awards granted at zero cost will vest. The target level is set at a total growth of 3% versus the 2020 budget figure, in which case 60% of the full value awards and cash incentive awards granted at zero cost will vest and the maximum level is set at a total growth of 5% versus the 2020 budget figure in which case all the full value awards and cash incentive awards granted at zero cost will vest
The estimated futurepay-outs for the PRSOP optionsfull value awards and SEUcash incentive awards granted at zero cost have been valued using the grant date fair value for the awards.
MICP.MICP. Payment under the MICP is based on achievement ofpre-determined financial goals and personal objectives set by the Board each year. The threshold level is set at 90% achievement of the financial goals and the target payment is earned for 100% achievement of the financial goals. The maximum payment is earned for 130% achievement of the financial goals. The potential awards for 20172020 are detailed in the table in the row under the grant date heading labelled (4). As this is an annualnon-equity incentive plan, there is no grant date for this award.is disclosed.
61
| | 102 |
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END 20172020
Option Awards | Stock Awards | |||||||||||||||||||||||||||||||||||||||||||
Name and Principal Position | | Number of Securities Underlying Unexercised Options Exercisable | | | Number of Securities Underlying Unexercised Options Unexercisable | | | Equity Incentive Plans Awards: Number of Securities Underlying Unexercisable | | | Option Exercise Price | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested | | | Market Value of Shares or Units of Stock That Have not Vested | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested | | |||||||||||||||||
($) | ($) | ($) | ||||||||||||||||||||||||||||||||||||||||||
Mr. Patrick S. Williams | 1 | 10 | 2,268 | 43.95 | 02/23/2025 | |||||||||||||||||||||||||||||||||||||||
President and Chief | 1 | 11 | 1,530 | 70.60 | 02/21/2027 | |||||||||||||||||||||||||||||||||||||||
Executive Officer | 1 | 14 | 1,663 | 68.20 | 02/20/2028 | |||||||||||||||||||||||||||||||||||||||
2 | 14 | 4,988 | 68.20 | 02/20/2028 | ||||||||||||||||||||||||||||||||||||||||
3 | 17 | 5,511 | 0.00 | 03/15/2024 | ||||||||||||||||||||||||||||||||||||||||
4 | 17 | 16,535 | 0.00 | 03/15/2024 | ||||||||||||||||||||||||||||||||||||||||
6 | 16 | 1,483 | 81.07 | 02/25/2029 | ||||||||||||||||||||||||||||||||||||||||
6 | 18 | 1,323 | 95.70 | 02/24/2030 | ||||||||||||||||||||||||||||||||||||||||
7 | 16 | 4,448 | 81.07 | 02/25/2029 | ||||||||||||||||||||||||||||||||||||||||
7 | 18 | 3,967 | 95.70 | 02/24/2030 | ||||||||||||||||||||||||||||||||||||||||
8 | 16 | 3,697 | 0.00 | 03/15/2023 | ||||||||||||||||||||||||||||||||||||||||
8 | 18 | 3,297 | 0.00 | 03/15/2024 | ||||||||||||||||||||||||||||||||||||||||
9 | 16 | 0.00 | 02/25/2022 | 11,091 | 1,006,286 | |||||||||||||||||||||||||||||||||||||||
9 | 18 | 0.00 | 02/24/2023 | 9,892 | 897,501 | |||||||||||||||||||||||||||||||||||||||
Mr. Ian P. Cleminson | 1 | 14 | 387 | 68.20 | 02/20/2028 | |||||||||||||||||||||||||||||||||||||||
Executive Vice President and | 2 | 14 | 1,161 | 68.20 | 02/20/2028 | |||||||||||||||||||||||||||||||||||||||
Chief Financial Officer | 3 | 17 | 787 | 0.00 | 02/20/2028 | |||||||||||||||||||||||||||||||||||||||
4 | 17 | 1,776 | 0.00 | 02/25/2028 | ||||||||||||||||||||||||||||||||||||||||
5 | 15 | 374 | 61.83 | 05/05/2022 | ||||||||||||||||||||||||||||||||||||||||
6 | 16 | 273 | 81.07 | 02/25/2029 | ||||||||||||||||||||||||||||||||||||||||
6 | 18 | 286 | 95.70 | 02/24/2030 | ||||||||||||||||||||||||||||||||||||||||
7 | 16 | 819 | 81.07 | 02/25/2029 | ||||||||||||||||||||||||||||||||||||||||
7 | 18 | 406 | 95.07 | 02/24/2030 | ||||||||||||||||||||||||||||||||||||||||
7 | 18 | 450 | 95.07 | 02/24/2030 | ||||||||||||||||||||||||||||||||||||||||
8 | 16 | 418 | 0.00 | 02/25/2029 | ||||||||||||||||||||||||||||||||||||||||
8 | 18 | 437 | 0.00 | 02/24/2030 | ||||||||||||||||||||||||||||||||||||||||
9 | 16 | 0.00 | 02/25/2022 | 1,253 | 113,685 | |||||||||||||||||||||||||||||||||||||||
9 | 18 | 0.00 | 02/24/2023 | 1,310 | 118,856 | |||||||||||||||||||||||||||||||||||||||
Dr. Philip J. Boon | 1 | 12 | 331 | 70.60 | 02/21/2027 | |||||||||||||||||||||||||||||||||||||||
Executive Vice President and | 1 | 14 | 424 | 68.20 | 02/20/2028 | |||||||||||||||||||||||||||||||||||||||
Chief Operating Officer | 2 | 12 | 993 | 70.60 | 02/21/2027 | |||||||||||||||||||||||||||||||||||||||
2 | 14 | 140 | 68.20 | 02/20/2028 | ||||||||||||||||||||||||||||||||||||||||
2 | 14 | 1,130 | 68.20 | 02/20/2028 |
Option Awards | Stock Awards | |||||||||||||||||||||||||||||||||||||||||||
Name and Principal Position | Number of Securities Underlying Unexercised Options Exercisable | Number of Securities Underlying Unexercised Options Unexercisable | Equity Awards: | Option Exercise Price | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested | Market Value of Shares or Units of Stock That Have not Vested | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested | |||||||||||||||||||||||||||||||||||
($) | ($) | ($) | ($) | |||||||||||||||||||||||||||||||||||||||||
Mr. Patrick S. Williams | (1) | (8) | 2,268 | 43.95 | 02/23/25 | |||||||||||||||||||||||||||||||||||||||
President and Chief | (1) | (9) | 2,347 | 44.18 | 02/22/26 | |||||||||||||||||||||||||||||||||||||||
Executive Officer | (1) | (11) | 1,530 | 70.60 | 02/21/27 | |||||||||||||||||||||||||||||||||||||||
(2) | (8) | 6,805 | 43.95 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||
(2) | (9) | 7,040 | 44.18 | 02/22/26 | ||||||||||||||||||||||||||||||||||||||||
(2) | (11) | 4,589 | 70.60 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||
(3) | (8) | 5,444 | 0.00 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||
(3) | (9) | 5,350 | 0.00 | 02/22/26 | ||||||||||||||||||||||||||||||||||||||||
(3) | (10) | 25,000 | 0.00 | 02/22/27 | ||||||||||||||||||||||||||||||||||||||||
(3) | (11) | 7,517 | 0.00 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||
(4) | (8) | 16,331 | 0.00 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||
(4) | (9) | 16,051 | 0.00 | 02/22/26 | ||||||||||||||||||||||||||||||||||||||||
(4) | (11) | 20,865 | 0.00 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||
Mr. Ian P. Cleminson | (1) | (8) | 558 | 43.95 | 02/23/25 | |||||||||||||||||||||||||||||||||||||||
Executive Vice President | (1) | (9) | 450 | 44.18 | 02/22/26 | |||||||||||||||||||||||||||||||||||||||
and Chief Financial Officer | (1) | (11) | 302 | 70.60 | 02/21/27 | |||||||||||||||||||||||||||||||||||||||
(2) | (8) | 1,677 | 43.95 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||
(2) | (9) | 1,349 | 44.18 | 02/22/26 | ||||||||||||||||||||||||||||||||||||||||
(2) | (11) | 529 | 70.60 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||
(2) | (11) | 378 | 70.60 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||
(3) | (8) | 1,230 | 0.00 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||
(3) | (9) | 939 | 0.00 | 02/22/26 | ||||||||||||||||||||||||||||||||||||||||
(3) | (10) | 3,000 | 0.00 | 02/22/27 | ||||||||||||||||||||||||||||||||||||||||
(3) | (11) | 912 | 0.00 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||
(4) | (8) | 3,688 | 0.00 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||
(4) | (9) | 2,820 | 0.00 | 02/22/26 | ||||||||||||||||||||||||||||||||||||||||
(4) | (11) | 2,530 | 0.00 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||
Dr. Philip J. Boon | (1) | (7) | 511 | 46.03 | 02/14/24 | |||||||||||||||||||||||||||||||||||||||
Executive Vice President | (1) | (8) | 427 | 44.18 | 02/23/25 | |||||||||||||||||||||||||||||||||||||||
and Chief Operating Officer | (1) | (9) | 510 | 44.18 | 02/22/26 | |||||||||||||||||||||||||||||||||||||||
(1) | (11) | 331 | 70.60 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||
(2) | (8) | 776 | 43.95 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||
(2) | (8) | 506 | 43.95 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||
(2) | (9) | 1,528 | 44.18 | 02/22/26 | ||||||||||||||||||||||||||||||||||||||||
(2) | (11) | 993 | 70.60 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||
(3) | (7) | 1,054 | 0.00 | 02/14/24 | ||||||||||||||||||||||||||||||||||||||||
(3) | (8) | 940 | 0.00 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||
(3) | (9) | 1,065 | 0.00 | 02/22/26 | ||||||||||||||||||||||||||||||||||||||||
(3) | (10) | 3,000 | 0.00 | 02/22/27 | ||||||||||||||||||||||||||||||||||||||||
(3) | (11) | 998 | 0.00 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||
(4) | (8) | 2,819 | 0.00 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||
(4) | (12) | 6,000 | 0.00 | 11/01/25 | ||||||||||||||||||||||||||||||||||||||||
(4) | (13) | 6,000 | 0.00 | 11/01/25 | ||||||||||||||||||||||||||||||||||||||||
(4) | (14) | 8,000 | 0.00 | 11/01/25 | ||||||||||||||||||||||||||||||||||||||||
(4) | (9) | 3,194 | 0.00 | 02/22/26 | ||||||||||||||||||||||||||||||||||||||||
(4) | (11) | 2,770 | 0.00 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||
(5) | (12) | 881 | 33.93 | 05/15/18 |
62
| | 103 |
Option Awards | Stock Awards | 3 | 11 | 3,000 | 0.00 | 02/22/2027 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name and Principal Position | Number of Securities Underlying Unexercised Options Exercisable | Number of Securities Underlying Unexercised Options Unexercisable | Equity Awards: | Option Exercise Price | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested | Market Value of Shares or Units of Stock That Have not Vested | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 | 12 | 1,489 | 0.00 | 02/21/2027 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 | 17 | 862 | 0.00 | 02/20/2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 | 13 | 8,000 | 0.00 | 01/11/2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 | 17 | 2,584 | 0.00 | 02/20/2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
5 | 15 | 374 | 61.83 | 05/05/2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
6 | 16 | 296 | 81.07 | 02/25/2029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
6 | 18 | 258 | 95.70 | 02/24/2030 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
7 | 16 | 365 | 81.07 | 02/25/2029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
7 | 16 | 523 | 81.07 | 02/25/2029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
7 | 18 | 774 | 95.70 | 02/24/2030 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
8 | 16 | 453 | 0.00 | 02/25/2029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
8 | 18 | 395 | 0.00 | 02/24/2030 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
9 | 16 | 0.00 | 02/25/2029 | 1,359 | 123,302 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
9 | 18 | 0.00 | 02/24/2030 | 1,184 | 107,424 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
($) | ($) | ($) | ($) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mr. Brian R. Watt | (1) | (6) | 429 | 41.31 | 02/20/23 | 1 | 12 | 242 | 70.60 | 02/21/2027 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Vice President, | (1) | (7) | 441 | 46.03 | 02/14/24 | 1 | 14 | 310 | 68.20 | 02/20/2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Corporate Development | (1) | (8) | 441 | 43.95 | 02/23/25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
and Investor Relations | (1) | (9) | 431 | 44.18 | 02/22/26 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Corporate Development and | 2 | 12 | 725 | 70.60 | 02/21/2027 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investor Relations | 2 | 14 | 930 | 68.20 | 02/20/2028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 | 12 | 1,088 | 0.00 | 02/22/2027 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 | 17 | 631 | 0.00 | 02/20/2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 | 12 | 3,262 | 0.00 | 02/21/2027 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 | 17 | 1,891 | 0.00 | 02/20/2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
5 | 15 | 374 | 61.83 | 05/05/2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
6 | 16 | 212 | 81.07 | 02/25/2029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
6 | 18 | 185 | 95.70 | 02/21/2030 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) | (11) | 242 | 70.60 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(2) | (6) | 1,286 | 41.31 | 02/20/23 | 7 | 16 | 136 | 81.07 | 02/25/2029 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(2) | (7) | 283 | 46.03 | 02/14/24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(2) | (7) | 1,038 | 46.03 | 02/14/24 | 7 | 16 | 499 | 81.07 | 02/25/2029 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(2) | (8) | 1,322 | 43.95 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(2) | (9) | 702 | 44.18 | 02/22/26 | 7 | 18 | 291 | 95.70 | 02/24/2030 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(2) | (9) | 592 | 44.18 | 02/22/26 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(2) | (11) | 725 | 70.60 | 02/21/27 | 7 | 18 | 262 | 95.70 | 02/24/2030 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3) | (7) | 908 | 0.00 | 02/14/24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3) | (8) | 970 | 0.00 | 02/23/25 | 8 | 16 | 324 | 0.00 | 02/25/2029 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3) | (9) | 901 | 0.00 | 02/21/26 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3) | (10) | 3,000 | 0.00 | 02/22/27 | 8 | 18 | 282 | 0.00 | 02/21/2030 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3) | (11) | 729 | 0.00 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(4) | (6) | 3,537 | 0.00 | 02/23/23 | 9 | 16 | 0.00 | 02/25/2022 | 971 | 88,099 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(4) | (8) | 2,909 | 0.00 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(4) | (9) | 2,704 | 0.00 | 02/22/26 | 9 | 18 | 0.00 | 02/24/2023 | 846 | 76,758 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(4) | (11) | 2,022 | 0.00 | 02/21/27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dr. Ian M. McRobbie | (1) | (6) | 1,768 | 41.31 | 02/20/23 | 1 | 12 | 950 | 70.60 | 02/21/2027 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Vice President, | (1) | (7) | 1,782 | 46.03 | 02/14/24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research and Technology | (1) | (8) | 1,774 | 43.95 | 02/23/25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Vice President | 1 | 14 | 1,138 | 68.20 | 02/20/2028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
and Chief Technology Officer | 3 | 11 | 3,000 | 0.00 | 02/22/2027 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) | (9) | 1,426 | 44.18 | 02/22/26 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) | (11) | 950 | 70.60 | 02/21/27 | 3 | 12 | 4,274 | 0.00 | 02/21/2027 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3) | (6) | 4,861 | 0.00 | 02/20/23 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3) | (7) | 3,675 | 0.00 | 02/14/24 | 3 | 17 | 2,315 | 0.00 | 02/20/2028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3) | (8) | 3,903 | 0.00 | 02/23/25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3) | (9) | 2,981 | 0.00 | 02/22/26 | 5 | 15 | 374 | 61.83 | 05/05/2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3) | (10) | 3,000 | 0.00 | 02/22/27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3) | (11) | 2,864 | 0.00 | 02/21/27 | 6 | 16 | 919 | 81.07 | 02/25/2029 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(5) | (12) | 881 | 33.93 | 05/15/18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
6 | 18 | 789 | 95.70 | 02/24/2030 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
8 | 16 | 1,406 | 0.00 | 02/25/2029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
8 | 18 | 1,207 | 0.00 | 02/24/2030 |
Footnotes to “Outstanding Equity Awards at Fiscal Year End 2017”2020” table:
(1) | SEUs issued under the CSOP. These are detailed in the columns headed “Number of Securities UnderlyingUn-Exercised Options” |
(2) | Options issued under the CSOP. These are detailed in the columns headed “Number of Securities UnderlyingUn-Exercised Options” |
| | 104 |
(3) | SEUs issued under the PRSOP. SEUs under the PRSOP which are not exercisable are detailed in the column headed “Equity Incentive Plans Awards” and those which are exercisable are detailed in the column headed “Number of Securities UnderlyingUn-Exercised Options Exercisable” |
(4) | Options issued under the PRSOP. Option awards under the PRSOP which are not exercisable are detailed in the column headed “Equity Incentive Plan Awards” and those which are exercisable are detailed in the column headed “Number of Securities UnderlyingUn-Exercised Options Exercisable” |
(5) | Options issued under the ShareSave plan. These are detailed in the columns headed “Number of Securities UnderlyingUn-Exercised Options” |
(6) | Cash Incentive Awards granted at market price issued under the Omnibus Plan. These are detailed in the column headed “Number of Securities Underlying Un-Exercised Options” |
(7) | Options |
(8) | Cash Incentive Awards granted at zero cost issued under the Omnibus Plan. Cash Incentive awards under the Omnibus Plan which are not exercisable are detailed in the column headed “Equity Incentive Plan Awards” and those which are exercisable are detailed in the column headed “Number of Securities Underlying Un-ExercisedOptions |
(9) | Full Value Awards issued under the Omnibus Plan. The number of units awarded are detailed in the column headed “Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested” and |
(10) | SEUs |
(11) | Additional SEUs vested on February 22, 2019 |
(12) | Options and SEUs have vesting date of February 21, 2020 |
63
(13) |
Options have vesting date of November 1, 2020 |
(14) | Options and SEUs have vesting date of February 20, 2021 |
(15) | Options have vesting date of November 1, 2021 |
(16) | Omnibus Full Value Awards, Options and Cash Incentive Awards have vesting date of February 25, 2022 |
(17) | Options and SEUs have vesting date of February 20, 2023 |
(18) | Omnibus Full Value Awards, Options and Cash Incentive Awards have vesting date of February 24, 2023 |
With respect tonon-vested or unearned performance based stock options, full value awards and SEUs, the number of shares reported in the table is based on the performance achieved for each performance goalsgoal in the previous fiscal year (2017)(2020), except where performance was below the threshold level, in which case the number of shares and SEUs reported is based on the threshold level, as detailed below:
For those |
In the case of the options and SEUs whichthat expire in February 2025, the number of shares reported is based on achieving the maximum2028, relative performance of 2% increase in102% for TSR per annum, the maximum performance of 3% increase inversus Russell 2000 index; EPS excluding Octane Additives per annum and achieving a growth in gross revenue, excluding Octane Additives per annum which delivers 44% ofwere less than the threshold level.
For those options and SEUs aligned to this measure as thesethat expire in February 2029, relative performance of TSR versus the Russell 2000 index was less than the threshold level; EPS and gross revenue, excluding Octane Additives were also less than the threshold level.
For those options and SEUs vestthat expire in February 20182030, relative performance of TSR versus the Russell 2000 index was less than the threshold level; EPS and this isgross revenue, excluding Octane Additives were also less than the expected outcome.threshold level.
The number of shares reported for Dr. Boon in the case of those which vest in November 2018, November 2019 and November 2020 is based on the full achievement of the performance measures as this is the expected outcome. The number of SEUs reported for Mr. P. Williams and each of the NEOs in the case of those granted in February 2017 and which vest in February 2019 are based on the full achievement of the performance measures as this is the expected outcome.
The market value of any shares which have not vested is calculated using the year endyear-end stock price of $70.60,$90.73, as an indication.
64
| | 105 |
OPTION EXERCISES AND STOCK VESTED DURING FISCAL 20172020
The following table provides information for the NEOs on exercises of stock option and cash based awards, (SEUs) and matching stock which transferred to the NEOswere granted as SEUs during the fiscal year 2017,2020, including the number of shares or SEUs acquired on exercise or transfer and the value realized.
Name and Principal Position | Option Awards | Stock Awards | ||||||||||||||
Number of Shares Acquired on Exercise | Value Realized on Exercise | Number of Shares Acquired on Vesting | Value Realized on Exercise | |||||||||||||
($) | ($) | |||||||||||||||
Mr. Patrick S. Williams | - | - | - | - | ||||||||||||
President and Chief | (1 | ) | 4,674 | 292,125 | - | - | ||||||||||
Executive Officer | (2 | ) | 2,078 | 34,225 | - | - | ||||||||||
(3 | ) | 6,232 | 102,828 | - | - | |||||||||||
(4 | ) | 14,023 | 876,858 | - | - | |||||||||||
Mr. Ian P. Cleminson | - | - | - | - | ||||||||||||
Executive Vice President and | (3 | ) | 1,684 | 41,898 | - | - | ||||||||||
Chief Financial Officer | (4 | ) | 3,473 | 246,270 | - | - | ||||||||||
(2 | ) | 561 | 13,784 | - | - | |||||||||||
(1 | ) | 1,158 | 81,755 | - | - | |||||||||||
(5 | ) | 881 | 33,152 | - | - | |||||||||||
Dr. Philip J. Boon | - | - | - | - | ||||||||||||
Executive Vice President and | (3 | ) | 287 | 4,870 | - | - | ||||||||||
Chief Operating Officer | (3 | ) | 1,247 | 21,162 | - | - | ||||||||||
(4 | ) | 3,163 | 199,269 | - | - | |||||||||||
(2 | ) | 507 | 10,769 | |||||||||||||
(1 | ) | 1,395 | 87,257 | - | - | |||||||||||
Mr. Brian R. Watt | (6 | ) | - | - | 315 | 19,609 | ||||||||||
Senior Vice President, | (4 | ) | 2,726 | 169,448 | - | - | ||||||||||
Corporate Development & Investor Relations | (5 | ) | 881 | 31,927 | - | - | ||||||||||
Dr. Ian M. McRobbie | - | - | - | - | ||||||||||||
Senior Vice President, | - | - | - | - | ||||||||||||
Research and Technology | - | - | - | - |
Name and Principal Position | Option Awards | Stock Awards | ||||||||||||||||||
Number of Shares Acquired on Exercise | Value Exercise | Number of Shares Vesting | Value Realized on Exercise | |||||||||||||||||
($) | ($) | |||||||||||||||||||
Mr. Patrick S. Williams | (1) | 11,219 | 866,556 | - | - | |||||||||||||||
President and Chief Executive Officer | (3) | 4,589 | 97,057 | - | - | |||||||||||||||
(4) | 33,654 | 3,480,833 | - | - | ||||||||||||||||
(5) | 184 | 3,870 | - | - | ||||||||||||||||
Mr. Ian P. Cleminson | (1) | 1,361 | 130,248 | - | - | |||||||||||||||
Executive Vice President and Chief Financial Officer | (2) | 302 | 7,580 | - | - | |||||||||||||||
(3) | 529 | 11,188 | - | - | ||||||||||||||||
(3) | 378 | 7,995 | ||||||||||||||||||
(4) | 4,081 | 374,432 | - | - | ||||||||||||||||
Dr. Philip J. Boon | (4) | 4,467 | 381,482 | - | - | |||||||||||||||
Executive Vice President and Chief Operating Officer | ||||||||||||||||||||
Mr. Brian R. Watt | - | - | - | - | ||||||||||||||||
Senior Vice President, Corporate Development & Investor Relations | ||||||||||||||||||||
Dr. Ian M. McRobbie | - | - | - | - | ||||||||||||||||
Senior Vice President and Chief Technology Officer |
Footnotes to the “Option Exercises and Stock Vested during Fiscal 2017”2020” table:
(1) | SEUs exercised which were issued under the PRSOP |
(2) | SEUs exercised which were issued under the CSOP |
(3) | Options exercised which were issued under the CSOP |
(4) | Options exercised which were issued under the PRSOP |
(5) | Options exercised which were issued under the ShareSave Plan |
The aggregate dollar amount realized on exercise of option awards, SEUs and matching shares was computed by calculating the closing price of all underlying common stock on the date of exercise or transfer, less the exercise price of the option, multiplied by the number of shares underlying the options or SEUs exercised or stock transferred.
65
| | 106 |
Name and Principal Position | Plan Name | Number of years credited service at March 31, 2010 | Present Value of Accumulated Benefits | Payments During Last Fiscal Year | ||||||||||
$ | $ | |||||||||||||
Dr. I. McRobbie Senior Vice President, Research and Technology | Innospec Limited Pension Plan | 10.25 | 1,025,202 | 47,573 | ||||||||||
Dr. P. Boon Executive Vice President, and Chief Operating Officer | Innospec Limited Pension Plan | 16.688 | 0 | 1,403,859 |
Name and Principal Position | Plan Name | Number of years credited service at March 31, 2010 | Present Value of Accumulated Benefits | Payments During Last Fiscal Year | ||||
$ | $ | |||||||
Dr. Ian M. McRobbie | Innospec Limited Pension Plan | 10.25 | 1,056,279 | 50,631 | ||||
Senior Vice President and Chief | ||||||||
Technology Officer |
Footnotes to “Pension Benefit” table:
The Company operated the Innospec Limited Pension Plan (“Pension Plan”) for relevant employees based in the U.K.. The Pension Plan was available to all employees in the U.K., but closed to future service accrual for all members on March 31, 2010. Dr. McRobbie was a member of this Pension Plan on that date. The Company does not participate in any other defined benefit pension arrangements in respect of any of the NEOs. The Defined Benefit Pension table therefore covers the Pension Plan only.
The number of years of credited service is based on service to March 31, 2010, when the Pension Plan closed to future service accrual.
The Pension Plan provides a pension on retirement of 1/57 of pensionable salary for each year of service. The amount of annual salary which is defined as pensionable under the Pension Plan is capped and at the time the plan closed, this cap was set at $171,797. Dr. McRobbie was not subject to the cap on pensionable salary as he joined the Pension Plan prior to the introduction of the cap. As a result, Dr. McRobbie’s pensionable salary was his full base salary.
• Pensionable salary under the Pension Plan is defined as base salary only, up to the pensions cap where relevant. Any bonus payments, incentive payments or supplementary payments are not treated as pensionable.
• Under the rules of the Pension Plan, normal retirement age is 65 although members can retire at 60 without an actuarial reduction. Retirement between the ages of 55 and 60 is permitted, but the pension payable is reduced by an amount determined by the actuarial advisors to the Trustees of the Pension Plan. If a member of the Pension Plan is made redundant by the Company and is already aged 50 or over, then, under the rules of the Pension Plan, they are able to take their pension immediately without any actuarial reduction. If, however, a member was under 50 at the time of severance, they would be entitled to unreduced pension benefits from age 55. From April 2010, the minimum age from which pension benefits can be paid increased to 55 (with the exception of certain members protected under U.K. pension legislation). Dr. McRobbie is classed as a protected member and was therefore unaffected by the change in April 2010. Any benefit paid would be in the normal form payable by the Pension Plan, namely a monthly pension with an option to surrender part of this pension for a tax-free lump sum, in line with U.K. tax regulations.
|
66
• If an individual chooses to transfer benefits into the Pension Plan from another plan, they will be provided with a service credit in lieu of the transferred in benefits. The amount of service credit given is calculated by the actuaries on behalf of the Trustees of the Pension Plan and is designed to be cost neutral to the Pension Plan. The right to transfer is subject to the approval of the Trustees of the Pension Plan, who have determined that with effect from April 1, 2010 no further transfers in will be accepted following the closure of the Pension Plan to future service accrual.
• Dr. McRobbie joined the Pension Plan on January 1, 2002 and received a service credit of 2.000 years in lieu of transferred in benefits from another plan. This is included in the total credited service in the table and equates to $206,103 of additional present value accumulated benefit which is included in the total “Present Value of Accumulated Benefit” in the table above.
• The present value of accumulated benefits as at December 31, 2020 has been calculated using the following principal assumptions:
Discount rate | 1.36% per annum | |
Post retirement pension increases | 2.35% per annum based on CPI on pensions in excess of the Guaranteed Minimum Pension | |
Pre-retirement decrements | Individuals are assumed to remain in service and retire at the earliest age at which they can take their full pension benefits unreduced in normal health and circumstances, except for Dr. McRobbie who has already started to take his pension benefits from the Pension Plan. | |
Post retirement mortality | Self-Administered Pension Schemes (“SAPS”) Series 2 All Pensioners (Amounts) tables with a multiplier of | |
Commutation | At retirement, individuals are assumed to commute 20% of their benefits in exchange for a cash lump sum based on the current factors in force, except for Dr. McRobbie who chose not to commute any of his benefits at the time he started to take them from the Pension Plan. |
67
| | 108 |
NON-QUALIFIED DEFERRED COMPENSATION
The following table provides information regarding The Innospec Inc. Non-qualified Deferred Compensation Plan during fiscal year 2020. Mr Williams is the only NEO who was eligible to participate in this plan during 2020. More information on the plan is provided in the Compensation Discussion and Analysis section of the Proxy under the section headed “Non-qualified Deferred Compensation Plan”.
Executive Contributions in Last Fiscal Year | Registrant Contributions in Last Fiscal Year | Aggregate Earnings (Losses) in Last Fiscal Year | Aggregate Withdrawals/ Distributions | Aggregate Balance at end of last Fiscal Year 2020 | ||||||
(1) | (2) | (3) | (4) | (5) | ||||||
($) | ($) | ($) | ($) | ($) | ||||||
Mr. Patrick S. Williams President and Chief Executive Officer | - | 12,109 | 1,493 | - | 51,825 |
Footnotes to the “Non-qualified Deferred Compensation” table
(1) | These amounts, if any, are included in the Summary Compensation Table in the “Salary” and “Non-Equity Incentive Compensation” columns for 2020. Mr. Williams did not make any contributions into the Deferred Compensation plan in 2020. |
(2) | The amount disclosed for Mr. Williams includes an employer elective deferral for $12,109, which accrued during fiscal year 2020 and credited to Mr. Williams’ account in 2021. These amounts are included in the Summary Compensation Table in the “All Other Compensation” column for 2020. |
(3) | These amounts are not included in the Summary Compensation Table because Plan earnings were not preferential or above market. |
(4) | Withdrawal and distribution amounts, if any, are not included in the Summary Compensation Table because these are pay-outs of prior years’ earnings and contributions. There were no withdrawals or distributions in 2020. |
(5) | These amounts are as of December 31, 2020 and do not take into account the amounts in the “Registrant Contributions in Last Fiscal Year” column in the table above that were accrued during fiscal year 2020 but were credited to Mr. Williams’ account in 2021 as detailed above. |
| | 109 |
POST EMPLOYMENT PAYMENTS
The following table quantifies the potential payments upon termination or change of control that any of our NEOs would receive assuming that the relevant termination event had occurred on December 31, 2017.2020. The potential payments relating to vested and unvested Stockstock options and full value awards include payments relating to SEUscash incentive awards as well as options.options and full value awards.
Name and Principal Position | Benefit | Retirement | Termination without cause | Termination in event of Change of Control | Death in Service | |||||||||||||
($) | ($) | ($) | ($) | |||||||||||||||
Mr. Patrick S. WilliamsPresident and Chief Executive Officer | Cash Severance - Salary and benefits | 0 | 1,008,000 | 2,016,000 | 0 | |||||||||||||
Cash Severance - Bonus | 0 | 756,000 | 1,512,000 | 0 | ||||||||||||||
Vested Stock options | 0 | 0 | 0 | 0 | ||||||||||||||
Unvested Stock options | 530,223 | 530,223 | 9,373,014 | 9,373,014 | ||||||||||||||
Life Assurance | 0 | 0 | 0 | 200,000 | ||||||||||||||
Total | 530,223 | 2,294,223 | 12,901,014 | 9,573,014 | ||||||||||||||
Mr. Ian P. CleminsonExecutive Vice President and Chief Financial Officer | Cash Severance - Salary and benefits | 0 | 358,186 | 716,371 | 0 | |||||||||||||
Cash Severance - Bonus | 0 | 169,864 | 339,728 | 0 | ||||||||||||||
Vested Stock options | 0 | 0 | 0 | 0 | ||||||||||||||
Unvested Stock options | 107,196 | 107,196 | 1,486,367 | 1,486,367 | ||||||||||||||
Life Assurance | 0 | 0 | 0 | 2,038,368 | ||||||||||||||
Total | 107,196 | 635,246 | 2,542,466 | 3,524,735 | ||||||||||||||
Dr. Philip J. BoonExecutive Vice President and Chief Operating Officer | Cash Severance - Salary and benefits | 0 | 390,313 | 780,625 | 0 | |||||||||||||
Cash Severance - Bonus | 0 | 185,928 | 371,855 | 0 | ||||||||||||||
Vested Stock options | 74,754 | 74,754 | 149,166 | 149,166 | ||||||||||||||
Unvested Stock options | 99,389 | 99,389 | 2,871,074 | 2,871,074 | ||||||||||||||
Life Assurance | 0 | 0 | 0 | 2,231,130 | ||||||||||||||
Total | 174,143 | 750,384 | 4,172,720 | 5,251,370 | ||||||||||||||
Mr. Brian R. Watt Senior Vice President, Corporate Development and Investor Relations | Cash Severance - Salary and benefits | 0 | 272,153 | 544,306 | 0 | |||||||||||||
Cash Severance - Bonus | 0 | 136,077 | 272,153 | 0 | ||||||||||||||
Vested Stock options | 148,770 | 148,770 | 462,587 | 462,587 | ||||||||||||||
Unvested Stock options | 99,512 | 99,512 | 1,295,617 | 1,295,617 | ||||||||||||||
Life Assurance | 0 | 0 | 0 | 1,632,919 | ||||||||||||||
Total | 248,282 | 656,512 | 2,574,663 | 3,391,123 | ||||||||||||||
Dr. Ian M. McRobbieSenior Vice President, Research and Technology | Cash Severance - Salary and benefits | 0 | 268,275 | 536,550 | 0 | |||||||||||||
Cash Severance - Bonus | 0 | 124,909 | 249,818 | 0 | ||||||||||||||
Vested Stock options | 127,875 | 127,875 | 730,516 | 730,516 | ||||||||||||||
Unvested Stock options | 84,952 | 84,952 | 1,219,847 | 1,219,847 | ||||||||||||||
Life Assurance | 0 | 0 | 0 | 1,498,905 | ||||||||||||||
Total | 212,827 | 606,011 | 2,736,731 | 3,449,268 |
Name and Principal Position | Benefit | Retirement | Termination without cause | Termination in event of Change of Control | Death in Service | |||||||||||||
($) | ($) | ($) | ($) | |||||||||||||||
Mr. Patrick S. Williams President and Chief Executive Officer | Cash Severance - Salary and benefits | 0 | 1,170,000 | 2,340,000 | 0 | |||||||||||||
Cash Severance - Bonus | 0 | 994,500 | 1,989,000 | 0 | ||||||||||||||
Vested Stock options | 136,896 | 136,896 | 136,896 | 136,896 | ||||||||||||||
Unvested Stock options | 207,140 | 207,140 | 12,098,214 | 12,098,214 | ||||||||||||||
Life Assurance | 0 | 0 | 0 | 200,000 | ||||||||||||||
Total | 344,036 | 2,508,536 | 16,564,110 | 12,435,110 | ||||||||||||||
Mr. Ian P. Cleminson Executive Vice President and Chief Financial Officer | Cash Severance - Salary and benefits | 0 | 397,636 | 795,272 | 0 | |||||||||||||
Cash Severance - Bonus | 0 | 190,022 | 380,044 | 0 | ||||||||||||||
Vested Stock options | 0 | 0 | 0 | 0 | ||||||||||||||
Unvested Stock options | 56,234 | 56,234 | 1,600,186 | 1,600,186 | ||||||||||||||
Life Assurance | 0 | 0 | 0 | 2,280,264 | ||||||||||||||
Total | 56,234 | �� | 643,892 | 2,775,502 | 3,880,450 | |||||||||||||
Dr. Philip J. Boon Executive Vice President and Chief Operating Officer | Cash Severance - Salary and benefits | 0 | 421,875 | 843,749 | 0 | |||||||||||||
Cash Severance - Bonus | 0 | 202,141 | 404,282 | 0 | ||||||||||||||
Vested Stock options | 26,652 | 26,652 | 1,159,779 | 1,159,779 | ||||||||||||||
Unvested Stock options | 83,536 | 83,536 | 1,680,021 | 1,680,021 | ||||||||||||||
Life Assurance | 0 | 0 | 0 | 2,425,694 | ||||||||||||||
Total | 110,188 | 734,204 | 4,087,831 | 5,265,494 | ||||||||||||||
Mr. Brian R. Watt Senior Vice President, Corporate Development and Investor Relations | Cash Severance - Salary and benefits | 0 | 288,971 | 577,942 | 0 | |||||||||||||
Cash Severance - Bonus | 0 | 144,485 | 288,971 | 0 | ||||||||||||||
Vested Stock options | 19,466 | 19,466 | 414,141 | 414,141 | ||||||||||||||
Unvested Stock options | 70,052 | 70,052 | 1,222,958 | 1,222,958 | ||||||||||||||
Life Assurance | 0 | 0 | 0 | 1,733,825 | ||||||||||||||
Total | 89,518 | 522,974 | 2,504,012 | 3,370,924 |
| | 110 |
Name and Principal Position | Benefit | Retirement | Termination without cause | Termination in event of Change of Control | Death in Service | |||||||||||||
($) | ($) | ($) | ($) | |||||||||||||||
Dr. Ian M. McRobbie Senior Vice President and Chief Technology Officer | Cash Severance - Salary and benefits | 0 | 275,253 | 550,506 | 0 | |||||||||||||
Cash Severance - Bonus | 0 | 128,830 | 257,661 | 0 | ||||||||||||||
Vested Stock options | 19,124 | 19,124 | 679,094 | 679,094 | ||||||||||||||
Unvested Stock options | 45,325 | 45,325 | 1,207,395 | 1,207,395 | ||||||||||||||
Life Assurance | 0 | 0 | 0 | 1,545,964 | ||||||||||||||
Total | 64,449 | 468,532 | 2,694,656 | 3,432,453 |
Footnotes to “Post Employment Payments” table:
In the case of resignation or dismissal for cause, none of the NEOs would be entitled to any post-employment payments from the Company.
The NEOs are treated in line with all other employees in the event of retirement or change of control in terms of payments relating to stock options, full value awards and cash incentive awards. In the case of retirement, under the rules of the CSOP and the Omnibus Plan, any CSOP or Omnibus options or cash incentive awards granted at market price will vest and become exercisable; whilst under the rules of the PRSOP and Omnibus Plan full value awards or cash incentive awards granted at zero price which have not vested will lapse. The value of any stock options, full value awards and cash incentive awards which will become exercisable under each scenario, using the 2020 year end stock price of $90.73, is included in the table above, as an indication.
The employment agreement for each NEO includes a change in control clause. This specifies that, in the event of a change in control of the Company, if the Company terminates the Executive Officer within twelve months of the change of control, or if the Executive Officer terminates his employment within twelve months for good cause, the Executive Officer will be entitled to a compensation payment. If the Company terminates the employment of the Executive Officer during this period, the payment is calculated as twenty-four months compensation defined as base salary, bonus at target and any car allowance from the date of notice of termination. If the Executive Officer terminates his employment, the payment is calculated as twenty-four months compensation, defined as above, from the date of the change of control. In addition, under the rules of the CSOP, PRSOP and Omnibus Plan, all options, full value awards and cash incentive awards would vest on the change of control. The NEOs are treated in the same way as other employees who hold options, full value awards or cash incentive awards under the plans. Change of control is deemed to have occurred if a person or group becomes the beneficial owner of 30% or more of the combined voting power of the Company; there is a consolidation or merger and the Company is not the surviving Company; the stockholders of the Company approve plans or proposals for a liquidation or dissolution of the Company or, if following a cash offer or merger, the members of the Board cease to constitute a majority of the Board. The amounts detailed in the Post Employment Payments table include the compensation payments and the value of any stock options, full value awards and cash incentive awards, which will become exercisable in these scenarios, using the 2020 year-end stock price of $90.73, as an indication.
NEOs based in the U.K. are provided with life assurance cover at six times their base salary if they die in service. In the case of the Executive Officers based in the U.S., the death in service cover is 1.25 times base salary, with the maximum payment capped at $200,000. The amount of these potential payments for each NEO is included in the table above, as an indication.
|
| | 111 |
68
If the Company terminates the employment of an Executive Officer without cause, the Executive Officer would normally be eligible for a severance payment to cover loss of salary and other direct compensation for the duration of the notice period specified in their employment agreement. All the NEOs have a twelve-month notice period. In addition, in line with the rules of the CSOP, PRSOP and Omnibus Plan, any CSOP and Omnibus options and cash incentive awards granted at market price |
69
|
|
Name | Fees Earned or | Option Awards (Fair Market Value) | Total | |||||||
$ | $ | $ | ||||||||
Mr. Hugh G. C. Aldous | 103,000 | 32,904 | 135,904 | |||||||
Mr. Milton C. Blackmore | 164,000 | 32,904 | 196,904 | |||||||
Mr. David F. Landless | 106,000 | 32,904 | 138,904 | |||||||
Mr. Lawrence J. Padfield | 90,000 | 32,904 | 122,904 | |||||||
Mr. Robert I. Paller | 94,000 | 32,904 | 126,904 | |||||||
Mr. Joachim Roeser | 105,000 | 32,904 | 137,904 |
The director’s compensation is a flat annual fee based on the following arrangement:
|
70
|
71
Name | Number of Options | Grant Price | Date of Grant | |||||||
$ | ||||||||||
Mr. Hugh G. C. Aldous | 283 | 0.00 | 02/21/17 | |||||||
850 | 70.60 | 02/21/17 | ||||||||
441 | 0.00 | 02/22/16 | ||||||||
1,030 | 44.18 | 02/22/16 | ||||||||
444 | 0.00 | 02/23/15 | ||||||||
1,035 | 43.95 | 02/23/15 | ||||||||
977 | 46.03 | 02/14/14 | ||||||||
1,089 | 41.31 | 02/20/13 | ||||||||
1,522 | 29.56 | 02/23/12 | ||||||||
1,660 | 27.11 | 02/22/11 | ||||||||
4,335 | 10.38 | 02/17/10 | ||||||||
Mr. Milton C. Blackmore | 283 | 0.00 | 02/21/17 | |||||||
850 | 70.60 | 02/21/17 | ||||||||
441 | 0.00 | 02/22/16 | ||||||||
1,030 | 44.18 | 02/22/16 | ||||||||
444 | 0.00 | 02/23/15 | ||||||||
1,035 | 43.95 | 02/23/15 | ||||||||
977 | 46.03 | 02/14/14 | ||||||||
Mr. David Landless | 283 | 0.00 | 02/21/17 | |||||||
850 | 70.60 | 02/21/17 | ||||||||
1,000 | 0.00 | 05/05/16 | ||||||||
404 | 0.00 | 05/05/16 | ||||||||
922 | 48.28 | 05/05/16 | ||||||||
Mr. Lawrence J. Padfield | 283 | 0.00 | 02/21/17 | |||||||
850 | 70.60 | 02/21/17 | ||||||||
441 | 0.00 | 02/22/16 | ||||||||
1,030 | 44.18 | 02/22/16 | ||||||||
444 | 0.00 | 02/23/15 | ||||||||
1,035 | 43.95 | 02/23/15 | ||||||||
977 | 46.03 | 02/14/14 | ||||||||
1,108 | 40.58 | 05/15/13 | ||||||||
Mr. Robert I. Paller | 283 | 0.00 | 02/21/17 | |||||||
850 | 70.60 | 02/21/17 | ||||||||
441 | 0.00 | 02/22/16 | ||||||||
1,030 | 44.18 | 02/22/16 | ||||||||
444 | 0.00 | 02/23/15 | ||||||||
1,035 | 43.95 | 02/23/15 | ||||||||
977 | 46.03 | 02/14/14 | ||||||||
1,089 | 41.31 | 02/20/13 | ||||||||
1,522 | 29.56 | 02/23/12 | ||||||||
1,660 | 27.11 | 02/22/11 | ||||||||
3,673 | 12.25 | 05/24/10 | ||||||||
Mr. Joachim Roeser | 283 | 0.00 | 02/21/17 | |||||||
850 | 70.60 | 02/21/17 | ||||||||
441 | 0.00 | 02/22/16 | ||||||||
1,030 | 44.18 | 02/22/16 | ||||||||
444 | 0.00 | 02/23/15 | ||||||||
1,035 | 43.95 | 02/23/15 | ||||||||
977 | 46.03 | 02/14/14 | ||||||||
1,089 | 41.31 | 02/20/13 | ||||||||
1,522 | 29.56 | 02/23/12 | ||||||||
1,660 | 27.11 | 02/22/11 |
72
|
The following table summarizes information, as of December 31, 2017 relating to current equity compensation plans of the Corporation approved by security holders pursuant to which grants of options, full value awards and cash incentive awards, the NEOs are treated the same way as other employees who hold options, restricted stock, restricted stock units or other rights to acquire stock have been granted from time to timefull value awards and cash incentive awards under the CSOP, PRSOP, NEDSOP andCo-Investment Plan.plans. The Corporation does not have any equity compensation plans which have not been approved by security holders. Additional information about the CSOP, PRSOP andCo-Investment Plan can be foundamounts detailed in the Compensation Discussion and Analysis section ofpost-employment payments table include the proxy statement and information about the NEDSOP can be found in the Director Compensation section of the proxy statement.
Plan Category | No. of securities to be issued upon exercise of outstanding options, warrants and rights | Weighted average exercise price of outstanding options, warrants and rights | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) | |||||||||
(a) | (b) | (c) | ||||||||||
Equity compensation plans approved by security holders | 334,885 | $ | 12.367 | 459,272 | ||||||||
Equity compensation plans not approved by security holders | - | - | - | |||||||||
Total | 334,885 | $ | 12.367 | 459,272 |
The Corporation has retained and continues to retain Smith, Gambrell & Russell, LLP, a law firm with which Mr. Paller is Of Counsel. During the fiscal year ended December 31, 2017 the Corporation paid Smith, Gambrell & Russell, LLP, $435,000 in fees for services provided during the period.
Pursuant to the Corporation’s Code of Ethics Policy, all senior officers must disclose to the Board of Directors any material transaction or relationship that could reasonably be expected to give rise to a conflict of interests. The Code of Ethics Policy also states that no employee may seek to obtain special treatment from the Corporation for family members, friends or for businesses in which family members or friends have an interest. During the year ended December 31, 2017 the Corporation has not made any charitable contributions to any charity on which any Director serves as an Executive Officer.
73
|
The independent registered public accounting firm of the Corporation, selected by the Audit Committee for the fiscal year ended December 31, 2018 is KPMG LLP.
The Board has adopted a written Audit Committee Charter.
As part of fulfilling its responsibilities, the Audit Committee:
Based upon these reviews and discussions, the Audit Committee has recommended to the Board of Directors,severance payments and the Boardvalue of Directors has approved, thatany share options, full value awards and cash incentive awards which will become exercisable, using the Corporation’s audited consolidated financial statements be included in the Corporation’s Annual Report on Form10-K for the fiscal2020 year ended December 31, 2017 filed with the SEC.
No portionend stock price of this Audit Committee Report shall be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, through any general statement incorporating by reference in its entirety the Proxy Statement in which this report appears, except to the extent that the Corporation specifically incorporates this report or a portion of it by reference. In addition, this report shall not be deemed to be filed under either the Securities Act or the Exchange Act.
The foregoing report has been approved by all members of the Audit Committee.
DAVID F. LANDLESS, Chair
HUGH G. C. ALDOUS
JOACHIM ROESER
74$90.73.
Principal Accountant Fees and Services
The Board of Directors are seeking ratification of KPMG LLP’s appointment at the 2018 Annual Meeting of Stockholders in respect of the 2018 fiscal year as described in Proposal 5 in this Proxy Statement.
Aggregate fees for professional services rendered for the Corporation by KPMG Audit and other global KPMG member firms for the fiscal years 2017 and 2016 were:
Fee type
| Fiscal 2017
| Fiscal 2016
| ||||||
Audit (excluding expenses) | 1,500 | 1,369 | ||||||
Audit Related | - | - | ||||||
Tax | - | - | ||||||
Other | - | - | ||||||
Total | 1,500 | 1,369 |
Audit CommitteePre-Approval Policies and Procedures
The Audit Committeepre-approves all audit and permittednon-audit services provided by the Corporation’s independent registered public accounting firm. The Audit Committee may delegatepre-approval authority to the Audit Committee Chairman, provided all such delegatedpre-approval decisions are reported to the Audit Committee at its next regularly scheduled meeting. Generalpre-approval of certain audit, audit related and tax services, which are detailed as to type of service, is granted by the Audit Committee at each quarterly meeting. The Audit Committee subsequently reviews fees that are paid for suchpre-approved services. Specificpre-approval is required for all other services that are requested of our independent registered public accounting firm. These requests are reviewed quarterly, and the status of all such requests and services is reviewed with the Audit Committee.
In fiscal years 2017 and 2016, $nil and $nil, respectively, were paid to the Corporation’s independent registered public accounting firm for which thede minimis exception was used.The Audit Committee reviewed and approved the audit andnon-audit services rendered by the Corporation’s independent registered public accounting firm to the Corporation during the fiscal year 2017 and concluded such services were compatible with maintaining their independence.
75
The table “Beneficial Owners at fiscalyear-end 2017” sets out certain information with respect to the beneficial ownership of the Corporation’s Common Stock as of December 31, 2017 by holders of more than 5% of the Corporation’s outstanding Common Stock. The table “Stock Ownership of Directors and Executive Officers” sets out informationwith regard to the Directors of the Corporation, our Named Executive Officers, and all current Directors and Executive Officers of the Corporation as a group. As of December 31, 2017 excluding treasury stock, there were 24,776,422 shares of Common Stock outstanding. According to the rules adopted by the SEC, a person is the “beneficial owner” of securities if he or she has or shares the power to vote them or to direct their investment or has the right to acquire beneficial ownership of such securities within sixty days through the exercise of an option, warrant, right of conversion of a security or otherwise. The percentage of the Corporation’s Common Stock beneficially owned by a person assumes that the person has exercised all options and converted all convertible securities that the person holds which are exercisable or convertible within sixty days of the date as of which such information is provided in the applicable table. To the knowledge of the Corporation, each stockholder has sole voting and investment power with respect to the stock indicated as beneficially owned, unless otherwise indicated in a footnote. Unless otherwise indicated, the business address of each person is the Corporation’s corporate address.
|
Name and Address of Beneficial Owner | Amount and Nature of Beneficial Ownership | Percent of Class | ||||||||
BlackRock, Inc. | (1) | 3,460,770 | 14.30 | % | ||||||
55 East 52nd Street | ||||||||||
New York | ||||||||||
NY 10022 | ||||||||||
FMR LLC | (2) | 2,673,955 | 11.077 | % | ||||||
245 Summer Street | ||||||||||
Boston | ||||||||||
MA 02210 | ||||||||||
The Vanguard Group | (3) | 2,241,169 | 9.28 | % | ||||||
100 Vanguard Boulevard | ||||||||||
Malvern | ||||||||||
Pennsylvania | ||||||||||
PA 19355 | ||||||||||
Dimensional Fund Advisors LP | (4) | 1,403,568 | 5.82 | % | ||||||
Building One | ||||||||||
6300 Bee Cave Road | ||||||||||
Austin | ||||||||||
TX 78746 |
Based on a review of filings with the SEC, the Corporation is unaware of other holders of more than 5% of the outstanding shares of Innospec Inc. Common Stock.
Notes:
|
76
77
|
The following table sets out the amount of the Corporation’s common stock beneficially owned by each of the Directors, the CEO, the CFO and the other NEOs of the Corporation:
Name | Shares Owned Directly or Indirectly | Shares Underlying Options Exercisable within 60 days | Total | Percent of Class | ||||||||||||||
Mr. Hugh G. C. Aldous | (1) | 31,750 | 11,062 | 42,812 | * | |||||||||||||
Mr. Milton C. Blackmore | (2) | 7,000 | 1,479 | 8,479 | * | |||||||||||||
Dr. Philip J. Boon | 34,558 | 4,806 | 39,364 | * | ||||||||||||||
Mr. Ian P. Cleminson | 22,997 | 6,287 | 29,284 | * | ||||||||||||||
Mr. David F. Landless | 0 | 0 | 0 | * | ||||||||||||||
Dr. Ian M. McRobbie | 40,889 | 0 | 40,889 | * | ||||||||||||||
Mr. Robert I. Paller | 7,681 | 10,400 | 18,081 | * | ||||||||||||||
Mr. Lawrence J. Padfield | 2,019 | 3,584 | 5,603 | * | ||||||||||||||
Mr. Joachim Roeser | 5,260 | 6,727 | 11,987 | * | ||||||||||||||
Mr. Brian R. Watt | 29,849 | 11,102 | 40,951 | * | ||||||||||||||
Mr. Patrick S. Williams | 174,242 | 89,283 | 263,525 | * | ||||||||||||||
Directors and Executive Officers as a group (13 persons) | (3) | 395,671 | 154,863 | 550,534 | 2.22 |
Footnotes to “Stock Ownership” table:
Section 16(a) of the Exchange Act requires the Corporation’s Directors and Officers, and persons who beneficially own more than 10% of a registered class of the Corporation’s Common Stock and other equity securities, to file initial reports of ownership and reports of changes in ownership of the Corporation’s Common Stock or other equity securities with the SEC. Such persons are required by SEC regulations to furnish the Corporation with copies of all Section 16(a) forms they file.
Based solely upon a review of the copies of such forms furnished to the Corporation, or written representations that no Form 5 filings were required, the Corporation believes that each of its Officers, Directors and beneficial owners of more than 10% of the Common Stock complied with all Section 16(a) filing requirements applicable to them during fiscal 2017.
78
As of the date of this Proxy Statement, management is not aware of any matters to be presented at the Annual Meeting of Stockholders other than the matters specifically stated in the Notice of Annual Meeting of Stockholders and discussed in this Proxy Statement. If any other matter or matters are properly brought before the meeting, the persons named in the enclosed Proxy Form have discretionary authority to vote the proxy on each such matter in accordance with their judgement.
SOLICITATION AND EXPENSES OF SOLICITATION
The solicitation of proxies will be made initially through the internet and bye-mail. The Corporation’sCompany’s Directors, Executive Officers and employees may also solicit proxies in person, orvia computer, by telephone or email without additional compensation. In addition, proxies may be solicited by certain banking institutions, brokerage firms, custodians, trustees, nominees and fiduciaries that will mail material to or otherwise communicate with the beneficial owners of shares of the Corporation’sCompany’s Common Stock. All expenses of solicitation of proxies will be paid by the Corporation.Company.
A copy of the Corporation’s 2017Company’s 2020 Annual Report on Form10-K for the fiscal year ended December 31, 20172020 is now available to stockholders via the internet atwww.envisionreports.com/iosp. Stockholders who require a printed copy of the Annual Report on Form10-K may obtain one by writing to or calling our investor relations department: Investor Relations, Innospec Inc., Innospec Manufacturing Park, Oil Sites Road, Ellesmere Port, Cheshire, CH65 4EY, England, telephone+44-151-355-3611, or bye-mail toinvestor@innospecinc.com.
STOCKHOLDERS’ PROPOSALS FOR THE 2022 ANNUAL MEETING OF STOCKHOLDERS
79
|
The CorporationCompany anticipates holding its 20192022 Annual Meeting of Stockholders on May 8, 2019.4, 2022.
Under the regulations of the SEC, any stockholder wishing to make a proposal to be acted upon at the 20192022 Annual Meeting of Stockholders and have it included in our proxy materials must present such proposals to the Secretary of the Corporation notCompany no later than November 12, 2018.23, 2021.
| | 112 |
Stockholder proposals or Director nominations not included in a proxy statement for an annual meeting must comply with the advance notice procedures and information requirements set out in theby-laws Bylaws of the CorporationCompany in order to be properly brought before that Annual Meeting of Stockholders. Under the Corporation’sby-laws,Company’s Bylaws, any stockholder desiring to make a proposal to be acted upon at the 20192022 Annual Meeting of Stockholders must present such proposals to the Corporate Secretary not before February 8, 2019 or4, 2022 and not later than March 10, 2019.6, 2022.
By order of the Board of DirectorsBoard:
David B. Jones
Vice President, General Counsel,
Chief Compliance Officer and Corporate Secretary
March 22, 2018
PLEASE VOTE VIA THE INTERNET OR BY TELEPHONE IN ACCORDANCE WITH THE INSTRUCTIONS ON YOUR NOTICE OR PROXY CARD OR ALTERNATIVELY, IF YOU HAVE REQUESTED WRITTEN MATERIALS SIGN, DATE AND RETURN YOUR PROXY CARD IN THE RETURN ENVELOPE PROVIDED.19, 2021
80
TABLE OF CONTENTS
PLEASE VOTE VIA THE INTERNET OR BY TELEPHONE IN ACCORDANCE WITH THE INSTRUCTIONS ON YOUR NOTICE OR PROXY CARD OR ALTERNATIVELY, IF YOU HAVE REQUESTED WRITTEN MATERIALS SIGN, DATE AND RETURN YOUR PROXY CARD IN THE RETURN ENVELOPE PROVIDED. |
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
|
A-2
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
A-3
INNOSPEC INC.
2018 OMNIBUS LONG-TERM INCENTIVE PLAN
SECTIONMR A SAMPLE DESIGNATION (IF ANY) ADD 1
1.1.Purpose. The Innospec Inc. 2018 Omnibus Long-Term Incentive Plan (the “Plan”) has been established by Innospec Inc., a Delaware corporation, (the “Company”) ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 000000000.000000 ext
000000000.000000 ext 000000000.000000 ext C123456789 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext Your vote matters – here’s how to (i) attract and retain persons eligible to participate in the Plan; (ii) motivate Participants, by means of appropriate incentives, to achieve long-range goals; (iii) provide incentive compensation opportunities that are competitive with those of other similar companies; and (iv) further align the interests of Participants with those of the Company’s other stockholders through compensation that is based on the Company’s shares; and thereby promote the long-term financial interest of the Company and the Related Companies including the growth in value of the Company’s shares and enhancement of long-term stockholder return. Capitalized terms in the Plan are defined in Section 2.
1.2.Participation. Subject to the terms and conditions of the Plan, the Committee shall determine and designate, from time to time, from among the Eligible Individuals, those persons who will be granted one or more Awards under the Plan, and thereby become “Participants” in the Plan.
1.3.Operation and Administration. The operation and administration of the Plan, including the Awards made under the Plan, shall be subject to the provisions of Section 9 (relating to operation and administration).
1.4.History. The Plan was approved by the Board of Directors for submission to the stockholders, for approval at the 2018 Annual Meeting of Stockholders. To the extent not prohibited by Applicable Laws, Awards which are to use shares of Stock reserved under the Plan that are contingent on the approval by the Company’s stockholdersvote! You may be granted prior to that meeting contingent on such approval. The Plan shall be unlimited in duration and, in the event of Plan termination, shall remain in effect as long as any Awards under it are outstanding; provided, however, that no Awards may be granted under the Plan after theten-year anniversary of the date on which the stockholders approved the Plan. The Plan is intended to replace the Innospec Inc. Company Stock Option Plan, the Innospec Inc.Non-Employee Directors’ Stock Option Plan, and the Innospec Inc. Performance Related Stock Option Plan (the “Prior Plans”). The Prior Plans were adopted and approved by stockholders in 2008 and approved by stockholders, as each was amended, again in 2011. Following the approval of the Plan by the stockholders, no additional grants will be made pursuant to the Prior Plans.
SECTION 2
2.1. “Administrator” means the Board or any of its Committees as will be administering the Plan, in accordance with Section 9.
2.2. “Applicable Laws” means the requirements relating to the administration of equity-based awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan.
2.3. “Award Agreement” means the written agreement, including an electronic agreement, setting forth the terms and conditions applicable to each Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan.
2.4. “Award” means any award or benefit granted under the Plan, including, without limitation, the grant of Options, Cash Incentive Awards and Full Value Awards.
2.5. “Board” means the Board of Directors of the Company.
A-4
2.6. “Cause” shall mean, in the reasonable judgment of the Committee, (i) the willful and continued failure by the Participant to substantially perform his duties with the Company or any Related Company (other than any such failure resulting from the Participant’s Disability), (ii) the willful engaging by the Participant in conduct which is demonstrably injurious to the Company or any Related Company, monetarily or otherwise, (iii) the engaging by the Participant in egregious misconduct involving moral turpitude to the extent that the Participant’s credibility and reputation no longer conform to the standard for employees, directors or service providers, as applicable, of the Company and Related Companies, or (iv) the Participant is convicted of a felony. For purposes hereof, no act, or failure to act, on the Participant’s part shall be deemed “willful” unless done, or omitted to be done, by the Participant not in good faith and without reasonable belief that such action was in the best interest of the Company or Related Company.
2.7. “Change in Control” means the first to occur of any of the following:
2.8. “Code” means the United States Internal Revenue Code of 1986, as amended. A reference to any provision of the Code shall include reference to any successor provision of the Code.
2.9. “Committee” has the meaning set forth in Section 9.1.
2.10. “Common Stock” or “Stock” means the common stock of the Company.
2.11. “Company” has the meaning set forth in Section 1.1.
2.12. “Consultant” means any natural person engaged as a consultant or advisor by the Company or a Parent or Subsidiary or other Related Company (as determined by the Committee) to render bona fide services to such entity and such services are not in connection with the sale of shares of Stock in a capital-raising transaction, and do not directly or indirectly promote or maintain a market for the Company’s securities.
2.13. “Director” means a member of the Board.
A-5
2.14. “Disability” means, except as otherwise provided by the Committee in an Award Agreement, that the Participant has been determined to be eligible for long-term disability benefits under the long-term disability plan in which the Participant participates and which is sponsored by the Company or a Related Company; or if the Participant does not participate in a long-term disability plan sponsored by the Company or a Related Company, then the Participant shall be considered to have a “Disability” if the Committee determines, under standards comparable to those of the Company’s long-term disability plan, that the Participant would be eligible for long-term disability benefits if he or she participated in such plan or if the Committee determines, under standards for disability that apply pursuant to applicable statute in the country in which such Participant works, that such Participant would be considered disabled pursuant to such statute.
2.15. “Eligible Individual” means any Employee, Consultant or Director; provided, however, that to the extent required by the Code, an ISO may only be granted to an Employee of the Company or a Parent or Subsidiary. An Award may be granted to an Employee, Consultant or Director, in connection with hiring, retention or otherwise, prior to the date the Employee, Consultant or Director first performs services for the Company or the Subsidiaries, provided that such Awards shall not become vested prior to the date the Employee, Consultant or Director first performs such services.
2.16. “Employee” means any person, including officers and Directors, employed by the Company or any Parent or Subsidiary of the Company or a Related Company (as determined by the Committee). Neither service as a Director nor payment of a director’s fee by the Company will be sufficient to constitute “employment” by the Company.
2.17. “Exchange Act” means the Securities Exchange Act of 1934, as amended.
2.18. “Exercise Price” of each Option granted under this Plan shall be established by the Committee or shall be determined by a method established by the Committee at the time the Option is granted.
2.19. “Expiration Date” has the meaning set forth in Section 4.6.
2.20. “Fair Market Value” means, as of any date, the value of Common Stock determined as follows:
2.21. A “Full Value Award” is a grant of one or more shares of Stock or a right to receive one or more shares of Stock in the future, with such grant subject to one or more conditions, as determined by the Committee.
2.22. An “Incentive Stock Option” or an “ISO” is an Option that is intended to satisfy the requirements applicable to an “incentive stock option” described in Section 422(b) of the Code.
A-6
2.23. A“Non-Qualified Option or an “NQO” is an Option that is not intended to be an “incentive stock option” as that term is described in Section 422(b) of the Code or aTax-Qualified Option.
2.24. An “Option” entitles the Participant to purchase shares of Stock at an Exercise Price established by the Committee. Any Option granted under this Plan may be either an ISO, an NQO or aTax-Qualified Option, as determined in the discretion of the Committee.
2.25. “Outside Director” means a Director of the Company who is not an officer or employee of the Company or the Related Companies.
2.26. “Parent” means a parent corporation within the meaning of Section 424(e) of the Code.
2.27. “Participant” means the holder of an outstanding Award.
2.28. “Performance-Based Compensation” has the meaning ascribed to such term under Section 162(m) of the Code and the regulations thereunder.
2.29. “Performance Measures” means performance goals based on any one or more of the following Company, Subsidiary, operating unit or division performance measures: (i) earnings, including, but not limited to, operating income, earnings before or after taxes, earnings before or after interest, depreciation, amortization, or extraordinary or special items or book value per share (which may exclude nonrecurring items);(ii) pre-tax income orafter-tax income; (iii) earnings per share of Stock (basic or diluted); (iv) operating profit; (v) revenue, revenue growth or rate of revenue growth; (vi) return on assets (gross or net), return on investment, return on capital, or return on equity; (vii) returns on sales or revenues; (viii) operating expenses; (ix) stock price appreciation; (x) cash flow(s); (xi) implementation or completion of critical projects or processes; (xii) economic value created; (xiii) cumulative earnings per share growth; (xiv) operating margin or profit margin; (xv) common stock price or total stockholder return; (xvi) cost targets, reductions and savings, productivity and efficiencies; and (xvii) any combination of any of the foregoing. Each goal may be expressed on an absolute and/or relative basis, may be based on or otherwise employ comparisons based on internal targets, the past performance of the Company and/or the past or current performance of other companies or may be applied to the performance of the Company relative to a market index, a group of other companies or a combination thereof, and in the case of earnings-based measures, may use or employ comparisons relating to capital, stockholders equity and/or shares outstanding, investments or to assets or net assets, and may (but need not) provide for adjustments for restructurings, extraordinary, and any other unusual,non-recurring, or similar changes.
2.30. “Period of Restriction” means the period during which the transfer of shares of Stock are subject to restrictions and therefore, the shares of Stock are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator.
2.31. “Plan” has the meaning set forth in Section 1.1.
2.32. “Prior Plans” has the meaning set forth in Section 1.4.
2.33. “Related Company” means any corporation, partnership, joint venture, limited liability company or other entity during any period in which a controlling interest in such entity is owned, directly or indirectly, by the Company (or by any entity that is a successor to the Company), and any other business venture designated by the Committee in which the Company (or any entity that is a successor to the Company) has, directly or indirectly, a significant interest (whether through the ownership of securities or otherwise), as determined in the discretion of the Committee.
A-7
2.34. “Retirement” means the occurrence of a Participant’s Termination Date due to the voluntary termination of employment with the consent of the Committee prior to such Termination Date.
2.35. “Securities Act” means the Securities Act of 1933, as amended.
2.36. “Subsidiary” means a “subsidiary corporation,” whether now or hereafter existing, as defined in Section 424(f) of the Code.
2.37.“Tax-Qualified Option” means an Option granted that satisfies the requirements of Exhibit A to this Plan.
2.38. “Termination Date” means the date on which a Participant both ceases to be an employee of the Company and the Related Companies and ceases to perform material services for the Company and the Related Companies (whether as a director or otherwise), regardless of the reason for the cessation; provided that a “Termination Date” shall not be considered to have occurred during the period in which the reason for the cessation of services is a leave of absence approved by the Company or the Related Company which was the recipient of the Participant’s services; and provided, further that, with respect to an Outside Director, “Termination Date” means the date on which the Outside Director’s service as an Outside Director terminates for any reason. If, as a result of a sale or other transaction, the entity for which the Participant performs services ceases to be a Related Company (and such entity is or becomes an entity separate from the Company), the occurrence of such transaction shall be the Participant’s Termination Date. With respect to Awards that constitute Deferred Compensation, references to the Participant’s termination of employment (including references to the Participant’s employment termination, and to the Participant terminating employment, a Participant’s separation from service, and other similar reference) and references to a Participant’s termination as a Director (including separation from service and other similar references) shall mean the date that the Participant incurs a “separation from service” within the meaning of Section 409A of the Code.
SECTION 3
SHARES OF STOCK AND PLAN LIMITS
3.1.Shares of Stock and Other Amounts Subject to Plan. The shares of Stock for which Awards may be granted under the Plan shall be subject to the following:
|
A-8
3.2.Adjustments. In the event of a corporate transaction involving the Company (including, without limitation, any share dividend, share split, extraordinary cash dividend, recapitalization, reorganization, merger, amalgamation, consolidation, share exchangesplit-up,spin-off, sale of assets or subsidiaries, combination or exchange of shares), the Committee shall, in the manner it determines equitable in its sole discretion, adjust Awards to reflect the transactions. Action by the Committee may include: (i) adjustment of the number and kind of shares which may be delivered under the Plan; (ii) adjustment of the number and kind of shares subject to outstanding Awards; (iii) adjustment of the Exercise Price of outstanding Options; and (iv) any other adjustments that the Committee determines to be equitable (which may include, without limitation, (A) replacement of Awards with other Awards which the Committee determines have comparable value and which are based on shares of a company resulting from the transaction, and (B) cancellation of the Award in return for cash payment of the current value of the Award, determined as though the Award is fully vested at the time of payment, provided that in the case of an Option, the amount of such payment will be the excess of value of the shares of Stock subject to the Option at the time of the transaction over the Exercise Price). However, in no event shall this Section 3.2 be construed to permit a modification (including a replacement) of an Option if such modification either: (i) would result in accelerated recognition of income or imposition of additional tax under Section 409A of the Code; or (ii) would cause the Option subject to the modification (or cause a replacement Option) to be subject to Section 409A of the Code, provided that the restriction of this clause (ii) shall not apply to any Option that, at the time it is granted or otherwise, is designated as being deferred compensation subject to Section 409A of the Code.
3.3.Plan Limitations. Subject to Section 3.2, the following additional maximums are imposed under the Plan:
A-9
For the avoidance of doubt, the limitations of this Section 3.3(c) do not apply to any Award that is not intended to constitute Performance-Based Compensation.
For the avoidance of doubt, the limitations of this Section 3.3(d) do not apply to any Award that is not intended to constitute Performance-Based Compensation.
|
A-10
SECTION 4
4.1.Grant of Options. Subject to the terms and conditions of the Plan, the Administrator, at any time and from time to time, may grant Options to an Eligible Individual in such amounts as the Administrator, in its sole discretion, will determine. Each Option will be designated in the Award Agreement as either an ISO, an NQO or aTax-Qualified Option (subject to the terms ofExhibit A to the Plan). Notwithstanding a designation for a grant of Options as ISOs, however, to the extent that the aggregate Fair Market Value of the shares of Stock with respect to which ISOs are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds $100,000, such Options will be treated as NQOs. For purposes of this Section 4.1, ISOs will be taken into account in the order in which they were granted, the Fair Market Value of the shares of Stock will be determined as of the time the Option with respect to such shares of Stock is granted, and calculation will be performed in accordance with Section 422 of the Code and Treasury Regulations promulgated thereunder. Each Eligible Individual to whom an Option is granted may, by notice in writing within 30 days of the date of grant, disclaim in whole or in part his rights under the Option, in which case the Option shall for all purposes be deemed never to have been granted.
4.2.Option Agreement. Each Award of an Option will be evidenced by an Award Agreement that will specify the date of grant of the Option, the Exercise Price, the term of the Option, the number of shares of Stock subject to the Option, the exercise restrictions, if any, applicable to the Option, including the dates upon which the Option is first exercisable in whole and/or part, and such other terms and conditions as the Administrator, in its sole discretion, may determine.
4.3.Term of Option. The term of each Option will be stated in the Award Agreement; provided, however, that the term will be no more than 10 years from the date of grant thereof. In the case of an ISO granted to a Participant who, at the time the ISO is granted, owns capital stock representing more than 10% of the total combined voting power of all classes of capital stock of the Company or any Parent or Subsidiary, the term of the ISO will be five years from the date of grant or such shorter term as may be provided in the Award Agreement.
4.4.Exercise Price. The Exercise Price shall not be less than 100% of the Fair Market Value of a share of Stock on the date of grant (or, if greater, the par value, if any, of a share of Stock). In addition, in the case of an ISO granted to an Employee who owns capital stock representing more than 10% of the voting power of all classes of capital stock of the Company or any Parent or Subsidiary, the per share Exercise Price will be no less than 110% of the Fair Market Value per share of Stock on the date of grant. Notwithstanding the foregoing provisions of this Section 4.4, Options may be granted with a per share Exercise Price of less than 100% of the Fair Market Value per share of Stock on the date of grant pursuant to a transaction described in, and in a manner consistent with, Section 424(a) of the Code.
4.5.Minimum Vesting. Notwithstanding the foregoing, and subject to Sections 3.3(g), 8 and 9, in no event shall an Option granted to any Participant become exercisable or vested prior to the earlier to occur of (i) the first anniversary of the date on which it is granted and (ii) the Participant’s Termination Date occurs by reason of death or Disability. In the event the Participant’s Termination Date occurs for any reason other than death, Disability, Retirement or an involuntary termination without Cause, any unvested Options shall be forfeited, and in the event the Participant’s Termination Date occurs by reason of death, Disability, Retirement or an involuntary termination without Cause, unvested Options shall be exercisable only as determined by the Committee in its sole discretion pursuant to its authority in Section 9.
4.6.Exercise Period. The Option shall not be exercisable prior to the date that the vesting conditions have been satisfied as provided in Section 4.5 of the Plan, and the Option shall not be exercisable after the
A-11
Company’s close of business on the last business day that occurs prior to the Expiration Date. The “Expiration Date” shall be the earliest to occur of:
4.7.Manner of Exercise. An Option may be exercised, in whole or in part, by the delivery to the secretary of the Company, or his duly appointed agent, of an Option exercise agreement covering not less than all the shares of Stock over which the Option is then to be exercised, with the notice of exercise in the prescribed form duly completed and signed by the Participant together with a remittance of the Exercise Price payable in respect of the shares of Stock over which the Option is to be exercised.
4.8.Payment of Option Exercise Price. The payment of the Exercise Price of an Option granted under this Section 4 shall be subject to the following:
4.9.No Repricing. Except for either adjustments pursuant to Section 3.2 (relating to the adjustment of shares of Stock), or reductions of the Exercise Price approved by the Company’s stockholders, the Exercise Price for any outstanding Option may not be decreased after the date of grant nor may an outstanding Option granted under the Plan be surrendered to the Company as consideration for the grant of a replacement Option with a lower Exercise Price. Except as approved by Company’s stockholders, in no event shall any Option granted under the Plan be surrendered to Company in consideration for a cash payment or the grant of any other Award if, at the time of such surrender, the Exercise Price of the Option is greater than the then current Fair Market Value of a share of Stock. In addition, no repricing of an Option shall be permitted without the approval of Company’s stockholders if such approval is required under the rules of any stock exchange on which Stock is listed.
SECTION 5
5.1.Grant of Full Value Award. Subject to the terms and conditions of the Plan, the Administrator, at any time and from time to time, may grant Full Value Awards to Eligible Individuals in such amounts as the Administrator, in its sole discretion, will determine.
A-12
5.2.Full Value Award Agreement. Each Full Value Award will be evidenced by an Award Agreement that will specify the Period of Restriction, the number of shares of Stock granted, and such other terms and conditions as the Administrator, in its sole discretion, may determine.
5.3.Conditions. A Full Value Award may be subject to one or more of the following, as determined by the Committee:
The grant of Full Value Awards may also be subject to such other conditions, restrictions and contingencies, as determined by the Committee.
SECTION 6
Subject to the terms and conditions of the Plan, the Administrator, at any time and from time to time, may grant Cash Incentive Awards to Eligible Individuals in such amounts as the Administrator, in its sole
A-13
discretion, may determine. A Cash Incentive Award is the grant of a right to receive a payment of cash that is contingent on service conditions or on achievement of performance objectives or any other applicable conditions over a specified period as established and determined by the Committee. The grant of Cash Incentive Awards may also be subject to such other conditions, restrictions and contingencies, as determined by the Committee, including provisions relating to deferred payment.
SECTION 7
PERFORMANCE-BASED COMPENSATION
7.1.Grants of Performance-Based Compensation. The Committee may designate a Full Value Award or Cash Incentive Award granted to any Participant as Performance-Based Compensation within the meaning of Section 162(m) of the Code and regulations thereunder. To the extent required by Section 162(m) of the Code, any Full Value Award or Cash Incentive Award so designated shall be conditioned on the achievement of one or more Performance Measures as determined by the Committee and the following additional requirements shall apply:
7.2.Grants Not Intended as Performance-Based Compensation. Nothing in this Section 7 shall preclude the Committee from granting Full Value Awards or Cash Incentive Awards under the Plan or the Committee, the Company or any Related Company from granting any Cash Incentive Awards outside of the Plan that are not intended to be Performance-Based Compensation; provided, however, that, at the time of grant of Full Value Awards or Cash Incentive Awards by the Committee, the Committee shall designate whether such Awards are intended to constitute Performance-Based Compensation. To the extent that the provisions of this Section 7 reflect the requirements applicable to Performance-Based Compensation, such provisions shall not apply to the portion of the Award, if any, that is not intended to constitute Performance-Based Compensation.
SECTION 8
8.1.Award Agreement. Subject to the provisions of Section 3.2 (relating to the adjustment of shares), the occurrence of a Change in Control shall have the effect, if any, with respect to any Award as set forth in the Award Agreement or, to the extent not prohibited by the Plan or the Award Agreement, as provided by the Committee.
A-14
8.2.Accelerated Vesting. Except as otherwise provided in an Award Agreement, on the consummation of a Change in Control, all Options which have not otherwise expired or been forfeited or cancelled shall become immediately exercisable and vested, and all other Awards which have not otherwise expired or been forfeited or cancelled shall become fully vested.
8.3.Committee Actions On A Change in Control. On a Change in Control, the Committee may cancel any outstanding Awards in return for cash payment of the current value of the Award, determined with the Award fully vested at the time of payment pursuant to Section 8.2, provided that in the case of an Option, the amount of such payment will be the excess of value of the shares of Stock subject to the Option at the time of the transaction over the Exercise Price; provided, further, that in the case of an Option, such Option will be cancelled with no payment if, as of the Change in Control, the value of the shares of Stock subject to the Option at the time of the transaction are equal to or less than the Exercise Price. However, in no event shall this Section 8.3 be construed to permit a payment if such payment would result in accelerated recognition of income or imposition of additional tax under Section 409A of the Code.
SECTION 9
9.1.Administration. The authority to control and manage the operation and administration of the Plan shall be vested in a committee (the “Committee”) in accordance with this Section 9. The Committee shall be selected by the Board, and shall consist of two or more members of the Board. Unless otherwise provided by the Board, the Compensation Committee of the Board shall serve as the Committee. As a committee of the Board, the Committee is subject to the overview of the Board. If the Committee does not exist, or for any other reason determined by the Board, and to the extent not prohibited by Applicable Law, the Board may take any action under the Plan that would otherwise be the responsibility of the Committee.
9.2.Selection of Committee. So long as the Company is subject to Section 16 of the Exchange Act, the Committee shall be selected by the Board and shall consist of not fewer than two members of the Board or such greater number as may be required for compliance with Rule16b-3 issued under the Exchange Act and shall be comprised of persons who are independent for purposes of applicable stock exchange listing requirements and who would meet the requirements of a“non-employee director” within the meaning ofRule 16b-3 under the Securities Exchange Act of 1934. Any Award granted under the Plan which is intended to constitute Performance-Based Compensation (including Options) shall be granted by a Committee consisting solely of two or more “outside directors“ within the meaning of Section 162(m) of the Code and applicable regulations.
9.3.Powers of Committee. The Committee’s administration of the Plan shall be subject to the following:
A-15
9.4.Delegation by Committee. Except to the extent prohibited by Applicable Law, the Committee may allocate all or any portion of its responsibilities and powers to any one or more of its members and may delegate all or any part of its responsibilities and powers to any person or persons selected by it. Any such allocation or delegation may be revoked by the Committee at any time.
9.5.Information to be Furnished to Committee. The Company, Subsidiaries and any applicable Related Company shall furnish the Committee with such data and information as it determines may be required for it to discharge its duties. The records of the Company, Subsidiaries and any applicable Related Company as to an employee’s or Participant’s employment (or other provision of services), termination of employment (or cessation of the provision of services), leave of absence, reemployment and compensation shall be conclusive on all persons unless determined to be incorrect. Participants and other persons entitled to benefits under the Plan must furnish the Committee such evidence, data or information as the Committee considers desirable to carry out the terms of the Plan.
9.6.Liability and Indemnification of Committee. No member or authorized delegate of the Committee shall be liable to any person for any action taken or omitted in connection with the administration of the Plan unless attributable to his own fraud or willful misconduct; nor shall the Company or any Related Company be liable to any person for any such action unless attributable to fraud or willful misconduct on the part of a director or employee of the Company or Related Company. The Committee, the individual members thereof, and persons acting as the authorized delegates of the Committee under the Plan, shall be indemnified by the Company against any and all liabilities, losses, costs and expenses (including legal fees and expenses) of whatsoever kind and nature which may be imposed on, incurred by or asserted against the Committee or its members or authorized delegates by reason of the performance of a Committee function if the Committee or its members or authorized delegates did not act dishonestly or in willful violation of the law or regulation under which such liability, loss, cost or expense arises. This indemnification shall not duplicate but may supplement any coverage available under any applicable insurance.
SECTION 10
The Board may, at any time, amend or terminate the Plan, and the Board or the Committee may amend any Award Agreement, provided that no amendment or termination may, in the absence of written consent to the
A-16
change by the affected Participant (or, if the Participant is not then living, the affected beneficiary), adversely affect the rights of any Participant or beneficiary under any Award granted under the Plan prior to the date such amendment is adopted by the Board (or the Committee if applicable); and further provided that adjustments pursuant to Section 3.2 shall not be subject to the foregoing limitations of this Section 10; and further provided that the provisions of Section 4.9 (relating to Option repricing) cannot be amended unless the amendment is approved by the Company’s stockholders. Approval by the Company’s stockholders will be required for any material revision to the terms of the Plan, with the Committee’s determination of “material revision” to take into account the exemptions under NASDAQ’s rules. No amendment or termination shall be adopted or effective if it would result in accelerated recognition of income or imposition of additional tax under Section 409A of the Code or, except as otherwise provided in the amendment, would cause amounts that were not otherwise subject to Section 409A of the Code to become subject to Section 409A of the Code.
SECTION 11
11.1.General Restrictions. Delivery of shares of Stock or other amounts under the Plan shall be subject to the following:
11.2.Tax Withholding. All distributions under the Plan are subject to withholding of all applicable taxes, and the Committee may condition the delivery of any shares of Stock or other benefits under the Plan on satisfaction of the applicable withholding obligations. Except as otherwise provided by the Committee and subject to Applicable Law, such withholding obligations may be satisfied (i) through cash payment by the Participant; (ii) through the surrender of shares of Stock which the Participant already owns; or (iii) through the surrender of shares of Stock to which the Participant is otherwise entitled under the Plan (including shares otherwise distributable pursuant to the Award); provided, however, that such shares of Stock under this clause (iii) may be used to satisfy not more than the maximum individual tax rate for the Participant in applicable jurisdiction for such Participant (based on the applicable rates of the relevant tax authorities (for example, federal, state, and local), including the Participant’s share of payroll or similar taxes, as provided in tax law, regulations, or the authority’s administrative practices, not to exceed the highest statutory rate in that jurisdiction, even if that rate exceeds the highest rate that may be applicable to the specific Participant).
11.3.Grant and Use of Awards. In the discretion of the Committee, an Eligible Individual may be granted any Award permitted under the provisions of the Plan, and more than one Award may be granted to an Eligible Individual. Subject to Section 4.9 (relating to repricing), Awards may be granted as alternatives to or replacement of awards granted or outstanding under the Plan, or any other plan or arrangement of the Company or a Subsidiary or a Related Company (including a plan or arrangement of a business or entity, all or a portion of which is acquired by the Company or a Subsidiary or a Related Company). Subject to the overall limitation on the number of shares of Stock that may be delivered under the Plan, the Committee may use available shares of Stock as the form of payment for compensation, grants or rights earned or due under any other compensation plans or arrangements of the Company or a Subsidiary or a Related Company,
A-17
including the plans and arrangements of the Company or a Subsidiary or a Related Company assumed in business combinations. Notwithstanding the provisions of Section 4.4, Options granted under the Plan in replacement for awards under plans and arrangements of the Company or a Subsidiary or a Related Company assumed in business combinations may provide for Exercise Prices that are less than the Fair Market Value of the shares of Stock at the time of the replacement grants, if the Committee determines that such Exercise Price is appropriate to preserve the economic benefit of the award. The provisions of this Section shall be subject to the provisions of Section 11.13.
11.4.Dividends and Dividend Equivalents. An Award (other than an Option) may provide the Participant with the right to receive dividend or dividend equivalent payments with respect to shares of Stock subject to the Award; provided, however, that no dividend or dividend equivalents granted in relation to Full Value Awards that are subject to vesting shall be settled prior to the date that such Full Value Award (or applicable portion thereof) becomes vested and is settled. Any such settlements, and any such crediting of dividends or dividend equivalents or reinvestment in shares of Stock, will be subject to the Company’sBy-laws as well as Applicable Law and further may be subject to such conditions, restrictions and contingencies as the Committee shall establish, including the reinvestment of such credited amounts in share of Stock equivalents. The provisions of this Section shall be subject to the provisions of Section 11.13.
11.5.Settlement of Awards. The obligation to make payments and distributions with respect to Awards may be satisfied through cash payments, the delivery of shares of Stock, the granting of replacement Awards, or combination thereof as the Committee shall determine; provided, however, that if a Cash Incentive Award is settled in shares of Stock, it must satisfy the minimum vesting requirements related to Full Value Awards (as described in Section 5.4, including the limited exception described in Section 3.3(g)). Satisfaction of any such obligations under an Award, which is sometimes referred to as “settlement” of the Award, may be subject to such conditions, restrictions and contingencies as the Committee shall determine. The Committee may permit or require the deferral of any Award payment or distribution, subject to such rules and procedures as it may establish, which may include provisions for the payment or crediting of interest or dividend equivalents, and may include converting such credits into deferred share of Stock equivalents. Except for Options designated at the time of grant or otherwise as intended to be subject to Section 409A of the Code, this Section 11.5 shall not be construed to permit the deferred settlement of Options, if such settlement would result in deferral of compensation under Treas. Reg.§1.409A-1(b)(5)(i)(A)(3) (except as permitted in Sections (i) and (ii) of that section). Each Subsidiary shall be liable for payment of cash due under the Plan with respect to any Participant to the extent that such benefits are attributable to the services rendered for that Subsidiary by the Participant. Any disputes relating to liability of a Subsidiary for cash payments shall be resolved by the Committee. The provisions of this Section shall be subject to the provisions of Section 11.13.
11.6.Transferability. Except as otherwise provided by the Committee, Awards under the Plan are not transferable except as designated by the Participant by willvote online or by the laws of descent and distribution.
11.7.Form and Time of Elections. Unless otherwise specified herein, each election required or permitted to be made by any Participant or other person entitled to benefits under the Plan, and any permitted modification, or revocation thereof, shall be in writing filed with the Committee at such times, in such form, and subject to such restrictions and limitations, not inconsistent with the terms of the Plan, as the Committee shall require.
11.8.Agreement With Company. An Award under the Plan shall be subject to such terms and conditions, not inconsistent with the Plan, as the Committee shall, in its sole discretion, prescribe. The terms and conditions of any Award to any Participant shall be reflected in such form of written (including electronic) document as is determined by the Committee. A copy of such document shall be provided to the Participant, and the Committee may, but need not require that the Participant sign a copy of such document. Such document is referred to in the Plan as an “Award Agreement” regardless of whether any Participant signature is required.
11.9.Action by Company or Subsidiary. Any action required or permitted to be taken by the Company or any Subsidiary or Related Company shall be by resolution of its board of directors, or by action of one or more
A-18
members of the board (including a committee of the board) who are duly authorized to act for the board, or (except to the extent prohibited by Applicable Law or applicable rules of any stock exchange) by a duly authorized officer of such company.
11.10.Gender and Number. Where the context admits, words in any gender shall include any other gender, words in the singular shall include the plural and the plural shall include the singular.
11.11.Limitation of Implied Rights.
11.12.Evidence. Evidence required of anyone under the Plan may be by certificate, affidavit, document or other information which the person acting on it considers pertinent and reliable, and signed, made or presented by the proper party or parties.
11.13.Limitations under Section 409A. The provisions of the Plan shall be subject to the following:
A-19
A-20
UKTAX-QUALIFIED OPTIONS
The purpose of this Exhibit A is to provide, in accordance with Schedule 4 to the Income Tax (Earnings and Pensions) Act 2003 of the United Kingdom (“Schedule 4”), benefits for employees in the form ofTax-Qualified Options. The Committee may, when granting an Option to an Employee, designate it as aTax-Qualified Option. If they do so, the provisions of the Innospec Inc. 2018 Omnibus Long-Term Incentive Plan (the “Plan”) will apply to it, as amended by this Exhibit A.
SECTION 1 OF EXHIBIT A
DEFINITIONS
Words used in thisExhibit A have the same meaning as in the Plan unless amended as stated below:
1.1. “Control” has the meaning given in s995 Income Tax Act 2007 of the United Kingdom.
1.2. “Employee” means an employee or director of a Participating Company but does not include anyone who is:
1.3. “HMRC” means Her Majesty’s Revenue and Customs of the United Kingdom.
1.4. “Market Value” in relation to a Share on a particular day means:
and any restriction referred to in Section 4 of this Exhibit A will be ignored when determining Market Value.
1.5. “Ordinary Share Capital” has the meaning given in s989 Income Tax Act 2007 of the United Kingdom.
1.6. “Participating Company” means:
A-21
1.7. “Recognised Stock Exchange” has the meaning given in s1005 of the Income Tax Act 2007 of the United Kingdom.
1.8. “Retirement” shall be interpreted consistently with the interpretation of that term in s524 Income Tax (Earnings and Pensions) Act 2003 of the United Kingdom and applicable guidance from HMRC.
1.9. “Schedule 4” means Schedule 4 to the Income Tax (Earnings and Pensions) Act 2003 of the United Kingdom.
1.10. “Schedule 4 Plan” means a plan in relation to which the requirements of Parts 2 to 6 of Schedule 4 are (and are being) met.
1.11. “Shares” means, subject to Section 2 of this Exhibit A, shares of Common Stock which satisfy paragraphs 16 to 20 of Schedule 4.
1.12. “Subsidiary” means a company which is a subsidiary of the Company within the meaning of s1159 Companies Act 2006 of the United Kingdom which is under the Control of the Company.
1.13. “Takeover Offer” means either:
and for these purposes the reference to the “whole of the issued ordinary share capital” and “all the Shares” shall not be taken to include any capital or Shares held by the person making the offer or a person connected with that person (within the meaning of s718 Income Tax (Earnings and Pensions) Act 2003 of the United Kingdom), and it does not matter whether the offer is made to different shareholders by different means.
1.14.“Tax-Qualified Option” means an Option to which this Exhibit A applies.
1.15.“Tax-Qualified Option Expiration Date” has the meaning set forth in Section 9.4 of this Exhibit A.
SECTION 2 OF EXHIBIT A
SHARES
If any Shares which are subject to aTax-Qualified Option cease to satisfy paragraphs 16 to 20 of Schedule 4 and this Exhibit A ceases to be a Schedule 4 Plan, or theTax-Qualified Options become exercisable pursuant to Section 10.4 of this Exhibit A, the definition of “Shares” above is changed automatically to “shares of Common Stock”.
SECTION 3 OF EXHIBIT A
RESTRICTIONS ON TERMS OFTAX-QUALIFIED OPTIONS
3.1. ATax-Qualified Option can only be satisfied by the delivery of Shares. The Committee may not permit or require the deferral of any settlement of aTax-Qualified Option, and the relevant Shares shall be delivered no later than 30 days from the date of exercise.
3.2. The Exercise Price of aTax-Qualified Option may not be paid by the tendering of shares of Stock.
A-22
3.3. If the Exercise Price of aTax-Qualified Option (or any tax or social security withholding obligation arising in connection with its exercise) is funded by the sale of Shares acquired on exercise, the Shares must first be acquired by the Participant, and cannot be sold before the exercise of the Option.
3.4. ATax-Qualified Option cannot be transferred during the Participant’s life, although it may be transmitted to the Participant’s personal representatives on the Participant’s death.
3.5. Any provisions in the Award Agreement for aTax-Qualified Option shall comply with the requirements of Schedule 4.
3.6. The Company shall ensure that the Participant has an enforceable right to aTax-Qualified Option (in accordance with its terms) from its date of grant.
SECTION 4 OF EXHIBIT A
NOTIFICATION OF TERMS OFTAX-QUALIFIED OPTION
4.1. The Company will ensure that the Participant is notified of the following (which must be determined on the date of grant of the Option) as soon as practicable after grant of aTax-Qualified Option:
4.2. The notification may be given wholly or partly through the Award Agreement relating to theTax-Qualified Option.
SECTION 5 OF EXHIBIT A
EXERCISE PRICE
The Exercise Price of aTax-Qualified Option will not be less than Market Value of a Share on the date of grant.
SECTION 6 OF EXHIBIT A
HMRC LIMIT
The aggregate Market Value of:
A-23
must not be more than the amount permitted under paragraph 6(1) of Schedule 4 (currently £30,000). To the extent that aTax-Qualified Option is purportedly granted over a number of Shares which would result in this limit being exceeded the Option shall be automatically limited and take effect so that this limit is not exceeded, and theTax-Qualified Option shall be deemed not to have been granted to the extent that it exceeds this limit. For the purposes of this Section, Market Value is calculated as at the date of grant of the relevant option.
SECTION 7 OF EXHIBIT A
ADJUSTMENT OF OPTIONS
7.1. Adjustments may be made toTax-Qualified Options under Section 3.2 of the Plan only where there is a variation of the share capital of which Shares form part and:
7.2. An annual return relating to the Plan (as amended by this Exhibit A) submitted to HMRC following any such adjustment must include a declaration that the Plan (as amended by this Exhibit A) continues to comply with Schedule 4.
SECTION 8 OF EXHIBIT A
MATERIAL INTEREST
A Participant may not exercise aTax-Qualified Option while he is excluded from participation in a Schedule 4 Plan under paragraph 9 of Schedule 4 (material interest provisions).
SECTION 9 OF EXHIBIT A
EXERCISE – ADDITIONAL PROVISIONS
9.1. ATax-Qualified Option shall vest and become exercisable on the third anniversary of the date of grant of the Option (or such later date as may be provided in the Award Agreement) save where it may be exercised earlier in accordance with the other provisions of this Section 9, Section 10 of this Exhibit A or Section 8 of the Plan. ATax-Qualified Option shall not be exercisable before any such date or time.
9.2. Notwithstanding the provisions of Sections 4.5 and 4.6 of the Plan, but save to the extent otherwise prohibited by any other provision of the Plan (as amended by this Exhibit A), a Participant may exercise aTax-Qualified Option for the period of six months after ceasing to be an Employee for any of the following reasons:
A-24
9.3. If a Participant dies before the lapse of aTax-Qualified Option, hisTax-Qualified Option may be exercised by his personal representatives at any time within 12 months after his death, notwithstanding any earlier lapse in accordance with the rules of the Plan.
9.4. ATax-Qualified Option shall not be exercisable after the Company’s close of business on the last business day that occurs prior to theTax-Qualified Option Expiration Date. TheTax-Qualified Option Expiration Date shall be the earliest to occur of the following:
in each case save where Section 9.3 of this Exhibit A applies in which case theTax-Qualified Option Expiration Date shall be the last day of the period referred to in that Section 9.3. Section 4.6 of the Plan shall not apply to aTax-Qualified Option.
9.5. Except for rights determined by reference to a date before the date of issue, or any restriction notified in accordance with Section 4.1(c) of this Exhibit A, Shares issued in satisfaction of the exercise of an Option shall rank equally in all respects with Shares of the same class in issue at the date of issue.
SECTION 10 OF EXHIBIT A
CORPORATE EVENTS
10.1.Change in Control. The provisions of this Section 10 of Exhibit A have effect in addition to any provisions provided in the Award Agreement or by the Committee pursuant to Section 8 of the Plan. Notwithstanding the foregoing, no such provision provided in the Award Agreement shall have effect if it would affect the status of the Plan as amended by this Exhibit A as a Schedule 4 Plan, and no such provision provided by the Committee shall have effect if it would affect such status as a Schedule 4 Plan unless it is determined that the Plan as amended by this Exhibit A should cease to be a Schedule 4 Plan.
A-25
10.2.Takeover Offer. If any person obtains Control of the Company as a result of making a Takeover Offer (other than pursuant to a Reorganisation), anyTax-Qualified Options that are not exchanged pursuant to Section 10.4 of this Exhibit A may, subject to Section 10.4, be exercised within [40] days after the time when the person making the offer has obtained Control of the Company and any conditions subject to which the Takeover Offer is made have been satisfied.
10.3.Non-UK Company Reorganisation Arrangement. If anon-UK company reorganisation arrangement (as defined in Schedule 4) applicable to or affecting:
becomes binding on the shareholders covered by it, then any Options that are not exchanged pursuant to Section 10.4 of this Exhibit A may be exercised within 40 days of the arrangement becoming binding.
10.4.Option exchange.
10.5.Shares Ceasing to be Subject to Schedule 4. If Section 10.2 or 10.3 of this Exhibit A applies and, as a result of the event by virtue of which that paragraph applies, Shares in the Company would no longer meet the requirements of Part 4 of Schedule 4, the Committee, acting fairly and reasonably, may decide that theTax-Qualified Options may be exercised under that Section only within a 20 day period after the relevant event.
10.6.Lapse Following Corporate Event. Where aTax-Qualified Option becomes exercisable pursuant to this Section 10 of Exhibit A, if it is not exercised by the end of the period specified for exercise it shall then lapse (save where Section 9.3 of this Exhibit A applies).
10.7.Extent of Exercise Following Corporate Event. Where aTax-Qualified Option becomes exercisable pursuant to this Section 10, it shall be exercisable in full, subject to any contrary provision in the Award Agreement.
A-26
SECTION 11 OF EXHIBIT A
COMMITTEE’S POWERS
11.1. The Committee’s powers under the Plan are further restricted in relation toTax-Qualified Options as described in this Section.
11.2. No amendment to the Plan or this Exhibit A shall apply in relation toTax-Qualified Options if it would result in the Plan as amended by this Exhibit A ceasing to be a Schedule 4 Plan, unless it is determined that it should so cease.
11.3. This Exhibit A, and the Plan as amended by this Exhibit A, shall at all times be interpreted in a manner consistent with Schedule 4 and any other legislative provisions applying to Schedule 4 Plans, save where it is determined that the Plan as amended by this Exhibit A should cease to be a Schedule 4 Plan.
11.4. Any exercise of discretion in relation to an outstandingTax-Qualified Option must be done in a fair and reasonable manner.
11.5. An annual return submitted to HMRC following any change to a term of aTax-Qualified Option which is necessary to comply with Parts 2 to 6 of Schedule 4 must include a declaration that the Plan continues to comply with Schedule 4 from the date of the change.
A-27
| ||||||
B-2
B-3
The purpose of the Plan, which shall be known as the Innospec Inc. ShareSave Plan 2008 (the “Plan”) is to provide a means through which the Company and its Group Members may attract able persons to enter and remain in the employ of the Group and to provide a means whereby employee and directors of the Group can acquire common stock, thereby strengthening their commitment to the welfare of the Company and the Group and promoting an identity of interest between stockholders and these employees and directors.
The definitions in Part A shall apply to the Plan except where expressly provided otherwise.
In the Plan, unless otherwise specified:
The Plan was originally adopted as approved by the stockholders of the Company and effective from 6 May 2008. Subject to the approval of stockholders at the 2018 Annual Meeting of Stockholders, the Plan will be renewed for an additional ten (10) year period, such renewal to take effect from May 6, 2018. No awards shall be made under the Plan unless the Plan has been approved by the stockholders. No awards shall be made under Part A until that Part has been approved by HM Revenue & Customs.
The Plan shall terminate on the tenth anniversary of the date on which its renewal is approved by the Company’s stockholders or at any earlier time by the passing of a resolution by the Committee. Termination of the Plan shall be without prejudice to the subsisting rights of a participant in the Plan.
B-4
The present maximum aggregate number of Shares which may be issued under the Plan is 750,000 subject to any future increase in this limit which may be substituted at the discretion of the Committee upon approval by the stockholders of the Company. Subject to stockholder approval at the 2018 Annual Meeting of Stockholders in May 2018, this will be increased to a maximum aggregate number of shares of 1,650,000. For the purposes of the limit in this Rule 4 any Shares subject to an option or other rights granted under the Plan which have lapsed, been renounced or otherwise become incapable of being exercised or vesting shall not be treated as issued.
The Plan comprises three parts:
and references to a Part of the Plan shall be construed accordingly.
On every occasion that the Committee resolves to make awards under the Plan it shall have complete discretion as to whether to invite Eligible Employees to participate in Part A, Part B or Part C of the Plan.
All Plan Shares issued under the Plan shall, as to voting, dividend, transfer and other rights, including those arising on a liquidation of the Company, rank equally in all respects and as one class with the Plan Shares in issue at the date of such issue save as regards any rights attaching to such Plan Shares by reference to a record date prior to the date of such issue.
The Company shall at all times use its reasonable endeavors to keep available sufficient authorized but unissued Plan Shares to satisfy all rights under the Plan which the Committee has determined will be satisfied by the issue of Plan Shares.
While Plan Shares are admitted to trading on NASDAQ the Company shall, at its expense, make application for, and use its reasonable endeavors to obtain admission to trading on NASDAQ for Plan Shares allotted on the exercise of rights granted under the Plan.
B-5
Notwithstanding any other provision of the Plan:
By applying for any Option (or other award under this Plan) an Option Holder is deemed to have agreed to the provisions of this Rule 7.
The Company shall be responsible for, and shall have the conduct of, the administration of the Plan. The Committee may from time to time make, amend or rescind regulations for the administration of the Plan provided that such regulations shall be consistent with the Rules and not cause any of the provisions of Schedule 3 which are relevant to the Plan to cease to be satisfied.
The decision of the Committee shall be final and binding in all matters relating to the administration of the Plan, including but not limited to the resolution of any dispute concerning, or any inconsistency or ambiguity in the Rules or any document used in connection with the Plan.
The cost of introducing and administering the Plan shall be met by the Company. The Company shall be entitled, if it wishes, to charge an appropriate part of such cost to a Subsidiary. The Company shall also be entitled, if it wishes, to charge to a Subsidiary the opportunity cost of issuing Plan Shares to an Option Holder employed by the Subsidiary in relation to his exercise of an Option.
B-6
Subject to the further provisions in this Rule 9, the provisions of Rule 11 of Part A and the provisions of Rule 19 of Part B, the Committee may from time to time amend the rules of the Plan.
An amendment may not adversely affect existing rights under the Plan except where the amendment has been approved by those who would be adversely affected by the amendment in such manner as would be required by the Company’s articles of incorporation (with appropriate changes) if the Plan Shares subject to those rights which would be so adversely affected had been issued or transferred to them (so that they had become shareholders in the Company) and constituted a separate class of shares.
No alteration to the Rules of this Plan shall be effective without stockholder approval to the extent that such approval is required by any applicable law, regulatory authority or the rules of any relevant exchange.
No amendment shall be made that would result in any provision of Part B of the Plan failing to comply with Rule16b-3 under the Exchange Act or qualify under Section 423 of the Internal
B-7
Revenue Code. In addition to the extent necessary to comply with Rule16b-3 under the Exchange Act or Section 423 of the Code (or any successor rule or provision or applicable law or regulation) the Company shall obtain stockholder approval with respect to any amendment in such a manner and to such a degree as required.
The Committee shall, as soon as reasonably practicable, notify anyone adversely affected by any amendment to the Rules under this Rule 9 and explain how it affects his position under the Plan.
Save as provided for by law and subject to Rule 10.4, any notice, document or other communication given by, or on behalf of, the Committee or to any person in connection with the Plan shall be deemed to have been duly given if delivered to him at his place of work, if he is in Relevant Employment, if sent bye-mail to suche-mail address as may be specified by him from time to time, or sent through the post in apre-paid envelope to the postal address last known to the Company to be his address and, if so sent, shall be deemed to have been duly given on the date of posting.
Save as provided for by law and subject to Rule 10.4, any notice, document or other communication so sent to an Option Holder shall be deemed to have been duly given notwithstanding that such Option Holder is then deceased (and whether or not the Committee has notice of his death) except where his personal representatives have established their title to the satisfaction of the Committee and supplied to the Committee ane-mail or postal address to which notices, documents and other communications are to be sent.
Save as provided for by law and subject to Rule 10.4, any notice, document or other communication given to the Committee in connection with the Plan shall be delivered or sent by post to the Company Secretary at the Company’s registered office or such othere-mail or postal address as may from time to time be notified to Option Holders but shall not in any event be duly given unless and until it is actually received at the registered office or suche-mail or postal address and shall be deemed to have been duly given on the date of such receipt.
For the avoidance of doubt, the Option Certificate and Notice of Option may not be executed or delivered bye-mail or other such similar electronic communication.
Subject to Rule 23.2 of Part B of the Plan the formation, existence, construction, performance, validity and all aspects whatsoever of the Plan, any term of the Plan and any Option granted under it shall be governed by English law.
B-8
Subject to Rule 23.2 of Part B of the Plan the English courts shall have jurisdiction to settle any dispute which may arise out of, or in connection with, the Plan.
The jurisdiction agreement contained in this Rule 11 is made for the benefit of the Company only, which accordingly retains the right to bring proceedings in any other court of competent jurisdiction.
By applying to participate in the Plan, an Option Holder is deemed to have agreed to submit to such jurisdiction.
B-9
In this Plan, unless the context otherwise requires, the following words and expressions have the following meanings:
| ||
| ||
B-10
| ||
| ||
| ||
| ||
| ||
| ||
| ||
B-11
| ||
| ||
B-12
B-13
The Committee may, in its absolute discretion, resolve to issue Invitations at such time as it shall in its discretion determine provided always that an Invitation may not be issued during a Proscribed Period.
If the Committee announces its intention to issue Invitations, it shall issue an Invitation to every person who is, or will on the Grant Date be, an Eligible Employee.
An Invitation shall be accompanied by an Application Form to be used by the recipient of the Invitation to apply for the grant of the Option referred to in the Invitation and to apply to enter into a Savings Contract approved by the Committee for the purpose of that issue of Invitations and linked to the Option.
An Invitation shall state:
B-14
Subject to this Rule 2.4 an Invitation shall be in such form as the Committee may determine from time to time.
An Application Form shall require an Applicant to state:
B-15
and shall authorize the Committee to enter on the Application Form, on behalf of the Applicant, such monthly savings contribution, not exceeding the maximum stated on the Application Form, or as the Committee determines under Rule 3.6.
Subject to this Rule 2.5 an Application Form shall be in such form as the Committee may determine from time to time.
An Application shall be deemed to be for the grant of an Option over the maximum whole number of Plan Shares which may be acquired at the Exercise Price out of the expected repayment (including any bonus where permitted under Rule 2.4.6 and requested by the Applicant pursuant to Rule 2.5.4) under the Savings Contract linked to the Option at the applicable Bonus Date.
The recipient of an Invitation who wishes to apply for the grant of the Option referred to in the Invitation shall submit to the Committee, within the period specified in the Invitation, a duly completed Application Form.
The Committee may, in its absolute discretion, from time to time set a maximum limit on the total number of Plan Shares which may be placed under Option under the Plan in response to an issue of Invitations (but no such limit shall invalidate any Option granted prior to such limit being set).
The Company may from time to time grant Options to Eligible Employees.
The Committee shall grant the Option referred to in each Invitation in respect of which the Committee has received a valid Application and, where Rule 3.6.4 applies, which has been selected by lot.
The Committee shall grant an Option by passing a resolution. The Grant Date shall be the date on which the Committee passes the resolution or such later date as is specified in the resolution and allowed by Rules 3.7 and 3.8. The grant of an Option or Options shall be evidenced by a deed executed by or on behalf of the Committee. The deed or a statement providing details of the grant shall be issued to each Applicant who has been granted an Option as soon as reasonably practicable following the grant of the Option.
An Option Certificate shall state:
B-16
Subject thereto, an Option Certificate shall be in such form as the Committee may determine from time to time.
An Option shall be granted over the number of Plan Shares for which the Applicant is deemed under Rule 2.6 or 3.6, as appropriate, to have applied.
If the Committee receives Applications for the grant of Options over a number of Plan Shares in excess of any of the limits in Rule 2.8, it shall, to the extent necessary to eliminate the excess, take the following steps in the following order or such other steps as it may agree in advance with HM Revenue & Customs:
Each Application shall be deemed to have been withdrawn or amended accordingly and the Committee shall amend each Application Form to reflect any reduction in the bonus or the monthly savings contribution resulting therefrom.
For the purpose of applying this Rule 3.6, if an Applicant has made multiple Applications, the Applications shall be treated as a single Application and the monthly savings contributions applied for in the Applications shall be aggregated.
An Option may be granted only during the period of thirty days beginning on the earliest of the dates referred to in the definition of “Market Value” and used for the purpose of determining the Exercise Price or, if Rule 3.6 applies, during the period of forty two days beginning on the earliest of such dates.
B-17
An Option may not be granted:
The Committee may not grant an Option to an individual who is not an Eligible Employee on the Grant Date.
An Option shall be personal to the Eligible Employee to whom it is granted and, subject to Rule 6.1, shall not be capable of being transferred, charged or otherwise alienated and shall lapse immediately if the Option Holder purports to transfer, charge or otherwise alienate the Option.
The Exercise Price shall be determined by the Committee and may be any price but shall not be less than the higher of:
Subject to Rules 6 and 7, an Option may not be exercised before the Bonus Date.
Subject to Rule 6.1, an Option may not be exercised more than six months after the Bonus Date and if not exercised by that date shall lapse immediately.
Subject to Rule 6, an Option may be exercised only while the Option Holder is in Relevant Employment and if an Option Holder ceases to be in Relevant Employment, any Option granted to him shall lapse immediately. This Rule 5.3 shall apply where the Option Holder ceases to be in Relevant Employment in any circumstances (including, in particular, but not by way of limitation, where the Option Holder is dismissed unfairly, wrongfully, in breach of contract or otherwise).
B-18
The number of Plan Shares which may be acquired on the exercise of an Option shall be limited to the maximum whole number which may be acquired at the Exercise Price out of the repayment (including any interest or bonus that has been taken into account in determining the number of Plan Shares over which the Option was granted) received by the Option Holder under the Savings Contract linked to the Option.
An Option may, to the extent it has become exercisable, be exercised in whole or in part. If exercised in part, the unexercised part of the Option shall lapse.
Subject to any necessary consents and to compliance by the Option Holder with the Rules, the Committee shall, as soon as reasonably practicable and in any event not later than thirty days after the date of exercise of the Option, issue or transfer to the Option Holder, or procure the issue or transfer to the Option Holder of, the number of Plan Shares specified in the Notice of Exercise and shall deliver or procure the delivery to the Option Holder of a definitive share certificate in respect of such Plan Shares.
For the purpose of Rules 5.4 and 5.6, the repayment received under a Savings Contract shall exclude the repayment of any contribution the due date for payment of which falls after any date on which the Option Holder ceases to be in Relevant Employment.
Notwithstanding the remaining provisions of these Rules, if an Option Holder dies before the Bonus Date, his personal representatives shall be entitled to exercise his Options at any time during the twelve month period after his death. If not so exercised by the end of that period, the Options shall lapse immediately.
B-19
Notwithstanding the remaining provisions of these Rules, if an Option Holder dies during the period of six months after the Bonus Date, his personal representatives shall be entitled to exercise his Options at any time during the twelve month period after the Bonus Date. If not so exercised, the Options shall lapse immediately.
Subject to Rule 6.4, notwithstanding Rules 5.1 and 5.3, if an Option Holder ceases to be in Relevant Employment by reason of:
he shall be entitled to exercise his Options at any time during the period of six months after the date he ceases to be in Relevant Employment except that in the case of cessation of employment by reason of a circumstance within Rules 6.2.1, 6.2.2, 6.2.3, 6.2.4 or 6.2.5 occurring within the six month period after an event to which Rule 6.2.6 applied he shall be entitled to exercise his Options within the six month period after such cessation of employment. If not so exercised, the Options shall lapse immediately.
If an Option Holder ceases to be in Relevant Employment for a reason other than those referred to in Rules 6.1 and 6.2 and within three years after the Grant Date, the Option shall lapse immediately.
If an Option Holder ceases to be in Relevant Employment for a reason other than those referred to in Rules 6.1 and 6.2 and more than three years after the Grant Date, he shall be entitled to exercise the Option at any time during the six month period thereafter. If not so exercised, the Option shall lapse immediately.
If, at the relevant Bonus Date, an Option Holder holds an office or employment in a company which is not a Constituent Company but which is a member of the Group he shall be entitled to exercise his Options at any time during the six month period thereafter.
B-20
If an Option Holder gives, or is deemed under the terms of his Savings Contract to have given, notice that he intends to cease paying contributions under his Savings Contract, the Option linked to the Savings Contract shall lapse immediately unless the Option has already become exercisable in accordance with the rules of the Plan.
For the purpose of Rules 5.3, 6.2, 6.3, and 9.1.2, an Option Holder shall not be treated as ceasing to be in Relevant Employment until he no longer holds any office or employment with a member of the Group.
Notwithstanding Rule 5.1, if a person other than a New Holding Company obtains Control of the Company as a result of:
(in either case, other than any shares already held by him or a person acting in concert with him) all Options may be exercised, subject to Rule 7.2, at any time during the period of six months beginning with the time when the person making the offer or proposed acquisition (as the case may be) has obtained Control of the Company and any condition subject to which the offer or proposed acquisition is made has been satisfied. If not so exercised, the Options shall lapse at the expiry of the six month period.
Notwithstanding Rule 5.1, if a person becomes entitled or bound to acquire shares in the Company under sections 979 and 983 of the Companies Act 2006 (or equivalent legislation), all Options may be exercised at any time during the period beginning with the date the person serves a notice under section 979 and ending seven clear days before the date on which the person ceases to be entitled to serve such a notice. If not so exercised, the Options shall cease to be exercisable and shall lapse when the person ceases to be entitled to serve such a notice.
B-21
Notwithstanding Rule 5.1, if, under section 899 of the Companies Act 2006 (or equivalent legislation), the Court sanctions a compromise or arrangement proposed for the purposes of, or in connection with, a scheme for the reconstruction of the Company or its amalgamation with any other company or companies, all Options may be exercised within six months of the court sanctioning the compromise or arrangement. Any Option not so exercised shall cease to be exercisable and shall lapse at the end of such six month period.
If the Company passes a resolution for voluntarywinding-up all Options may be exercised within the following six months. Any Option not so exercised shall cease to be exercisable and shall lapse at the end of such six month period.
If aNon-UK Company Reorganisation arrangement applicable to or affecting all of the ordinary share capital of the Company or all of the shares of the same class of shares as the share to which the Option relates or all the shares, or all the shares of that same class, which are held by a class of shareholders identified by reference otherwise than by reference to their employments or directorships or their participating in a Relevant Share Option Scheme becomes binding on the shareholders covered by it, then an Option may be exercised within the period of six months of the date on which theNon-UK Company Reorganisation becomes binding.
If the shares subject to an Option cease to satisfy the conditions in paragraphs 18 to 22 of Schedule 3:
For the purpose of Rule 7, a person shall be deemed to have obtained Control of the Company if he and others acting in concert with him have together obtained Control of it.
The Committee shall, as soon as reasonably practicable, notify each Option Holder of the occurrence of any of the events referred to in this Rule and explain how this affects his position under the Plan.
If in consequence of any of the events specified in rules 7.1, 7.2, 7.3 or 7.5 the shares to which an Option relates no longer meet the requirements of paragraphs 17 to 22 of Schedule 3, the Option may be exercised no later than 20 days after the day on which the event specified in these rules occurs, notwithstanding that the shares no longer meet the requirements of paragraphs 17 to 22 of Schedule 3 provided no exercise will take place outside the window specified for exercise in any of paragraphs 7.1, 7.2, 7.3 or 7.5.
B-22
An Option which is exercised during the period of 20 days ending with the date on which the event specified in rules 7.1, 7.2, 7.3 or 7.5 occurs will be treated as if it was made in accordance with the provisions of those rules provided always that if an Option is exercised in reliance on this provision and such event does not occur within the period of 20 days of such exercise, the exercise of the Option is to be treated as having had no effect and the Option shall remain in force in accordance with the provisions of the Rules.
If the person referred to in Rules 7.1, 7.2 or 7.3, including a New Holding Company is a company, an Option Holder may, at any time during the period set out in Rule 8.2, by agreement with the Acquiring Company, release his Option in consideration of the grant to him of a new option which is equivalent to the Option but which relates to shares in:
The period referred to in Rule 8.1 is:
If the Option Holder does not release the Option within the relevant period referred to in this Rule 8.2, the Option shall lapse at the expiry of such relevant period.
The New Option shall not be regarded for the purpose of this Rule 8 as equivalent to the Option unless:
B-23
The Grant Date of the New Option shall be deemed to be the same as the Grant Date of the Option.
In the application of the Plan to the New Option, where appropriate, references to “Company” and “Plan Shares” shall be read as if they were references to the company to whose shares the New Option relates and the New Plan Shares, respectively, save that in the definition of “Committee” the reference to “Company” shall be read as if it were a reference to Innospec.
An Option shall lapse on the earliest of:
Subject to Rule 10.5, in the event of a Reorganisation, the number of Plan Shares subject to an Option, the description of the Plan Shares, the Exercise Price, or any one or more of these as necessary, shall automatically be adjusted to take account of such Reorganisation provided always that the provisions of paragraph 28(3A) are complied with.
B-24
Subject to Rule 10.3, no adjustment shall be made to the Exercise Price which would result in the Plan Shares subject to an Option being issued directly to the Option Holder at a price per Plan Share lower than the nominal value of a Plan Share and, if an adjustment would so result, the Exercise Price shall be the nominal value of a Plan Share.
Notwithstanding Rule 10.2, an adjustment may be made which would result in the Plan Shares subject to an Option being issued at a price per Plan Share lower than the nominal value of a Plan Share if and to the extent that the Committee is authorized to capitalise from the Company’s reserves a sum equal to the amount by which the aggregate nominal value of the Plan Shares subject to the Options which are adjusted exceeds the aggregate adjusted Exercise Price under such Options. If such an adjustment is made, on the subsequent exercise of the Option, the Committee shall capitalise such sum and apply the sum in paying up such excess.
The Committee shall, as soon as reasonably practicable, notify each Option Holder of any adjustment made under this Rule 10 and explain how this affects his position under the Plan. The Committee may call in for endorsement or cancellation andre-issue any Option Certificate in order to take account of such adjustment.
Prior to HM Revenue & Customs approval of this Part A of the Plan under Schedule 3, the Committee may make such amendments to the Rules as may be necessary or desirable in order to obtain such approval.
After HM Revenue & Customs approval of the Plan under Schedule 3, the Committee may from time to time amend the rules of the Plan, in its discretion acting reasonably
B-25
It is the intention of the Company to have this Part B of the Plan qualify as an “Employee Stock Purchase Plan” under Section 423 of the United States Internal Revenue Code. The provisions of the Plan shall, accordingly, be construed so as to extend and limit participation in a manner consistent with the requirement of that section of the Code. Any provision of the Plan which is inconsistent with Section 423 shall without further act or amendment by the Company be reformed to comply with the requirements of Section 423. This Section 1 shall take precedence over all other provisions in Part B of the Plan.
For the purposes of this Part B the following words shall have the following meanings:
| ||
| ||
| ||
| ||
| ||
| ||
| ||
|
B-26
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
| ||
|
B-27
|
Any person who is an Employee as of the Offering Date of a given Offering Period shall be eligible to participate in such Offering Period under this Part B of the Plan, subject to the requirements of Rule 5.1 and the limitations imposed by Section 423(b) of the Code.
At the discretion of the Committee, employees who are citizens or residents of a foreign jurisdiction may be excluded if granting them an option under the Plan would violate the laws of such jurisdiction, or if compliance with the laws of that jurisdiction would cause the Plan to violate Section 423 of the Code.
The Committee reserves the right to employ less stringent restrictions prior to the Offering Date of any Offering Period so long as those standards are set in a nondiscriminatory manner and are not more restrictive than those set forth above.
Notwithstanding any provisions of the Plan to the contrary, no Employee shall be granted an option under this Part B of the Plan if:
This Part B of the Plan shall be implemented by a series of Offering Periods and shall continue until terminated in accordance with Rule 19 hereof. The Committee shall have the power to change the duration and/or the frequency of Offering Periods with respect to future offerings without stockholder approval provided always that for the purposes of this Part B of the Plan, no Offering Period shall exceed 27 months in any circumstances.
B-28
An eligible Employee may become a participant in this Part B of the Plan by completing a subscription agreement and any other required documents (“Enrolment Documents”) provided by the Company and submitting them to the Designated Broker by 4:00 p.m. Eastern Time on the 20th of the month prior to the applicable Offering Date, unless a different time for submission of the Enrolment Documents is set by the Committee. The Enrolment Documents and their submission may be electronic, as directed by the Company. The Enrolment Documents shall set forth the dollar amount of the participant’s Compensation (subject to Rule 6.1 below) to be paid as Contributions pursuant to the Plan.
Payroll deductions shall commence on the first payroll paid after the Offering Date, or the closest payroll date to the Offering Date which is administratively feasible, and shall end not later than the last payroll paid on or prior to the Purchase Date of the Offering Period to which the Enrolment Documents are applicable, unless sooner terminated by the participant pursuant to Rule 6.2.
A participant shall elect to have payroll deductions made on each payday during the Offering Period, not to exceed such amount as the Committee may specify for the purposes of the relevant Offering Period, in a specified dollar amount of such participant’s Compensation on each payday during the Offering Period. All payroll deductions made by a participant shall be credited to his or her account under the Plan. A participant may not make any additional payments into such account. Any election made under this Rule 6.1 must also be administratively feasible.
B-29
A participant may elect to increase or decrease the rate or amount of his or her Contributions with respect to the next Offering Period by completing and filing with the Company new Enrolment Documents authorizing a change in the payroll rate. An increase or decrease (other than a discontinuance of Contributions) in the rate or amount of a participant’s Contribution shall be effective at the beginning of the next Offering Period. The new Enrolment Documents for increasing or decreasing Contributions (other than a discontinuance) must be completed and received by 4:00 p.m. Eastern Time on the 20th of the month prior to the applicable Offering Date, unless a different time for submission of the Enrolment Documents is set by the Committee. If the election is not timely filed, the election will become effective as of the beginning of the next Offering Period.
Notwithstanding the foregoing, to the extent necessary to comply with Section 423(b)(8) of the Code and Rule 3.2 herein, an Employee’s payroll deductions may be decreased during any Offering Period scheduled to end during the current calendar year to $0.00.
The Committee will establish procedures for all elections hereunder.
A participant shall be prohibited to elect to have payroll deductions made on each payday during the Offering Period:
On the Offering Date of each Offering Period, each eligible Employee participating in such Offering Period shall be granted an option to purchase on or before the applicable Purchase Date pursuant to Rule 8 a number of Shares, with the maximum number of Shares set forth in the Enrolment Documents in accordance with the formula provided in Rule 8, subject to any adjustment pursuant to Rule 18, and provided further that such purchase shall be subject to the limitations set forth in Rules 3 and 13.
Prior to the end of each Offering Period, each participant will be contacted and asked to confirm his or her intent to exercise his or her option. Upon confirmation, the participant’s option for the purchase of Shares will be exercised as soon as administratively feasible on or before the Purchase Date of each Offering Period, but after the participant has made his or her final contribution to the Plan in accordance with the Enrolment Documents.
B-30
The maximum number of Shares subject to the option to be purchased by each participant shall be determined as of the Offering Date of an Offering Period by dividing the participant’s total contributions for that Offering Period indicated in his or her Enrolment Documents, by the Purchase Price, subject to any adjustment pursuant to Rule 18, and provided further that such purchase shall be subject to the limitations set forth in Rules 3 and 13.
The Shares purchased upon exercise of an option hereunder shall be deemed to be transferred to the participant as promptly as practicable upon request or after the Purchase Date. During his or her lifetime, a participant’s option to purchase Shares hereunder is exercisable only by him or her. If a participant chooses not to exercise his or her option in the Plan, the participant will have his or her contributions returned with interest (unless otherwise specified in the Enrolment Documents). If a participant fails to respond to the request, the contributions will be returned with interest (unless otherwise specified in the Enrolment Documents) at the close of the Offering Period.
As promptly as practicable upon request or after a Purchase Date the number of Shares purchased by each participant upon exercise of his or her option shall be deposited into an account established in the participant’s name with the Designated Broker. Any payroll deductions accumulated in a participant’s account that are not applied toward the purchase of Shares due to limitations imposed by the Plan shall be returned to the participant with interest (unless otherwise specified in the Enrolment Documents) as soon as administratively feasible.
At anytime following thirty (30) days from the Purchase Date of Shares, a participant may withdraw all or any number of whole Shares credited to his or her account by directing the Designated Broker to cause his or her Shares to be:
If a participant ceases to be an Employee prior to the Purchase Date of an Offering Period by reason of:
B-31
the participant (or his personal representatives in the case of his death) may exercise his options within a period of three months following the date on which he ceases to be an Employee provided that:
If a participant ceases to be an Employee for any reason other than those in Rule 11.1, or if an Employee ceases to be an Employee in the circumstances in Rule 11.1 and chooses not to exercise his option, the Contributions credited to his account (together with interest unless otherwise specified in the Enrolment Documents) will be refunded to the Employee or his beneficiary or estate as the case may be, through normal payroll processing as soon as administratively practicable following such termination.
Any interest which shall accrue on the Contributions of a participant in the Plan:
Subject to adjustment as provided in Rule 18, the maximum number of Shares that shall be made available for sale under the Plan (including this Part B) shall be 750,000. Subject to stockholder approval at the 2018 Annual Meeting of Stockholders in May 2018, the maximum number of shares that shall be made available for sale under the Plan (including this Part B) shall be increased to 1,650,000. If the Committee determines that, during a given Offering Period, the number of Shares with respect to which options are to be exercised may exceed:
the Committee shall make a pro rata allocation of the Shares available for purchase on such Offering Date or during such Offering Period, as applicable, in as uniform a manner as shall be practicable, and as it shall determine in its sole discretion to be equitable among all participants exercising options to purchase Common Stock during the Offering Period, and may continue the Plan as then in effect, or terminate the Plan pursuant to Rule 19 below. The Committee may make a pro rata allocation of the Shares available on the Offering Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any authorization of additional Shares for issuance under the Plan by the Company’s stockholders subsequent to such Offering Date.
B-32
A participant shall have no interest or voting rights in Shares covered by his or her option until such Option has been exercised. A participant shall not be deemed holder of, or have any of the rights of a holder with respect to Shares subject to options under this Plan unless and until the participant’s Shares acquired upon exercise of such options are recorded in the books of the Company (or its transfer agent).
Shares to be delivered to a participant under the Plan will be registered in the name of the participant or in the name of the participant and his or her spouse.
The Company may, in its sole discretion, permit a participant to designate (in such form as it shall permit) a beneficiary who is to receive any Shares and cash, if any, from the participant’s account under the Plan in the event of such participant’s death subsequent to the end of an Offering Period but prior to delivery to him or her of such Shares and cash. In addition, if so permitted by the Committee, a participant may designate a beneficiary who is to receive any Shares from the participant’s account under the Plan in the event of such participant’s death prior to the Purchase Date of an Offering Period. If a participant is married and the designated beneficiary is not the spouse, spousal consent shall be required for such designation to be effective.
Such designation of beneficiary may be changed by the participant and his or her spouse (if any) at any time by submission of the required notice which required notice may be electronic. In the event of the death of a participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such participant’s death the Company shall deliver such Shares and/or cash to the executor or administrator of the estate of the participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such Shares and/or cash to the spouse or to any one or more dependents or relatives of the participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.
Neither Contributions credited to a participant’s account nor any rights with regard to the exercise of an option or to receive Shares under the Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution, or as provided in Rule 14) by the participant. Any such attempt at assignment, transfer, pledge or other disposition shall be without effect, except that the Company may treat such act as an election to withdraw funds in accordance with Rule 6.2.
Any Contributions received or held by the Company under the Plan may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such Contributions.
B-33
Individual accounts will be maintained for each participant in the Plan. Statements of accounts will be provided to participating Employees by the Company or the Designated Broker at least annually, which statements will set forth the amounts of Contributions, the per Share Purchase Price, the number of Shares purchased and the remaining cash balance, if any.
Subject to any required action by the stockholders of the Company, the number of Shares covered by each option under the Plan that has not yet been exercised, the number of Shares that have been authorized for issuance under the Plan but have not yet been placed under option (collectively, “Reserves”), the maximum number of Shares of Common Stock that may be purchased by a participant in an Offering Period, the number of Shares set forth in Rule 13.1, and the price per Share of each option under the Plan that has not yet been exercised, shall be proportionately adjusted for any increase or decrease in the number of issued Shares resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Common Stock (including any such change in the number of Shares effected in connection with a change in domicile of the Company), or any other increase or decrease in the number of Shares effected without receipt of consideration by the Company; provided, however, that conversion of any convertible securities of the Company shall not be deemed to have been “effected without receipt of consideration.” Such adjustment shall be made by the Committee, whose determination in that respect shall be final, binding and conclusive. Except as expressly provided herein, no issue by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of Shares subject to an option.
In the event of a dissolution or liquidation of the Company, any Offering Period then in progress will terminate immediately prior to the consummation of such action, unless otherwise provided by the Committee.
In the event of a Corporate Transaction, each option outstanding under the Plan shall be assumed or an equivalent option shall be substituted by the successor corporation or a parent or Subsidiary of such successor corporation. In the event that the successor corporation refuses to assume or substitute for outstanding options, each Offering Period then in progress shall be shortened and a new Purchase Date shall be set (“New Purchase Date”), as of which date any Offering Period then in progress will terminate.
The New Purchase Date shall be on or before the date of consummation of the transaction and the Committee shall notify each participant in writing, at least ten (10) days prior to the New Purchase Date, that the Purchase Date for his or her option has been changed to the New Purchase Date and that his or her option will be exercised automatically (subject to Rule 8) on the New Purchase Date, unless prior to such date he has withdrawn from the Offering Period as provided in Rule 6.2.
B-34
For purposes of this Rule 18, an option granted under the Plan shall be deemed to be assumed, without limitation, if, at the time of issuance of the stock or other consideration upon a Corporate Transaction, each holder of an option under the Plan would be entitled to receive upon exercise of the option the same number and kind of shares of stock or the same amount of property, cash or securities as such holder would have been entitled to receive upon the occurrence of the transaction if the holder had been, immediately prior to the transaction, the holder of the number of Shares covered by the option at such time (after giving effect to any adjustments in the number of Shares covered by the option as provided for in this Rule 18); provided however that if the consideration received in the transaction is not solely common stock of the successor corporation or its parent corporation (as defined in Section 424(e) of the Code), the Committee may, with the consent of the successor corporation, provide for the consideration to be received upon exercise of the option to be solely common stock of the successor corporation or its parent equal in Fair Market Value to the per Share consideration received by holders of Common Stock in the transaction.
The Committee may, if it so determines in the exercise of its sole discretion, also make provision for adjusting the Reserves, as well as the Purchase Price of each outstanding option, in the event that the Company effects one or more reorganizations, recapitalizations, rights, offerings or other increases or reductions of Shares of its outstanding Common Stock, and in the event of the Company’s being consolidated with or merged into any other corporation.
The Committee may at any time and for any reason terminate or amend this Part B of the Plan. Except as provided in Rule 18, no such termination may affect options previously granted, provided that this Part B of the Plan or an Offering Period may be terminated by the Committee on a Purchase Date or by the Committee’s setting a new Purchase Date with respect to an Offering Period then in progress if the Committee determines that termination of this Part B of the Plan and/or the Offering Period is in the best interests of the Company and the stockholders or if continuation of this Part B of the Plan and/or the Offering Period would cause the Company to incur adverse accounting charges as a result of a change after the Effective Date in the generally accepted accounting rules applicable to the Plan.
Except as provided in Rule 18 and in this Rule 19, no amendment to the Plan shall make any change in any option previously granted that adversely affects the rights of any participant.
To the extent necessary to comply with Rule16b-3 under the Exchange Act, or under Section 423 of the Code (or any successor rule or provision or any applicable law or regulation), the Company shall obtain stockholder approval in such a manner and to such a degree as so required.
Without stockholder consent and without regard to whether any participant rights may be considered to have been adversely affected, the Committee shall be entitled to change the
B-35
Offering Periods, limit the frequency and/or number of changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than US dollars, permit payroll withholding in excess of the amount designated by a participant in order to adjust for delays or mistakes in the Company’s processing of properly completed withholding elections, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each participant properly correspond with amounts withheld from the participant’s Compensation, and establish such other limitations or procedures as the Committee determines in its sole discretion advisable that are consistent with the Plan.
Shares shall not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such Shares pursuant thereto shall comply with all applicable provisions of law, domestic or foreign, including, without limitation, the Securities Act of 1933, as amended, the Exchange Act, the rules and regulations promulgated thereunder, applicable state securities laws and the requirements of any stock exchange upon which the Shares may then be listed, and shall be further subject to the approval of counsel for the Company with respect to such compliance.
As a condition to the exercise of an option, the Company may require the person exercising such option to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by any of the aforementioned applicable provisions of law.
The term of this Part B of the Plan shall be ten (10) years from the Effective Date unless sooner terminated under Rule 19. Following stockholder approval, if granted at the 2018 Annual Meeting of Stockholders, the plan shall be extended for a further ten (10) years from May 6, 2018.
The terms and conditions of options granted hereunder to, and the purchase of Shares by, persons subject to Section 16 of the Exchange Act shall comply with the applicable provisions of Rule16b-3. This Plan shall be deemed to contain, and such options shall contain, and the Shares issued upon exercise thereof shall be subject to, such additional conditions and restrictions as may be required by Rule16b-3 to qualify for the maximum exemption from Section 16 of the Exchange Act with respect to Plan transactions.
The Plan and Enrolment Documents do not constitute an employment contract. Nothing in this Plan or Enrolment Documents shall in any way alter theat-will nature of a participant’s employment or be deemed to create in any way whatsoever any obligation on part of any participant to continue in the employ of the Company or Designated Subsidiaries, or on part of the Company or Designated Subsidiary to continue the employment of the participant.
B-36
The validity, construction and effect of this Part B of the Plan, Rules 1 to 11 of the introduction to the Plan in respect of their application to any option granted under this Part B of the Plan, any rules and regulations relating to the Plan and any option granted hereunder shall be determined in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of laws.
This Plan is not intended to be a deferred compensation plan as defined under Section 409A of the Code and any guidance issued thereunder (“Section 409A Standards”). Notwithstanding the foregoing, to the extent that this Plan and or options granted under this Plan at any time become subject to Section 409A Standards, the Committee shall have the authority to amend the Plan in order to comply with Section 409A Standards, and the Plan and all options exercised pursuant to the Plan shall be effected, interpreted, and applied in a manner consistent with the 409A Standards. To the extent that options exercised under the Plan become subject to 409A Standards and such options granted under the Plan subject any participant to gross income inclusion, interest, or additional tax pursuant to, or would be prohibited by, Code Section 409A, those terms are to that extent superseded by the applicable Section 409A Standards.
B-37
On each occasion that the Committee resolves to grant Options or Stock Equivalent Units under this Part C the provisions in Part A shall apply to such Options or Stock Equivalent Units as modified by this Part C.
In this Part C of the Plan, unless the context otherwise requires, the following words and expressions have the following meanings:
B-38
Words not otherwise defined in this Part C shall have the meanings given to them in Part A of the Plan.
2.
Rule 2 of Part A of the Plan shall apply to this Part C subject to the following modifications:
Rule 3 of Part A shall apply subject to the following modifications:
B-39
“firstly, it shall amend the Notional Dollar Repayment Value in relation to the Option as it determines in its absolute discretion;”.
In respect of any Eligible Employees to which this Part C may apply the Committee may determine that there shall not be a Savings Body and that alternative arrangements may be made for those Eligible Employees for the saving of Monthly Contributions. Such arrangements may include Option Holders making personal arrangements for saving Monthly Contributions and providing such evidence as the Committee may require at the date of exercise to demonstrate that such savings have been made and retained by the relevant Option Holder. Where this Rule 2.3 applies references to “Savings Body”, “Savings Contract” and “Savings” in the rules of the Plan shall be construed accordingly and the rules of the Plan shall be applied as far as possible in the same manner as they do where a Savings Body is involved in the operation of the Plan.
Rules 4, 5 and 6 of Part A shall apply subject to the following modifications:
An Option can only be exercised in respect of such number of Plan Shares as is determined below:
A is the maximum number of Plan Shares in respect of which the Option subsists; and
B is the number of Monthly Contributions actually made by the Option Holder prior to the date of effective exercise of the Option;
B-40
In respect of any Option granted under this Part C that is effectively exercised the Committee may choose to satisfy any rights the Option Holder has under the Plan by a cash payment to the Option Holder and in such circumstances the Option Holder will have no right to the allotment or transfer to him of Plan Shares on the exercise of his Option.
Where the exercise of an Option is to be satisfied by the payment of cash the quantum of such payment shall be calculated as follows:
N x (MV – EP)
Where:
N is the number of Plan Shares that could have been acquired on the relevant Exercise Date determined in accordance with Rule 3.2 of this Part C (on the assumption that the Option Holder could acquire Plan Shares);
MV is the Market Value of a Plan Share on the relevant date of exercise (for this purpose, the definition of “Market Value” shall be applied replacing references to “Invitation Date” with “relevant date of exercise”); and
EP is the Exercise Price for a Plan Share under the relevant Option.
Any payment under this Part C shall be subject to deduction of all taxes (including withholding taxes and other payroll taxes), social security contributions and other contributions as may be lawfully made and required by any taxation authority.
Any references to HM Revenue & Customs approval, agreement or consent shall be disregarded for the purposes of this Part C.
Subject to Rule 2.3 of this Part C, any reference to “Savings Contract” shall be construed as a reference to the contract between the Savings Body and the Option Holder in respect of the Savings for the purposes of this Part C.
Exercise is conditional on the tax liability being established, which for the purposes of this Part C will treated as the date of the sale of the Shares (where the Option Holder chooses to sell immediately) or the transfer of shares into the Option Holder’s named account (where the Option Holder chooses to retain their Shares).
B-41
7.2.1 the definition of “Option” shall be replaced with “Stock Equivalent Unit” as defined in this Part C and references to an Option, Option Certificate and New Option in the remainder of Part A or Part C shall be modified accordingly;
7.2.2 the definition of “Plan Shares” shall be replaced with “Notional Shares” which shall mean a notional share equal in value to a Plan Share but having no legal rights attributable to a Share, and references to Plan Shares in the remainder of Part A (with the exception of Rule 4 and Rule 7.1.2) and Part C (with the exception of Rule 7.4) shall be amended accordingly;
7.2.3 Rules 2.8, 3.6, 5.7, 7.6, 7.9, 8.3.1 and 10.2 of Part A shall not apply in respect of a Stock Equivalent Unit;
7.2.4 Rule 8.1 of Part A shall be amended so that all references to shares in any of the bodies referred to in Rule 8.1.1 to 8.1.3 shall be to notional shares in that body such that any New Option shall be granted as a Stock Equivalent Unit; and
7.2.5 paragraph 3 of Rule 6 of this Part C shall be replaced with “Exercise is conditional on the tax liability being established.”.
N x (MV – EP)
N is the number of Notional Shares that could have been acquired on the relevant Exercise Date determined in accordance with Rule 3.2 of this Part C;
MV means, in the Relevant Currency at the Conversion Rate on the Exercise Date, an amount per Notional Share equal to the Market Value of a Plan Share on the relevant date of exercise (for this purpose, the definition of “Market Value” shall be applied replacing references to “Invitation Date” with “relevant date of exercise”); and
EP is the Exercise Price for a Notional Share under the relevant Stock Equivalent Unit.
B-42
Electronic Voting InstructionsIMPORTANT ANNUAL MEETING INFORMATIONAvailable 24 hours a day, 7 days a week!Instead of mailing your proxy, you may choose one of the voting methods outlined below to vote your proxy.VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR.Proxies submitted by the Internet or telephone must be received by 1:00 a.m., Eastern Daylight Time, on May 9, 2018.Vote by Internet
this card. Online Go to www.envisionreports.com/iospOr or scan the QR code with your smartphoneFollow— login details are located in the steps outlined on the secure websiteVote by telephone
shaded bar below. Phone Call toll free 1-800-652-VOTE (8683) within the USA, US territories &and Canada on a touch tone telephoneFollow the instructions provided by the recorded message
Save paper, time and money! Sign up for electronic delivery at www.envisionreports.com/iosp Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas.
2021 Annual Meeting Proxy Card 1234 5678 9012 345
IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION,VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.A Proposals — The Board recommendsof Directors recommend a vote FOR all the nominees listed and FOR Proposals 2, 3 4 and 5.
4. 1. Re-electionElection of two Class II Directors: 01 - 01—Milton C. Blackmore
For Withhold02 - 02—Robert I. Paller
For Withhold
2. Ratification of the appointment of one Class 1 Director: Elizabeth K. Arnold. 4. Ratification of the appointment of Innospec Inc.’s independent registered public accounting firm: 3. Say on Pay - Pay—An advisory vote on the approval of executive compensation.4. Approval of the Innospec, Inc. Sharesave Plan 2008 (as amended and restated).
For Against Abstain3. Approval of the Innospec Inc. 2018 Omnibus Long-Term Incentive Plan.5. Proposal to ratify the Company’s independent public accounting firm for 2018.
For Withhold For Against Abstain6. To transact such other business as may properly come before the meeting or any adjournment thereof.B Non-Voting ItemsChange of Address — Please print your new address below. Comments — Please print your comments below. Meeting AttendanceMark the box to the right if you plan to attend the Annual Meeting.C Authorized Signatures — This section must be completed for your vote to be counted. — Datecount. Please date and Sign Below
sign below. Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title.
Date (mm/dd/yyyy) — Please print date below. Signature 1 — Please keep signature within the box. Signature 2 — Please keep signature within the box. C 1234567890 J N T MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND 1UPX 499301 MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND 03EO8B
2018 Annual Meeting Admission Ticket2018The 2021 Annual Meeting of Stockholders of Innospec Inc. Stockholders
will be held on Wednesday, May 9, 2018,5, 2021 at 10:00 a.m. Local00am Eastern Time, virtually via the internet at www.meetingcenter.io/237172316. To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form. The Four Seasons 1435 Brickell Ave, Miami, FL 33131Upon arrival, please presentpassword for this admission ticket and photo identificationmeeting is — OTL2021. Important notice regarding the Internet availability of proxy materials for the Annual Meeting of Stockholders. The material is available at: www.envisionreports.com/iosp Small steps make an impact. Help the environment by consenting to receive electronic delivery, sign up at the registration desk.IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION,www.envisionreports.com/iosp qIF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. Proxy —q Innospec Inc.
+ Notice of 20182021 Annual Meeting of Stockholders
Proxy Solicited by Board of Directors for Annual Meeting –— May 9, 2018
5, 2021 Patrick S. Williams and Ian P. Cleminson, or any of them, each with the power of substitution, are hereby authorized to represent and vote the shares of the undersigned, with all the powers which the undersigned would possess if personally present, at the Annual Meeting of Stockholders of Innospec Inc. to be held on May 9, 20185, 2021 or at any postponement or adjournment thereof. Shares represented by this proxy will be voted by the stockholder. If no such directions are indicated, the Proxies will have authority to vote FOR all nominees and FOR Proposals 2, 3 4 and 5.4. In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting. (Items to be voted appear on reverse side.)side) C Non-Voting Items Change of Address — Please print new address below. Comments — Please print your comments below.